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 The views in this book are solely those of the author, and do not represent the views of 
the Georgia Institute of Technology. 
 This book is not intended as a substitute for the medical advice of physicians.  The reader 
should regularly consult a physician in matters relating to his/her health and particularly with 
respect to any symptoms that may require diagnosis or medical attention.  Any information in the 
book that the reader chooses to implement should be done under the strict guidance and 
supervision of a licensed health care practitioner. 
 
 





 Why did I write this book, what are its contents, what is new, who is the intended 
audience, and how will readers benefit from it? 
Motivation 
 For most of the past decade, I have been developing text mining procedures to identify 
potential discovery of new treatments for serious diseases.  During this period, it became clear to 
me that discovery of new treatments for serious diseases, while both interesting and challenging, 
would be insufficient to reverse or eliminate disease.  It became evident that eliminating the 
foundational causes of disease was at least as important as applying new treatments, if there were 
to be any hope for full or partial reversal of disease. 
 Toward that end, I developed a holistic medical principle that would form the bedrock of 
a healing protocol: Removal of cause is a necessary, but not sufficient, condition for restorative 
treatment to be effective (where 'removal' encompasses 'neutralization' in those cases where 
actual 'removal' is not possible).  To prevent any disease, the foundational causes that underlay 
the disease symptoms need to be identified and removed as comprehensively, thoroughly, and 
rapidly as possible.  To reverse disease (if irreversible damage has not been done and genetic 
predisposition is not a dominant factor), the preventive steps above need to be implemented as 
well.  If the preventive protocols are inadequate for reversing disease progression, they need to 
be augmented by treatments.  The first step in either disease prevention or reversal is to identify 
the full spectrum of potential foundational causes, or contributing factors, for the disease(s) of 
interest. 
 It also became evident to me that much of the information required to identify and 
eliminate these foundational causes of disease is in the literature already, but is not being 
extracted and exploited adequately.  There is little financial incentive for much of the research 
community to focus on eliminating causes relative to instituting new treatments.  Additionally, 
extracting these foundational causes comprehensively from the literature is a complex text 
mining problem.  I firmly believe that the Literature-Related Discovery and Innovation (LRDI) 
text mining approach I had been developing for more than a decade is uniquely capable of 
identifying these foundational causes (and treatments) comprehensively. 
 About three years ago, I started a series of proof-of-principle demonstrations to show that 
foundational causes (and treatments, in some cases) could be identified comprehensively and 
efficiently for single diseases.  In these demonstrations, I have been identifying an order of 
magnitude more foundational causes for each disease than any other published papers have 
reported. 
 However, it became clear to me that identifying foundational causes for any one disease 
provides a limited perspective on the potential comprehensive damage resulting from 
foundational causes.  To produce a deeper understanding of the health degradation and 
restoration processes, foundational causes for 'all' diseases collectively need to be identified. 




 Moreover, it also became clear to me that many foundational causes are not seeing the 
light of day in the published literature for myriad reasons, and those unpublished foundational 
causes might be as important, if not more important, than those appearing in the published 
literature.  Thus, not only would the foundational causes for all diseases have to be addressed in 
any documentation of such a massive study, but the unique text mining approach that generated 
these foundational causes would have to be examined in detail, and the myriad reasons for 
foundational causes having been excluded from the published literature would have to be 
addressed as well. 
 The study identifying foundational causes for 'all' diseases was initiated in early 2014, 
and fully completed in 2015.  Then, the issue of appropriate documentation arose.  My initial 
thoughts were to publish a series of journal articles.  One or more articles would address the 
voluminous foundational causes that were identified, at least one article would address the 
innovative text mining approach that generated these results, and at least one article would 
address the many reasons important foundational causes are being excluded from the biomedical 
literature. 
 Unfortunately, the separate journal publication approach would have fragmented the 
results, and would have greatly decremented the value of an integrated interdisciplinary 
presentation.  Producing a book allowed a full exposition and integration of the study's results 
and conclusions, not constrained by journal limitations. 
Contents 
 The overall theme of this book is preventing and reversing chronic diseases using the 
holistic medical principle: removal of cause is a necessary, but not sufficient, condition for 
restorative treatment to be effective.  The specific focus of this book is identifying, 
categorizing, and analyzing the pervasive foundational causes of ~4000 diseases, allowing these 
actionable causes to then be eliminated. 
 These foundational causes are based on analysis of hundreds of thousands of biomedical 
journal articles from the premier medical literature.  The foundational causes are categorized and 
analyzed by discipline, as well as by the underlying main sources of these causes. 
 There is a substantial section outlining the deficiencies and distortions of the premier 
biomedical literature on which this book is based.  These inadequacies lead to  
1) concealment of the full extent of the pervasive foundational causes of chronic disease;  
2) reduced perceptions of health risk among individuals and policy-makers;  
3) inadequate regulation and public health policy at the national and global levels. 
There is also a lengthy section describing the text mining/ information technology advances that 
allowed the pervasive foundational causes to be extracted efficiently from the huge volumes of 
biomedical journal articles retrieved. 





 While the individual direct foundational causes identified in this book are 'known', in the 
sense that they exist in the published literature, they have not been integrated anywhere near the 
extent they are integrated in this book.  The new 'insights' in this book are:  
1) the enormity of potential foundational causes that are possible;  
2) the enormity of potential foundational causes that have to be eliminated for any person to 
prevent or reverse chronic disease (assuming irreversible damage has not been done or 
overwhelming genetic predisposition is not operable);  
3) the enormity of potential combinations of foundational causes that have to be identified and 
researched (many of whose individual components have not yet been identified); and  
4) the depth to which each potential foundational cause must be eliminated for prevention or 
reversal to occur. 
Most papers addressing chronic disease take the form: here's a symptom(s); here's what my drug 
can do to suppress that symptom(s), and here're some of the other symptoms that can arise as a 
result of my drug.  They're using a 22-caliber handgun for a problem that requires a howitzer! 
 Additionally, one chapter (#9) has been devoted to integrating the myriad approaches by 
which foundational causes have been prevented from appearing in the literature; these causes are 
therefore not amenable to identification through text mining.  The potential enormity of these 
'known unknowns' cannot be underestimated!  I have not seen any other source that integrates the 
full spectrum of the types of suppressive approaches identified in Chapter 9. 
Audience 
 There are three communities to whom this book is targeted.  First is the 'disease 
prevention and reversal' community.  This encompasses the public health community, medical 
practitioners involved clinically with disease prevention and reversal, and individuals interested 
in what the present approach has to offer (they should heed the warnings in the Disclaimer).  The 
pervasive foundational cause taxonomies in Chapters 3 and 8 should be of particular interest to 
this community.  Additionally, the cataracts researcher and clinician community might have 
interest in the identification of foundational causes for cataracts used as an example in Chapter 5. 
 Second is the text mining and information technology community.  This would cover the 
full spectrum of researchers interested in extraction of useful information from any type of text, 
since the techniques developed in this book can be readily adapted to extracting useful 
information from myriad types of text.  The concepts and algorithms in Chapters 2 and 7 should 
be of special interest to this community. 
 The third community is harder to define.  There is one segment of this book (Chapter 9) 
that addresses myriad reasons for foundational causes (deliberately or non-deliberately) either 
not entering the published literature, or entering the published literature in distorted form.  While 




professional disciplines that would have an interest in Chapter 9 could be identified (such as 
bioethicists), it would behoove every citizen to understand how well the published literature 
reflects what is actually needed for improved health.  If significant foundational causes are not 
represented accurately in the published literature, the 'red flags' should be raised. 
Benefits 
 The interested reader will gain a deeper understanding of the main causative factors that 
drive chronic diseases and (to some extent) infectious diseases, and will also gain an 
understanding of the broad spectrum of rigorous actions required to prevent and/ or reverse these 
diseases.  The reader will be able to see why there are no 'magic bullets' to prevent or reverse 
these diseases, and will be able to understand why motivation, discipline, and hard work are 
required to achieve, or regain, good health.  Finally, the motivated reader will see that much of 
what is required to reverse serious disease may not be in the far future, but may potentially be 
available in the here and now, for selected individuals! 
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 Removal of cause is a necessary, but not sufficient, condition for restorative treatment to 
be effective.  To prevent any disease, the foundational causes that underly the disease symptoms 
need to be identified and removed as comprehensively, thoroughly, and rapidly as possible. To 
reverse disease (if irreversible damage has not been done and strong genetic predisposition is not 
a dominant factor), the preventive steps above need to be implemented, and treatments to reverse 
progression (if necessary) need to be applied.  The first step in either prevention or reversal 
protocols is to identify the full spectrum of potential foundational causes (or contributing factors) 
for the diseases of interest. 
 The main purpose of this book is to identify the pervasive foundational causes of disease 
published in the open literature.  An advanced text mining/ information technology approach was 
developed to:  
1) retrieve large numbers of biomedical journal records that covered all ~4000 diseases in the 
Pubmed MeSH tree and had a high probability of containing cause-disease linkage information; 
and  
2) provide targeted queries for extracting foundational causes from MeSH and text fields in these 
retrieved biomedical records. 
The key element of this text mining approach was to generate MeSH and text terms that would 
link to MeSH and text representations of foundational causes in the retrieved records, and then to 
separate and extract the foundational causes from their combinations with the linking terms. 
 Over 800 foundational and actionable causes are (conservatively) identified that impact 
thirty or more diseases.  A hierarchical taxonomy consisting of five broad categories at the top 
level (Lifestyle, Iatrogenic, Biotoxic, Occupational/Environmental, 
Psychosocial/Socioeconomic) has been generated to categorize these pervasive foundational 
causes. 
 Lifestyle pervasive causes include: excessive fat, sugar, salt, meat, refined 
carbohydrates, and high-temperature cooking; malnutrition, starvation, dehydration; sedentary 
lifestyle, especially prolonged sitting; inadequate sleep; substance abuse (cocaine, 
methamphetamine, etc, excessive alcohol and smoking). 
 Iatrogenic pervasive causes include drug side-effects, surgical complications, 
radiotherapy side effects, and diagnostics side-effects. 
 Drugs that produce highly pervasive side-effects include antineoplastic agents, anti-
infective agents, anti-inflammatory agents, cardiovascular agents, central nervous system agents, 
immunosuppressive agents, hematologic agents, and steroids/hormones.  Drugs that produce 
moderately pervasive side-effects include antihypertensive agents, gastrointestinal agents, lipid 
regulating agents, dermatologic agents, vaccines/ vaccination, anti-bone-loss agents, antidiabetic 
agents, and antirheumatic agents.  Drugs that produce pervasive side-effects include anti-allergic 
agents, anti-hypotensive agents, and antithyroid agents. 




 Surgeries that produce highly pervasive complications include transplantation (especially 
solid organ and cell), cardiovascular, orthopedic, gastrointestinal, kidney/ urologic, and brain/ 
neural.  Surgeries that produce moderately pervasive complications include dental/ oral/ nose/ 
ear, gynecologic, respiratory/ thorax, and liver/ spleen.  Surgeries that produce pervasive 
complications include ocular, breast, dermal/ tissue/ neck, thyroid, pancreas, and general 
procedures. 
 Diagnostics that produce pervasive side-effects include iodinated radio-contrast agents, 
invasive diagnostic procedures, diagnostic errors, and ionizing radiation. 
 Biotoxic foundational causes include: aflatoxin; myriad bacteria and viruses.  
 Occupational/Environmental foundational causes include: industrial and household 
chemicals and materials, especially hydrocarbons, solvents, and many other chemical 
compounds that emphasize chlorine, nitrogen, chromium, and carbon; agricultural chemicals, 
especially pesticides/ herbicides/ insecticides; materials, especially heavy metals, particulates, 
and nanometer-sized materials; electromagnetic radiation, especially ionizing (e.g, gamma rays, 
x-rays), non-ionizing (e.g., wireless communications), non-visible, and visible; sound, especially 
noise and ultrasound; both high and low temperature, and traumatic levels of force. 
 Psychosocial/ socioeconomic foundational causes emphasize psychological, especially 
variants of abuse (including child abuse, sexual abuse, and partner abuse) and psychological 
stress. 
 Genetic causes were not addressed in this book or included in the taxonomy.  The main 
focus of the book is on foundational causes that are somewhat actionable (action could, at least 
in theory, be taken to attenuate, neutralize, or eliminate them).  It is difficult to modify a person's 
genetic endowment presently, but that may not be true in the future.  Genetic manipulation is in 
its infancy, and may some day be the treatment of choice for genetically-based diseases. 
 There appear to be five main sources of the 800 pervasive foundational causes: Direct 
Technology, Indirect Technology, Inadequate Regulation, Individual Choice, Poverty. 
 Direct Technology (the degree of direct impact of technology on the foundational cause) 
plays a strong role in Lifestyle, Iatrogenic, and Occupational/ Environmental pervasive 
foundational causes, and may play a role in whether exposure to bacteria and viruses results in 
symptoms and diseases.  Modern technology impacts the growing, processing, and preparation of 
foods, and many of the adverse effects identified can be traced back to the use (mis-use) of 
technology.  The Iatrogenic adverse effects are mainly due to the high-technology-based drugs, 
surgery, therapies, and diagnostics.  The Occupational/ Environmental adverse effects result 
mainly from the employment of modern technology in commerce and in the workplace. 
 Indirect Technology reflects those adverse behaviors enabled by Direct Technology.  
One example is reduced labor because of modern technology, leading to the highly damaging 
sedentary lifestyle that exists today.  Another example is large numbers of people able to live in 
inhospitable northen climates because of modern transportation, food logistics, clothing, and 




shelter.  This results in less exposure to sunlight and less Vitamin D production, contributing to 
diseases related in part to Vitamin D deficiency such as multiple sclerosis, schizophrenia, and 
chronic inflammatory bowel disease. 
 Inadequate Regulation is strongly coupled to the introduction of high technology in all 
aspects of life.  Many of the problems with foods resulted from relatively unregulated chemicals, 
materials, and other contaminants entering the food supply during agriculture and livestock 
practices.  Many of the Occupational/ Environmental exposures arose from relatively 
unregulated harmful substances entering the workplace and the environment, especially in, but 
not limited to, less developed countries.  Many of the Iatrogenic problems could be traced to 
drugs and other procedures entering practice with insufficient statistically powerful front-end 
long-term testing in humans, and inadequate evaluation of side-effects. 
 Individual Choice reflects decisions by people to choose unhealthy dietary components, 
sedentary activities, recreational drugs, elective drugs and surgery, unhealthy occupations, 
unhealthy residential environments, unhealthy relationships, etc.  There is the unwritten corollary 
assumption that these people have adequate knowledge about the consequences of their choices, 
and there are no other major factors that limit their choices.  For many people, this assumption is 
false.  They have very limited knowledge about the consequences of these choices, either 
through  
1) accurate information not being available, or  
2) apathy in searching out this information, or, as Chapter 9 implies,  
3) being provided incorrect information. 
 Poverty limits individual choices about diet, occupations, and environment, and plays a 
strong role in malnutrition and the diseases of deficiency resulting therefrom directly and 
indirectly.  By limiting access to modern medicine, poverty avoids some of the causative side-
effects listed in the taxonomy, but at the same time, denies many of the benefits available from 
modern medicine.  Poverty is probably responsible for many of the communicable diseases 
among children in the world today, especially in third-world countries. 
 Many, if not most, people are exposed to at least tens of the ~800 pervasive foundational 
causes identified in this book, and perhaps tens more of the foundational causes that did not 
reach the threshold of pervasive.  Given the potential synergistic effects of these causes acting in 
concert, the opportunity for contracting one or more of the diseases mentioned in this book is 
significant.  As a result, the large number of increasing non-communicable diseases observed 
globally should come as no surprise.  To prevent serious disease, or reduce the effects of disease 
once contracted, the major foundational causes applicable to each individual must be identified, 
and eliminated/ neutralized as comprehensively, thoroughly, and rapidly as practicable. 
 Finally, what is the main takeaway message from this book?  The industrial revolution 
produced rapid technology implementation accompanied by inadequate technology regulation, 
licensing, and safety monitoring.  In parallel, individuals made poor informed choices, as well as 




uninformed choices, in their use of, and exposure to, this technology.  This has led to the 
replacement of communicable diseases with non-communicable diseases as the leading cause of 
mortality and illness globally.  Modern technology has become an integral part of our lifestyle, 
impacting the growing and processing of food, the medical diagnostics/ treatments/ surgeries, 
commerce, and the environment. 
 To minimize these adverse effects of technology on health, strong regulation, licensing, 
and safety testing and monitoring are required.  There are both technical deficiencies and 
parochial organizational incentives that limit regulation and safety monitoring, and many of 
these deficiencies and disincentives are listed in Chapter 9. 
 The lack of stringent safety monitoring is particularly troublesome.  Databases for 
collecting the fundamental safety information of adverse effects are typically passive, and can 
under-represent real-world adverse effects by an order of magnitude or more.  Many clinical and 
field trials of potential toxic agents typically have little statistical power because of their limited 
size.  Many times the participant samples don't represent the user population adequately.  Animal 
experiments are not always translatable to human outcomes. 
 Combinations of potentially toxic stimuli are not tested, which excludes those 
foundational causes that only exert toxic effects in combinations, and downgrades the impacts of 
synergistic combinations of known toxins.  Clinical and field trials for licensing especially, but 
also safety monitoring, are typically very limited in time horizon.  There are diseases that don't 
appear until three-five decades after the initiating stimulus because of potential latencies, and 
both drug and non-drug technologies are typically introduced into practice well before the long-
term safety tests have been performed. 
 In essence, the citizens of this planet have become the testbed in a global experiment to 
identify the short- and long-term impacts of technologies on our health. 
 







 I have been text mining the premier technical and medical literatures for over two 
decades, with emphasis on potential discovery of new treatments for serious diseases in the past 
decade [1-12, 14-15].  Our research group identified orders of magnitude more potential 
discovery of new treatments than any of the other literature-based discovery practitioners [14].  
However, during this decade, it became clear to me that discovery of new treatments for serious 
disease would be insufficient to reverse or eliminate the disease.  It became evident that 
elimination/ neutralization of the foundational causes of disease is at least as important as 
applying new treatments, if there were to be any hope for full or partial reversal of disease. 
 Toward that end, I developed a holistic medical principle that would form the bedrock of 
a healing protocol: Removal of cause is a necessary, but not sufficient, condition for restorative 
treatment to be effective [12].  To prevent any disease, the foundational causes that underlie the 
disease symptoms need to be identified and removed as comprehensively, thoroughly, and 
rapidly as possible.  To reverse disease (if irreversible damage has not been done and genetic 
predisposition is not a dominant factor), the preventive steps above need to be implemented, and 
treatments to reverse progression (if necessary) need to be applied.  The first step in disease 
prevention or reversal is to identify the full spectrum of potential foundational causes, or 
contributing factors, for the disease(s) of interest. 
 It is also evident that much of the information required to identify and eliminate these 
foundational causes of disease is in the literature already, but is not being extracted and exploited 
adequately.  There is little financial incentive for much of the research community to focus on 
eliminating causes relative to instituting new treatments.  Additionally, extracting these 
foundational causes comprehensively from the literature is a complex text mining problem.  To 
compound the problem, there are no uniform definitions of causes, resulting in foundational 
causes (tangible causes over which we have some control, like smoking, diet, exposure to 
harmful chemicals and radiations, etc) being classified along with diseases/ symptoms in general 
causative categories labeled as e.g. 'risk factors'. 
 In 2012, in order to do a proof-of-principle test of foundational cause identification, I 
initiated a study to identify published foundational causes for chronic kidney disease (CKD), and 
included identification of published CKD treatments as well in the study.  I categorized the 
foundational causes into two definitional groups, direct and indirect.  Direct foundational causes 
are those where the cause co-occurs with the disease in a given document, and can also be 
viewed as a potential innovation.  Indirect foundational causes are those where the cause and 
disease occur in separate documents, and where identification of the cause for the disease can be 
viewed as a literature-based discovery.  Direct and indirect treatments were defined in a similar 
manner. 




 The results were astounding [12]!  There were ~800 direct foundational causes identified 
for CKD, and ~100 indirect foundational causes identified.  There were also ~800 direct 
treatments identified for CKD, and ~100 indirect treatments.  As was discussed in [12], these 
were very conservative numbers.  Far more direct and indirect foundational causes and 
treatments for CKD were possible to identify.  The sheer volume of results provided a more 
complete picture of how patients develop CKD, and a more comprehensive picture of what was 
required to prevent and possibly reverse CKD. 
 I then initiated foundational causes identification studies (for a few other chronic 
diseases) that are presently in different states of completion.  However, in the process of 
performing these single disease studies, it also became clear to me that identifying foundational 
causes and treatments for any one disease provides a limited perspective on the potential 
comprehensive damage resulting from foundational causes.  To produce a deeper understanding 
of the health degradation and restoration processes, foundational causes and treatments for all 
diseases collectively need to be identified. 
 Examining all diseases for potential causes would allow:  
1) a comprehensive discipline hierarchical taxonomy for categorizing foundational causes to be 
constructed;  
2) a comprehensive latent (underlying) variable taxonomy for categorizing the main sources of 
these foundational causes to be constructed;  
3) the generation of very large amounts of potential discovery of foundational causes by 
extrapolating known foundational causes of diseases to closely related diseases of interest;  
4) a better understanding of the myriad pathways through which a given foundational cause can 
impact myriad diseases and symptoms;  
5) maximization of the number of important diseases potentially impacted by individual causes 
or causes operating synergistically, for the purpose of setting public health policy;  
6) increased confidence (through greater statistics) that a foundational cause is really a 
foundational cause and not an anomoly. 
I emphasize foundational causes, because once these causes have been identified, their removal 
would be actionable (from different perspectives) by public health researchers, practitioners, and 
policy makers.  Obviously, some foundational causes would be eliminated more easily than 
others. 
 At the end of the CKD paper, I outlined in general terms how a study identifying 
foundational causes and treatments for myriad diseases could be executed.  After the CKD study 
was completed, I focused on the foundational causes component of this multi-disease study.  The 
present book describes the detailed approach taken to identify:  
1) the foundational causes of the ~4000 diseases listed in the Pubmed MeSH tree;  




2) the further culling of these foundational causes into pervasive foundational causes of disease 
(those that impact at least a threshold number of myriad diseases);  
3) the disciplines into which these foundational causes can be categorized; and  
4) the underlying latent factors that constitute the main sources of these pervasive foundational 
causes. 
 An important component of this book (Chapter 9) is a detailed discussion of why even 
the voluminous foundational causes that were identified may be a highly under-reported 
representation of what exists in the global community.  Chapter 9 also presents some examples 
of negative human and economic consequences of the under-reporting of foundational causes. 
1B. Structure of Book 
 Chapter 2 presents a summary of the text mining methodology used to identify the 
individual and pervasive foundational causes, and Chapter 7 presents a very detailed text mining 
methodology. 
 Chapter 3 contains the results of the text mining and analyses, with the centerpiece being 
the taxonomy that categorizes the pervasive foundational causes, and Chapter 8 is a detailed 
expansion of Chapter 3.  Chapter 8 contains the central detailed results of this book, which is the 
taxonomy of pervasive foundational causes including illustrative examples (for each sub-
category of foundational causes) relating cause to disease. 
 Chapter 4 contains discussion and conclusions, with much of the focus on the latent 
variables that characterize the main sources of the foundational causes.  Chapter 5 contains 
suggested further research that would expand the results of the present study.  It also contains an 
example of identifying foundational causes of a single disease, cataracts, using.a streamlined text 
mining approach. 
 The remaining chapters supplement and illuminate the summary material in Chapters 1-4. 
 Chapter 6 contains the background material for the book, and a detailed definition of 
foundational causes.  6A contains the Background material for the Literature-Related Discovery 
and Innovation (LRDI) text mining approach that constituted the bulk of the information 
technology component of this study, and 6B contains the Background material on studies 
performed to identify causes of multiple diseases.  6C contains a detailed definition of 
foundational cause. 
 Chapter 9 describes the under-reporting of adverse events by different methods and for 
different reasons, and conveys the critical message that what is not being reported in the 
biomedical literature may be as important as the voluminous information that is being 
reported.  Section 9C provides some examples of human and economic consequences resulting 
from under-reporting of adverse events and negative findings. 
 




Chapter 2  
SUMMARY METHODOLOGY  
(see Chapter 7 for detailed methodology) 
2A. Data Sources 
 Selected records obtained with the Pubmed search engine of Medline are used as the 
source of all data. 
2B. Study Selection 
 A direct foundational cause i of disease j exists when i co-occurs with j in a document 
and has been judged to be a cause of j.  For purposes of this book, a toxic stimulus was deemed a 
foundational cause if  
1) the research author stated/ implied/ inferred the toxic stimulus was a cause and  
2) the information presented supported the research author's conclusion. 
A threshold of two papers/ documents or more was used for computational purposes; there had to 
be at least two papers/ documents in which the foundational cause co-occurred with the disease 
in order for the foundational cause to be considered to have an impact.  Had only one paper/ 
document been used as the threshold, the number of diseases impacted by a given foundational 
cause would have increased by anywhere from 50% to 150%. 
 To obtain pervasive foundational causes, matrices of foundational causes vs disease were 
generated from the extracted data, where the contents of cell i,j were the numbers of papers in 
which cause i co-occured with disease j.  Then, for each foundational cause, an integration was 
performed over each matrix cell to  arrive at the numbers of cells (diseases) that contained two or 
more entries.  Pervasive causes were then arbitrarily divided into highly pervasive, moderately 
pervasive, and pervasive groupings.  Numbers of diseases/ symptoms/ conditions impacted by 
each type were: highly pervasive, >100; moderately pervasive, 70-100; pervasive, 30-70. 
2C. Data Extraction 
 Three approaches were used to identify direct foundational causes of disease.  The first 
approach used MeSH Qualifiers to retrieve the records for analysis.  The second used generic 
MeSH terms (relatively unamibiguously related to foundational causes) to retrieve the records, 
and the third used text terms applied to the Title field to retrieve the records.  The query terms in 
the MeSH Qualifiers and text Title field approaches served as linking terms to allow straight-
forward extraction of the potential foundational causes terms. 
 One approach was used to identify a few sample indirect causes of disease, where an 
indirect cause i of disease j exists when i (which is not a direct foundational cause of disease j) 
has been identified as a direct foundational cause of disease/ symptom k, and disease/ symptom k 




is closely related to disease j.  A normalized diseases/ symptoms square matrix was used to 
quantify the closeness of any two diseases/ symptoms. 
 Why are these indirect foundational causes important?  As I state in section 8A4, 
"indirect foundational causes of a disease may be potential direct foundational causes of the 
disease that have not yet been identified through research.  If this is true, having a systematic 
approach to identifying potential direct foundational causes of disease would open up vast areas 
for future biomedical research.  This book presents such a systematic approach." 
 







 A hierarchial taxonomy consisting of six broad categories at the top level (Lifestyle, 
Iatrogenic, Biotoxic, Occupational/Environmental, Psychosocial/Socioeconomic, and Genetics) 
was generated to categorize the pervasive foundational causes.  The first five categories will be 
summarized in this section; the Genetics causes will not be discussed further, as mentioned 
previously. 
 Two main top-level types of results were selected for presentation and discussion.  First, 
identifying those foundational causes that are pervasive, or quasi-universal; they impact large 
numbers of diseases and symptoms.  Second, identifying a few sample indirect foundational 
causes of diseases, and showing that there may be many thousands of such indirect impacts 
potentially identifiable using the present technique. 
3A1. Direct Foundational Causes 
 Many caveats showing why the numbers of foundational causes presented here may be 
vast under-representations of the numbers of operational foundational causes are presented in 
detail in Chapter 9.  Summarily, many adverse events are not reported and published in the 
literature [70-125], or, if they are reported and published, many are not accessed due to 
inadequate search algorithms.  The under-reporting occurs at the patient, doctor, researcher, 
journal, corporate, and Federal agency levels, mainly because of myriad incentives and few 
disincentives for under-reporting.  See Chapter 9 for further examples. 
 Over-reporting cannot be excluded as well.  As is shown in Chapter 9, there are strong 
publication pressures especially in academia, and, depending on the nature of the foundational 
cause, a finding not warranted by the data could be rushed into publication. 
Top-Level Taxonomy of Direct Foundational Causes of Disease 
 Table 3-1 reflects the top-level categories of the direct foundational causes of disease 
taxonomy, and it is followed by a more detailed description of the contents in each of the 
categories listed in Table 3-1.  The three columns in Table 3-1 reflect categorization by type of 
foundational cause (Lifestyle, Iatrogenic, Biotoxic Agents, Occupational/ Environmental 
Exposures, Psychosocial/ Socioeconomic, and Genetics); category assignments are not unique.  
The findings in the first five categories will now be summarized by sub-category; more detailed 
findings and categorizations, along with many illustrative examples, are shown in Chapter 9. 





TABLE 3-1  Top-Level Taxonomy of Direct Pervasive Foundational Causes of Disease 











2C. Surgery/ Invasive Procedures 















4A1.  Industrial/ Household Chemicals/ Materials 
4A2.  Agricultural Chemicals 
4A3.  Materials 
4B. Physical/ 
Mechanical 
4B1.  Electromagnetic Radiation 
4B2.  Sound 
4B3.  Temperature 
4B4.  Force/ Pressure/ Physical Trauma 
4B5.  Other 
5. 5A. Psychological 










6A. Polymorphism/ Genotypes/ Haplotypes  
6B. Mutations  
6C. Linkages  
6D. Risk Alleles  
6E.  Genotoxicity  
6F.  Familial  
6G. Congenital  
   
End of Table 3-1 




More Detailed Description of Table 3-1 Category Contents 
1. Lifestyle 
 Lifestyle includes choices mainly under individual control, and is divided arbitrarily into 
Diet, Activity, Substance Abuse, Other. 
1A. Diet 
1A1.  Summary of Results 
Poor diet reflects the adverse effects of excesses and deficiencies of dietary components.  It has 
been used to induce myriad diseases in test animals, and it was a critical disease factor from 
many epidemiological and case studies.  The most highly pervasive components of this diet sub-
category tend to be high-fat, high-sugar, high-salt, high-meat, high-refined carbohydrates, and 
the high-temperature cooking that results in harmful products (e.g., advanced glycation end 
products, heterocyclic amines and nitrosamines, polycyclic aromatic hydrocarbons, and 
acrylamides). 
 Many deficiencies listed in the literature may be symptoms of metabolic problems, not 
foundational causes in the present sense.  Thus, a Vitamin A deficiency may be due to 
insufficient Vitamin A intake (foundational cause), or some metabolic problem that results in 
reduced Vitamin A levels (symptom).  Deficiencies of water, fiber, protein, legumes/ pulses, 
minerals, melatonin, and other nutrients (sunlight, selenium in soil, germs/ hygiene hypothesis) 
may result in adverse effects, but the only deficiencies that reach the pervasive threshold are the 
more general ones of malnutrition, starvation, and dehydration.  
 Many food additives are accompanied by adverse effects, and these effects may be under-
diagnosed and under-researched.  Many of the excesses and deficiencies mentioned above are the 
result of substances being added to, or removed from, the fresh whole food.  The large numbers 
of additives include phosphates/ phosphorous, glycerin, sodium glutamate, palmitate, 2,3-
pentanedione, etc.  None of the specific additives reach the level of pervasive in the present 
results.  Depending on how one defines 'food additives', those with the widest impacts tend to 
include the major items listed under excesses above, such as fat, sugar, and salt.  These 
components are typically added to foods for taste enhancement, not nutritional improvement. 
1A2. Caveats on Interpreting Diet Results 
 See boxed caveats in Chapter 8. 
1B. Activity 
 The main sub-categories of Activity are exercise, sedentary lifestyle, and sleep.  Exercise 
in the right amounts at the right intensity is viewed as beneficial, but excessive exercise in time 
and intensity (as well as related heat stroke) could be harmful.  Sedentary lifestyle (lack of 
exercise) is problematic, and mentioned quite often.  Prolonged sitting in all its variants appears 
to be a highly under-recognized factor contributing to many diseases.  Its importance will 




probably increase substantially with the advent of increased computer use for work and 
recreation.  Insufficient sleep, both in quality and duration, is a problem area as well. 
1C. Substance Abuse 
 Substance abuse includes 'recreational' drugs of all types (cocaine, methamphetamine, 
etc), other substances such as laxatives, common household products not usually identified as 
recreational drugs (such as mothballs), and especially excessive cigarette smoking and alcohol.  
Excessive alcohol use is implicated as a contributor to myriad diseases.  Results for very 
moderate use, especially beer and red wine, are somewhat mixed.  There may be a hormetic 
(beneficial) effect operating at very low doses (~ one drink per day), although consensus does 
not exist on that point. 
1D. Other 
 Relatively few items are placed into this category, such as tattooing and body piercing. 
 The individual foundational causes identified with Lifestyle are usually studied in 
isolation, and synergistic effects are typically not identified.  Given the number of Lifestyle 
component combinations that could be synergistic, and adding in  
1) the foundational causes from the remaining categories identified here to the potential 
combinations and  
2) foundational causes that surface only when operating in synergy but which have not yet been 
identified here as individual foundational causes, 
it is clear that only the tip of the foundational causes iceberg is being exposed in this book. 
2. Iatrogenic 
 Iatrogenic reflects diseases, symptoms, and injuries resulting from medical treatment, 
and is divided into four sub-categories: Drugs; Radiotherapy; Surgeries/ Invasive Procedures; 
Diagnostic Agents/ Procedures.  Iatrogenic is a massive category, due mainly to the large 
numbers of drugs and surgeries that have side-effects and complications.  The main categories 
are presented in this section, and illustrative examples of adverse effects from the main drugs and 
surgeries/ treatments are presented in Chapter 8.  For purposes of brevity when generating the 
drug categories, each drug is listed in one category only in Chapter 8. 
 The more frequently a drug is used, or the more frequently surgery or invasive treatments 
are employed, the more opportunity for side-effects and complications, and the more opportunity 
for publications describing these side-effects and complications.  This book does not provide an 
indication of how often such side-effects and complications would occur as a percentage of use. 
2A. Drugs 
 The Iatrogenic drug sub-category differs (from a text mining perspective) from the two 
categories that follow: Biotoxic Agents and Environmental/ Occupational Exposure.  For drugs 




that address symptoms related to a given disease, the Iatrogenic effects range in publication 
frequency from rare to modest (in the disease core literature).  For drugs that primarily address 
symptoms not related to the disease of interest, publication frequency related to Iatrogenic effects 
is high (in the disease core literature). 
 Thus, for example, an antineoplastic drug that co-occurs in a paper with a cancer sub-type 
would rarely be shown having an adverse impact on the cancer, and would most frequently be 
shown as having a side-effect causing some other disease/ symptom.  An antineoplastic drug that 
co-occurs with a non-cancer disease would almost always be a side-effect from the drug used for 
treating cancer (unless its application to the non-cancer disease was being explored in the study).  
Thus, an antineoplastic drug/ drug category that co-occurs with Mild Cognitive Impairment 
(MCI) would almost always, if not always, reflect an MCI side-effect resulting from cancer 
treatment.  Almost every paper (in the disease core literature) dealing with Biotoxic Agents and 
Environmental/ Occupational Exposure relates to causing one or more disease-related symptoms. 
 The most highly pervasive drug categories include antineoplastic agents, anti-infective 
agents, anti-inflammatory agents, cardiovascular agents, central nervous system agents, 
immunologic factors, hematologic agents, and steroids/ hormones.  Moderately pervasive drug 
categories include antihypertensive agents, gastrointestinal agents, lipid regulating agents, 
dermatologic agents, vaccines/ vaccination, anti-bone-loss agents, antidiabetic agents, and 
antirheumatic agents.  Pervasive drug categories include anti-allergic agents, anti-hypotensive 
agents, antithyroid agents. 
 There are many specific drugs identified with very high frequencies.  The main message 
here is that drugs across the board are not benign.  Individually, drugs can contribute to causing 
serious disease.  Drug combinations (with both drugs and non-drugs) may have the potential to 
exacerbate the adverse effects of individual drugs through synergistic effects. 
2B. Radiotherapy 
 Radiotherapy has an extremely large number of side-effects/ complications, being 
associated with numerous neoplastic and non-neoplastic diseases. 
2C. Surgery; Invasive Procedures 
 The following categorization is not unique.  Some procedures could be assigned to 
multiple categories. 
 The most highly pervasive surgeries include transplantation, cardiovascular, orthopedic, 
gastrointestinal, kidney/ urologic, and brain/ neural.  Moderately pervasive surgeries include 
dental/ oral/ nose/ ear, gynecologic, respiratory/ thorax, and liver/ spleen.  Pervasive surgeries 
include ocular, breast, dermal/ tissue/ neck, thyroid, pancreas, and general procedures. 
 Transplantation in particular covers an extremely broad category of foundational causes, 
and these foundational causes operate on different levels.  There are foundational causes due to 
the transplant preparation process, the surgery, the immune suppression drugs, and foundational 
causes that appear to be the result of the transplant (the transplant left the person more 




susceptible to disease).  As in the case of drugs, these absolute numbers of complications from 
all surgical and invasive procedures must be considered in light of the numbers of procedures 
performed. 
2D. Diagnostic Agents/Procedures 
 The main diagnostic sources are radio-contrast agents (especially iodinated agents), 
invasive diagnostic procedures, and diagnostic errors.  Ionizing radiation for diagnostics is also 
causative. 
3. Biotoxic Agents 
 Biotoxic Agents reflect mainly the biological substances to which we are exposed 
naturally, but sometimes accidentally, and sometimes by design.  This category is divided into 
five sub-categories: Mycotoxins; Exotoxins; Bacteria/ Fungi/ Parasites; Viruses; Other.  It was 
also large, due mainly to the large numbers of bacteria and viruses. 
3A. Mycotoxins 
 Only aflatoxins reached the pervasive level. 
3B. Exotoxins 
 For purposes of the present analysis, a substance was considered an exotoxin if it was 
administered externally, through experiments or otherwise.  Thus, amyloid beta, an endogenous 
substance, could be viewed as an endotoxin when internal processes are being discussed, but also 
as an exotoxin when given in laboratory experiments.  As a group, mycotoxins were pervasive, 
but no individual exotoxin could be identified as pervasive. 
3C. Bacteria/ Fungi/ Parasites 
3D. Viruses 
 Bacteria and viruses are dominant in sub-categories 3C and 3D.  Bacteria are somewhat 
ubiquitous, so the flexibility of cause removal for this sub-category is much less than for the 
Lifestyle and Iatrogenic categories.  Unlike the Iatrogenic drug category, where the disease 
causative nature of the drug depends on whether the drug is used as a treatment for a specific 
disease, the causative nature of the bacteria and viruses is unambiguous.  Almost every Title 
containing a virus or bacterium describes a disease or symptom caused by the bacterium or virus. 
3E. Other 
 The Other category consists mainly of toxic plants. 
4. Occupational/ Environmental Exposures 
 Occupational/ Environmental Exposures are those typically man-made substances and 
radiations to which we are exposed in our jobs and larger environment.  It is divided into 




chemicals/ materials and physical/ mechanical, and the further divisions of these major 
categories are also shown.  This category is also massive, due mainly to the large numbers of 
chemicals and materials.  Restriction to pervasive foundational causes masks the true impact of 
the 'chemicals' component.  At lower frequencies of occurrence in records, there are massive 
numbers of chemicals identified as foundational causes, and many of their impacts are quite 
serious.  Additionally, extraction of the very lowest frequency text representations of 
foundational causes from the retrieved records is most difficult.  Thousands of direct 
foundational causes may have gone unidentified, both in the 'chemicals' category and in other 
categories in this taxonomy as well. 
4A. Chemicals/Materials 
4A1. Industrial and Household Chemicals/ Materials 
 This particular sub-category (which includes hydrocarbons, solvents, other chemical 
compounds, etc) is very broad, with large numbers of these myriad chemical compounds in the 
literature.  All the chemical types mentioned have copious adverse effects, especially compounds 
containing chlorine, nitrogen, chromium, and carbon. 
4A2. Agricultural Chemicals 
 This sub-category (which includes pesticides, herbicides, insecticides, etc) impacts the 
larger population through the food supply, and has devastating effects on the agricultural 
workforce.  Given the ubiquitous nature of agricultural chemicals and industrial/ household 
chemicals in daily life, eliminating them will be challenging. 
4A3. Materials 
 The materials/ particulates (e.g., heavy metals, particulates, nanoparticles, etc) that 
constitute this category are broadly-based, and in many cases have become part of the average 
lifestyle. 
4B. Physical/ Mechanical 
 The main components of this sub-category, the different forms of radiation emitted to the 
environment (electromagnetic [ionizing, non-ionizing, visible, non-visible], noise, ultrasound, 
high temperature, low temperature, high pressure, high force, physical trauma) are ubiquitous.  
Avoiding exposure to these emissions (e.g., electromagnetic fields/ wireless communications, 
vehicle exhausts, noise, metals in agriculture, etc) would require a major change in lifestyle (and 
probably location) for most people.  The 'Other' category is an amalgam of traumatic injuries due 
to pets and various diseases transmitted by pets (or animals in general). 
5. Psychosocial/ Socioeconomic 
 Psychosocial/ Socioeconomic are those foundational causes that reflect personal 
problems, social interactions, larger societal interactions, and economic relationships.  Stress in 
all its variants was a major causative factor, especially psychological stress.  There were large 




numbers of papers focused on variants of abuse, including child abuse, sexual abuse, and partner 
abuse.  Sociological and economic types of causes seemed to play less of a direct role. 
End of More Detailed Description of Table 3-1 Category Contents 




3A2. Indirect Foundational Causes 
 Presently, a highly time-consuming manual approach only has been used to identify 
indirect foundational causes of disease.  Four simple examples will be shown to display the 
process.  The diseases/ symptoms selected are Chronic Kidney Disease (CKD) and Cataracts, 
and the goal is to generate discovery of potential new foundational causes for these diseases. 
3A2a. CKD 
 From the Disease-Disease square matrix normalized, a number of diseases can be 
identified that have a stronger than average relationship with CKD.  One of these is 
Hypertension.  From the Title text version of the causes-Diseases matrix, 1,3-dipropyl-8-
sulfophenylxanthine is listed as a direct foundational cause of Hypertension.  A search of 
Pubmed validates this statement in a number of articles.  The adenosine receptors antagonist, 
1,3-dipropyl-8-sulfophenylxanthine, was not listed as a direct foundational cause of any kidney 
disease.  Therefore, 1,3-dipropyl-8-sulfophenylxanthine is a candidate indirect foundational 
cause (potential discovery) of CKD through the two-link path 'cause-Hypertension-CKD'. 
 Also, from the same matrix, Childhood Adversity is listed as a direct foundational cause 
of Hypertension.  A search of Pubmed validates this statement in a number of articles.  
Childhood Adversity was not listed as a direct foundational cause of any kidney disease.  
Therefore, Childhood Adversity is also a candidate indirect foundational cause (potential 
discovery) of CKD through the two-link path 'cause-Hypertension-CKD'. 
3A2b. Cataracts 
 From the Disease-Disease square matrix normalized, a number of diseases/ symptoms 
can be identified that have a stronger than average relationship with Cataracts.  One of these is 
Diabetes.  From the Title text version of the causes-Diseases matrix, 'brominated 
trihalomethanes' is listed as a direct foundational cause of Diabetes.  A search of Pubmed 
validates this statement in a number of articles.  'Brominated trihalomethanes' was not listed as a 
direct foundational cause of Cataracts.  Therefore, 'Brominated trihalomethanes' is a candidate 
indirect foundational cause (potential discovery) of Cataracts through the two-link path 'cause-
Diabetes-Cataracts. 
 From the same matrix, Splenectomy is listed as a direct foundational cause of Diabetes.  
A search of Pubmed validates this statement in a number of articles.  The surgical procedure, 
Splenectomy, was not listed as a direct foundational cause of Cataracts.  Therefore, Splenectomy 
is also a candidate indirect foundational cause (potential discovery) of Cataracts through the two-
link path 'cause-Diabetes-Cataracts'. 
 Identification of indirect foundational causes is an area highly recommended for future 
research.  Far more is possible with an algorithm that exploits the network properties of the 
causes-Diseases matrix coupled to the Disease-Disease matrix.  The greater the number of 
indirect pathways between the potential/ indirect foundational cause of interest and the disease of 
interest, the greater the chances the indirect (potential direct) foundational cause will be a direct 




foundational cause.  The stronger the linkages between the diseases on these indirect pathways, 
the greater the chances the indirect (potential direct) foundational cause will be a direct 
foundational cause. 
 





DISCUSSION AND CONCLUSIONS 
 Approximately 800 direct pervasive foundational causes are identified in this book.  
Thousands more toxic stimuli were identified that fell below the numerical threshold selected for 
pervasive, but given the conservative approach used for computing impacts, many of these 
additional toxic stimuli may in reality be direct pervasive foundational causes as well. 
 These direct pervasive foundational causes are divided into six categories (Lifestyle, 
Iatrogenic, Biotoxic Agents, Occupational/ Environmental Exposures, Psychosocial/ 
Socioeconomic, Genetics) for clarity of exposition, and only the first five are examined.  There 
appear to be a handful of latent variables constituting the major sources for the pervasive 
foundational causes: Direct Technology, Indirect Technology, Inadequate Regulation, Individual 
Choice, Poverty.  Each of these five major sources (latent variables) will be discussed now. 
 Direct Technology (the degree of direct impact of technology on the foundational cause) 
plays a strong role in Lifestyle, Iatrogenic, and Occupational/ Environmental pervasive 
foundational causes.  In addition, through its impact on the immune and other critical systems, 
modern technology may play a role in whether exposure to bacteria and viruses results in 
symptoms and diseases.  Modern technology impacts the growing, processing, and preparation of 
foods, and many of the adverse effects identified can be traced back to the use (mis-use) of 
technology.  The Iatrogenic adverse effects are mainly due to the technology-based drugs, 
surgery, and diagnostics.  The Occupational/ Environmental adverse effects result mainly from 
the employment of modern technology in commerce and in the workplace. 
 Indirect Technology reflects those adverse behaviors enabled by Direct Technology.  
One example is reduced labor because of modern technology, leading to the highly damaging 
sedentary lifestyle that exists today.  Another example is large numbers of people able to live in 
inhospitable northen climates because of modern transportation, food logistics, clothing, and 
shelter.  This results in less exposure to sunlight and less Vitamin D production, contributing to 
diseases related in part to Vitamin D deficiency such as multiple sclerosis, schizophrenia, and 
chronic inflammatory bowel disease. 
 Inadequate Regulation is strongly coupled to the introduction of high technology in all 
aspects of life.  Many of the problems with foods derive from relatively unregulated chemicals, 
materials, and other contaminants entering the food supply during agriculture and animal 
husbandry.  Many of the Occupational/ Environmental exposures arise from relatively 
unregulated harmful substances entering the workplace and the environment, especially in less 
developed countries, but in more developed countries as well.  Many of the Iatrogenic problems 
could be traced to drugs and other procedures entering practice with insufficient front-end long-
term testing, and inadequate evaluation of side-effects. 
 Two major aspects of Inadequate Regulation revolve around insufficient safety: 
inadequate safety data gathering, and inadequate safety testing.  Much of the adverse impact data 
gathering tends to be from passive surveillance systems, where response rates can be an order of 




magnitude less than real-world incidence rates, or more.  Pre-market testing, in many cases, 
suffers from inadequate sample sizes, unrepresentative samples, insufficient long-term testing, 
and insufficient combination testing to identify potential  synergistic effects.  Insufficient long-
term testing on humans is particularly troubling, since many serious diseases may have decadal 
latency periods from specific toxic stimuli.  Additionally, results from animal testing (which 
could be long-term from the perspective of many short-lived animals used in testing) do not 
necessarily translate to human outcomes. 
 Individual Choice reflects decisions by people to choose unhealthy dietary components, 
sedentary activities, recreational drugs, elective drugs and surgery, unhealthy occupations, 
unhealthy residential environments, unhealthy relationships, etc.  There is the unwritten corollary 
assumption that people have adequate knowledge about the consequences of these choices, and 
there are no other major factors that limit their choices.  For many people, this is a highly 
unrealistic assumption.  They have very limited knowledge about the consequences of these 
choices, either through  
1) accurate information not being available, or  
2) apathy in searching out this information, or, as Chapter 9 implies,  
3) being provided incorrect information. 
 Poverty limits individual choices about diet, occupations, and environment.  Poverty 
plays a strong role in malnutrition and the diseases of deficiency resulting therefrom, directly and 
indirectly.  By limiting access to modern medicine, poverty avoids some of the causative side-
effects listed in the taxonomy, but at the same time, denies many of the benefits available from 
modern medicine.  Poverty is probably responsible for many of the communicable diseases 
among children in the world today, especially in third-world countries. 
 Many, if not most, people are exposed to at least tens of the ~800 direct pervasive 
foundational causes identified in this book, and perhaps tens more of the foundational causes that 
did not reach the threshold of pervasive.  Given the potential synergistic effects of these causes 
acting in concert, the opportunity for contracting one or more of the diseases mentioned in this 
book is significant.  To prevent serious disease, or reduce the effects of disease once contracted, 
the major foundational causes applicable to each individual must be identified, and eliminated as 
comprehensively, thoroughly, and rapidly as practicable. 
 The health policy that derives from the above findings would contain two main 
components: persuasion and mandates.  Persuasion would be applied to influence Lifestyle/ 
Individual Choice, which is the 'low-hanging fruit' of foundational causes.  Mandates would be 
applied to influence Inadequate Regulation, the next level up on the tree.  Effective persuasion 
and mandates depend strongly on the most scientifically accurate biomedical information being 
placed in the biomedical literature, and then communicated to the public in a straight-forward 
manner. 




 This book has taken a large step in identifying the voluminous pervasive foundational 
causes that need to be eliminated.  Because of the  limitations mentioned previously, the results 
from the analyses of this book should be viewed as proof-of-principle demonstration.  To 
enhance these results, an adequately resourced study using an in-house Medline database would 
need to be performed in order to allow more comprehensive queries to be used and greater 
amounts of source data to be accessed. 
 However, while the addition of more foundational causes obtainable with an expanded 
study would provide a more complete picture of foundational causes, the elimination of the 
specific and categorical causes identified here may be adequate to prevent or (alone or in concert 
with treatments) reduce/ halt/ reverse the progression of many major diseases.  The main 
problem is identifying the 'mix' of foundational causes to be removed for any individual patient, 
and especially the degree of foundational cause removal required for halting/ reversing the 
progression of any disease. 
 For example, does a poor diet have to be improved by 50% to be effective in disease 
reversal?  90%?  In the multiple sclerosis (MS) reversal study summarized in Chapter 9, sub-
section D, where Dr. Terri Wahls was able to reverse her MS, Dr. Wahls' symptom removal and 
especially damage reversal were not effective until her diet achieved near-'pristine' status.  There 
is no reason to believe  
1) that similar dietary improvement would not be required to reverse any disease (for those cases 
where the damage may not yet be irreversible or genetic predisposition is not overly dominant), 
or  
2) that similar improvement in other types of cause removal would not be required to reverse any 
disease. 
 The degree of cause removal required for reversal (with or without the requirement for 
additional treatments) would probably be different among patients.  The major roadblock would 
be individual choice.  It would require high discipline and compliance on the part of the patient.  
For those patients who are willing (like Dr. Wahls) to do whatever it takes to reverse their 
disease, and who have no intrinsic limitations based on strong genetic predisposition or 
irreversible damage, the findings in this book offer a starting point for an effective protocol. 
 





SUGGESTED FURTHER RESEARCH 
 This book has identified a large number of pervasive foundational causes (within the 
context of a much larger number of foundational causes, most of which have not yet shown to be 
pervasive), and has also implied that many more pervasive and non-pervasive foundational 
causes await to be uncovered.  To achieve the latter, three research efforts are suggested. 
5A. Larger Study on Pervasive Foundational Causes of Disease 
 First, an adequately-resourced study using more databases, more records, more fields, 
and more complex queries would identify many more potential foundational causes.  Most of 
these potential foundational causes would probably have low occurrence frequency in retrieved 
journal records, but would result in a more populated causes-diseases matrix.  An in-house 
version of Medline is highly recommended, as it would circumvent the limitations of most search 
engines used now.  Adding records indexed in the Science Citation Index journals that are not 
indexed in Pubmed would also prove valuable. 
5B. Semi-Automated Protocol for Identifying Potential Indirect Foundational Causes of 
Disease 
 Second, a more automated and comprehensive protocol for identifying indirect 
foundational causes is recommended.  Given the linkages among the various biological systems 
(neural, immune, endocrine, circulatory, etc), a foundational 'cause' that impacts any of these 
systems would have some ripple effect on the other systems, and therefore on other diseases.  
Prioritizing these indirect foundational causes would be important, as it could show which 
potential indirect foundational causes for a particular disease should be researched.  Having a 
priorited list of indirect foundational causes (potential direct foundational causes) would open 
the door to vast amounts of potential biomedical research. 
5C. More Streamlined Approaches for Identifying Foundational Causes for Single Diseases 
- Cataracts Example 
5C1. Overview 
 The only single disease for which the foundational causes identification technique has 
been used (and published) is CKD [12].  The CKD study did not incorporate the streamlining 
advances made in the present pervasive foundational causes study.  There would be value in 
having more detailed foundational causes identified for other specific diseases, allowing the 
recommended healing approaches in the CKD study and the present pervasive foundational 
causes study to be tested and demonstrated for specific diseases.  I recommend strongly that 
myriad streamlining approaches for foundational cause identification be developed and applied 
to myriad different diseases. 
 I also recommend that items additional to foundational causes be examined in parallel, 
including treatments, mechanisms, signalling pathways, biomarkers, etc.  The present approach 




can be expanded straight-forwardly to include these other items, and a full network of linkages 
can be readily established. 
 Examining individual diseases allows the full core database for a single disease to be 
retrieved and analyzed, because of the smaller retrievals required for a single disease compared 
to the massive retrievals for the present pervasive foundational causes study.  In turn, the single 
disease study allows much lower frequency foundational causes to be identified, since there is no 
requirement that they be pervasive.  Obviously, the single disease studies will have substantial 
overlap with the present pervasive foundational cause study because of the pervasive 
foundational causes they share in common. 
 I'll end this chapter with an example of a single disease foundational cause identification 
study, performed using the more streamlined techniques developed for the present pervasive 
foundational causes study.  The purpose of this example is to show the level of detail possible 
with the single disease study compared to the broader pervasive foundational cause study.  This 
example should be viewed as the starting point for developing new methods to streamline the 
analytical effort even further, and to add on other quantities of interest. 
5C2. Cataracts Foundational Cause Identification Example 
5C2a. Objectives 
 The purpose of this brief example is to identify foundational (tangible) and actionable 
causes of cataracts. 
5C2b. Methodology 
 The methods used are similar to those for the larger study in this book.  Selected records 
obtained with the PUBMED search engine of Medline were used as the source of all data.  Three 
approaches were used to identify direct foundational causes of disease.  The first approach used 
MeSH Qualifiers to retrieve the records for analysis. The second used generic MeSH terms 
(relatively unamibiguously related to causes) to retrieve the records, and the third used text terms 
applied to the Title field to retrieve the records.  The query terms in the MeSH Qualifiers and 
text Title field approaches served as linking terms to allow straight-forward extraction of the 
potential foundational causes terms.  For further details on each of these approaches, see Chapter 
7. 
5C2c. Summary of Results 
 Approximately 500 direct and 25 indirect foundational and actionable causes for cataracts 
were identified, and categorized in the same hierarchial taxonomy as was used in the larger 
pervasive foundational causes study of this book. 
 Lifestyle foundational causes included: 




 excessive fat, sugar, glucose, galactose, glycemic loading, salt, protein/ meat/ milk, 
refined carbohydrates, calories, cholesterol, soy/ genistein, herbs/ St. John's Wort, selenium, 
linoleic acid, linolenic acid, water, fried snacks, and maternal caffeine; 
 deficient water (dehydration), fruit, vegetables, tryptophan, protein, thiamine, iron, 
methionine, tannic acid, magnesium, zinc, Vitamin A, inositol pentaphosphate, histidine, 
ascorbic acid. beta-carotene, and general malnutrition; 
 sedentary lifestyle, including prolonged sitting; 
 inadequate sleep; and 
 substance abuse (LSD, maternal methamphetamine, excessive alcohol and smoking). 
 Iatrogenic foundational causes included: 
 drug side-effects, especially from antineoplastic agents, anti-infective agents, central 
nervous system agents, immunosuppressive agents, antihypertensive agents, lipid regulating 
agents, and steroids/hormones, and somewhat less from anti-inflammatory agents, cardiovascular 
agents, antidiabetic agents, and dermatologic agents; 
 surgical complications, especially ocular, transplantation, kidney, and gynecologic; 
 therapeutic ionizing radiation in the ocular region (radiotherapy, iodine brachytherapy, 
and nuclear medicine); 
 diagnostics centered around ionizing radiation (radiography, X-Ray Computed 
Tomography, and fluoroscopy). 
 Non-ionizing MRI was also causal, as were phenylephrine, phenazine-methosulfate, and 
D-xylose. 
 Biotoxic foundational causes included: 
 Exotoxins (e.g., bee sting, bovine lens membrane protein, CA++, Calcium, phospholipid 
hydroperoxides, spermine, tgf-beta, xenobiotics, butterfly hair; 
 Bacteria/ Fungi/ Parasites (e.g., eye-fluke, parasite, and xanthurenic acid); 
 Viruses (e.g., hbv intrauterine, herpes simplex virus type 1, hiv-1, measles, puumala 
virus, rubella virus, and viral hepatitis b); and 
 'Other' (e.g., 3-hydroxyanthranilic acid, 3-Hydroxykynurenine, 4' -pyridyl) - 1 piperazine 
aryloxypropanol or aryloxypropyl derivatives, and 4-hydroxynonenal). 
 Occupational/ Environmental foundational causes included: 
 industrial/ household chemicals/ materials, especially hydrocarbons, solvents, and many 
other chemical compounds that emphasized carbon, nitrogen, and sulfur; 




 agricultural chemicals, especially pesticides/ herbicides/ insecticides; 
 materials, especially heavy metals and particulates; 
 electromagnetic radiation, especially ionizing, non-ionizing, non-visible, and visible; 
sound/ noise; both high and low temperature; and traumatic levels of force. 
 Psychosocial/ socioeconomic foundational causes included: 
 low education, low socioeconomic status, nonprofessional occupation, social class, low 
income, and poverty. 
5C2d. More Detailed Results in Taxonomy 
 The majority of causes shown in the boxed taxonomy below are direct causes of 
cataracts; they are not highlighted.  Indirect causes of cataracts are highlighted by bolding, 
italicizing, and underlining.  For example: brominated flame retardants. 
 Appendix 5-1 contains a table of the indirect causes highlighted in the taxonomy.  These 
indirect causes for cataracts are direct causes of diabetes, a disease closely linked to cataracts, or 
direct causes of aggregated/ glycated/ oxidized proteins, conditions characteristic of cataracts.  
The small numbers of indirect causes of cataracts shown in Appendix 1 are the tip of a much 
larger iceberg.  Many more indirect causes could have been identified, both from more extensive 
examination of diabetes and aggregated/ glycated/ oxidized proteins, and from examination of 
other diseases and characteristic conditions closely linked to cataracts.





TAXONOMY OF FOUNDATIONAL CAUSES OF CATARACTS 
1.  LIFESTYLE 
The Lifestyle category is sub-divided into Diet, Activity, Substance Abuse, Other 
1A. Diet 
Poor Diet is ubiquitous.  It is used to induce cataracts in test animals, and it is a critical cataract 
factor from many epidemiological and case studies. Excesses of dietary components in both 
directions, both too much and too little, can be harmful.  In particular, excesses of total fat/ 
vegetable oil/ non-olive oil, sugar (sucrose/ sorbitol/ fructose/ sugar alcohols/ xylose), glucose, 
galactose, glycemic loading, salt, protein/ meat/ milk/ liquid protein, total/ refined 
carbohydrates/ rice gruel, calories, cholesterol, soy/ genistein, herbs/ St. John's Wort, selenium, 
linoleic acid, linolenic acid, water, fried snacks, and maternal caffeine have adverse impacts on 
cataract development. 
Many deficiencies listed in the literature are symptoms, not foundational causes in the present 
sense.  Thus, a Vitamin A deficiency may be due to insufficient Vitamin A intake, or some 
metabolic problem that results in reduced Vitamin A.  Deficiencies of water (dehydration), 
fruit, vegetables, tryptophan, protein, thiamine, iron, methionine, tannic acid, magnesium, zinc, 
Vitamin A, inositol pentaphosphate, histidine, ascorbic acid. beta-carotene, and general 
malnutrition have adverse effects on cataract development 
Food/ dietary additives are another problem area.  Foods are modified from their original state 
to enhance taste, appearance, and shelf life, among other characteristics.  While some additives 
are harmless, many are accompanied by adverse effects.  Adverse reactions to additives may be 
under-diagnosed and under-researched.  Many of the excesses and deficiencies mentioned 
above are the result of substances being added to, or removed from, the fresh whole food.  
Additives identified include monosodium-L-glutamate and excessive vitamin/ mineral 
supplements, including multivitamins, Vitamin C/ ascorbic acid and Vitamin E, and 
Menadione.  The literature is mixed on the harmful impacts of the latter two vitamins.  
Additionally, depending on how one defines 'food additives', those with the widest impacts 
tend to include the major items listed under excesses above, such as fat, sugar, and salt, which 
tend to be added to foods for taste enhancement. 
1B. Activity 
The main sub-categories of Activity are exercise, sedentary lifestyle, and sleep. 
Exercise in the right amounts at the right intensity is viewed as beneficial in reducing cataract 
incidence, especially walking and running. 
Sedentary lifestyle (lack of exercise) is problematic.  Prolonged sitting appears to be an under-
recognized factor contributing to cataract development.  The link between prolonged sitting 




and cataracts is unclear; is it from the reduced circulation characteristic of the sitting, or from 
the toxic radiation emanating from the (typically) TV or computer monitor screens being 
watched while sitting?  Its importance will probably increase substantially, with the advent of 
increased computer use for work and recreation and the attendant prolonged sitting required. 
Insufficient sleep, and its under-production of melatonin, is hypothesized to result in 
insufficient detoxification of carbonyls, and the resultant enhancement of cataract potential.  
This general area of the role of sleep in detoxification of ocular structures appears to be heavily 
under-researched, and there may be other physical, chemical, and biological mechanisms 
operable in the detoxification of ocular structures due to deep and adequate sleep. 
1C. Substance Abuse 
Substance abuse includes maternal methamphetamine, LSD, alcohol, and nicotine abuse, and 
especially excessive alcohol and smoking. 
1D. Other 
Relatively few items are placed into this category, such as excessive childbearing and 
excessive work hours per day. 
The foundational causes identified with Lifestyle are usually studied individually, and 
synergistic effects are typically not identified. Given the number of Lifestyle component 
combinations that could be synergistic, and adding in the causes from the remaining categories 
to the potential combinations, it is clear that only the tip of the cataract foundational causes 
iceberg is being exposed in the present study. 
2. Iatrogenic 
The 'side-effects' from drugs and the complications from surgery and invasive treatments 
predominate in this category.  One needs to be careful here.  The more frequently a drug is 
used, or the more frequently surgery or invasive treatments are employed, the more opportunity 
for side-effects and complications, and the more opportunity for publications describing these 
side-effects and complications. 
2A. Drugs 
Appendix 5-2 lists the specific drugs identified by drug class.  The main drug classes, both by 
numbers of drugs and numbers of records identified, include antineoplastic agents, anti-
infective agents, central nervous system agents, immunosuppressive agents, antihypertensive 
agents, lipid regulating agents, and steroids/ hormones.  The next level includes anti-
inflammatory agents, cardiovascular agents, antidiabetic agents, and dermatologic agents. 
The main message here is that drugs across the board are not benign. Individually, they can 
contribute to causing serious disease, and in the combinations that many people take, they may 
have the potential to exacerbate the causes of individual drugs through synergistic effects.  





Radiotherapy is identified as a cause under the headings of radiotherapy. iodine brachytherapy, 
and nuclear medicine.  All these terms focus on ionizing radiation in the ocular region for 
therapeutic purposes. 
2C. Surgery; Invasive Procedures 
Appendix 5-3 lists the specific causal surgeries by class.  The categorization is not unique; 
some procedures could be assigned to multiple categories.  The main surgical classes are 
ocular, transplantation, kidney, and gynecologic.  There are a large number of transplantation 
records, and the main causal components tend to be the radiation and drugs required for 
immunosuppression such that the organs/ cells would not be rejected.  As in the case of drugs, 
these absolute numbers of complications from all surgical and invasive procedures must be 
considered in light of the numbers of procedures performed. 
2D. Diagnostic Agents/ Procedures 
The main diagnostic causes are centered around ionizing radiation, including radiography, X-
Ray Computed Tomography, and fluoroscopy.  Non-ionizing MRI is also causal, as are 
phenylephrine, phenazine-methosulfate, and D-xylose. 
3. Biotoxic Agents 
Biotoxic Agents reflect mainly the biological substances to which we are exposed naturally, 
but sometimes accidentally, and sometimes by design.  This category is divided into sub-
categories shown, and is modest in size compared to drugs. 
Exotoxins include bee sting, bovine lens membrane protein, CA++, Calcium,  phospholipid 
hydroperoxides, spermine, tgf-beta/tgf-beta2, xenobiotics, butterfly hair,  2-Deoxy-D-
ribose,and 6-Hydroxydopamine.  For purposes of the present analysis, a substance is 
considered an exotoxin if it is administered externally during experiments.  Thus, amyloid beta, 
an internal substance, could be viewed as an endotoxin when internal processes are being 
discussed, but also as an exotoxin when given in laboratory experiments. 
Bacteria/ Fungi/ Parasites include eye-fluke, parasite, and xanthurenic acid. Viruses include 
hbv intrauterine, herpes simplex virus type 1, hiv-1, measles, puumala virus, rubella virus, and 
viral hepatitis b.  'Other' includes 3-hydroxyanthranilic acid, 3-Hydroxykynurenine, 4' -pyridyl 
- 1 piperazine aryloxypropanol or aryloxypropyl derivatives, and 4-hydroxynonenal. 
4. Occupational/ Environmental Exposures 
Occupational/ Environmental Exposures are those typically (not always) man-made substances 
and radiations to which we are exposed in our jobs and larger environment.  It was divided into 
chemicals/ materials and physical/ mechanical, and the further divisions of these major 
categories are also shown.  This category is large, due mainly to the large numbers of 




chemicals, materials, and radiation types. 
4A. Chemicals/ Materials 
4A1. Industrial/ Household Chemicals/ Materials 
This particular sub-category (which includes hydrocarbons, solvents, other chemical 
compounds, etc) is broad. 
Hydrocarbons include polycyclic aromatic hydrocarbons, dibenzo[a,e]fluoranthene, 1,2-
benzoanthracene, phenanthrene, naphthalene, naphthalene and dimethyl Sulfoxide, styrene, JP-
8/Jet Fuel, polychlorinated biphenyls (PCBs), and tetrachlorodibenzo-p-dioxin. 
Solvents include 3,4-dimethyl-2,5-hexanedione and brominated trihalomethanes.  
Chemical Compounds include carbon monoxide, carbon tetrachloride, 1,2-naphthoquinone, 
boron hydride disulfide, dimethyl sulfoxide, ethylene oxide, Formaldehyde, formaldehyde-
methanol, paraformaldehyde H2O2, nitric oxide, nitrocompounds, nitrogen oxides, nitrates, 
organic nitrate explosives, oxygen, sodium iodate, TNT, selenite, and sulfur dioxide.  
'Other' includes paraphenylenediamine, arsenic, ionomycin, calcium ionophore, CA2++, 
alloxan, 4-diethylaminoethoxy-alpha-ethyl-benzhydrol/ RGH-6201, ethylnitrosourea, 
methylnitrosourea, N-methyl-N-nitrosourea, glutaraldehyde, hair dyes, N-butyl-N-(4-
hydroxybutyl)-nitrosamine, Peroxynitrite, S-(1,2-dichlorovinyl)-L-cysteine/ (DCVC), silica, 
guanidinium chloride, chlorophenates, mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), 
mono(2-ethyl-5-oxohexyl) phthalate (MEOHP), brominated flame retardants, and bisphenol 
A, p,p'-DDE. 
4A2. Agricultural Chemicals 
This sub-category (pesticides, herbicides, insecticides, etc) includes triazin-derivative, methyl 
isocyanate, diamide, aminotriazole, 3-aminotriazole and carbon tetrachloride, 3-aminotriazole 
and light, diquat, juglone, mirex, and paraquat.  It impacts the larger population through the 
food supply, and has devastating effects on the agricultural workforce. 
A3. Materials 
The materials/ particulates sub-category includes heavy metals, particulates, etc 
'Heavy metals' includes gold, cadmium, lead, mercury, methylmercury, palladium, plutonium, 
iron, and nickel. 
'Particulates' includes smoke, solid fuel in unflued indoor stoves, biomass fuel smoke, biomass 
fuels, biomass stoves, diesel exhaust, exposure to fire and dust per day, cheap cooking fuels, 
indoor biofuel exposure, kerosene cookstoves, rice straw fuels, wood fuel, and urban residence. 
The materials that constitute this category are broadly-based, and in many cases have become 




part of the average lifestyle. 
4B. Physical/ Mechanical 
The main components of this sub-category, the different forms of radiation and other physical 
phenomena in the environment (electromagnetic [ionizing, non-ionizing, visible, non-visible], 
sound, high temperature, low temperature, high pressure, high force, physical trauma) are 
ubiquitous. Avoiding exposure to these emissions would require a change in lifestyle for most 
people. 
4B1. Electromagnetic Radiation 
Ionizing radiation includes radioactive air pollution, particle radiation, particulate radiation, 
chernobyl nuclear accident, cobalt radioisotopes, cobalt-60, cosmic radiation, gamma ray, 
heavy ions, nuclear reactors, nuclear warfare, actinide radiation, alpha particles radiation, CNS 
radiation, cranial radiation, helium ion radiation, high-let radiation, infrared radiation, radiation 
injuries, x-rays, space radiation, TBI radiation, total cranium radiation, radioactive pollutants, 
radioisotopes, radium, radon, uranium, RA224/RA-224/radium-224 radiation, proton radiation, 
protons, RU-106 radiation, PD-103 radiation, and neutron radiation. 
Non-Ionizing radiation includes microwaves and mobile phone base station. 
Non-Visible radiation includes uvr, uvr 300nm, uvr-b, uv, uva, uvb, sunlight, photosensitizing 
agents and sun exposure, puva, p-uva, uvb and l-buthionine sulfoximine, and solar radiation. 
Visible radiation includes blue light, diode-laser, light, light artificial, shorter wavelengths-
environmental lighting, riboflavin and exposure to daylight fluorescent lamps, photons, photo-
oxidation, laser, welding. 
'Other' includes electric, electrical injuries, electricity, electrocution, and lightning. 
4B2. Sound includes noise. 
4B3. Temperature includes burn, heat, high temperature, hot temperature, thermal, and cold. 
4B4. Force/ Pressure/ Physical Trauma includes mechanical stress, ocular compression, and 
traumatic. 
4B5. 'Other' includes altitude and latitude. 
5. Psychosocial/ Socioeconomic 
Psychosocial/ Socioeconomic are those causes that reflect personal problems, social 
interactions, larger societal interactions, and economic relationships. This category includes 
low education, low socioeconomic status, nonprofessional occupation, social class, low 
income, and poverty.  The causes in this category are proxy causes for the more immediate 
causes such as poor diet and adverse environmental/ occupational exposures.  Low income/ 




low education are associated with poor diet, occupations with adverse exposures, and 
residences in higher adverse exposure neighborhoods. 
 
 
5C2e. Discussion of Taxonomy Results 
 Approximately 500 direct foundational causes and 25 indirect foundational causes of 
cataracts were identified.  Given the streamlined nature of the query, there may be more direct 
causes (probably relatively rare) remaining to be identified, and many more indirect causes 
remaining to be identified. 
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5C2g. Appendices to Chapter 5 
Appendix 5-1  Cataract Indirect Causes - Validated 
CAUSE LINK 
2-Deoxy-D-ribose PROTEIN AGGREGATION 
6-Hydroxydopamine PROTEIN AGGREGATION 
JP-8/Jet Fuel PROTEIN AGGREGATION 
dibenzo[a,e]fluoranthene PROTEIN AGGREGATION 





brominated trihalomethanes DIABETES 
mono(2-ethyl-5-hydroxyhexyl) phthalate/(MEHHP) DIABETES 
mono(2-ethyl-5-oxohexyl) phthalate/ (MEOHP) DIABETES 
pancreaticoduodenectomy DIABETES 
Clomipramine DIABETES 
polychlorinated biphenyls/PCBs DIABETES 
basiliximab DIABETES 
polyinosinic:polycytidylic acid DIABETES 
noise DIABETES 
Splenectomy DIABETES 
brominated flame retardants DIABETES 
tetrachlorodibenzo-p-dioxin/TCDD DIABETES 
bisphenol A DIABETES 
p,p'-DDE DIABETES 
  




Appendix 5-2  Drugs and Drug Classes Identified 
2A1. Antineoplastic Agents 
chemotherapy; antineoplastic combined chemotherapy protocols; vincristine sulfate; tamoxifen; 
PARP inhibitors; 3-Aminobenzamide; nitroaspirin; mitomycin C; methylglyoxal; methotrexate; 
buthionine sulfoximine; iodoacetic acid; Interferon-alpha; Imatinib; hydroxyurea; H-89; 
doxorubicin; cytostatics; Cyclophosphamide; buthionine sulfoximine; busulphan; busulfan; 
bleomycin; ara C; 1-beta-D-arabinofuranosyl-cytosine/ 1-beta-D-arabinofuranosylcytosine; 
antimetabolites; antiestrogen; Androgen deprivation therapy; 5-fluorouracil; streptozotocin; 
2A2. Anti-Infective Agents 
-Anti-Bacterial Agents/ Anti-Fungal Agents/ Anti-Parasite Agents 
antimalarial agents; valinomycin; tetracyclines; propamidine isethionate; plumbagin; hyperbaric 
oxygen therapy; nigericin; Naphthoquinone; mepacrine; hygromycin B; erythromycin; 
disophenol; daptomycin; CJ-13,454; chloroquine; chlorhexidine; Calcimycin; 2,6-diiodo-4-
nitrophenol; 
-Antiviral/ Antiretroviral Agents  
Ribavirin; Pegylated interferon; HAART; ganciclovir implantation; dibenzyl derivatives; 
Amantadine; indinavir; saquinavir; stavudine; didanosine 
2A3. Anti-Inflammatory Agents 
ibuprofen; gout medication; gamma secretase modulator; E2012; colchicine; CJ-12,918; 
allopurinol; 
2A4. Cardiovascular Agents 
ouabain; isosorbide; calmidazolium; beta-blocker; amiodarone; adrenaline; 
2A5. Central Nervous System Agents 
-Analgesics and Pain Relievers 
xylazine; N-acetyl-p-benzoquinone imine; ketamine-xylazine; Chloral hydrate; benzodiazepams; 
aspirin long-term; Acetaminophen; 
-Depressants/ Antidepressants and Stimulants 
venlafaxine; tricyclic antidepressants; tranquilizers; selective/serotonin reuptake inhibitors; 
Ritalin; phenylpiperazine; phenobarbital; paroxetine; monoamine oxidase inhibitors; 
Methylphenidate; iprindole; fluvoxamine; amitriptyline; Clomipramine; 
-Mood Stabilizers 




antipsychotic agents; anti-epileptic drugs; anticonvulsants; ziprasidone; trifluoperazine; 
thioxanthenes; quetiapine; prochlorperazine; phenytoin; phenothiazines; phenothiazine 
derivatives; perphenazine; olanzapine; Methotrimeprazine; dilantin; Dibenzothiazepines; 
diazepam; Chlorpromazine; Carbamazepine; butyrophenols; 
-Neurotransmitters 
2A6. Immunologic Factors 
-Immunosuppressive Agents/ Immunosuppression 
tacrolimus; Prednisone; prednisolone; Mycophenolic Acid; Immunosuppressive Agents; 
Cyclosporin; Azathioprine/ Azathioprin; basiliximab; 
-Immunostimulation Agents 
Concanavalin A; polyinosinic:polycytidylic acid; 







2A8. Steroids/ Hormones 
-Steroids/Hormones 
testosterone; pregnadienes; megestrol acetate; hydroxyprogesterones; hormone replacement 
therapy; estrogens; estradiol; dexamethasone; desoxycorticosterone; cortisone; budesonide; 
androstadienes; androgens; aldosterone; adrenocorticotropic hormone/ ACTH; 
-Corticosteroids/glucocorticoids 
triamcinolone; Triamcinolone Acetonide; triamcinolone AND photodynamic therapy; systemic 
cortical steroids; solumedrol; Pregnenediones; Methylprednisolone Hemisuccinate; 
Methylprednisolone; Hydrocortisone; cortisol; corticosteroid; glucocorticoids; Fluorometholone; 
fluocortolone; Fluocinolone Acetonide; fludrocortisone acetate; dexamethasone phosphate; 
dermocorticosteroids; deflazacort; Decadron; Cortodoxone; Betamethasone; beclomethasone 
dipropionate; Beclomethasone; 17-alpha-Hydroxyprogesterone 




2A9. Antihypertensive Agents 
timolol; spironolactone; potassium-sparing diuretics; diuretics; Pilocarpine; PD 78787; 
nifedipine; indapamide; furosemide; calcium channel blockers; 3-[4-[4-(3-methylphenyl)-1-
piperazinyl]butyl]-2,4-imidazolinedione; 
2A10. Gastrointestinal Agents 
SDZ ICT 322 
2A11. Lipid Regulating Agents 
3-beta(2-diethylaminoethoxy) androst-5-en-17-one hydrochloride/ 3 beta-(2-
diethylaminoethoxy)- androst-5-en-17-oneHCl/ U18666A; triparanol; lovastatin; simvastatin; 
statins; 
2A12. Dermatologic Agents 
Nicotinamide; methoxypsoralen/ methoxsalen/ 8-MOP; isotretinoin; 
2A13. Vaccines/Vaccination 
rubella vaccination; 
2A14. Anti-Bone-Loss Agents 
2A15. Antidiabetic Agents 
oral hypoglycemic agents; NVS001; sulfamides; PPARgamma agonist; PPARdelta agonist; 
insulin; Ciglitazone; 
2A16. Antirheumatic Agents 
2A17. Anti-Allergic Agents 
Epinephrine; 
2A18. Anti-Hypotensive Agents 
2A19. Antithyroid Agents 
thyroid hormones; 
2A20. Antiemetic Agents 
RG 12915; 5-HT3 antagonist; 
2A21. Ocular Agents 
myotics; Miochol; Echothiophate iodide/ Echothiophate; 




2A22. Urological/Renal Agents 
Finasteride; Cysteamine; 
2A23. Other 
chlorphentermine; oral contraceptives; 




Appendix 5-3  Surgeries And Invasive Treatments Identified 
2C. Surgery; Invasive Treatments 
The following categorization is not unique.  Some procedures could be assigned to multiple 
categories. 
2C1. Transplantation 
transplantation; transplantation conditioning; stem cell transplantation; solid organ transplants; 
renal transplantation; kidney transplantation; bone marrow transplantation; corneal 
transplantation; pancreas transplantation; 
2C2. CardioVascular  
2C3. Gastrointestinal  
2C4. Kidney/Urologic  
Propecia; renal dialysis; hemodialysis;  
2C5. Brain/Neural  
mannitol;  
2C6. Orthopedic  
orthopedic surgery;  
2C7. Dental/ Oral/ Nose/ Ear 
2C8. Gynecologic  
surgical menopause; hysterectomy; ovariectomy;  
2C9. Respiratory/Thorax  
2C10. Liver/Spleen  
Splenectomy 
2C11. Ocular  
photodynamic therapy; photochemotherapy; trabeculectomy-air; trabeculectomy; trabeculectomy 
with mitomycin c; sulfur hexafluoride; vitrectomy; silicone; silicone lens; silicone oil; 
perfluorohexyloctane; retinal attachment surgery; keratoplasty; laser coagulation; laser corneal 
surgery; laser epilation; laser iridectomy; laser iridotomy; laser photoablation; laser 
photocoagulation; laser therapy; lasik; lens implanatation; lens implementation; penetrating 
keratoplasty; photorefractive keratectomy; radial keratotomy; glaucoma surgery; 




2C12. Breast  
2C13. Dermal/Tissue/Neck  
2C14. Thyroid  
thyroidectomy; 
2C15. Pancreas  
pancreaticoduodenectomy;  
2C16. General Procedures  
2C17. Other  
hyperbaric oxygen therapy; 
 






6A. LRDI Background 
 LRDI [1-3] is a text mining approach that  
a) integrates discovery generation from disparate literatures with the wealth of knowledge 
contained in prior art to  
b) potentially prevent and reverse chronic and infectious diseases [4-12] and 
c) potentially solve technical problems that appear intractable [13].   
The LRDI discovery component operates by linking two or more literature concepts that have not 
been linked heretofore (i.e., disjoint) in order to produce novel, interesting, plausible, and 
intelligible knowledge (i.e., potential discovery).  The disjoint literatures can be linked by 
matching of common text [7] and/ or common references [9] and/ or other common features.  
The LRDI innovation component reflects the potential improvement of present practice or 
exploitation of dormant but promising prior discovery.  The present book uses LRDI discovery 
and innovation components to identify direct (Innovation) and indirect (Discovery) foundational 
causes of large numbers of diseases and symptoms. 
 LRDI's main focus has been medical applications.  A comprehensive review of published 
LRDI techniques [1,14-15] concluded that none (except for the author's; e.g. [7]) generated 
actual discovery; most generated innovation.  Additionally, most were focused on finding 
treatments rather than finding and eliminating foundational causes.  The author's systemic and 
integrative approach (in the present LRDI incarnation) gives equal weight to discovery (and 
innovation) of causes and treatments.  The treatments cover the total system as well as specific 
organs and sub-systems.  A review of the LRDI literature shows LRDI applications to single 
diseases, focused on identifying discovery in treatments.  A review of the larger medical 
literature shows that no study, LRDI or otherwise, examines the breadth of causes, diseases, and 
symptoms shown in the present book. 
 There have been six generations of LRDI to date.  The first two generations (2004-2009) 
tended to use combinations of biomedical terms and classes of potential solutions of interest in 
the queries for identifying potential discovery treatments [4-7].  These early LRDI generations 
also included a Latent Semantic Analysis approach to help identify discoveries for alternative 
methods of water purification [13].  The background, methodology, and lessons learned from 
these first two LRDI generations were summarized in a Special Issue of Technology Forecasting 
and Social Change [1-2, 8]. 
 The first generation used combinations of query terms like ('protein oxidation' AND 
'plant extracts').  The second generation used more complex combinations like (('protein 
aggregates' AND 'Lewy bodies') AND 'plant extracts'), and examined large numbers of 
combinatorials as part of the query for potential discovery [4-7].  The third generation (2010) 




used more functional terms (e.g., 'inhibit viral entry'), and included adjacency operators (e.g., 
'inhibit' within five words of 'viral entry') that allowed application to full text [10]. The third 
generation was also the first of our LRDI studies to address infectious disease (SARS), and 
showed the LRDI approach was equally applicable to chronic and infectious diseases.  These 
first three LRDI generations restricted potential treatment discovery to non-drug approaches and 
substances. 
 The fourth generation (2011-2012) removed the restriction to non-drug discovery only, 
and allowed all types of discovery to be considered for potential treatments [11].  The fourth 
generation also allowed concepts to be linked through citations as well as text, and was the first 
of our LRDI studies to show the common features of very disparate diseases [9].  The fifth 
generation (2012-2013) used an enhanced version of the functional approach, removed all 
solution class restrictions, and gave equal weight to determining causes and treatments [12].  The 
evolution of LRDI, and the major study results, are described in more detail in a 2012 update [3], 
which the interested reader is advised to examine for more specifics.  The concept behind LRDI 
will be summarized now. 
 Discovery is ascertaining something previously unknown or unrecognized.  More 
formally, “Discovery in science is the generation of novel, interesting, plausible, and intelligible 
knowledge about the objects of study” [16].  It can result from uncovering previously unknown 
information, or synthesis of publicly available knowledge whose independent segments have 
never been combined, and/ or invention.  In turn, the discovery could derive from logical 
exploitation of a knowledge base, and/ or from spontaneous creativity (e.g., Edisonian 
discoveries from trial and error). [17].  Innovation reflects the metamorphosis from present 
practice to some new, hopefully “better” practice.  It can  
1) be based on existing non-implemented knowledge,  
2) follow discovery directly, or  
3) resuscitate dormant discovery that has languished for decades. 
 LRDI is a systematic approach to bridging unconnected disciplines based on text mining 
procedures.  LRDI allows potentially radical discovery to be hypothesized using either the 
technical literature alone, or the literature and its authors (e.g., text analysis followed by 
workshops or panels).  In the LRDI context, discovery is linking two or more literature concepts 
that have not been linked heretofore (i.e., disjoint), in order to produce novel, interesting, 
plausible, and intelligible knowledge.  Thus, simply linking two or more disparate concepts is a 
necessary, but not sufficient, condition for LRDI.  In particular, concepts may be disjoint because 
the value of their integration has not been recognized previously, or they may be disjoint because 
there appears to be little value in linking them formally. 
 There are two types of discovery approaches commonly used in LRDI: open discovery 
systems (ODS) and closed discovery systems (CDS).  In ODS, one starts with a problem and 
arrives at a solution; e.g., what are new potential treatments for cancer.  In CDS, one starts with a 
problem literature and a solution literature, or two problem literatures, and tries to understand the 




intermediate mechanisms that link the two literatures.  For example, what are the mechanisms 
through which drug X can treat breast cancer, or what are the mechanisms by which chemical Y 
can cause uterine cancer?  The main focus of the indirect foundational causes component of the 
present book is on LRDI ODS, since the goal is to identify potential foundational causes of 
disease. 
 There are two main LRDI methods for extrapolating knowledge and insights from one 
discipline/ technology to another: literature-based discovery (LBD) and literature-assisted 
discovery (LAD).  The LBD approach uses technical experts to access and examine the literature 
from ‘external’ disciplines to help solve problems in the ‘internal’ discipline.  The main LBD 
focus is finding potential discovery from literature analysis.  The LAD approach uses technical 
experts from ‘external’ disciplines in a variety of interactive and/ or independent creative modes 
for the same purpose.  The main LAD focus is using the literature’s authors to find potential 
discovery.  Combining LBD with LAD for full LRDI exploits the strengths of each while 
eliminating the weaknesses. 
 ODS LBD first surfaced in Swanson’s 1986 pioneering paper on potential treatments for 
Raynaud’s Phenomenon (RP).  The general theory behind Swanson’s ODS LBD approach, 
applied to two separate literatures, is based upon the following considerations [18]. 
 Assume that two  disjoint literatures can be generated, the first literature AB having a 
central theme A and sub-themes B, and the second literature BC having a central theme(s) B and 
sub-themes C.  Further assume that linkages can be generated through the B themes that connect 
both literatures (e.g., AB-->BC).  Those linkages that connect the disjoint components of the two 
literatures (e.g., the components of AB and BC whose intersection is zero) are candidates for 
discovery, since the disjoint themes C identified in literature BC could not have been obtained 
from reading literature AB alone. 
 One interesting ‘discovery’ from Swanson’s initial paper was that dietary 
eicosapentaenoic acid (theme A from literature AB) can decrease blood viscosity (theme B from 
both literatures AB and BC) and alleviate symptoms of RP (theme C from literature BC).  There 
was no mention of eicosapentaenoic acid in the RP literature, but the acid was linked to the 
disease through the blood viscosity themes in both literatures. 
 There have been many papers written since 1986 that could be categorized as ODS LBD, 
and many of them were examined critically in the author's ARIST paper [14].  ODS LBD has 
powerful capabilities intrinsically; given  
1) the large number of extant disparate medical/ technical disciplines and their literatures, and  
2) the number of possible connections among all these disciplines,  
there is much opportunity for potential discovery. 
 Unfortunately, the focus of almost all these past ODS LBD studies has been identification 
of potential treatments to eliminate symptoms, with almost no effort on identifying potential 
foundational causes that may be contributing to these symptoms.  This includes both 




foundational causes operating in isolation as well as foundational causes functioning as co-
promoters.  The present LRDI incarnation places equal emphasis on identifying foundational 
causes and treatments, and views one critically important component of treatments as the 
removal of foundational cause(s).  The present incarnation also places equal emphasis on 
discovery and innovation, and assigns primary importance to the integration of disparate 
knowledge from the core and non-core disease literatures. 
 Blake, in a comprehensive 2011 ARIST article on text mining, shows no advances in 
ODS LBD that would alter the author's ARIST conclusions [19].  Smalheiser [20] shows that the 
Swanson ABC model is only one of several different types of models that can contribute to the 
development of the next generation of literature-based discovery tools.  He emphasizes the need 
to develop a series of objective literature-based 'interestingness' measures, which can customize 
the output of these systems for different types of scientific investigations. 
 In the past decade, a number of semantic relation-based approaches have been 
promulgated.  Cohen et al [21] use semantic indexing to identify empirically sequences of 
relationships known as 'discovery patterns', such as "drug x INHIBITS substance y, substance y 
CAUSES disease z" that link pharmaceutical substances to diseases they are known to treat.  
These sequences are derived from semantic predications extracted from the biomedical literature, 
and subsequently utilized to direct the search for known treatments for a held out set of diseases.  
Hu et al [22] present a biomedical semantic-based association rule system that significantly 
reduces spurious/ useless/ biologically irrelevant connections (the B terms in the ABC approach) 
through semantic filtering.  Miller et al [23] advance the hypothesis of "cortisol as part of a 
mechanistic link elucidating the observed correlation between decreased testosterone in aging 
men and diminished sleep quality".  Hristovski et al [24] overview myriad approaches to 
literature-based discovery, emphasizing semantic relations, especially 'discovery patterns'.  The 
focus of these approaches is mainly potential treatments, and they achieve neither the breadth nor 
the volume of innovation and discovery of the author's approach. 




6B. Causes of Multiple Diseases Background 
(see Section 6C for definition of foundational causes) 
 There have been two generic types of approaches for identifying risk factors/ 
foundational causes for single or multiple diseases.  One is assembling large teams of people to 
collect/ analyze large amounts of data from which relations among foundational causes/ risk 
factors and diseases can be inferred.  The other is to examine data from myriad databases using 
automated/ semi-automated information technology approaches. 
 The best examples of the former are the Global Burden of Disease studies that have been 
performed over the past two decades, their analytical spinoffs [25-30], and related studies of 
more limited extent [31-35].  The value of these studies has been summarized well by Lopez 
[26], where he states in part: "Debates about health priorities are likely to be better informed if 
there is a reasonable understanding among policy makers of the comparative importance of 
various diseases and injuries in the population, at different ages, and how this pattern of health 
loss is changing over time.....the results can provide a meaningful accounting of the relative 
importance of different conditions in causing premature death and disability.....This was the basis 
for undertaking the first Global Burden of Disease (GBD) Study.....one might argue that health 
strategies and policies would be better served by a similarly complete and comparable 
understanding of the causes of various diseases and injuries, particularly those that account for 
substantial health loss in populations.....The challenge is how to adequately capture and quantify 
the full disease burden from risk factor exposures in a comprehensible and readily interpretable 
way so that policy discussions can be reliably informed by the outcomes, and thus respond 
appropriately.....Risk factor quantification is a powerful and compelling tool to support calls for 
policy action to improve health.....there is an urgent need to quantify important risks for major 
disease and injury outcomes not well covered by the current set of risk factors, including risks 
affecting mental health outcomes, and to expand the list of risk factors being investigated, 
including emerging environmental factors that are likely to significantly affect population 
health." 
 Examples of the information technology approaches include training neural networks to 
identify risk factors for specific diseases/ conditions [36-38], machine learning-based methods to 
quantify risk factors for diseases/ conditions [39-40], data based clustering and rule based 
prediction to identify risk factors for diseases/ conditions [41-42], Bayesian networks to identify 
risk factors [43-47], association rules to identify risk factors [48-49], decision trees to identify 
risk factors [50-54], and text/ data mining approaches [55-57].  Additionally, there is a 
substantial literature on information technology approaches for identifying adverse events 
resulting from drugs and surgery [58-70], a very limited sub-set of the total foundational causes 
addressed in this book. 
 Unfortunately, all the approaches based solely on searching the medical literature are 
severely limited in the depth and breadth of their output by the well-documented under-
reporting of adverse events stemming from foundational causes, only a small sample of which is 
referenced here [71-125].  Chapter 9 addresses some of the myriad reasons for this under-
reporting of adverse events and negative findings. 




 The information technology approaches for identifying risk factors typically address one 
disease, or a limited number of diseases, and some incorporate myriad sources of data to arrive at 
risk factors.  Both the Global Burden of Disease-type large-scale studies and the information 
technology approaches tend to include more than foundational causes in their typical risk factors. 
 This book concentrates solely on foundational causes, and identifies orders of magnitude 
more foundational causes/ risk factors than any of the above studies, albeit to less detail.  None 
of the above studies identifies indirect foundational causes.  This book identifies a few indirect 
foundational causes to illustrate the methodology, and shows that the present approach for 
identifying potential indirect causes has the capability to  
1) identify thousands, perhaps many thousands, of indirect foundational causes, and  
2) open up vast areas for biomedical research. 




6C. Foundational Cause - Definition 
  The myriad causes reported in this book are termed 'foundational'.  A foundational cause 
is a tangible stimulus or behavior that can contribute to a symptom.  Thus, excesses of calcium, 
water, exercise, drugs, environmental exposures, etc, can contribute to a symptom(s), and severe 
deficiencies of calcium, water, or exercise can also contribute to a symptom(s).  Abuse, poverty, 
educational status, etc, can contribute to symptoms as well, even though categorizations into 
excesses and deficiencies may be less applicable.  A foundational cause is defined as pervasive if 
it impacts at least a threshold number of myriad diseases. 
 A symptom(s)/ disease(s) is the result of imbalance between the strength of the toxic 
stimuli and the person's innate ability to neutralize the effects of the toxic stimuli, including the 
genetic factors that were not included in this book.  The two are not independent; the toxic 
stimuli can affect the capabilities of the defensive system to neutralize incoming toxic stimuli.  
Thus, the incoming toxic stimuli can be viewed as a 'signature' of individual toxic stimuli, with 
different weightings assigned to each toxic stimulus, and the defense can also be viewed as a 
'signature', with different weightings assigned to the health of the body's defensive mechanisms.  
Whether a symptom will materialize as a result of one or more toxic stimuli depends on whether 
the defensive 'signature' is able to neutralize the 'signature' of the incoming toxic stimuli. 
 Thus, not every person who eats a high-salt diet or undergoes radiocontrast diagnosis gets 
CKD, but some (more than expected randomly) do.  There were a number of cases in the 
literature where relatively few people were reported to have adverse reactions to a given toxic 
stimulus.  Identifying the offensive-defensive 'signature' relationships that allow toxic stimuli to 
translate into symptoms (within the context of understanding genetic polymorphisms and the 
resulting variations in biological pathways) will play a significant role in explaining why some 
people develop a disease and others do not when exposed to the same agent.  Understanding the 
complex web of gene-environment interactions is the central challenge of modern medicine; our 
identification of myriad individual toxic stimuli and defensive system deficiencies is the first 
step in this long journey. 
 For purposes of this book, we term a toxic stimulus a (foundational) cause if  
1) the research author stated/ implied/ inferred the toxic stimulus was a cause and  
2) the information presented supported the research author's conclusion.   
We recognize, however, that this toxic stimulus was in all probability one component of a more 
complex offensive-defensive 'signature' imbalance that resulted in the symptom of interest. 
 





DETAILED TEXT MINING METHODOLOGY 
7A. Methodology used to Retrieve Causes-Related Articles 
7A1. Identification of Foundational Causes of Disease 
 This book focuses on identifying 'all' direct and indirect foundational causes for 
thousands of diseases and symptoms.  It extrapolates, and significantly advances, the techniques 
used in our recent study on identifying foundational causes (and treatments) of a single disease, 
chronic kidney disease (CKD).  In the CKD study, approximately 900 direct and indirect causes 
of CKD were identified [12]. 
 The goal of this book is to develop a quasi-streamlined methodology for identifying the 
full spectrum of potential foundational causes of disease, and then relate these foundational 
causes to the full spectrum of diseases and symptoms.  Expanding queries developed in past 
studies (to identify foundational causes for single-diseases (such as [12])) to all diseases and 
symptoms is not practical because of the sheer magnitude of query terms required. 
 The first step in designing and developing a specific query for retrieving records is 
identifying the databases(s) and search engine(s) that will be used in the retrieval process, since 
the query format has to be tailored to the database and search engine characteristics.  Medline 
was selected as the database to be used, since it is the main repository of records from the 
premier biomedical journals.  Pubmed was selected as the source search engine for the Medline 
database rather than Thomson Medline (which was used in the CKD study [12]). 
 Much larger retrievals were expected for the studies in this book  relative to the CKD 
study because of the numbers of foundational causes and diseases expected.  In Pubmed, the full 
retrieval can be downloaded at once; in Thompson, only 500 records per download are allowed.  
When downloading hundreds of thousands of records (as was done in the present studies), 
download time becomes important.  Typically, ~600,000 records occupying ~2GB storage were 
imported from Pubmed in slightly over an hour for the present study. 
 Also, Pubmed introduces records at an earlier stage of processing.  For example, a search 
of Thomson Medline using the text term 'virus' in the Title for records published in 2014 (search 
performed on 19 May 2014) retrieved 3789 records, whereas a search of Pubmed on the same 
day with the same query retrieved 4951 records.  For the above reasons, and since the proximity 
search capability of Thomson Medline would not be used for this book, Pubmed was used as the 
data source. 
 Three approaches were used to develop queries for identifying foundational causes for all 
diseases: one highly streamlined, and two far less streamlined.  The highly streamlined approach 
used only MeSH Qualifiers to retrieve the records from Pubmed for analysis.  The first of the 
less streamlined approaches used generic MeSH terms (relatively unamibiguously related to 
foundational causes) to retrieve the records from Pubmed for analysis, and the second of the less 
streamlined approaches used text terms (applied to the Title field) to retrieve the records from 




Pubmed for analysis.  The results of all three approaches were integrated in the main body of the 
text to provide the final taxonomy for foundational causes (Chapters 3 and 8); the details of the 
three approaches follow. 
7A1a. MeSH Qualifiers Approach 
7A1a1. MeSH format causes 
 An offshoot of the MeSH Qualifier concept was used for identifying foundational causes.  
There are 83 topical MeSH Qualifiers used for indexing and cataloging in conjunction with 
MeSH Heading descriptors.  All 83 were examined in more or less detail for applicability to 
identifying foundational causes of disease.  Four were selected (after extensive validation) as 
producing highly relevant results when used in isolation: adverse effects, toxicity, 
pathogenicity, poisoning.  A few limited combinations of the remaining MeSH Qualifiers were 
examined, but none were deemed to have sufficient relevance.  These four MeSH Qualifiers 
selected constituted the query, and could also be viewed as linking terms for retrieving relevant 
foundational causes of disease. 
 This simplified query (consisting of four MeSH Qualifiers) was entered into Pubmed for 
the time interval 2004-2014.  On 10 May 2014, 592,074 records (all with Abstracts) were 
retrieved and downloaded, and were imported into the Vantage Point software used for the text 
analysis.  591,884 unique Abstracts were displayed by the software.  There were 595,730 MeSH 
terms (with MeSH Qualifiers) listed.  All MeSH terms that included at least one of the above 
four Qualifiers were placed in a separate group, containing a total of 116,538 MeSH terms with 
Qualifiers.  The software integrated over the MeSH Qualifiers to yield 9,038 MeSH Headings 
(no Qualifiers shown).  These MeSH Headings were the foundational causes for the 4,000+ 
diseases expressed in MeSH terminology. 
 It was desired to generate a causes-diseases/ symptoms matrix for display and analytic 
purposes.  Therefore, the diseases and symptoms needed to be identified and grouped.  A 
detailed examination of the remaining MeSH Qualifiers, and observation of MeSH Qualifier 
patterns in the records where foundational causes Qualifiers appeared, showed that the following 
MeSH Qualifiers tended to be associated with diseases and symptoms: etiology, chemically 
induced, complications, pathology, diagnosis, immunology, microbiology, parasitology, 
physiopathology, virology, epidemiology, radiation effects, metabolism, drug effects, prevention 
and control.  All MeSH terms that included at least one of the above fifteen MeSH Qualifiers 
were placed in a separate group, containing a total of 353,383 MeSH terms with Qualifiers.  The 
software integrated over the MeSH Qualifiers to yield 17,142 MeSH Headings (no Qualifiers 
shown). 
 However, this initial list went beyond diseases and symptoms, and required further 
filtering.  The National Institutes of Health (NIH) generates a Web site entitled MeSH Tree 
Structures (http://www.nlm.nih.gov/mesh/trees.html), which lists all the MeSH Headings in the 
different branches of the MeSH tree.  The MeSH Headings listed for all diseases and symptoms 
were downloaded and intersected with the above initial list of 17,142 MeSH Headings.  A 
perusal of this filtered list, compared with the unfiltered list, showed a number of items that were 




not listed in the NIH MeSH tree under one of the three categories, but, nevertheless, were 
impacted by the items listed as 'causes'.  For the most part, these additional items could be 
viewed as processes and mechanisms.  Therefore, the first 5,000 items in the list of 17,142 
MeSH Headings were inspected visually, and all those that could be impacted by the 'causes' 
were added to the filtered list.  Substantial sampling was performed to validate any selections in 
question.  The resulting list of 5,870 diseases and symptoms was inspected visually, and any 
terms that were not diseases or symptoms (typically biomarkers) were removed.  There were 
4,147 diseases in the final list. 
 It became clear at this point that two different matrices would be preferable for 
identifying  
1) direct foundational causes and  
2) indirect foundational causes.   
For identifying and tabulating direct foundational causes, a causes-diseases/ symptoms matrix 
would offer the most credibility.  For identifying indirect causes, a causes-diseases/ symptoms 
matrix linked to a diseases/ symptoms square matrix would be preferable, because foundational 
causes could then be linked to the disease(s) of interest through other diseases and symptoms that 
were closely related to the disease(s) of interest. 
 Thus, assume i is a direct cause of disease j1, and is not a direct cause of disease j2.  
Also, assume disease j1 is strongly related to disease j2.  Then, in the terminology of this book, i 
is assumed to be a potential indirect cause of disease j2, with the potential of being converted to 
a direct cause.  This latter assumption of potential conversion to direct cause would have to be 
validated by lab experiments and clinical trials; hence the potential of the indirect causes for 
opening up these vast additional areas of biomedical research to ascertain whether they can be 
shown to be direct causes! 
 In the MeSH Qualifiers causes-diseases-only matrix, there are 8046 foundational causes 
(MeSH terminology) and 4147 diseases (MeSH Headings No Explode).  Foundational causes 
that could be viewed as quasi-universal or pervasive are those that impacted more than a 
threshold number of diseases. 
 For identifying indirect foundational causes, two matrices sharing a common axis are 
plotted with this data.  The upper matrix is a square symmetrical matrix of diseases and 
symptoms (hereafter abbreviated as Diseases) on each axis.  The lower matrix is a plot of 
foundational causes vs Diseases.  The intersection of foundational cause i with Disease j is 
defined as a direct foundational cause of Disease j if the matrix cell contains an entry, and a 
potential indirect foundational cause if the matrix cell does not contain an entry. 
 To identify potential indirect foundational causes of Disease j, direct foundational causes 
of Diseases strongly associated with Disease j are identified, and hypothesized to be potential 
indirect foundational causes of Disease j.  Thus, for example, if Hypertension is shown to be 
strongly related to CKD, and substance X is a direct cause of Hypertension but not a direct cause 




of CKD, then substance X is hypothesized to be an indirect cause of CKD.  The stronger the 
relationship between the two Diseases, and the more strong pathways that exist linking other 
Diseases (for which substance X is a direct foundational cause) to CKD, the stronger is the basis 
for the assumption that substance X is a potential indirect foundational cause of CKD, and is in 
fact a Discovery in the Swanson sense of discovery [18] (heretofore applied only to potential 
treatments). 
 What constitutes a strong relationship/ association between two Diseases that would form 
a credible basis for hypothesizing potential discovery of indirect causes?  Two metrics were 
examined.  One metric was co-occurrence of two Disease MeSH terms well beyond that 
expected randomly.  Thus, if there are Nt total records in a database, then:  
1) the probability of MeSH term A occuring in any one record would be Na (the number of 
records that contain MeSH term A in the database) divided by Nt;  
2) the probability of MeSH term B occurring in any one record would be Nb/Nt;  
3) the probability of MeSH terms A and B co-occurring in one record by chance would be 
(Na/Nt)*(Nb/Nt); and,  
4) the co-occurrence expected by chance would be (Na/Nt)*(Nb/Nt)*Nt, or (Na*Nb)/Nt.   
Thus, if the actual co-occurrence Cab of two Disease MeSH terms A and B is substantially larger 
than (Na*Nb)/Nt, the linkage between Diseases A and B is assumed to be strong.  The higher the 
ratio of actual co-occurrence to expected co-occurrence, the stronger is the assumed relationship. 
 The other metric examined was the Inclusion Index based on the smaller of the two 
frequencies of occurrence, defined as Cab/MIN(Na,Nb).  Because of better behavior at the limits, 
the latter metric was selected for estimating the strength of the relationship between the two 
diseases A and B.  The Disease-Disease matrix was normalized using the Inclusion Index.  The 
combination of the foundational causes-Diseases matrix and the normalized Diseases-Diseases 
matrix formed a foundational causes-Diseases network, which allowed both direct foundational 
causes to be identified from the foundational causes-Diseases matrix and indirect foundational 
causes to be identified by tracking potential foundational causes through myriad pathways in the 
Diseases-Diseases component of the network. 
 Finally, while this MeSH Qualifier linking approach was developed for, and applied to, 
potential foundational causes, it can be easily modified for identifying potential treatments, 
identifying potential biomarkers, identifying potential mechanisms, etc. 
7A1a2. Chemical Registry Number Causes 
 Pubmed contains two fields called Registry Number and Substance Name.  Registry 
Number contains identifiers representing the substances mentioned in the article when such 
identifiers are included in the MeSH record for the substance.  Substance Name may contain any 
of three types of supplementary concept record (SCR) data:  




1) MeSH SCR chemical and drug terms (Class 1);  
2) protocol terms (Class 2); and  
3) non-MeSH rare disease terms (Class 3) from the National Institutes of Health (NIH) Office of 
Rare Diseases.   
The MeSH Database and MeSH Browser contain all of these terms. 
 These two fields are combined into one field in the VP software (Chemical Registry 
Number-CRN), and may contain foundational causes that are not shown in the Title or MeSH 
Heading fields.  This CRN field was examined for potential causes in the MeSH Qualifiers-
retrieved database only.  There were no associated linking terms in the CRN field that would 
allow extraction of foundational causes only, so the CRN terms had to be inspected visually.  
These CRN terms could be causes, treatments, and biomarkers mainly.  They were read to a pre-
selected cutoff frequency, and additional terms were identified at lower frequencies from 
intersection with externally-provided lists of toxic materials.  All 1,394 resulting CRN 
foundational causes terms were validated by visual inspection, and constituted the y-axis of the 
CRN foundational causes-Diseases matrix. 
7A1b. Generic MeSH Headings Approach 
 Generic MeSH Headings related relatively unambiguously to foundational causes were 
identified two ways.  Results from past studies were examined, especially the CKD study [12], 
and generic relevant MeSH Headings were extracted.  Second, a few of the most unambiguous 
generic MeSH terms identified from past studies were entered into Pubmed as query terms, and 
all the MeSH terms in the resultant retrieval (i.e., those that co-occurred with the entry terms) 
were examined for relevance.  There were 145 terms from both sources judged to produce highly 
relevant results (shown later).  These 145 terms constituted the generic MeSH Headings query 
for retrieving foundational causes of disease.  Pubmed was also used as the source search engine 
for the Medline database, for the reasons presented above. 
 This query was entered into Pubmed for the time interval 1994-2014.  On 18 October 
2014, 693,450 records (most with Abstracts) were retrieved and downloaded, and were imported 
into the Vantage Point software.  690,486 unique Abstracts were displayed by the software.  
There were 516,519 MeSH terms (mainly with, but some without, Qualifiers) listed, and 24,231 
Top Level MeSH Headings (Top Level MeSH Headings represent MeSH Headings that have 
been integrated over the MeSH Qualifiers).  In the remaining steps of the generic MeSH 
Headings approach, potential MeSH Headings from different sources are intersected with the 24, 
231 Top Level MeSH Headings, and integrated to arrive at the total foundational causes from 
generic MeSH Headings.  In addition, visual inspection of the highest frequency Top Level 
MeSH Headings was performed, to insure that no relevant MeSH Headings had been overlooked 
in the 'dot product' components of the process described above. 
 First, all MeSH terms that included at least one of the four Qualifiers shown in the 
previous MeSH Qualifiers section were placed in a separate group.  This group contained a total 




of 52,949 MeSH terms.  The software integrated over the MeSH Qualifiers to yield 6,543 MeSH 
Headings (no Qualifiers shown). 
 Second, the 9,038 MeSH Heading causes from the MeSH Qualifiers study in the previous 
MeSH Qualifiers section were imported.  Third, the 1,394 Chemical Registry Substances 
extracted in the MeSH Qualifiers study were imported.  Fourth, the 13,762 raw text causes 
extracted from the results of the Title text retrieval study of the next section were imported.   
 Then, these 6,543 MeSH Headings, combined with  
1) the 9,038 MeSH Heading causes from the MeSH Qualifiers study in the previous MeSH 
Qualifiers section,  
2) the 1,394 Chemical Registry Substances extracted in the MeSH Qualifiers study, and  
3) the 13,762 raw text causes extracted from the results of the Title text retrieval study of the 
next section,  
were intersected with the 24,231 Top Level MeSH Headings, to yield a total of 8,982 
foundational causes.  These were the foundational causes for 4,000+ diseases expressed in MeSH 
terminology from the relatively unambiguous MeSH Headings retrieval, and they constituted the 
y-axis of the Generic MeSH foundational causes-Diseases matrix. 
 Again, while this focused MeSH Heading approach was developed for identifying 
potential foundational causes, it could (with some work) be adapted to identifying potential 
treatments, potential biomarkers, potential mechanisms, etc. 
7A1c. Title Linking Phrases Approach 
 Because of limitations from use of MeSH terms (not all records have MeSH descriptors, 
not all MeSH terms are included in those records that have MeSH terms, not all MeSH 
descriptors used have appropriate Qualifiers attached. etc), a text-based approach for identifying 
causes was added.  While the Abstract field would have been most informative and appropriate, 
computer storage and software limitations would not allow the parsed Abstract field phrases to 
be opened.  Therefore, the record Title field was selected for analysis. 
 A query consisting of two components was used to retrieve the Pubmed records that had 
high probability of containing foundational causes.  The first component consisted of terms that, 
when they appeared in the Title, were associated with foundational causes in the Title relatively 
unambiguously.  These terms were validated a priori.  The second component consisted of terms 
that, when they co-occurred in the Title with disease names, were associated with foundational 
causes in the Title relatively unambiguously.  The full query used to retrieve records is shown 
later. 
 This query was entered into Pubmed for the time interval 1989-2014, 616,300 records 
(many with Abstracts) were retrieved and downloaded on 28 September 2014, and were 
imported into the Vantage Point software.  536,833 unique Abstracts were displayed by the 




software.  There were 5,452,563 Title phrases listed, which consisted of all single-word, double-
word, triple-word, and quadruple-word phrases that did not start or end with stop-words. 
 The foundational causes in the retrieved records were identified three ways.  First, the 
parsed Title phrases (arranged by inverse record frequency) were examined visually down to a 
threshold frequency, and foundational causes terms were extracted and validated.  Given the 
extremely large number of Title phrases, only a very small fraction could be examined visually. 
 Second, for lower frequency Title phrases, the strongest linking terms (e.g., -induced, -
related, -associated, -exposed, caused by, induced by, exposure to, exposed to, etc) were used to 
extract potential foundational causes phrases.  The extracted phrases were then stripped of the 
linking terms, combined to avoid duplication, and added to the foundational causes identified 
visually in the first part. 
 Finally, foundational causes from myriad other sources, including past studies, 
government-approved lists of toxic substances, MeSH-derived causes, and CRN-derived causes, 
were intersected with the full list of Title phrases, and added to the foundational causes identified 
in the first two parts. 
 There were 13,762 validated foundational causes that resulted from the above extraction 
techniques.  However, many reflected similar concepts, and could be combined using the VP 
software phrase combining capability.  After a three-step combination approach, 6,480 
foundational causes resulted, and they constituted the y-axis of the Title phrase foundational 
causes-diseases matrix.  Some were generic, but most were specific. 
 While the Title phrase linking terms were developed specifically for identifying causes, a 
similar approach could be used to develop linking terms for identifying potential treatments, 
potential biomarkers, or potential mechanisms.  Moreover, there could be substantial benefits 
gained by using Abstracts for phrase generation rather than Titles, and even full-text rather than 
Abstracts.  While use of proximity queries with the linking terms in the Title were not required, 
they would be required for use in Abstracts or full-text.  Adding proximity capability would be a 
minor modification to the form of the query developed below.  The major issue would be 
switching to a database search engine that had the capability of proximity searching. 




7B. Queries used to Retrieve Causes-Related Articles 
7B1. MeSH Qualifier Query 
 MeSH Headings have a number of Qualifiers associated with them to allow focus on 
items of interest.  Thus, the MeSH term Cadmium/ toxicity allows records to be retrieved related 
to the toxicity of Cadmium.  These MeSH Qualifiers may be perceived as linking terms to the 
MeSH Headings, allowing for 'surgical' extraction of MeSH Headings that meet desired criteria.  
Thus, if MeSH Qualifiers strongly related to foundational causes can be identified, they can be 
used to identify MeSH Headings that are potential foundational causes of disease.  As shown 
previously, the four MeSH Qualifiers listed below were selected as the query, and are presented 
in Pubmed format. 
Query 
adverse effects [sh] OR toxicity [sh] OR pathogenicity [sh] OR poisoning [sh] 
7B2. Title Text Term Query 
 Because many Medline records do not contain MeSH terms, and because MeSH term 
assignment may not always be complete, it was decided to augment the MeSH queries with a 
text query.  Due to computer and software limitations on storage and processing time, Titles 
were used as the text source rather than Abstracts or full-text. 
 This Title query consists of two parts: standalone terms, and terms that are intersected 
with diseases.  Most of these terms were derived by examining Titles of records that addressed 
foundational causes of disease, and selecting those terms that tended to appear frequently with 
the foundational causes.  The diseases used for the second group of terms were obtained by 
starting with Pubmed's list of all diseases (in MeSH terminology), converting them to text form, 
consolidating diseases to more generic descriptors, and adding some generic terms not in MeSH 
(such as cancer*). 
7B2a. Standalone Terms 
([ti] is the Pubmed tag for Title field) 
 cardiotoxic* [ti] OR genotoxic* [ti] OR hepatotoxic* [ti] OR immunotoxic* [ti] OR 
intoxicat* [ti] OR nephrotoxic* [ti] OR neurotoxic* [ti] OR ototoxic* [ti] OR phototoxic* [ti] 
OR phytotoxic* [ti] OR toxic-effect* [ti] OR toxic-potential* [ti] OR toxic-hazard* [ti] OR 
toxic-combin* [ti] OR toxicities [ti] OR toxicity [ti] OR toxicological-effect* [ti] OR 
toxicological-evaluation* [ti] OR toxicological-impact* [ti] OR toxicological-hazard* [ti] OR 
toxicological-assessment* [ti] OR toxin-associated [ti] OR toxin-related [ti] OR toxin-injur* [ti] 
OR toxin-risk* [ti] OR lethal-toxin* [ti] OR (toxin* [ti] AND (fatal* [ti] OR adverse [ti] OR 
morbid* [ti] OR mortality [ti] or anaphyla* [ti] OR harm [ti] OR damag* [ti] OR deteriorat* [ti] 
OR exacerbat* [ti] OR trigger* [ti] OR aggravat* [ti])) OR injury-associated [ti] OR risk-
associated [ti] OR virus-associated [ti] OR (Ionizing [ti] AND risk* [ti]) OR (risk-of [ti] AND 
adverse [ti]) OR (adverse-health-effect* [ti] AND (effects-of [ti] OR effect-of [ti])) OR adverse-




effect* [ti] OR injury-following [ti] OR related-consequences [ti] OR therapy-related [ti] OR 
traffic-related [ti] OR health-consequences [ti] OR long-term consequences [ti] OR anaphylactic-
reaction* [ti] OR cutaneous-reaction* [ti] OR hypersensitivity-reaction* [ti] OR transfusion-
reaction* [ti] OR skin-reaction* [ti] OR inflammation-reaction* [ti] OR inflammatory-reaction* 
[ti] OR reaction-associated [ti] OR foreign-body-reaction* [ti] OR tissue-reaction* [ti] OR 
infusion-reaction* [ti] OR systemic-reaction* [ti] OR (allergic [ti] AND reaction-to [ti]) OR 
teratogenicity [ti] OR teratogenic-effect* [ti] OR advanced-glycation [ti] OR allergenicity [ti] 
OR bioaccumulation [ti] OR carcinogen [ti] OR Carcinogenic [ti] OR carcinogenicity [ti] OR 
contaminat* [ti] OR disrupting-chemical* [ti] OR ((effects [ti] OR effect [ti]) AND subchronic 
[ti]) OR ((effects-of [ti] OR effect-of [ti]) AND prenatal [ti]) OR envenomation [ti] OR fatalities 
[ti] OR high-fat [ti] OR mutagenicity [ti] OR poisons [ti] OR poisoning [ti] OR precipitated-by 
[ti] OR precipitated-after [ti] OR precipitated-following [ti] OR side-effect* [ti] OR teratogenesis 
[ti] OR deleterious-effect* [ti] OR detrimental-effect* [ti] OR late-effect* [ti] OR adverse-
metabolic-effect* [ti] OR adverse-renal-effect* [ti] OR respiratory-effect* [ti] OR negative-
effect* [ti] OR adverse-reaction* [ti] OR (adversity [ti] AND (early [ti] OR child* [ti] OR life* 
[ti] OR social [ti] OR family [ti])) OR causative-agent [ti] OR caused-by [ti] OR exposure-to [ti] 
OR exposed-to [ti] OR exposures [ti] OR (damage-in [ti] AND mice [ti]) OR (damage-in [ti] 
AND rats [ti]) OR hepatic-damage [ti] OR liver-damage [ti] OR ((increased-risk* [ti] OR 
complications [ti] OR mutagenic [ti] OR adverse-outcome* [ti] OR life-threatening [ti] OR lung-
injury [ti] OR renal-injury [ti] OR susceptibility [ti] OR adverse [ti] OR allergic-reaction* [ti] 
OR anaphyla* [ti] OR cognitive-dysfunction [ti] OR cardiac-dysfunction [ti] OR (dysfunction 
[ti] AND in-rats [ti]) OR erectile-dysfunction [ti] OR renal-dysfunction [ti] OR mitochondrial-
dysfunction [ti] OR endothelial-dysfunction [ti] OR sexual-dysfunction [ti] OR ventricular-
dysfunction [ti] OR allograft-dysfunction [ti] OR thyroid-dysfunction [ti] OR graft-dysfunction 
[ti] OR liver-dysfunction [ti] OR diastolic-dysfunction [ti] OR vascular-dysfunction [ti] OR 
organ-dysfunction [ti] OR barrier-dysfunction [ti] OR myocardial-dysfunction [ti] OR systolic-
dysfunction [ti] OR voiding-dysfunction [ti] OR hepatic-dysfunction [ti] OR bladder-dysfunction 
[ti] OR bowel-dysfunction [ti] OR urinary-dysfunction [ti] OR swallowing-dysfunction [ti] OR 
anorectal-dysfunction [ti] OR cardiopulmonary-dysfunction [ti] OR fatal [ti] OR fibrosis [ti] OR 
high-incidence [ti] OR iatrogenic [ti] OR mortality [ti] OR morbidity [ti] OR risk* [ti]) AND 
(after [ti] OR following [ti] OR related-to [ti] OR resulting-from [ti] OR due-to [ti])) 
7B2b. Intersect with Diseases 
 (Expos* [ti] OR induce [ti] OR induced [ti] OR induces [ti] OR incarceration [ti] OR 
occupation* [ti] OR pathogen* [ti] OR pollut* [ti] OR poverty [ti] OR socioeconomic [ti] OR 
worker*) AND (Abdominal-Pregnancy [ti] OR Aberrant-Crypt-Foci [ti] OR Abnormal-
Karyotype [ti] OR Abnormal-Reflex [ti] OR Abnormalities [ti] OR Abnormality [ti] OR 
Abortion [ti] OR Abruptio-Placentae [ti] OR Abscess* [ti] OR Acalculous-Cholecystitis [ti] OR 
Acanthamoeba-Keratitis [ti] OR Acantholysis [ti] OR Acanthosis-Nigricans [ti] OR Acatalasia 
[ti] OR Accelerated-Idioventricular-Rhythm [ti] OR Accessory-Atrioventricular-Bundle [ti] OR 
Achlorhydria [ti] OR Achondroplasia [ti] OR Acid-Base-Imbalance* [ti] OR Acidosis [ti] OR 
Acne-Keloid [ti] OR Acne-Vulgaris [ti] OR Acrocephalosyndactylia [ti] OR Acrodermatitis [ti] 
OR Acrodynia [ti] OR Acromegaly [ti] OR Acro-Osteolysis [ti] OR Acrospiroma [ti] OR 
Actinomycosis [ti] OR Activated-Protein-C-Resistance [ti] OR Acute-Abdomen [ti] OR Acute-




Generalized-Exanthematous-Pustulosis [ti] OR Acute-Kidney-Injury [ti] OR Acute-Lung-Injury 
[ti] OR Acute-Phase-Reaction [ti] OR Adenocarcinoma* [ti] OR Adenofibroma [ti] OR 
Adenolymphoma [ti] OR Adenoma* [ti] OR Adenomyoma [ti] OR Adenomyosis [ti] OR 
Adenosarcoma [ti] OR Adiposis-Dolorosa [ti] OR Adrenal-Insufficiency [ti] OR Adrenocortical-
Hyperfunction [ti] OR Adrenoleukodystrophy [ti] OR Aerophagy [ti] OR Afibrinogenemia [ti] 
OR African-Horse-Sickness [ti] OR Agammaglobulinemia [ti] OR Agenesis-of-Corpus-
Callosum [ti] OR Ageusia [ti] OR Aggressive-Periodontitis [ti] OR Agnosia [ti] OR 
Agranulocytosis [ti] OR Agraphia [ti] OR AIDS-Arteritis [ti] OR AIDS-Dementia-Complex [ti] 
OR AIDS-Related-Complex [ti] OR Airway-Obstruction* [ti] OR Airway-Remodeling [ti] OR 
Akathisia [ti] OR Akinetic-Mutism [ti] OR Albinism [ti] OR Albuminuria [ti] OR Alcohol-
Withdrawal-Delirium [ti] OR Alcohol-Withdrawal-Seizures [ti] OR Alcoholism [ti] OR Alexia 
[ti] OR Alkalosis [ti] OR Alkaptonuria [ti] OR Alopecia [ti] OR alpha-1-Antitrypsin-Deficiency 
[ti] OR alpha-Mannosidosis [ti] OR alpha-Thalassemia [ti] OR Alternariosis [ti] OR Altitude-
Sickness [ti] OR Alveolar-Bone-Loss [ti] OR Alveolitis [ti] OR Amaurosis-Fugax [ti] OR 
Amblyopia [ti] OR Amebiasis [ti] OR Ameloblastoma [ti] OR Amelogenesis-Imperfecta [ti] OR 
Amenorrhea [ti] OR Amino-Acid-Metabolism [ti] OR Amnesia [ti] OR amyloid-Plaque [ti] OR 
Amyloidosis [ti] OR Anaemia [ti] OR Anaphylaxis [ti] OR Anaplasia [ti] OR Anaplasmosis [ti] 
OR Anastomotic-Leak [ti] OR Ancylostomiasis [ti] OR Anemia [ti] OR Anencephaly [ti] OR 
Anetoderma [ti] OR Aneurysm [ti] OR Angina [ti] OR Angiodysplasia [ti] OR Angioedema* [ti] 
OR Angiofibroma [ti] OR Angioid-Streaks [ti] OR Angiokeratoma [ti] OR Angiolipoma [ti] OR 
Angiomatosis [ti] OR Angiomyolipoma [ti] OR Anhedonia [ti] OR Aniridia [ti] OR Anisakiasis 
[ti] OR Aniseikonia [ti] OR Anisocoria [ti] OR Anisometropia [ti] OR Ankylosis [ti] OR 
Anodontia [ti] OR Anomia [ti] OR Anophthalmos [ti] OR Anorexia [ti] OR Anovulation [ti] OR 
Anoxia [ti] OR Anthracosilicosis [ti] OR Anthracosis [ti] OR Anthrax [ti] OR Antithrombin-III-
Deficiency [ti] OR Anuria [ti] OR Aortic-Coarctation [ti] OR Aortic-Valve-Insufficiency [ti] OR 
Aortic-Valve-Prolapse [ti] OR Aortitis [ti] OR Aphakia [ti] OR Aphasia [ti] OR Aphonia [ti] OR 
Aplasia [ti] OR Apnea [ti] OR Apoptosis [ti] OR Appendicitis [ti] OR Apraxia [ti] OR Apraxias 
[ti] OR Arachnoid-Cyst* [ti] OR Arachnoiditis [ti] OR Arcus-Senilis [ti] OR Argininosuccinic-
Aciduria [ti] OR Argyria [ti] OR Arnold-Chiari-Malformation [ti] OR Arrhythmia* [ti] OR 
Arterial-Stiffness [ti] OR Arterio-Arterial-Fistula [ti] OR Arteriolosclerosis [ti] OR 
Arteriosclerosis [ti] OR Arteriovenous-Fistula [ti] OR Arteriovenous-Malformations [ti] OR 
Arteritis [ti] OR Arthralgia [ti] OR Arthritis [ti] OR Arthrogryposis [ti] OR Arthropathy [ti] OR 
Arthus-Reaction [ti] OR Artificial-Lens-Implant-Migration [ti] OR Asbestosis [ti] OR Ascariasis 
[ti] OR Ascaridiasis [ti] OR Ascites [ti] OR Ascorbic-Acid-Deficiency [ti] OR Aspergillosis [ti] 
OR Asphyxia [ti] OR Asthenia [ti] OR Asthenopia [ti] OR Asthenozoospermia [ti] OR Asthma 
[ti] OR Astigmatism [ti] OR Astrocytoma [ti] OR Ataxia [ti] OR Atherosclerosis [ti] OR 
atherosclerotic-plaque [ti] OR Athetosis [ti] OR Atrial-Fibrillation [ti] OR Atrial-Flutter [ti] OR 
Atrial-Premature-Complexes [ti] OR Atrial-Remodeling [ti] OR Atrioventricular-Block [ti] OR 
Atrophic-Vaginitis [ti] OR Atrophy [ti] OR Autolysis [ti] OR Autonomic-Dysreflexia [ti] OR 
Avian-Leukosis [ti] OR Avitaminosis [ti] OR Azoospermia [ti] OR Azotemia [ti] OR Babesiosis 
[ti] OR babinski-Reflex [ti] OR Bacteremia [ti] OR Bacteriuria [ti] OR Balanitis [ti] OR 
Balanitis-Xerotica-Obliterans [ti] OR Balantidiasis [ti] OR Barrett-Esophagus [ti] OR Bell-Palsy 
[ti] OR Bell's-Palsy [ti] OR Beriberi [ti] OR Berylliosis [ti] OR beta-Thalassemia [ti] OR Bile-
Reflux [ti] OR Biliary-Atresia [ti] OR Biliary-Dyskinesia [ti] OR Biliary-Fistula [ti] OR Binge-




Drinking [ti] OR Biotinidase-Deficiency [ti] OR Bird-Fancier's-Lung [ti] OR Birth-Injuries [ti] 
OR Birth-Weight [ti] OR Bladder-Exstrophy [ti] OR Blast-Crisis [ti] OR Blastomycosis [ti] OR 
Blepharitis [ti] OR Blepharoptosis [ti] OR Blepharospasm [ti] OR Blindness [ti] OR Blister* [ti] 
OR Blood-Group-Incompatibility [ti] OR Blood-Loss [ti] OR Bluetongue [ti] OR Body-Weight 
[ti] OR Bone-Anteversion [ti] OR Bone-Cysts [ti] OR Bone-Demineralization [ti] OR Bone-
Malalignment [ti] OR Bone-Resorption [ti] OR Bone-Retroversion [ti] OR Botulism [ti] OR 
Brachial-Plexus-Neuritis [ti] OR Brachydactyly [ti] OR Bradycardia [ti] OR Brain-Concussion 
[ti] OR Brain-Damage [ti] OR Brain-Death [ti] OR Brain-Injur* [ti] OR Brain-Ischemia [ti] OR 
Branchioma [ti] OR Breast-Cyst* [ti] OR Breech-Presentation [ti] OR Brenner-Tumor* [ti] OR 
Bronchial-Fistula [ti] OR Bronchial-Hyperreactivity [ti] OR Bronchial-Spasm [ti] OR 
Bronchiectasis [ti] OR Bronchiolitis [ti] OR Bronchitis [ti] OR Bronchogenic-Cyst* [ti] OR 
Bronchomalacia [ti] OR Bronchopneumonia [ti] OR Bronchopulmonary-Sequestration [ti] OR 
Brucellosis [ti] OR Bruxism [ti] OR Bulbar-Palsy [ti] OR Bulbo-Spinal-Atrophy [ti] OR Bulimia 
[ti] OR Bundle-Branch-Block [ti] OR Burkitt-Lymphoma [ti] OR Bursitis [ti] OR Buschke-
Lowenstein-Tumor* [ti] OR Byssinosis [ti] OR Cachexia [ti] OR CADASIL [ti] OR Cafe-au-
Lait-Spots [ti] OR Calcification [ti] OR Calcinosis [ti] OR Calciphylaxis [ti] OR Calculi [ti] OR 
Callosities [ti] OR Cancer* [ti] OR Candidemia [ti] OR Candidiasis [ti] OR Capsule-
Opacification [ti] OR Carbohydrate-Metabolism [ti] OR Carbonyl-Stress [ti] OR 
Carboxymethyllysine [ti] OR Carcinogenesis [ti] OR Carcinoid-Tumor* [ti] OR Carcinoma* [ti] 
OR Carcinosarcoma* [ti] OR Cardiac-Arrest [ti] OR Cardiac-Complexes [ti] OR Cardiac-Output 
[ti] OR Cardiac-Tamponade [ti] OR Cardiogenic-Shock [ti] OR Cardiomegaly [ti] OR 
Cardiomyopath* [ti] OR cardiovascular-health [ti] OR cardiovascular-outcome* [ti] OR 
cardiovascular-risk [ti] OR Carney-Complex [ti] OR Carotid-Artery-Dissection [ti] OR Carotid-
Artery-Injuries [ti] OR Carotid-Body-Tumor* [ti] OR Carotid-Cavernous-Sinus-Fistula [ti] OR 
Catalepsy [ti] OR Cataplexy [ti] OR Cataract* [ti] OR Catatonia [ti] OR Causalgia [ti] OR 
Cellulitis [ti] OR Central-Nervous-System-Cyst* [ti] OR Central-Nervous-System-Helminthiasis 
[ti] OR Central-Nervous-System-Vascular-Malformation* [ti] OR Central-Serous-
Chorioretinopathy [ti] OR Cephalopelvic-Disproportion [ti] OR Cerebellar-Ataxia [ti] OR 
Cerebral-Amyloid-Angiopathy [ti] OR Cerebral-Palsy [ti] OR Cerebral-Phaeohyphomycosis [ti] 
OR Cerebral-Ventriculitis [ti] OR Cerebrospinal-Fluid-Otorrhea [ti] OR Cerebrospinal-Fluid-
Rhinorrhea [ti] OR Cerebrovascular-Trauma [ti] OR Cervical-Intraepithelial-Neoplasia [ti] OR 
Chagas-Cardiomyopathy [ti] OR Chalazion [ti] OR Chancre [ti] OR Chancroid [ti] OR 
Channelopathies [ti] OR Cheilitis [ti] OR Cheyne-Stokes-Respiration [ti] OR Chickenpox [ti] 
OR Chills [ti] OR Chloracne [ti] OR Choanal-Atresia [ti] OR Cholangiocarcinoma [ti] OR 
Cholangitis [ti] OR Cholecystitis [ti] OR Cholecystolithiasis [ti] OR Choledochal-Cyst* [ti] OR 
Choledocholithiasis [ti] OR Cholelithiasis [ti] OR Cholera [ti] OR Cholestasis [ti] OR 
Cholesteatoma [ti] OR Choline-Deficiency [ti] OR Chondroblastoma [ti] OR Chondrocalcinosis 
[ti] OR Chondrodysplasia-Punctata [ti] OR Chondroma [ti] OR Chondromalacia-Patellae [ti] OR 
Chondrosarcoma [ti] OR Chordoma [ti] OR Chorea [ti] OR Chorioamnionitis [ti] OR 
Choriocarcinoma [ti] OR Chorioretinitis [ti] OR Choristoma [ti] OR Choroidal-
Neovascularization [ti] OR Choroiditis [ti] OR Chromoblastomycosis [ti] OR Chromosomal-
Instability [ti] OR Chromosome-Aberration* [ti] OR Chromosome-Breakage [ti] OR 
Chromosome-Fragility [ti] OR Chromosome-Inversion [ti] OR Chylothorax [ti] OR Chylous-
Ascites [ti] OR Cicatrix [ti] OR Citrullinemia [ti] OR Cleft-Lip [ti] OR Cleft-Palate [ti] OR 




Clonorchiasis [ti] OR Clubfoot [ti] OR Cluster-Headache* [ti] OR Coccidioidomycosis [ti] OR 
Coccidiosis [ti] OR Colic [ti] OR Colitis [ti] OR Collagenous-Sprue [ti] OR Colloid-Cysts [ti] 
OR Coloboma [ti] OR Colonic-Polyps [ti] OR Colonic-Pseudo-Obstruction [ti] OR Color-
Vision-Defects [ti] OR Coma [ti] OR Common-Cold [ti] OR Common-Variable-
Immunodeficiency [ti] OR Commotio-Cordis [ti] OR Complication* [ti] OR Condylomata-
Acuminata [ti] OR Confusion [ti] OR Congenital-Hyperinsulinism [ti] OR Congenital-
Hypothyroidism [ti] OR Conjoined-Twins [ti] OR Conjunctivitis [ti] OR Constipation [ti] OR 
Constriction [ti] OR Contracture [ti] OR Coproporphyria [ti] OR Cor-Triatriatum [ti] OR 
Corneal-Dystrophies [ti] OR Corneal-Endothelial-Cell-Loss [ti] OR Corneal-Neovascularization 
[ti] OR Corneal-Opacity [ti] OR Corneal-Perforation [ti] OR Corneal-Wavefront-Aberration [ti] 
OR Coronary-Aneurysm* [ti] OR Coronary-Occlusion [ti] OR Coronary-Vasospasm* [ti] OR 
Coronary-Vessel-Anomalies [ti] OR Cough [ti] OR Cowpox [ti] OR Coxa-Valga [ti] OR Coxa-
Vara [ti] OR Craniocerebral-Trauma [ti] OR Craniofacial-Dysostosis [ti] OR 
Craniopharyngioma [ti] OR Craniosynostoses [ti] OR Croup [ti] OR Cryoglobulinemia [ti] OR 
Cryptococcosis [ti] OR Cryptogenic-Organizing-Pneumonia [ti] OR Cryptorchidism [ti] OR 
Cryptosporidiosis [ti] OR Cutaneous-Fistula [ti] OR Cutis-Laxa [ti] OR Cyanosis [ti] OR 
Cyclosporiasis [ti] OR Cystadenocarcinoma [ti] OR Cystadenoma [ti] OR Cystic-Fibrosis [ti] 
OR Cysticercosis [ti] OR Cystinosis [ti] OR Cystinuria [ti] OR Cystitis [ti] OR Cystocele [ti] OR 
Cysts [ti] OR Cytochrome-c-Oxidase-Deficiency [ti] OR Cytomegalovirus-Retinitis [ti] OR 
Dacryocystitis [ti] OR Dandruff [ti] OR Deafness [ti] OR Decalcification [ti] OR Decerebrate-
State [ti] OR Dehydration [ti] OR Delayed-Emergence-from-Anesthesia [ti] OR Delayed-Graft-
Function [ti] OR Delayed-Puberty [ti] OR Delirium [ti] OR Delta-Thalassemia [ti] OR Dementia 
[ti] OR Dendritic-Cell-Sarcoma [ti] OR Dengue [ti] OR Dental-Calculus [ti] OR Dental-Caries 
[ti] OR Dental-Deposits [ti] OR Dental-Enamel-Hypoplasia [ti] OR Dental-Fissures [ti] OR 
Dental-Fistula [ti] OR Dental-Leakage [ti] OR Dental-Occlusion [ti] OR Dental-Plaque [ti] OR 
Dental-Pulp-Calcification [ti] OR Dental-Pulp-Exposure [ti] OR Dental-Pulp-Necrosis [ti] OR 
Dentigerous-Cyst [ti] OR Dentin-Sensitivity [ti] OR Dentinogenesis-Imperfecta [ti] OR 
Dentofacial-Deformities [ti] OR Depression [ti] OR Dermatitis [ti] OR Dermatofibrosarcoma [ti] 
OR Dermatomycoses [ti] OR Dermatomyositis [ti] OR Dermoid-Cyst [ti] OR Desmoplastic-
Small-Round-Cell-Tumor* [ti] OR Dextrocardia [ti] OR Diabetes [ti] OR Diabetic [ti] OR 
Diaper-Rash [ti] OR Diaphragmatic-Eventration [ti] OR Diarrhea [ti] OR Diastema [ti] OR 
Dicrocoeliasis [ti] OR Dientamoebiasis [ti] OR Diffuse-Axonal-Injury [ti] OR Digestive-System-
Fistula [ti] OR Dihydropyrimidine-Dehydrogenase-Deficiency [ti] OR Dilatation [ti] OR 
Diphtheria [ti] OR Diphyllobothriasis [ti] OR Diplopia [ti] OR Dirofilariasis [ti] OR Discitis [ti] 
OR Disease* [ti] OR  [ti] OR Disorder* [ti] OR Disseminated-Intravascular-Coagulation [ti] OR 
Distemper [ti] OR Diurnal-Enuresis [ti] OR Diverticulitis [ti] OR Diverticulosis [ti] OR 
Diverticulum [ti] OR Dizziness [ti] OR Double-Outlet-Right-Ventricle [ti] OR Dracunculiasis 
[ti] OR Drowning [ti] OR Drug-Hypersensitivity [ti] OR Drug-Overdose [ti] OR Drug-Induced-
Liver-Injury [ti] OR Dry-Socket [ti] OR Ductus-Arteriosus [ti] OR Duodenal-Obstruction* [ti] 
OR Duodenitis [ti] OR Duodenogastric-Reflux [ti] OR Dupuytren-Contracture [ti] OR Dwarfism 
[ti] OR Dysarthria [ti] OR Dysautonomia [ti] OR Dysbiosis [ti] OR Dyscalculia [ti] OR 
Dysentery [ti] OR Dysfunction* [ti] OR Dysgammaglobulinemia [ti] OR Dysgerminoma [ti] OR 
Dysgeusia [ti] OR Dyskeratosis-Congenita [ti] OR Dyskinesia* [ti] OR Dyslexia [ti] OR 
Dyslipid* [ti] OR Dysmenorrhea [ti] OR Dysostoses [ti] OR Dyspareunia [ti] OR Dyspepsia [ti] 




OR Dysphonia [ti] OR Dysplasia [ti] OR Dyspnea [ti] OR Dyssomnias [ti] OR Dystocia [ti] OR 
Dystonia [ti] OR Dysuria [ti] OR Ear-Deformities [ti] OR Earache [ti] OR Ebstein-Anomaly [ti] 
OR Ecchymosis [ti] OR Eccrine-Porocarcinoma [ti] OR Echinococcosis [ti] OR Echinostomiasis 
[ti] OR Eclampsia [ti] OR Ecthyma [ti] OR Ectoparasitic-Infestations [ti] OR Ectopia-Cordis [ti] 
OR Ectopia-Lentis [ti] OR ectopic-Pregnancy [ti] OR Ectromelia [ti] OR Ectropion [ti] OR 
Eczema [ti] OR Edema* [ti] OR edentulous-Mouth [ti] OR Egg-Hypersensitivity [ti] OR 
Ehrlichiosis [ti] OR Eisenmenger-Complex [ti] OR Elephantiasis [ti] OR Elliptocytosis [ti] OR 
Emaciation [ti] OR Embolism* [ti] OR Embryo-Loss [ti] OR Emergencies [ti] OR Emphysema 
[ti] OR Emphysematous-Cholecystitis [ti] OR Empyema [ti] OR Encephalitis [ti] OR 
Encephalitozoonosis [ti] OR Encephalocele [ti] OR Encephalomalacia [ti] OR Encephalomyelitis 
[ti] OR Encephalopathy [ti] OR Enchondromatosis [ti] OR Endarteritis [ti] OR Endocardial-
Cushion-Defects [ti] OR Endocardial-Fibroelastosis [ti] OR Endocarditis [ti] OR Endodermal-
Sinus-Tumor* [ti] OR Endoleak [ti] OR Endolymphatic-Hydrops [ti] OR Endometrial-Stromal-
Tumors* [ti] OR Endometriosis [ti] OR Endometritis [ti] OR Endophthalmitis [ti] OR 
Endotoxemia [ti] OR Enophthalmos [ti] OR Entamoebiasis [ti] OR Enteritis [ti] OR Enterobiasis 
[ti] OR Enterocolitis [ti] OR Enterotoxemia [ti] OR Entropion [ti] OR Enuresis [ti] OR Enzootic-
Bovine-Leukosis [ti] OR Eosinophilia [ti] OR Eosinophilic-Granuloma [ti] OR Ependymoma [ti] 
OR Epidermal-Cyst* [ti] OR Epidermodysplasia-Verruciformis [ti] OR Epidermolysis-Bullosa 
[ti] OR Epididymitis [ti] OR Epiglottitis [ti] OR Epilepsia-Partialis-Continua [ti] OR Epilepsies 
[ti] OR Epilepsy [ti] OR Epiphyses [ti] OR Epiretinal-Membrane [ti] OR Epispadias [ti] OR 
Epistaxis [ti] OR Equinus-Deformity [ti] OR Erectile-Dysfunction [ti] OR Ergotism [ti] OR 
Eructation [ti] OR Eruption* [ti] OR Erysipelas [ti] OR Erysipeloid [ti] OR Erythema* [ti] OR 
Erythroblastosis [ti] OR Erythrokeratodermia-Variabilis [ti] OR Erythromelalgia [ti] OR 
Erythroplasia [ti] OR Esophageal-Achalasia [ti] OR Esophageal-and-Gastric-Varices [ti] OR 
Esophageal-Atresia [ti] OR Esophageal-Cyst* [ti] OR Esophageal-Fistula [ti] OR Esophageal-
Perforation* [ti] OR Esophageal-Spasm* [ti] OR Esophagitis [ti] OR Esotropia [ti] OR Essential-
Tremor* [ti] OR Esthesioneuroblastoma [ti] OR Ethmoid-Sinusitis [ti] OR Exanthema [ti] OR 
Exocrine-Pancreatic-Insufficiency [ti] OR Exophthalmos [ti] OR Exostoses [ti] OR Exotropia [ti] 
OR Exsanguination [ti] OR Eye-Injuries [ti] OR Facial-Asymmetry [ti] OR Facial-Dermatoses 
[ti] OR Facial-Hemiatrophy [ti] OR Facial-Neuralgia [ti] OR Facial-Paralysis [ti] OR Factor-V-
Deficiency [ti] OR Factor-VII-Deficiency [ti] OR Factor-X-Deficiency [ti] OR Factor-XI-
Deficiency [ti] OR Factor-XII-Deficiency [ti] OR Factor-XIII-Deficiency [ti] OR Failure-to-
Thrive [ti] OR Familial-Hypophosphatemic-Rickets [ti] OR Fanconi-Anemia [ti] OR Farmer's-
Lung [ti] OR Fasciculation [ti] OR Fasciitis [ti] OR Fascioliasis [ti] OR Fascioloidiasis [ti] OR 
Fatigue [ti] OR Fatty-Liver [ti] OR Favism [ti] OR Febrile-Neutropenia [ti] OR Fecal-Impaction 
[ti] OR Fecal-Incontinence [ti] OR Feline-Panleukopenia [ti] OR Feminization [ti] OR 
Femoracetabular-Impingement [ti] OR Fetal-Death* [ti] OR Fetal-Distress [ti] OR Fetal-Growth-
Retardation [ti] OR Fetal-Hypoxia [ti] OR Fetal-Macrosomia [ti] OR Fetal-Membranes [ti] OR 
Fetal-Resorption [ti] OR Fetal-Weight [ti] OR Fetofetal-Transfusion [ti] OR Fetomaternal-
Transfusion [ti] OR Fever [ti] OR Fibroadenoma* [ti] OR Fibroma* [ti] OR Fibromatosis [ti] OR 
Fibromyalgia [ti] OR Fibrosarcoma [ti] OR Fibrosis [ti] OR Fibrous-Tumor* [ti] OR Filariasis 
[ti] OR Fissure-in-Ano [ti] OR Fissured-Tongue [ti] OR Fistula [ti] OR Flatfoot [ti] OR 
Flatulence [ti] OR Flea-Infestation* [ti] OR Fluorosis [ti] OR Flushing [ti] OR Focal-Dermal-
Hypoplasia [ti] OR Folic-Acid-Deficiency [ti] OR Follicular-Cyst* [ti] OR Folliculitis [ti] OR 




Food-Hypersensitivity [ti] OR Foot-Deformities [ti] OR Foot-Dermatoses [ti] OR Foramen-
Ovale [ti] OR Foreign-Body-Reaction* [ti] OR Fournier-Gangrene [ti] OR Fowlpox [ti] OR 
Freemartinism [ti] OR Friedreich-Ataxia [ti] OR Frontal-Sinusitis [ti] OR Frontotemporal-
Dementia [ti] OR Frontotemporal-Lobar-Degeneration [ti] OR Fructose-Intolerance [ti] OR 
Fructose-1,6-Diphosphatase-Deficiency [ti] OR Fuchs'-Endothelial-Dystrophy [ti] OR 
Fucosidosis [ti] OR Fungemia [ti] OR Funnel-Chest [ti] OR Furcation-Defects [ti] OR 
Furunculosis [ti] OR Fusariosis) 
OR 
 (Expos* [ti] OR induce [ti] OR induced [ti] OR induces [ti] OR incarceration [ti] OR 
occupation* [ti] OR pathogen* [ti] OR pollut* [ti] OR poverty [ti] OR socioeconomic [ti] OR 
worker*) AND (Gagging [ti] OR Gait-Apraxia [ti] OR Gait-Ataxia [ti] OR Galactorrhea [ti] OR 
Galactosemia* [ti] OR Gallstone* [ti] OR Ganglioglioma [ti] OR Ganglion-Cyst* [ti] OR 
Ganglioneuroblastoma [ti] OR Ganglioneuroma* [ti] OR Gangliosidosis [ti] OR Gangrene [ti] 
OR Gastric-Antral-Vascular-Ectasia [ti] OR Gastric-Dilatation [ti] OR Gastric-Fistula [ti] OR 
Gastric-Outlet-Obstruction* [ti] OR Gastrinoma [ti] OR Gastritis [ti] OR Gastroenteritis [ti] OR 
Gastroesophageal-Reflux [ti] OR Gastrointestinal-Stromal-Tumor* [ti] OR Gastroparesis [ti] OR 
Gastroschisis [ti] OR Genomic-Instability [ti] OR Genu-Valgum [ti] OR Genu-Varum [ti] OR 
Geographic-Atrophy [ti] OR Geotrichosis [ti] OR Germinoma [ti] OR Giant-Cell-Arteritis [ti] 
OR Giant-Cell-Tumor-of-Bone [ti] OR Giant-Cell-Tumor* [ti] OR Giardiasis [ti] OR Gigantism 
[ti] OR Gingival-Hypertrophy [ti] OR Gingival-Overgrowth [ti] OR Gingival-Pocket* [ti] OR 
Gingival-Recession [ti] OR Gingivitis [ti] OR Glanders [ti] OR Glaucoma [ti] OR Glioblastoma 
[ti] OR Glioma [ti] OR Gliosarcoma [ti] OR Gliosis [ti] OR Glomerulonephritis [ti] OR 
Glomerulosclerosis [ti] OR Glomus-Jugulare-Tumor* [ti] OR Glomus-Tumor* [ti] OR Glomus-
Tympanicum-Tumor* [ti] OR Glossalgia [ti] OR Glossitis [ti] OR Glucagonoma [ti] OR 
Glucose-Intolerance [ti] OR Glucosephosphate-Dehydrogenase-Deficiency [ti] OR Glycat* [ti] 
OR Glycemia [ti] OR Glycosuria [ti] OR Glycosylat* [ti] OR Glycoxidation [ti] OR 
Gnathostomiasis [ti] OR Goiter [ti] OR Gonadal-Dysgenesis [ti] OR Gonorrhea [ti] OR Gout [ti] 
OR Graft-Occlusion* [ti] OR Granular-Cell-Tumor* [ti] OR Granuloma* [ti] OR 
Granulomatosis [ti] OR Granulomatous-Mastitis [ti] OR Granulosa-Cell-Tumor* [ti] OR Graves-
Ophthalmopathy [ti] OR Gynatresia [ti] OR Gynecomastia [ti] OR Gyrate-Atrophy [ti] OR 
Haematuria [ti] OR Haemonchiasis [ti] OR Hairy-Tongue [ti] OR Halitosis [ti] OR 
Hallucination* [ti] OR Hallux-Rigidus [ti] OR Hallux-Valgus [ti] OR Hallux-Varus [ti] OR 
Hamartoma [ti] OR Hand-Deformities [ti] OR Hand-Dermatoses [ti] OR Haploinsufficiency [ti] 
OR Hazard* [ti] OR Head-Injur* [ti] OR Headache* [ti] OR Hearing-Loss [ti] OR Heart-
Aneurysm* [ti] OR Heart-Arrest [ti] OR Heart-Block* [ti] OR Heart-Defect* [ti] OR Heart-
Failure [ti] OR Heart-Murmur* [ti] OR Heart-Septal-Defect* [ti] OR Heartburn [ti] OR Heel-
Spur* [ti] OR Helminthiasis [ti] OR Hemangioblastoma [ti] OR Hemangioendothelioma [ti] OR 
Hemangioma* [ti] OR Hemangiopericytoma [ti] OR Hemangiosarcoma [ti] OR Hemarthrosis [ti] 
OR Hematemesis [ti] OR Hematocele [ti] OR Hematocolpos [ti] OR Hematoma* [ti] OR 
Hematometra [ti] OR Hematuria [ti] OR Hemianopsia [ti] OR Hemifacial-Spasm* [ti] OR 
Hemiplegia [ti] OR Hemobilia [ti] OR Hemochromatosis [ti] OR Hemoglobinopathies [ti] OR 
Hemoglobinuria [ti] OR Hemolysis [ti] OR Hemoperitoneum [ti] OR Hemophilia [ti] OR 
Hemopneumothorax [ti] OR Hemoptysis [ti] OR Hemorrhag* [ti] OR Hemorrhoids [ti] OR 




Hemosiderosis [ti] OR Hemospermia [ti] OR Hemothorax [ti] OR Hepatic-Encephalopathy [ti] 
OR Hepatic-Insufficiency [ti] OR Hepatitis [ti] OR Hepatoblastoma [ti] OR Hepatolenticular-
Degeneration [ti] OR Hepatomegaly [ti] OR Hereditary-Angioedema [ti] OR Hernia* [ti] OR 
Heroin-Dependence [ti] OR Herpangina [ti] OR Herpes-Genitalis [ti] OR Herpes-Labialis [ti] 
OR Herpes-Simplex [ti] OR Herpes-Zoster [ti] OR Heterotopic-Pregnancy [ti] OR Hiccup* [ti] 
OR Hidradenitis [ti] OR Hidrocystoma [ti] OR Hip-Contracture [ti] OR Hip-Dislocation* [ti] OR 
Hirsutism [ti] OR Histiocytic-Necrotizing-Lymphadenitis [ti] OR Histiocytic-Sarcoma [ti] OR 
Histiocytoma [ti] OR Histiocytosis [ti] OR Histoplasmosis [ti] OR HIV-Enteropathy [ti] OR 
HIV-Seropositivity [ti] OR HIV/AIDS [ti] OR Hoarseness [ti] OR Holoprosencephaly [ti] OR 
Homocystinuria [ti] OR Hot-Flashes [ti] OR Hutchinson's-Melanotic-Freckle [ti] OR 
Hyalohyphomycosis [ti] OR Hydatidiform-Mole [ti] OR Hydranencephaly [ti] OR Hydroa-
Vacciniforme [ti] OR Hydrocephalus [ti] OR Hydronephrosis [ti] OR Hydrophthalmos [ti] OR 
Hydropneumothorax [ti] OR Hydrops-Fetalis [ti] OR Hydrothorax [ti] OR Hymenolepiasis [ti] 
OR Hyperacusis [ti] OR Hyperaldosteronism [ti] OR Hyperalgesia [ti] OR Hyperammonemia [ti] 
OR Hyperamylasemia [ti] OR Hyperandrogenism [ti] OR Hyperargininemia [ti] OR 
Hyperbilirubinemia [ti] OR Hypercalcemi* [ti] OR Hypercalciuria [ti] OR Hypercapnia [ti] OR 
Hypercellularity [ti] OR Hypercementosis [ti] OR Hypercholesterol* [ti] OR Hypercoagul* [ti] 
OR Hyperemesis-Gravidarum [ti] OR Hyperemi* [ti] OR Hyperesthesia [ti] OR 
Hypergammaglobulinemia [ti] OR Hyperglyc* [ti] OR Hyperhidrosis [ti] OR 
Hyperhomocystein* [ti] OR Hyperinsulin* [ti] OR Hyperkal* [ti] OR Hyperkeratosis [ti] OR 
Hyperkinesi* [ti] OR Hyperleptinemia* [ti] OR Hyperlipid* [ti] OR Hyperlipoproteinemia* [ti] 
OR Hyperlysinemias [ti] OR Hypermagnesemi* [ti] OR Hypernatremia [ti] OR Hyperopia [ti] 
OR Hyperostosis [ti] OR Hyperoxaluria [ti] OR Hyperoxia [ti] OR Hyperparathyroid* [ti] OR 
Hyperphagia [ti] OR Hyperphosphat* [ti] OR Hyperpigmentation [ti] OR Hyperpituitarism [ti] 
OR Hyperplasia [ti] OR Hyperprolactinemia [ti] OR Hypersecretion [ti] OR Hypersensitivity [ti] 
OR Hypersomnolence [ti] OR Hypersplenism [ti] OR Hypertelorism [ti] OR Hypertension [ti] 
OR Hypertensive-Encephalopathy [ti] OR Hypertensive-Retinopathy [ti] OR Hyperthyroidism 
[ti] OR Hyperthyroxinemia [ti] OR Hypertrichosis [ti] OR Hypertriglycerid* [ti] OR 
Hypertrophy [ti] OR Hyperuric* [ti] OR Hyperventilation [ti] OR Hypervitaminosis [ti] OR 
Hypervolemia [ti] OR Hypesthesia [ti] OR Hyphema [ti] OR Hypoalbuminemia [ti] OR 
Hypoaldosteronism [ti] OR Hypoalphalipoproteinemia* [ti] OR Hypobetalipoproteinemia* [ti] 
OR Hypocalcemi* [ti] OR Hypocapnia [ti] OR Hypodermyiasis [ti] OR Hypoglyc* [ti] OR 
Hypogonadism [ti] OR Hypohidrosis [ti] OR Hypokalemi* [ti] OR Hypokinesi* [ti] OR 
Hypolipid* [ti] OR Hypolipoproteinemias [ti] OR Hypomagnesemi* [ti] OR Hypomethylation 
[ti] OR Hyponatremi* [ti] OR Hypoparathyroidism [ti] OR Hypoperfusion [ti] OR 
Hypophosphat* [ti] OR Hypopigmentation [ti] OR Hypopituitarism [ti] OR Hypoplasia [ti] OR 
Hypoprothrombinemia* [ti] OR Hypospadias [ti] OR Hypotension [ti] OR Hypothermia [ti] OR 
Hypothyroid* [ti] OR Hypotrichosis [ti] OR Hypoventilation [ti] OR Hypovolemia [ti] OR 
Hypoxemia [ti] OR Hypoxia [ti] OR Ichthyosis [ti] OR IgA-Deficiency [ti] OR IgG-Deficiency 
[ti] OR Ileitis [ti] OR Ileus [ti] OR Iliac-Aneurysm [ti] OR Illness [ti] OR Illusions [ti] OR 
Immersion-Foot [ti] OR Immunoblastic-Lymphadenopathy [ti] OR Impacted-Tooth [ti] OR 
Imperforate-Anus [ti] OR Impetigo [ti] OR Implant-Capsular-Contracture [ti] OR Impotence [ti] 
OR Incontinentia-Pigmenti [ti] OR Inert-Gas-Narcosis [ti] OR Infarction* [ti] OR Infect* [ti] OR 
Infertility [ti] OR Inflammation [ti] OR Inflammatory [ti] OR Influenza [ti] OR Ingrown-Nails 




[ti] OR Inhalant-Abuse* [ti] OR (Injury-in [ti] AND Mice [ti]) OR (injury-in [ti] AND rats [ti]) 
OR Insect-Bite* [ti] OR Insect-Sting* [ti] OR Insomnia* [ti] OR Insulin-Coma [ti] OR Insulin-
Resistance [ti] OR Insulinoma [ti] OR Intellectual-Disability [ti] OR Intermittent-Claudication 
[ti] OR Interstitial-Pneumonias [ti] OR Intertrigo [ti] OR Intervertebral-Disc-Degeneration [ti] 
OR Intervertebral-Disc-Displacement [ti] OR Intestinal-Atresia [ti] OR Intestinal-Fistula* [ti] 
OR Intestinal-Obstruction* [ti] OR Intestinal-Perforation* [ti] OR Intestinal-Polyposis [ti] OR 
Intestinal-Polyps [ti] OR Intestinal-Pseudo-Obstruction [ti] OR Intestinal-Volvulus [ti] OR 
Intracranial-Arteriosclerosis [ti] OR Intracranial-Arteriovenous-Malformations [ti] OR 
Intracranial-Embolism* [ti] OR Intracranial-Hypotension [ti] OR Intraoperative-Awareness [ti] 
OR Intraoperative-Complications [ti] OR Intussusception [ti] OR Iridocyclitis [ti] OR Iritis [ti] 
OR Iron-Overload [ti] OR Ischemia [ti] OR Ischemic-Attack [ti] OR Ischemic-Contracture [ti] 
OR Isolated-Noncompaction-of-the-Ventricular-Myocardium [ti] OR Isosporiasis [ti] OR 
Jaundice [ti] OR Jaw-Cyst* [ti] OR Joint-Deformities [ti] OR Joint-Instability [ti] OR Joint-
Loose-Bodies [ti] OR Keloid [ti] OR Keratitis [ti] OR Keratoacanthoma [ti] OR 
Keratoconjunctivitis [ti] OR Keratoconus [ti] OR Keratoderma [ti] OR Keratosis [ti] OR 
Kernicterus [ti] OR Ketosis [ti] OR Kidney-Calculi [ti] OR Kidney-Failure [ti] OR Klatskin's-
Tumor [ti] OR Krukenberg-Tumor [ti] OR Kuru [ti] OR Kwashiorkor [ti] OR Kyphosis [ti] OR 
Labyrinthitis [ti] OR Lacrimal-Duct-Obstruction* [ti] OR Lactose-Intolerance [ti] OR Larva-
Migrans [ti] OR Laryngismus [ti] OR Laryngitis [ti] OR Laryngomalacia [ti] OR 
Laryngopharyngeal-Reflux [ti] OR Laryngostenosis [ti] OR Latex-Hypersensitivity [ti] OR 
Lathyrism [ti] OR Leber-Congenital-Amaurosis [ti] OR Lecithin-Acyltransferase-Deficiency [ti] 
OR Leg-Dermatoses [ti] OR Leg-Length-Inequality [ti] OR Legionellosis [ti] OR Leiomyoma 
[ti] OR Leiomyomatosis [ti] OR Leiomyosarcoma [ti] OR Leishmania* [ti] OR Lens-
Subluxation [ti] OR Lentigo [ti] OR Leprosy [ti] OR Leptospirosis [ti] OR Lethargy [ti] OR 
Leukemia [ti] OR Leukemic-Infiltration [ti] OR Leukemoid-Reaction [ti] OR Leukoaraiosis [ti] 
OR Leukocytosis [ti] OR Leukodystrophy [ti] OR Leukoedema [ti] OR Leukoencephalitis [ti] 
OR Leukoencephalopath* [ti] OR Leukokeratosis [ti] OR Leukomalacia [ti] OR Leukopenia [ti] 
OR Leukoplakia [ti] OR Leukorrhea [ti] OR Leukostasis [ti] OR Leydig-Cell-Tumor [ti] OR 
Lice-Infestation* [ti] OR Lichen-Nitidus [ti] OR Lichen-Planus [ti] OR Lichen-Sclerosus-et-
Atrophicus [ti] OR Limb-Deformit* [ti] OR Linear-IgA-Bullous-Dermatosis [ti] OR Lingual-
Thyroid [ti] OR Linitis-Plastica [ti] OR Lipid-Metabolism [ti] OR Lipidoses [ti] OR Lipid-
Peroxid* [ti] OR Lipodystrophy [ti] OR Lipoma [ti] OR Lipomatosis [ti] OR Lipoperoxidation 
[ti] OR Liposarcoma [ti] OR Lipoxidation [ti] OR Lissencephalies [ti] OR Lissencephaly [ti] OR 
Listeriosis [ti] OR Lithiasis [ti] OR Livedo-Reticularis [ti] OR Liver-Cirrhosis [ti] OR Liver-
Failure [ti] OR Liver-Injury [ti] OR Loiasis [ti] OR Lordosis [ti] OR Low-Tension-Glaucoma [ti] 
OR Lower-Extremity-Deformit* [ti] OR Lower-Urinary-Tract-Symptom* [ti] OR Ludwig's-
Angina [ti] OR Lung-Injury [ti] OR Lupus-Erythematosus [ti] OR Lupus-Nephritis [ti] OR 
Lupus-Vulgaris [ti] OR Lyme-Neuroborreliosis [ti] OR Lymphadenitis [ti] OR 
Lymphangiectasis [ti] OR Lymphangioleiomyomatosis [ti] OR Lymphangioma [ti] OR 
Lymphangiomyoma [ti] OR Lymphangiosarcoma [ti] OR Lymphangitis [ti] OR Lymphatic-
Metastas* [ti] OR Lymphedema [ti] OR Lymphocele [ti] OR Lymphocytic-Choriomeningitis [ti] 
OR Lymphocytosis [ti] OR Lymphogranuloma-Venereum [ti] OR Lymphohistiocytosis [ti] OR 
Lymphoma [ti] OR Lymphomatoid-Granulomatosis [ti] OR Lymphomatoid-Papulosis [ti] OR 
Lymphopenia) 





 (Expos* [ti] OR induce [ti] OR induced [ti] OR induces [ti] OR incarceration [ti] OR 
occupation* [ti] OR pathogen* [ti] OR pollut* [ti] OR poverty [ti] OR socioeconomic [ti] OR 
worker*) AND (Macroalbuminuria [ti] OR Macrocephaly [ti] OR Macroglossia [ti] OR Macular-
Degeneration [ti] OR Magnesium-Deficiency [ti] OR Malacoplakia [ti] OR Malaria [ti] OR 
Malformations-of-Cortical-Development [ti] OR Malformed-Nails [ti] OR Malignant-Catarrh [ti] 
OR Malignant-Hyperthermia [ti] OR Malnutrition [ti] OR Malocclusion [ti] OR 
Mandibulofacial-Dysostosis [ti] OR Mansonelliasis [ti] OR Marijuana-Abuse [ti] OR Mast-Cell-
Sarcoma [ti] OR Mastitis [ti] OR Mastocytoma [ti] OR Mastocytosis [ti] OR Mastodynia [ti] OR 
Mastoiditis [ti] OR Maternal-Death [ti] OR Maxillary-Sinusitis [ti] OR Measles [ti] OR Meckel-
Diverticulum [ti] OR Mediastinal-Cyst [ti] OR Mediastinal-Emphysema [ti] OR Mediastinitis [ti] 
OR Medullary-Sponge-Kidney [ti] OR Medulloblastoma [ti] OR Megacolon [ti] OR Melanoma* 
[ti] OR Melanosis [ti] OR Melena [ti] OR Melioidosis [ti] OR Meningeal-Carcinomatosis [ti] OR 
Meningioma* [ti] OR Meningism [ti] OR Meningitis [ti] OR Meningocele [ti] OR 
Meningoencephalitis [ti] OR Meningomyelocele [ti] OR Menopause [ti] OR Menorrhagia [ti] 
OR Menstruation-Disturbances [ti] OR Mental-Fatigue [ti] OR Mental-Retardation [ti] OR 
Mesenchymoma [ti] OR Mesenteric-Cyst* [ti] OR Mesenteric-Lymphadenitis [ti] OR 
Mesenteric-Vascular-Occlusion [ti] OR Mesial-Movement-of-Teeth [ti] OR Mesothelioma [ti] 
OR Metabolic-Acidosis [ti] OR Metabolic-Syndrome [ti] OR Metabolism [ti] OR Metal-
Metabolism [ti] OR Metaplasia [ti] OR Metatarsalgia [ti] OR Methemoglobinemia [ti] OR 
Metrorrhagia [ti] OR Mevalonate-Kinase-Deficiency [ti] OR Microalbuminuria [ti] OR 
Microcephaly [ti] OR Micrognathism [ti] OR Microinflammation [ti] OR Micronuclei [ti] OR 
Microphthalmos [ti] OR Microsatellite-Instability [ti] OR Microscopic-Polyangiitis [ti] OR 
Microsporidiosis [ti] OR Microstomia [ti] OR Microvascular-Angina [ti] OR Migraine* [ti] OR 
Miliaria [ti] OR Milk-Hypersensitivity [ti] OR Milk-Sickness [ti] OR Mink-Viral-Enteritis [ti] 
OR Miosis [ti] OR Mite-Infestation* [ti] OR Mitochondrial-Encephalomyopath* [ti] OR 
Mitochondrial-Myopath* [ti] OR Mitral-Valve-Insufficiency [ti] OR Mitral-Valve-Prolapse [ti] 
OR Mixed-Tumor* [ti] OR Molluscum-Contagiosum [ti] OR Monieziasis [ti] OR Monilethrix 
[ti] OR Monkeypox [ti] OR Monoclonal-Gammopathy [ti] OR Mononeuropath* [ti] OR 
Morning-Sickness [ti] OR Morphine-Dependence [ti] OR Motion-Sickness [ti] OR Mouth-
Breathing [ti] OR Mucinoses [ti] OR Mucinosis [ti] OR Mucocele [ti] OR Mucolipidoses [ti] OR 
Mucopolysaccharidoses [ti] OR Mucopolysaccharidosis [ti] OR Mucormycosis [ti] OR 
Mucositis [ti] OR Multicystic-Dysplastic-Kidney [ti] OR Multiple-Acyl-Coenzyme-A-
Dehydrogenase-Deficiency [ti] OR Multiple-Carboxylase-Deficiency [ti] OR Multiple-
Chemical-Sensitivity [ti] OR Multiple-Myeloma [ti] OR Multiple-Organ-Failure* [ti] OR 
Multiple-Pulmonary-Nodules [ti] OR Multiple-System-Atrophy [ti] OR Mumps [ti] OR Muscle-
Cramp* [ti] OR Muscle-Hypertonia [ti] OR Muscle-Hypotonia [ti] OR Muscle-Rigidity [ti] OR 
Muscle-Spasticity [ti] OR Muscle-Weakness [ti] OR Muscular-Atrophy [ti] OR Muscular-
Dystroph* [ti] OR Mutism [ti] OR Myalgia [ti] OR Myasthenia-Gravis [ti] OR Mycetoma [ti] 
OR Mycoses [ti] OR Mycosis-Fungoides [ti] OR Mycotoxicosis [ti] OR Mydriasis [ti] OR 
Myelinolysis [ti] OR Myelitis [ti] OR Myelolipoma [ti] OR Myiasis [ti] OR Myocardial-
Bridging [ti] OR Myocardial-Ischemia [ti] OR Myocardial-Reperfusion-Injury [ti] OR 
Myocardial-Stunning [ti] OR Myocarditis [ti] OR Myoclonic-Cerebellar-Dyssynergia [ti] OR 
Myoclonic-Epileps* [ti] OR Myoclonus [ti] OR Myoepithelioma [ti] OR Myoglobinuria [ti] OR 




Myokymia [ti] OR Myoma [ti] OR Myopath* [ti] OR Myopia [ti] OR Myositis [ti] OR Myotonia 
[ti] OR Myotonic-Dystrophy [ti] OR Myringosclerosis [ti] OR Myxedema [ti] OR Myxoma [ti] 
OR Myxomatosis [ti] OR Myxosarcoma [ti] OR Narcolepsy [ti] OR Nasal-Obstruction* [ti] OR 
Nasal-Polyp* [ti] OR Nasal-Septal-Perforation [ti] OR Nasopharyngitis [ti] OR Nausea [ti] OR 
Necatoriasis [ti] OR Necrobiosis-Lipoidica [ti] OR Necrobiotic-Xanthogranuloma [ti] OR 
Necrolytic-Migratory-Erythema [ti] OR Necrosis [ti] OR Neointima [ti] OR Neoplasia [ti] OR 
Neoplasm* [ti] OR Neoplastic-Cell* [ti] OR Neovascularization [ti] OR Nephritis [ti] OR 
Nephrocalcinosis [ti] OR Nephrogenic-Fibrosing-Dermopathy [ti] OR Nephrolithiasis [ti] OR 
Nephroma [ti] OR Nephropath* [ti] OR Nephrosclerosis [ti] OR Nephrosis [ti] OR Nerve-
Degeneration [ti] OR Nerve-Injur* [ti] OR Nervous-System-Malformation* [ti] OR 
Nesidioblastosis [ti] OR Neural-Tube-Defect* [ti] OR Neuralgia [ti] OR Neurilemmoma [ti] OR 
Neuritis [ti] OR Neuroacanthocytosis [ti] OR Neuroaspergillosis [ti] OR Neuroaxonal-Dystroph* 
[ti] OR Neuroblastoma [ti] OR Neurocysticercosis [ti] OR Neurocytoma [ti] OR 
Neuroectodermal-Tumor* [ti] OR Neuroendocrine-Tumor* [ti] OR Neurofibroma [ti] OR 
Neurofibromatos* [ti] OR Neurofibrosarcoma [ti] OR Neurogenic-Bowel [ti] OR Neurogenic-
Inflammation [ti] OR Neurogenic-Urinary-Bladder [ti] OR Neuroma [ti] OR Neuromyelitis-
Optica [ti] OR Neuronal-Ceroid-Lipofuscinoses [ti] OR Neuropath* [ti] OR 
Neuroschistosomiasis [ti] OR Neurosyphilis [ti] OR Neurothekeoma [ti] OR Neutropenia [ti] OR 
Nevus [ti] OR Night-Blindness [ti] OR Night-Terror* [ti] OR Nocturia [ti] OR Nocturnal-
Enuresis [ti] OR Nocturnal-Paroxysmal-Dystonia [ti] OR Noma [ti] OR Nondisjunction [ti] OR 
Nonodontogenic-Cysts [ti] OR Nonvital-Tooth [ti] OR No-Reflow-Phenomenon [ti] OR Nose-
Deformities [ti] OR Nut-Hypersensitivity [ti] OR Nystagmus [ti] OR Obesity [ti] OR Obstetric-
Labor-Complications [ti] OR Ochronosis [ti] OR Ocular-Hypotension [ti] OR Odontogenic-
Cyst* [ti] OR Odontogenic-Tumor* [ti] OR Odontoma [ti] OR Oedema [ti] OR 
Oligodendroglioma [ti] OR Oligohydramnios [ti] OR Oligomenorrhea [ti] OR Oligospermia [ti] 
OR Oliguria [ti] OR Olivopontocerebellar-Atrophies [ti] OR Onchocerciasis [ti] OR Onycholysis 
[ti] OR Onychomycosis [ti] OR Oophoritis [ti] OR Open-Bite [ti] OR Ophthalmia [ti] OR 
Ophthalmoplegia [ti] OR Opisthorchiasis [ti] OR Optic-Atrophy [ti] OR Optic-Disk-Drusen [ti] 
OR Optic-Nerve-Glioma [ti] OR Optic-Neuritis [ti] OR Oral-Fistula* [ti] OR Orbital-Cellulitis 
[ti] OR Orbital-Myositis [ti] OR Orbital-Pseudotumor* [ti] OR Orchitis [ti] OR Oroantral-
Fistula* [ti] OR Orthostatic-Intolerance [ti] OR Ossification [ti] OR Osteitis [ti] OR 
Osteoarthritis [ti] OR Osteoarthropath* [ti] OR Osteoblastoma [ti] OR Osteochondritis [ti] OR 
Osteochondrodysplasias [ti] OR Osteochondroma [ti] OR Osteochondrosis [ti] OR 
Osteodystrophy [ti] OR Osteogenesis-Imperfecta [ti] OR Osteolysis [ti] OR Osteoma [ti] OR 
Osteomalacia [ti] OR Osteomyelitis [ti] OR Osteonecrosis [ti] OR Osteopenia [ti] OR 
Osteopetrosis [ti] OR Osteophyte [ti] OR Osteoporosis [ti] OR Osteosarcoma [ti] OR 
Osteosclerosis [ti] OR Ostertagiasis [ti] OR Otitis [ti] OR Otomycosis [ti] OR Otosclerosis [ti] 
OR Ovarian-Cyst* [ti] OR Overactive-Urinary-Bladder [ti] OR Overbite [ti] OR Overnutrition 
[ti] OR Overweight [ti] OR Oxidative-Stress [ti] OR Oxyuriasis [ti] OR Pachyonychia-Congenita 
[ti] OR Pain [ti] OR Pallor [ti] OR Pancreatic-Cyst* [ti] OR Pancreatic-Fistula* [ti] OR 
Pancreatic-Insufficiency [ti] OR Pancreatic-Pseudocyst [ti] OR Pancreatitis [ti] OR Pancytopenia 
[ti] OR Panniculitis [ti] OR Panuveitis [ti] OR Papilledema [ti] OR Papilloma [ti] OR 
Paracoccidioidomycosis [ti] OR Paraganglioma [ti] OR Paragonimiasis [ti] OR Parakeratosis [ti] 
OR Paralyses [ti] OR Paralysis [ti] OR Paraneoplastic [ti] OR Paraparesis [ti] OR Paraphimosis 




[ti] OR Paraplegia [ti] OR Paraproteinemias [ti] OR Parapsoriasis [ti] OR Parasitemia [ti] OR 
Parasomnias [ti] OR Parasystole [ti] OR Paratuberculosis [ti] OR Paresis [ti] OR Paresthesia [ti] 
OR Paronychia [ti] OR Parotitis [ti] OR Paroxysmal-Hemicrania [ti] OR Pars-Planitis [ti] OR 
Pasteurellosis [ti] OR Peanut-Hypersensitivity [ti] OR Pediatric-Obesity [ti] OR Pelger-Huet-
Anomaly [ti] OR Peliosis-Hepatis [ti] OR Pellagra [ti] OR Pelvic-Organ-Prolapse [ti] OR 
Pemphigoid [ti] OR Pemphigus [ti] OR Penile-Induration [ti] OR Periapical-Granuloma* [ti] OR 
Periarthritis [ti] OR Pericardial-Effusion [ti] OR Pericarditis [ti] OR Pericoronitis [ti] OR Peri-
Implantitis [ti] OR Perinephritis [ti] OR Periodontal-Atrophy [ti] OR Periodontal-Attachment-
Loss [ti] OR Periodontal-Cyst* [ti] OR Periodontal-Pocket [ti] OR Periodontitis [ti] OR 
Periostitis [ti] OR Peritonitis [ti] OR Periventricular-Nodular-Heterotopia [ti] OR Persistent-
Hyperplastic-Primary-Vitreous [ti] OR Persistent-Vegetative-State [ti] OR Peste-des-Petits-
Ruminants [ti] OR Phaeohyphomycosis [ti] OR Phantom-Limb [ti] OR Pharyngitis [ti] OR 
Phencyclidine-Abuse* [ti] OR Phenylketonuria* [ti] OR Pheochromocytoma [ti] OR Phimosis 
[ti] OR Phlebitis [ti] OR Photophobia [ti] OR Phyllodes-Tumor [ti] OR Piebaldism [ti] OR 
Piedra [ti] OR Pilomatrixoma [ti] OR Pilonidal-Sinus [ti] OR Pinealoma [ti] OR Pinguecula [ti] 
OR Pituitary-ACTH-Hypersecretion [ti] OR Pituitary-Apoplexy [ti] OR Pityriasis [ti] OR 
Placenta [ti] OR Placental-Insufficiency [ti] OR Plagiocephaly [ti] OR Plague [ti] OR Plasma-
Cell-Granuloma* [ti] OR Plasmacytoma [ti] OR Platelet-Storage-Pool-Deficiency [ti] OR 
Platybasia [ti] OR Pleural-Effusion [ti] OR Pleurisy [ti] OR Pleurodynia [ti] OR 
Pleuropneumonia [ti] OR Pneumatosis-Cystoides-Intestinalis [ti] OR Pneumocephalus [ti] OR 
Pneumoconiosis [ti] OR Pneumonia [ti] OR Pneumopericardium [ti] OR Pneumoperitoneum [ti] 
OR Pneumorrhachis [ti] OR Pneumothorax [ti] OR Poliomyelitis [ti] OR Polyarteritis-Nodosa 
[ti] OR Polychondritis [ti] OR Polycystic-Kidney [ti] OR Polycythemia [ti] OR Polydactyly [ti] 
OR Polydipsia [ti] OR Polyendocrinopathies [ti] OR Polyhydramnios [ti] OR Polymyalgia-
Rheumatica [ti] OR Polymyositis [ti] OR Polyneuropathies [ti] OR Polyps [ti] OR 
Polyradiculopathy [ti] OR Polyuria [ti] OR Popliteal-Cyst* [ti] OR Porokeratosis [ti] OR Poroma 
[ti] OR Porphyria* [ti] OR Port-Wine-Stain [ti] OR Positive-Pressure-Respiration [ti] OR 
Posterior-Tibial-Tendon-Dysfunction [ti] OR Post-Exercise-Hypotension [ti] OR Postoperative-
Complications [ti] OR Postoperative-Nausea [ti] OR postoperative-vomiting [ti] OR Postpartum-
Thyroiditis [ti] OR Potassium-Deficiency [ti] OR Pouchitis [ti] OR Precancerous [ti] OR 
Precocious-Puberty [ti] OR Prediabetic-State [ti] OR Pre-Eclampsia [ti] OR Pre-Excitation [ti] 
OR Pregnancy-Complications [ti] OR Pregnancy-in-Diabetics [ti] OR Prehypertension [ti] OR 
Preleukemia [ti] OR Premature-Aging [ti] OR Premature-Birth [ti] OR Premature-Ejaculation [ti] 
OR Premature-Obstetric-Labor [ti] OR Prenatal-Injur* [ti] OR Presbycusis [ti] OR Presbyopia 
[ti] OR Priapism [ti] OR Primary-Dysautonomias [ti] OR Primary-Graft-Dysfunction* [ti] OR 
Primary-Myelofibrosis [ti] OR Primary-Ovarian-Insufficiency [ti] OR Proctitis [ti] OR 
Proctocolitis [ti] OR Progeria [ti] OR Prognathism [ti] OR Prolactinoma [ti] OR Prolonged-
Pregnancy [ti] OR Propionic-Acidemia [ti] OR Prosopagnosia [ti] OR Prostatism [ti] OR 
Prostatitis [ti] OR Prosthesis-Failure* [ti] OR Protein-C-Deficiency [ti] OR Protein-Deficiency 
[ti] OR Protein-S-Deficiency [ti] OR Protein-Energy-Malnutrition [ti] OR Protein-Losing-
Enteropathies [ti] OR Proteinuria [ti] OR Proteostasis-Deficiencies [ti] OR Protoporphyria [ti] 
OR Prurigo [ti] OR Pruritus [ti] OR Pseudobulbar-Palsy [ti] OR Pseudohypoaldosteronism [ti] 
OR Pseudohypoparathyroidism [ti] OR Pseudolymphoma [ti] OR Pseudomyxoma-Peritonei [ti] 
OR Pseudophakia [ti] OR Pseudorabies [ti] OR Pseudotumor-Cerebri [ti] OR Pseudoxanthoma-




Elasticum [ti] OR Psittacosis [ti] OR Psoriasis [ti] OR Psychomotor-Agitation [ti] OR Psychoses 
[ti] OR Pterygium [ti] OR Pubic-Symphysis-Diastasis [ti] OR Pudendal-Neuralgia [ti] OR 
Pulmonary-Alveolar-Proteinosis [ti] OR Pulmonary-Aspergillosis [ti] OR Pulmonary-Atelectasis 
[ti] OR Pulmonary-Atresia [ti] OR Pulmonary-Blastoma [ti] OR Pulmonary-Embolism [ti] OR 
Pulmonary-Emphysema [ti] OR Pulmonary-Eosinophilia [ti] OR Pulmonary-Nodule* [ti] OR 
Pulmonary-Sclerosing-Hemangioma [ti] OR Pulmonary-Valve-Insufficiency [ti] OR Pulpitis [ti] 
OR Pure-Autonomic-Failure [ti] OR Purine-Pyrimidine-Metabolism [ti] OR Purpura [ti] OR 
Pyelitis [ti] OR Pyelonephritis [ti] OR Pyoderma [ti] OR Pyometra [ti] OR Pyomyositis [ti] OR 
Pyonephrosis [ti] OR Pythiosis [ti] OR Pyuria [ti] OR Quadriplegia [ti] OR Rabies [ti] OR 
Radiation-Pneumonitis [ti] OR Radicular-Cyst* [ti] OR Radiculopathy [ti] OR Ranula [ti] OR 
Reactive-Oxygen-Species [ti] OR Rectal-Fistula [ti] OR Rectal-Prolapse [ti] OR Rectocele [ti] 
OR Rectovaginal-Fistula [ti] OR Recurrence [ti] OR Red-Cell-Aplasia [ti] OR Reflex-
Sympathetic-Dystrophy [ti] OR Refractive-Errors [ti] OR Renal-Aminoacidurias [ti] OR Renal-
Artery-Obstruction [ti] OR Renal-Colic [ti] OR Renal-Injury [ti] OR Renal-Insufficiency [ti] OR 
Renal-Osteodystrophy [ti] OR Renal-Tubular-Transport [ti] OR Reperfusion-Injury [ti] OR 
Respiratory-Aspiration [ti] OR Respiratory-Hypersensitivity [ti] OR Respiratory-Insufficiency 
[ti] OR Respiratory-Paralysis [ti] OR Respiratory-Sounds [ti] OR Respiratory-Tract-Fistula [ti] 
OR Restenosis [ti] OR Reticulocytosis [ti] OR Retinal-Artery-Occlusion [ti] OR Retinal-
Degeneration [ti] OR Retinal-Detachment [ti] OR Retinal-Drusen [ti] OR Retinal-
Neovascularization [ti] OR Retinal-Perforations [ti] OR Retinal-Telangiectasis [ti] OR Retinal-
Vein-Occlusion [ti] OR Retinitis [ti] OR Retinoblastoma [ti] OR Retinopathy [ti] OR 
Retinoschisis [ti] OR Retrognathia [ti] OR Retrograde-Degeneration [ti] OR 
Retropneumoperitoneum [ti] OR Rh-Isoimmunization [ti] OR Rhabdoid-Tumor* [ti] OR 
Rhabdomyolysis [ti] OR Rhabdomyoma [ti] OR Rhabdomyosarcoma [ti] OR Rheumatic-
Nodule* [ti] OR Rheumatoid-Nodule* [ti] OR Rhinitis [ti] OR Rhinophyma [ti] OR 
Rhinoscleroma [ti] OR Rhinosporidiosis [ti] OR Riboflavin-Deficiency [ti] OR Rickets [ti] OR 
Rigor-Mortis [ti] OR Rinderpest [ti] OR Root-Caries [ti] OR Root-Resorption [ti] OR Rosacea 
[ti] OR Rubella [ti] OR Rupture) 
OR 
 (Expos* [ti] OR induce [ti] OR induced [ti] OR induces [ti] OR incarceration [ti] OR 
occupation* [ti] OR pathogen* [ti] OR pollut* [ti] OR poverty [ti] OR socioeconomic [ti] OR 
worker*) AND (Sacroiliitis [ti] OR Salivary-Duct-Calculi [ti] OR Salivary-Gland-Calculi [ti] OR 
Salivary-Gland-Fistula [ti] OR Salpingitis [ti] OR Sarcocystosis [ti] OR Sarcoidosis [ti] OR 
Sarcoma [ti] OR Sarcopenia [ti] OR Scabies [ti] OR Scalp-Dermatoses [ti] OR Schistosomiasis 
[ti] OR Sciatica [ti] OR Scleredema-Adultorum [ti] OR Sclerema-Neonatorum [ti] OR Scleritis 
[ti] OR Scleroderma [ti] OR Scleromyxedema [ti] OR Sclerosis [ti] OR Scoliosis [ti] OR 
Scorpion-Sting* [ti] OR Scotoma [ti] OR Scrapie [ti] OR Scrub-Typhus [ti] OR Scurvy [ti] OR 
Seizures [ti] OR Seminoma [ti] OR Sepsis [ti] OR Septic-Shock [ti] OR Seroma [ti] OR Serositis 
[ti] OR Sertoli-Cell-Tumor* [ti] OR Sertoli-Leydig-Cell-Tumor [ti] OR Serum-Sickness [ti] OR 
Severe-Combined-Immunodeficiency [ti] OR Severe-Dengue [ti] OR Sex-Chromosome-
Aberrations [ti] OR Sex-Cord-Gonadal-Stromal-Tumor* [ti] OR Sexual-Dysfunction [ti] OR 
Shwartzman-Phenomenon [ti] OR Sialadenitis [ti] OR Sialometaplasia [ti] OR Sialorrhea [ti] OR 
Sickle-Cell-Trait [ti] OR Siderosis [ti] OR Silicosis [ti] OR Silicotuberculosis [ti] OR Single-




Umbilical-Artery [ti] OR Sinoatrial-Block [ti] OR Sinus-Arrest [ti] OR Sinus-Pericranii [ti] OR 
Sinusitis [ti] OR Situs-Inversus [ti] OR Skull-Fracture* [ti] OR Sleep-Apnea [ti] OR Sleep-
Bruxism [ti] OR Sleep-Deprivation [ti] OR Sleep-Paralysis [ti] OR Slipped-Capital-Femoral-
Epiphyses [ti] OR Smallpox [ti] OR Smooth-Muscle-Tumor* [ti] OR Snake-Bite* [ti] OR 
Sneezing [ti] OR Snoring [ti] OR Somatostatinoma [ti] OR Somnambulism [ti] OR Space-
Motion-Sickness [ti] OR Sparganosis [ti] OR Spasm [ti] OR Spasms [ti] OR Spastic-Paraplegia 
[ti] OR Spermatic-Cord-Torsion [ti] OR Spermatocele [ti] OR Sphenoid-Sinusitis [ti] OR 
Spherocytosis [ti] OR Sphincter-of-Oddi-Dysfunction [ti] OR Sphingolipidoses [ti] OR Spider-
Bite* [ti] OR Spina-Bifida [ti] OR Spinal-Cord-Compression [ti] OR Spinal-Cord-Injur* [ti] OR 
Spinal-Cord-Ischemia [ti] OR Spinal-Curvature* [ti] OR Spinal-Dysraphism [ti] OR Spinal-
Muscular-Atrophies-of-Childhood [ti] OR Spinal-Osteophytosis [ti] OR Spinocerebellar-Ataxias 
[ti] OR Spinocerebellar-Degeneration* [ti] OR Splenomegaly [ti] OR Splenosis [ti] OR 
Spondylarthritis [ti] OR Spondylarthropathies [ti] OR Spondylitis [ti] OR Spondylolisthesis [ti] 
OR Spondylolysis [ti] OR Spondylosis [ti] OR Sporotrichosis [ti] OR Sprue [ti] OR Starvation 
[ti] OR Status-Asthmaticus [ti] OR Status-Epilepticus [ti] OR Steatitis [ti] OR Steatorrhea [ti] 
OR Stenosis [ti] OR Steroid-Metabolism [ti] OR Stings [ti] OR Stomach-Volvulus [ti] OR 
Stomatitis [ti] OR Strabismus [ti] OR Striae-Distensae [ti] OR Striatonigral-Degeneration [ti] OR 
Stricture* [ti] OR Stroke [ti] OR Strongyloidiasis [ti] OR Stupor [ti] OR Stuttering [ti] OR 
Subacute-Combined-Degeneration [ti] OR Subacute-Sclerosing-Panencephalitis [ti] OR 
Subcutaneous-Emphysema [ti] OR Subdural-Effusion [ti] OR Substance-Abuse* [ti] OR 
Sudden-Death [ti] OR Sudden-Infant-Death* [ti] OR Sulfhemoglobinemia [ti] OR Sunburn [ti] 
OR Supernumerary-Tooth [ti] OR Suppuration [ti] OR Supranuclear-Palsy [ti] OR Surgical-
Shock [ti] OR Surgical-Wound-Dehiscence [ti] OR Sweating [ti] OR Swine-Erysipelas [ti] OR 
Syncope [ti] OR Syndactyly [ti] OR Syndrome* [ti] OR Synkinesis [ti] OR Synostosis [ti] OR 
Synovial-Cyst* [ti] OR Synovitis [ti] OR Syphilis [ti] OR Syringoma [ti] OR Syringomyelia [ti] 
OR Systolic-Murmurs [ti] OR Tabes-Dorsalis [ti] OR Tachycardia [ti] OR Tachypnea [ti] OR 
Taeniasis [ti] OR Takayasu-Arteritis [ti] OR Takotsubo-Cardiomyopathy [ti] OR Tarlov-Cysts 
[ti] OR Tauopathies [ti] OR Tauopathy [ti] OR TDP-43-Proteinopathies [ti] OR Telangiectasia 
[ti] OR Telangiectasis [ti] OR Tendinopath* [ti] OR Tendon-Entrapment [ti] OR Tennis-Elbow 
[ti] OR Tenosynovitis [ti] OR Teratocarcinoma* [ti] OR Teratogenesis [ti] OR Teratoma [ti] OR 
Testicular-Hydrocele* [ti] OR Tetanus [ti] OR Tetany [ti] OR Tetralogy-of-Fallot [ti] OR 
Thalassemia [ti] OR Thecoma [ti] OR Theileriasis [ti] OR Thiamine-Deficiency [ti] OR Thinness 
[ti] OR Thrombasthenia [ti] OR Thromboangiitis-Obliterans [ti] OR Thrombocythemia [ti] OR 
Thrombocytopenia [ti] OR Thrombocytosis [ti] OR Thromboembolism [ti] OR Thrombophilia 
[ti] OR Thrombophlebitis [ti] OR Thrombosis [ti] OR Thrombotic-Microangiopathies [ti] OR 
Thymoma [ti] OR Thyroglossal-Cyst* [ti] OR Thyroid-Crisis [ti] OR Thyroid-Dysgenesis [ti] 
OR Thyroid-Nodule* [ti] OR Thyroiditis [ti] OR Thyrotoxicosis [ti] OR Tick-Bite* [ti] OR 
Tick-Infestation* [ti] OR Tick-Paralysis [ti] OR Tick-Toxicoses [ti] OR Tics [ti] OR Tinea [ti] 
OR Tinnitus [ti] OR Tissue-Adhesions [ti] OR T-Lymphocytopenia [ti] OR Tonic-Pupil [ti] OR 
Tonsillitis [ti] OR Tooth-Abrasion [ti] OR Tooth-Ankylosis [ti] OR Tooth-Attrition [ti] OR 
Tooth-Avulsion [ti] OR Tooth-Demineralization [ti] OR Tooth-Discoloration* [ti] OR Tooth-
Erosion [ti] OR Tooth-Fracture* [ti] OR Tooth-Injur* [ti] OR Tooth-Loss [ti] OR Tooth-
Migration [ti] OR Tooth-Mobility [ti] OR Tooth-Resorption [ti] OR Tooth-Wear [ti] OR 
Toothache* [ti] OR Torsades-de-Pointes [ti] OR Torticollis [ti] OR Toxascariasis [ti] OR 




Toxemia [ti] OR Toxic-Shock [ti] OR Toxocariasis [ti] OR Toxoplasmosis [ti] OR Tracheitis [ti] 
OR Tracheobronchomalacia [ti] OR Tracheobronchomegaly [ti] OR Tracheoesophageal-Fistula 
[ti] OR Tracheomalacia [ti] OR Trachoma [ti] OR Transient-Tachypnea [ti] OR Translocation 
[ti] OR Transposition-of-Great-Vessels [ti] OR Trauma [ti] OR Traumatic-Shock [ti] OR 
Tremor* [ti] OR Trichiasis [ti] OR Trichinellosis [ti] OR Trichomonas-Vaginitis [ti] OR 
Trichosporonosis [ti] OR Trichostrongyloidiasis [ti] OR Trichostrongylosis [ti] OR Trichuriasis 
[ti] OR Tricuspid-Atresia [ti] OR Tricuspid-Valve-Insufficiency [ti] OR Trigeminal-Autonomic-
Cephalalgias [ti] OR Trigeminal-Neuralgia [ti] OR Trilogy-of-Fallot [ti] OR Trismus [ti] OR 
Trisomy [ti] OR Trombiculiasis [ti] OR Trophoblastic-Tumor* [ti] OR Trypanosomiasis [ti] OR 
Tubal-Pregnancy [ti] OR Tuberculoma [ti] OR Tuberculosis [ti] OR Tularemia [ti] OR Tungiasis 
[ti] OR Tympanic-Membrane-Perforation [ti] OR Typhlitis [ti] OR Typhus [ti] OR Tyrosinemias 
[ti] OR Ulcer* [ti] OR Unconsciousness [ti] OR Uniparental-Disomy [ti] OR Upper-Extremity-
Deformities [ti] OR Urachal-Cyst* [ti] OR Uraemia [ti] OR Uremia [ti] OR Ureteral-Calculi [ti] 
OR Ureteral-Obstruction* [ti] OR Ureterocele [ti] OR Ureterolithiasis [ti] OR Urethral-
Obstruction* [ti] OR Urethritis [ti] OR Urinary-Bladder-Calculi [ti] OR Urinary-Bladder-
Fistula* [ti] OR Urinary-Bladder-Neck-Obstruction* [ti] OR Urinary-Calculi [ti] OR Urinary-
Fistula [ti] OR Urinary-Incontinence [ti] OR Urinary-Retention [ti] OR Urinoma [ti] OR 
Urolithiasis [ti] OR Urticaria [ti] OR Urticaria-Pigmentosa [ti] OR Uterine-Cervical-Erosion [ti] 
OR Uterine-Cervical-Incompetence [ti] OR Uterine-Cervicitis [ti] OR Uterine-Inertia [ti] OR 
Uterine-Inversion [ti] OR Uterine-Perforation* [ti] OR Uterine-Prolapse [ti] OR Uterine-
Retroversion [ti] OR Uveitis [ti] OR Vaccinia [ti] OR Vaginal-Discharge* [ti] OR Vaginal-
Fistula* [ti] OR Vaginismus [ti] OR Vaginitis [ti] OR Vaginosis [ti] OR Varicocele [ti] OR 
Varicose-Veins [ti] OR Vasa-Previa [ti] OR Vascular-Calcification [ti] OR Vascular-Fistula [ti] 
OR Vascular-Malformations [ti] OR Vascular-Resistance [ti] OR Vascular-Stiffness [ti] OR 
Vascular-System-Injur* [ti] OR Vasculitis [ti] OR Vasoconstriction [ti] OR Vasoplegia [ti] OR 
Vasospasm [ti] OR Vein-of-Galen-Malformations [ti] OR Velopharyngeal-Insufficiency [ti] OR 
Venous-Insufficiency [ti] OR Venous-Thromboembolism* [ti] OR Ventilator-Induced-Lung-
Injury [ti] OR Ventricular-Dysfunction* [ti] OR Ventricular-Fibrillation* [ti] OR Ventricular-
Outflow-Obstruction* [ti] OR Ventricular-Premature-Complexes [ti] OR Ventricular-
Remodeling [ti] OR Vertebral-Artery-Dissection [ti] OR Vertebrobasilar-Insufficiency [ti] OR 
Vertigo [ti] OR Vesico-Ureteral-Reflux [ti] OR Vesicovaginal-Fistula* [ti] OR Vesicular-
Stomatitis [ti] OR Vestibular-Neuronitis [ti] OR VIRAL-Cell-Transformation [ti] OR Viremia 
[ti] OR Virilism [ti] OR Visceral-Prolapse [ti] OR Visna [ti] OR Vitamin-A-Deficiency [ti] OR 
Vitamin-B-12-Deficiency [ti] OR Vitamin-B-6-Deficiency [ti] OR Vitamin-B-Deficiency [ti] OR 
Vitamin-D-Deficiency [ti] OR Vitamin-E-Deficiency [ti] OR Vitamin-K-Deficiency [ti] OR 
Vitiligo [ti] OR Vitreoretinopathy [ti] OR Vitreous-Detachment [ti] OR Vocal-Cord-Dysfunction 
[ti] OR Vocal-Cord-Paralysis [ti] OR Vomiting [ti] OR Vulvar-Lichen-Sclerosus [ti] OR Vulvar-
Vestibulitis [ti] OR Vulvitis [ti] OR Vulvodynia [ti] OR Vulvovaginitis [ti] OR Waldenstrom-
Macroglobulinemia [ti] OR Wallerian-Degeneration [ti] OR Wandering-Spleen [ti] OR Warts [ti] 
OR Water-Electrolyte-Imbalance [ti] OR Wegener-Granulomatosis [ti] OR Wernicke-
Encephalopathy [ti] OR Wet-Macular-Degeneration [ti] OR Wheat-Hypersensitivity [ti] OR 
Whooping-Cough [ti] OR Wilms-Tumor [ti] OR Xanthogranuloma* [ti] OR Xanthomatosis [ti] 
OR Xeroderma-Pigmentosum [ti] OR Xerophthalmia [ti] OR Xerostomia [ti] OR Yang-




Deficiency [ti] OR Yaws [ti] OR Yin-Deficiency [ti] OR Zenker-Diverticulum [ti] OR Zoonoses 
[ti] OR Zoster-Sine-Herpete [ti] OR Zygomycosis [ti]) 
7B3. Linking Terms Used to Extract Causes from Titles 
 There were millions of Title phrases that had to be evaluated for potential causes.  Only 
the highest frequency phrases could be inspected visually.  To access the lower frequency terms, 
a number of linking terms were identified. 
 The linking terms were obtained through visually inspecting many records containing 
foundational causes in the Titles, and identifying those terms that appeared frequently with the 
foundational causes.  These linking terms include: -induced; caused by; induced by; -
contaminated; exposure to; exposure(s) [at end of phrase]; exposed to; poisoning [at end]; 
workers [at end]; -exposed [at end]; -related; -associated; -infected; abuse*; toxicity.  The 
inclusion of the term 'workers' was to identify industries that were noticeable contributors to 
disease.  The phrases that included the linking terms eventually had to be separated from the 
linking terms to identify the specific foundational causes and include them in the software 
matrices.  Other linking terms were virus* and generic bacterial headings, but these did not have 
to be separated from the phrases.  
7B4. Linking Terms Used to Extract Diseases from Titles 
 In order to identify disease terms in the Titles that occurred at low frequency, linking 
terms had to be identified.  The linking terms were obtained through visually inspecting many 
records containing diseases in the Titles, and identifying those that appeared frequently with the 
diseases.  These linking terms included: disease; syndrome; infection; cancer; *toxicity; *opathy.  
Since specific diseases did not always appear in record Titles when the foundational causes 
appeared, terms that implied damage or adverse effects were used, such as *toxicity.  So, for 
example, with a phrase like 'cadmium toxicity', 'cadmium' would be extracted as a foundational 
cause, and 'toxicity' would be listed as a proxy 'disease'. 
7B5. Generic MeSH Terms Strongly Related to Potential Causes 
 A number of records with MeSH term assignments either had no MeSH Qualifiers listed 
or insufficient MeSH Qualifiers.  In addition, while the MeSH Qualifiers used for the all-
Qualifier query captured a large number of foundational causes, they were incomplete. 
 To generate these generic MeSH terms strongly related to potential foundational causes, 
results from past studies were examined, especially the CKD study [12], and generic relevant 
MeSH Headings were extracted.  Also, a few of the most unambiguous generic MeSH terms 
identified from past studies were entered into Pubmed as query terms, and all the MeSH terms in 
the resultant retrieval (i.e., those that co-occurred with the entry terms) were examined for 
relevance.  Finally, the high and mid-frequency MeSH terms in the MeSH tree were inspected 
visually, and those that appeared to be generic and foundational cause-focused were selected as a 
query. 




 The MeSH Headings that resulted after the records were retrieved consisted of 
foundational causes, and other.  Because there were no linking terms that could be used to extract 
only the foundational causes MeSH Headings, the output had to be inspected visually, and those 
terms that appeared to be foundational causes had to be extracted manually and validated.  
Mainly, the high frequency output terms were the only ones evaluated from visual inspection. 
 Additionally, a dot product approach was used to identify foundational causes with lower 
frequency of occurrence in the MeSH Heading field of the generic MeSH term-derived database.  
Four external inputs were intersected with the MeSH Headings that resulted after the records 
were retrieved, and any unique MeSH Headings that were found were added to the list of those 
identified from visual inspection.  The four external inputs were:  
1) foundational causes identified from MeSH Qualifiers in the MeSH Qualifier-derived database;  
2) foundational causes identified from MeSH Qualifiers in the generic MeSH term-derived 
database;  
3) CRN terms from the MeSH Qualifier-derived database; and,  
4) text terms from the Title text term-derived database. 
 The following query was used to retrieve the records from Pubmed, where the first group 
of terms in parentheses consists of all diseases and symptoms from the MeSH tree expressed in 
the highest MeSH tree terminology, and the second group of terms in parentheses represents the 
MeSH terms strongly related to foundational causes: 
 ([MH] is the Pubmed tag for MeSH Heading; [MH:NOEXP] is the Pubmed tag for MeSH 
Heading No Explode) 
 (Bacterial Infections and Mycoses [MH] OR Cardiovascular Diseases [MH] OR 
Chemically-Induced Disorders [MH] OR Congenital, Hereditary, and Neonatal Diseases and 
Abnormalities [MH] OR Digestive System Diseases [MH] OR Disorders of Environmental 
Origin [MH] OR Endocrine System Diseases [MH] OR Eye Diseases [MH] OR Female 
Urogenital Diseases and Pregnancy Complications [MH] OR Hemic and Lymphatic Diseases 
[MH] OR Immune System Diseases [MH] OR Male Urogenital Diseases [MH] OR 
Musculoskeletal Diseases [MH] OR Neoplasms [MH] OR Nervous System Diseases [MH] OR 
Nutritional and Metabolic Diseases [MH] OR Occupational Diseases [MH] OR 
Otorhinolaryngologic Diseases [MH] OR Parasitic Diseases [MH] OR Pathological Conditions, 
Signs and Symptoms [MH] OR Respiratory Tract Diseases [MH] OR Skin and Connective 
Tissue Diseases [MH] OR Stomatognathic Diseases [MH] OR Virus Diseases [MH]) 
AND 
 ("Drug-Related Side Effects AND Adverse Reactions" [MH:NOEXP] OR Abnormalities, 
Drug Induced [MH:NOEXP] OR Abnormalities, Radiation-Induced [MH:NOEXP] OR 
Agricultural Workers Diseases [MH:NOEXP] OR Aids Related Opportunistic Infections 
[MH:NOEXP] OR Air Pollutants [MH:NOEXP] OR Air Pollutants, Occupational [MH:NOEXP] 




OR Air Pollutants, Radioactive [MH:NOEXP] OR Air Pollution [MH:NOEXP] OR Air 
Pollution, Indoor [MH:NOEXP] OR Air Pollution, Radioactive [MH:NOEXP] OR Alcohol 
Drinking [MH:NOEXP] OR Alcohol Related Disorders [MH:NOEXP] OR Alcoholic Beverages 
[MH:NOEXP] OR Alcoholic Intoxication [MH:NOEXP] OR Alcoholism [MH:NOEXP] OR 
Amphetamine Related Disorders [MH:NOEXP] OR Amphetamines [MH:NOEXP] OR Arsenic 
Poisoning [MH:NOEXP] OR Asthma, Aspirin-Induced [MH:NOEXP] OR Asthma, Exercise-
Induced [MH:NOEXP] OR Asthma, Occupational [MH:NOEXP] OR Behavior, Addictive 
[MH:NOEXP] OR Bullying [MH:NOEXP] OR Cadmium Poisoning [MH:NOEXP] OR Carbon 
Monoxide Poisoning [MH:NOEXP] OR Carbon Tetrachloride Poisoning [MH:NOEXP] OR 
Carcinogenicity Tests [MH:NOEXP] OR Carcinogens [MH:NOEXP] OR Carcinogens, 
Environmental [MH:NOEXP] OR Causality [MH:NOEXP] OR Cardiomegaly, Exercise-Induced 
[MH:NOEXP] OR Chemical Warfare Agents [MH:NOEXP] OR Chemically-Induced Disorders 
[MH:NOEXP] OR Child Abuse [MH:NOEXP] OR Child Abuse, Sexual [MH:NOEXP] OR 
Cholesterol, Dietary [MH:NOEXP] OR Ciguatera Poisoning [MH:NOEXP] OR Cocaine Related 
Disorders [MH:NOEXP] OR Cytomegalovirus Infections [MH:NOEXP] OR Dermatitis, 
Occupational [MH:NOEXP] OR Diet, Atherogenic [MH:NOEXP] OR Diet, High Fat 
[MH:NOEXP] OR Dietary Carbohydrates [MH:NOEXP] OR Dietary Fats [MH:NOEXP] OR 
Dietary Fats, Unsaturated [MH:NOEXP] OR Dietary Fiber [MH:NOEXP] OR Dietary Sucrose 
[MH:NOEXP] OR Domestic Violence [MH:NOEXP] OR Drug Contamination [MH:NOEXP] 
OR Drug Eruptions [MH:NOEXP] OR Drug Hypersensitivity [MH:NOEXP] OR Drug Overdose 
[MH:NOEXP] OR Drug-Induced Liver Injury [MH:NOEXP] OR Dyskinesia, Drug Induced 
[MH:NOEXP] OR Eating Disorders [MH:NOEXP] OR Environmental Exposure [MH:NOEXP] 
OR Environmental Illness [MH:NOEXP] OR Environmental Pollutants [MH:NOEXP] OR 
Environmental Pollution [MH:NOEXP] OR Environmental Pollution [MH:NOEXP] OR 
Escherichia Coli Infections [MH:NOEXP] OR Fast Foods [MH:NOEXP] OR Fluoride Poisoning 
[MH:NOEXP] OR Food Additives [MH:NOEXP] OR Food Contamination [MH:NOEXP] OR 
Food Hypersensitivity [MH:NOEXP] OR Foodborne Diseases [MH:NOEXP] OR Gas Poisoning 
[MH:NOEXP] OR Hazardous Substances [MH:NOEXP] OR Hazardous Waste [MH:NOEXP] 
OR Hearing Loss, Noise Induced [MH:NOEXP] OR Heavy Metal Poisoning, Nervous System 
[MH:NOEXP] OR Hepatitis A, Chronic [MH:NOEXP] OR Hepatitis B, Chronic [MH:NOEXP] 
OR Hepatitis C, Chronic [MH:NOEXP] OR Heroin Dependence [MH:NOEXP] OR 
Herpesviridae Infections [MH:NOEXP] OR Htlv I Infections [MH:NOEXP] OR 
Hypersensitivity [MH:NOEXP] OR Hypersensitivity, Delayed [MH:NOEXP] OR 
Hypersensitivity, Immediate [MH:NOEXP] OR Iatrogenic Disease [MH:NOEXP] OR Inhalation 
Exposure [MH:NOEXP] OR Iron Overload [MH:NOEXP] OR Lead Poisoning [MH:NOEXP] 
OR Lead Poisoning, Nervous System [MH:NOEXP] OR Lead Poisoning, Nervous System, 
Adult [MH:NOEXP] OR Lead Poisoning, Nervous System, Childhood [MH:NOEXP] OR 
Leukemia, Radiation Induced [MH:NOEXP] OR Manganese Poisoning [MH:NOEXP] OR 
Marijuana Abuse [MH:NOEXP] OR Maternal Exposure [MH:NOEXP] OR Mercury Poisoning 
[MH:NOEXP] OR Mercury Poisoning, Nervous System [MH:NOEXP] OR Morphine 
Dependence [MH:NOEXP] OR Mptp Poisoning [MH:NOEXP] OR Mushroom Poisoning 
[MH:NOEXP] OR Mutagenicity Tests [MH:NOEXP] OR Mutagens [MH:NOEXP] OR 
Neoplasms, Radiation Induced [MH:NOEXP] OR Neurotoxicity Syndromes [MH:NOEXP] OR 
Occupational Diseases [MH:NOEXP] OR Occupational Exposure [MH:NOEXP] OR Opioid 




Related Disorders [MH:NOEXP] OR Opportunistic Infections [MH:NOEXP] OR 
Organophosphate Poisoning [MH:NOEXP] OR Paternal Exposure [MH:NOEXP] OR Plant 
Poisoning [MH:NOEXP] OR Pneumonia, Ventilator-Associated [MH:NOEXP] OR Poisoning 
[MH:NOEXP] OR Poisons [MH:NOEXP] OR Prenatal Exposure Delayed Effects 
[MH:NOEXP] OR Psychoses, Substance Induced [MH:NOEXP] OR Radiation Effects 
[MH:NOEXP] OR Radiation Injuries [MH:NOEXP] OR Radioactive Hazard Release 
[MH:NOEXP] OR Radioactive Pollutants [MH:NOEXP] OR Respiratory Hypersensitivity 
[MH:NOEXP] OR Salmonella Food Poisoning [MH:NOEXP] OR Sedentary Lifestyle 
[MH:NOEXP] OR Shellfish Poisoning [MH:NOEXP] OR Sleep Deprivation [MH:NOEXP] OR 
Sleep Disorders [MH:NOEXP] OR Sodium Chloride, Dietary [MH:NOEXP] OR Sodium, 
Dietary [MH:NOEXP] OR Soil Pollutants [MH:NOEXP] OR Soil Pollutants, Radioactive 
[MH:NOEXP] OR Spouse Abuse [MH:NOEXP] OR Staphylococcal Food Poisoning 
[MH:NOEXP] OR Staphylococcal Infections [MH:NOEXP] OR Streptococcal Infections 
[MH:NOEXP] OR Substance Abuse, Intravenous [MH:NOEXP] OR Substance Withdrawal 
Syndrome [MH:NOEXP] OR Substance-Related Disorders [MH:NOEXP] OR Teratogens 
[MH:NOEXP] OR Tobacco Smoke Pollution [MH:NOEXP] OR Tobacco Use Disorder 
[MH:NOEXP] OR Toxicity Tests, Chronic [MH:NOEXP] OR Virus Diseases [MH:NOEXP] 
OR Vitamin D Deficiency [MH:NOEXP] OR Water Pollutants [MH:NOEXP] OR Water 
Pollutants, Chemical [MH:NOEXP] OR Water Pollutants, Radioactive [MH:NOEXP] OR Water 
Pollution [MH:NOEXP] OR Water Pollution, Chemical [MH:NOEXP]) 




7C. Quick Reference Listing of Query Terms in 7B 
 
7C1. MeSH Qualifier Query Terms 
 





7C2. Title Text Term Query 
(included after 7C5 below due to size) 
 
 







exposure(s) [at end of phrase] 
exposed to 
poisoning [at end] 
workers [at end] 






virus*    (these did not have to be separated from the phrases) 
generic bacterial headings (these did not have to be separated from the phrases) 
 












7C5. Generic MeSH Terms Strongly Related to Potential Causes 
 
7C5a. MeSH Heading Terms 
 
Bacterial Infections and Mycoses 
Cardiovascular Diseases 
Chemically-Induced Disorders 
Congenital, Hereditary, and Neonatal Diseases and Abnormalities 
Digestive System Diseases 
Disorders of Environmental Origin 
Endocrine System Diseases 
Eye Diseases 
Female Urogenital Diseases and Pregnancy Complications 
Hemic and Lymphatic Diseases 
Immune System Diseases 
Male Urogenital Diseases 
Musculoskeletal Diseases 
Neoplasms 
Nervous System Diseases 




Pathological Conditions, Signs and Symptoms 
Respiratory Tract Diseases 
Skin and Connective Tissue Diseases 
Stomatognathic Diseases 
Virus Diseases 




7C5b. MeSH Heading No Explode Terms 
 
"Drug-Related Side Effects AND Adverse Reactions" 
Abnormalities, Drug Induced 
Abnormalities, Radiation-Induced 
Agricultural Workers Diseases 
Aids Related Opportunistic Infections 
Air Pollutants 
Air Pollutants, Occupational 
Air Pollutants, Radioactive 
Air Pollution 
Air Pollution, Indoor 
Air Pollution, Radioactive 
Alcohol Drinking 













Carbon Monoxide Poisoning 






Chemical Warfare Agents 
Chemically-Induced Disorders 
Child Abuse 
Child Abuse, Sexual 
Cholesterol, Dietary 
Ciguatera Poisoning 




Diet, High Fat 
Dietary Carbohydrates 
Dietary Fats 








Drug-Induced Liver Injury 

















Hearing Loss, Noise Induced 
Heavy Metal Poisoning, Nervous System 
Hepatitis A, Chronic 
Hepatitis B, Chronic 
Hepatitis C, Chronic 
Heroin Dependence 
Herpesviridae Infections 








Lead Poisoning, Nervous System 
Lead Poisoning, Nervous System, Adult 
Lead Poisoning, Nervous System, Childhood 



























Prenatal Exposure Delayed Effects 
Psychoses, Substance Induced 
Radiation Effects 
Radiation Injuries 
Radioactive Hazard Release 
Radioactive Pollutants 
Respiratory Hypersensitivity 





Sodium Chloride, Dietary 
Sodium, Dietary 
Soil Pollutants 
Soil Pollutants, Radioactive 
Spouse Abuse 
Staphylococcal Food Poisoning 
Staphylococcal Infections 
Streptococcal Infections 
Substance Abuse, Intravenous 
Substance Withdrawal Syndrome 
Substance-Related Disorders 
Teratogens 
Tobacco Smoke Pollution 
Tobacco Use Disorder 
Toxicity Tests, Chronic 
Virus Diseases 
Vitamin D Deficiency 
Water Pollutants 
Water Pollutants, Chemical 
Water Pollutants, Radioactive 
Water Pollution 
Water Pollution, Chemical 





7C2. Title Text Term Query 
(details expanded) 
 



























(toxin* AND fatal*) 
(toxin* AND adverse) 
(toxin* AND morbid*) 
(toxin* AND mortality) 
(toxin* AND anaphyla) 
(toxin* AND harm) 
(toxin* AND damag*) 
(toxin* AND deteriorat*) 
(toxin* AND exacerbat*) 
(toxin* AND trigger*) 




(Ionizing AND risk*) 
(risk-of AND adverse) 
(adverse-health-effect* AND effects-of) 































(effect AND subchronic) 
(effects AND subchronic) 
(effect-of AND prenatal) 
























(adversity AND early) 
(adversity AND child*) 
(adversity AND life*) 
(adversity AND social) 






(damage-in AND mice) 
(damage-in AND rats) 
hepatic-damage 
liver-damage 
(increased-risk* AND after) 
(increased-risk* AND following) 
(increased-risk* AND related-to) 
(increased-risk* AND resulting-from) 
(increased-risk* AND due-to) 
(complications AND after) 
(complications AND following) 
(complications AND related-to) 
(complications AND resulting-from) 
(complications AND due-to) 
(mutagenic AND after) 
(mutagenic AND following) 
(mutagenic AND related-to) 
(mutagenic AND resulting-from) 
(mutagenic AND due-to) 
(adverse-outcome* AND after) 
(adverse-outcome* AND following) 
(adverse-outcome* AND related-to) 
(adverse-outcome* AND resulting-from) 
(adverse-outcome* AND due-to) 
(life-threatening AND after) 
(life-threatening AND following) 
(life-threatening AND related-to) 
(life-threatening AND resulting-from) 
(life-threatening AND due-to) 
(lung-injury AND after) 
(lung-injury AND following) 
(lung-injury AND related-to) 
(lung-injury AND resulting-from) 
(lung-injury AND due-to) 
(renal-injury AND after) 
(renal-injury AND following) 
(renal-injury AND related-to) 
(renal-injury AND resulting-from) 
(renal-injury AND due-to) 
(susceptibility AND after) 
(susceptibility AND following) 
(susceptibility AND related-to) 
(susceptibility AND resulting-from) 
(susceptibility AND due-to) 
(adverse AND after) 
(adverse AND following) 
(adverse AND related-to) 
(adverse AND resulting-from) 
(adverse AND due-to) 
(allergic-reaction* AND after) 
(allergic-reaction* AND following) 
(allergic-reaction* AND related-to) 
(allergic-reaction* AND resulting-from) 
(allergic-reaction* AND due-to) 
(anaphyla* AND after) 
(anaphyla* AND following) 
(anaphyla* AND related-to) 
(anaphyla* AND resulting-from) 
(anaphyla* AND due-to) 
(cognitive-dysfunction AND after) 
(cognitive-dysfunction AND following) 
(cognitive-dysfunction AND related-to) 
(cognitive-dysfunction AND resulting-from) 
(cognitive-dysfunction AND due-to) 
(cardiac-dysfunction AND after) 
(cardiac-dysfunction AND following) 
(cardiac-dysfunction AND related-to) 
(cardiac-dysfunction AND resulting-from) 
(cardiac-dysfunction AND due-to) 
((dysfunction AND in-rats) AND after) 
((dysfunction AND in-rats) AND following) 
((dysfunction AND in-rats) AND related-to) 
((dysfunction AND in-rats) AND resulting-from) 
((dysfunction AND in-rats) AND due-to) 
(erectile-dysfunction AND after) 
(erectile-dysfunction AND following) 
(erectile-dysfunction AND related-to) 
(erectile-dysfunction AND resulting-from) 
(erectile-dysfunction AND due-to) 
(renal-dysfunction AND after) 
(renal-dysfunction AND following) 
(renal-dysfunction AND related-to) 
(renal-dysfunction AND resulting-from) 
(renal-dysfunction AND due-to) 
(mitochondrial-dysfunction AND after) 
(mitochondrial-dysfunction AND following) 
(mitochondrial-dysfunction AND related-to) 
(mitochondrial-dysfunction AND resulting-from) 
(mitochondrial-dysfunction AND due-to) 
(endothelial-dysfunction AND after) 
(endothelial-dysfunction AND following) 
(endothelial-dysfunction AND related-to) 
(endothelial-dysfunction AND resulting-from) 




(endothelial-dysfunction AND due-to) 
(sexual-dysfunction AND after) 
(sexual-dysfunction AND following) 
(sexual-dysfunction AND related-to) 
(sexual-dysfunction AND resulting-from) 
(sexual-dysfunction AND due-to) 
(ventricular-dysfunction AND after) 
(ventricular-dysfunction AND following) 
(ventricular-dysfunction AND related-to) 
(ventricular-dysfunction AND resulting-from) 
(ventricular-dysfunction AND due-to) 
(allograft-dysfunction AND after) 
(allograft-dysfunction AND following) 
(allograft-dysfunction AND related-to) 
(allograft-dysfunction AND resulting-from) 
(allograft-dysfunction AND due-to) 
(thyroid-dysfunction AND after) 
(thyroid-dysfunction AND following) 
(thyroid-dysfunction AND related-to) 
(thyroid-dysfunction AND resulting-from) 
(thyroid-dysfunction AND due-to) 
(graft-dysfunction AND after) 
(graft-dysfunction AND following) 
(graft-dysfunction AND related-to) 
(graft-dysfunction AND resulting-from) 
(graft-dysfunction AND due-to) 
(liver-dysfunction AND after) 
(liver-dysfunction AND following) 
(liver-dysfunction AND related-to) 
(liver-dysfunction AND resulting-from) 
(liver-dysfunction AND due-to) 
(diastolic-dysfunction AND after) 
(diastolic-dysfunction AND following) 
(diastolic-dysfunction AND related-to) 
(diastolic-dysfunction AND resulting-from) 
(diastolic-dysfunction AND due-to) 
(vascular-dysfunction AND after) 
(vascular-dysfunction AND following) 
(vascular-dysfunction AND related-to) 
(vascular-dysfunction AND resulting-from) 
(vascular-dysfunction AND due-to) 
(organ-dysfunction AND after) 
(organ-dysfunction AND following) 
(organ-dysfunction AND related-to) 
(organ-dysfunction AND resulting-from) 
(organ-dysfunction AND due-to) 
(barrier-dysfunction AND after) 
(barrier-dysfunction AND following) 
(barrier-dysfunction AND related-to) 
(barrier-dysfunction AND resulting-from) 
(barrier-dysfunction AND due-to) 
(myocardial-dysfunction AND after) 
(myocardial-dysfunction AND following) 
(myocardial-dysfunction AND related-to) 
(myocardial-dysfunction AND resulting-from) 
(myocardial-dysfunction AND due-to) 
(systolic-dysfunction AND after) 
(systolic-dysfunction AND following) 
(systolic-dysfunction AND related-to) 
(systolic-dysfunction AND resulting-from) 
(systolic-dysfunction AND due-to) 
(voiding-dysfunction AND after) 
(voiding-dysfunction AND following) 
(voiding-dysfunction AND related-to) 
(voiding-dysfunction AND resulting-from) 
(voiding-dysfunction AND due-to) 
(hepatic-dysfunction AND after) 
(hepatic-dysfunction AND following) 
(hepatic-dysfunction AND related-to) 
(hepatic-dysfunction AND resulting-from) 
(hepatic-dysfunction AND due-to) 
(bladder-dysfunction AND after) 
(bladder-dysfunction AND following) 
(bladder-dysfunction AND related-to) 
(bladder-dysfunction AND resulting-from) 
(bladder-dysfunction AND due-to) 
(bowel-dysfunction AND after) 
(bowel-dysfunction AND following) 
(bowel-dysfunction AND related-to) 
(bowel-dysfunction AND resulting-from) 
(bowel-dysfunction AND due-to) 
(urinary-dysfunction AND after) 
(urinary-dysfunction AND following) 
(urinary-dysfunction AND related-to) 
(urinary-dysfunction AND resulting-from) 
(urinary-dysfunction AND due-to) 
(swallowing-dysfunction AND after) 
(swallowing-dysfunction AND following) 
(swallowing-dysfunction AND related-to) 
(swallowing-dysfunction AND resulting-from) 
(swallowing-dysfunction AND due-to) 
(anorectal-dysfunction AND after) 
(anorectal-dysfunction AND following) 
(anorectal-dysfunction AND related-to) 
(anorectal-dysfunction AND resulting-from) 
(anorectal-dysfunction AND due-to) 
(cardiopulmonary-dysfunction AND after) 
(cardiopulmonary-dysfunction AND following) 
(cardiopulmonary-dysfunction AND related-to) 
(cardiopulmonary-dysfunction AND resulting-from) 
(cardiopulmonary-dysfunction AND due-to) 
(fatal AND after) 
(fatal AND following) 
(fatal AND related-to) 
(fatal AND resulting-from) 
(fatal AND due-to) 




(fibrosis AND after) 
(fibrosis AND following) 
(fibrosis AND related-to) 
(fibrosis AND resulting-from) 
(fibrosis AND due-to) 
(high-incidence AND after) 
(high-incidence AND following) 
(high-incidence AND related-to) 
(high-incidence AND resulting-from) 
(high-incidence AND due-to) 
(iatrogenic AND after) 
(iatrogenic AND following) 
(iatrogenic AND related-to) 
(iatrogenic AND resulting-from) 
(iatrogenic AND due-to) 
(mortality AND after) 
(mortality AND following) 
(mortality AND related-to) 
(mortality AND resulting-from) 
(mortality AND due-to) 
(morbidity AND after) 
(morbidity AND following) 
(morbidity AND related-to) 
(morbidity AND resulting-from) 
(morbidity AND due-to) 
(risk* AND after) 
(risk* AND following) 
(risk* AND related-to) 
(risk* AND resulting-from) 
(risk* AND due-to) 







Each of these linking terms below were combined with each of the diseases listed below. 
 


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































AND Mice [ti]) (injury-in 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































 I acknowledge and appreciate the contribution of Michael B. Briggs in constructing the 
quick reference listing of query terms from the previous section. 
 





TAXONOMY OF PERVASIVE CAUSES WITH EXAMPLES 
8A. Overview 
 Table 8-1 is a taxonomy that categorizes the different types of pervasive foundational 
causes, and contains many illustrative examples of pervasive causes linked to diseases.  It is 
similar in structure to Table 3-1 in the main text (Chapter 3), but far more detailed with the 
illustrative examples.  The format in describing results in each category/ sub-category is to 
present some of the leading MeSH terms, Title text terms, and CRN terms that were identified in 
the study as pervasive causes, highlighted to distinguish levels of pervasiveness. 
 A threshold of two papers or more was used for computational purposes; there had to be 
at least two papers in which the foundational cause co-occurred with the disease in order for it to 
be considered to have an impact.  Had only one paper been used as the threshold, the number of 
diseases impacted by a given foundational cause would have increased by anywhere from 50% 
to 150%. 
 For each sub-category shown, the MeSH, Title, and CRN pervasive cause terms appear in 
parentheses after the sub-category heading, followed by record Titles selected to show the 
breadth of diseases impacted by the pervasive 'cause'.  These Titles will (in most cases) then be 
followed by a brief discussion of the findings.  The interested reader can insert the Title of the 
illustrative example in Pubmed, and retrieve the full record.  The main objective of showing the 
foundational 'causes' terms and Titles is to convey the breadth of potential pervasive foundational 
causes (that need to be eliminated for maximal restorative treatment effectiveness) to the reader. 
 The pervasive foundational causes were further arbitrarily divided into highly pervasive, 
moderately pervasive, and pervasive.  Numbers of diseases/ symptoms/ conditions impacted by 
each type were: highly pervasive, >100; moderately pervasive, 70-100; pervasive, 30-70.  In the 
taxonomy presentation of causes, the highly pervasive causes are bolded, italicized, and 
underlined, the moderately pervasive causes are italicized and underlined, and the pervasive 
causes are underlined.   
 There is a caveat here.  For those causes that are important and ubiquitous, there tend to 
be multiple MeSH terms (and Title terms) that describe different aspects.  Each MeSH term has 
its unique aspects, and cannot typically be combined with other seemingly related terms.  As an 
example, the MeSH term Smoking co-occurred with 1498 Disease MeSH terms in the MeSH 
Qualifiers-derived database.  By any measure, this is a highly pervasive foundational cause.  
Very related terms include Tobacco Smoke Pollution (467), Tobacco (565), Tobacco Products 
(43), and Nicotine (305).  So, the numbers associated with the leading MeSH term for a highly 
pervasive foundational cause (such as Smoking) should be viewed as the lower level of its true 
impact.  The same is true for Title text phrases. 
 Further, as Chapter 9 shows in far more detail, given the imperfections in  
1) the queries,  




2) the MeSH Headings and Qualifiers assignment process, and  
3) the (in)ability to extract causes from the Abstracts for these retrievals due to computer 
memory limitations,  
it is clear that the true impact of the foundational causes presented here will be quantitatively 
much higher than the numbers suggest.  For this reason, the results in this book should be 
viewed as a proof-of-principle demonstration.  To enhance the numbers of foundational causes, 
an adequately resourced study (with an in-house copy of Medline, along with access to the 
Science Citation Index journals) should be performed to gain a better understanding of the actual 
quantitative impact of large numbers of foundational causes on disease (based on the published 
literature). 
 The pervasive foundational causes identified are at different levels of importance to the 
diseases identified, and are at different levels of verification/ validation.  In the literature 
examined, some foundational causes were identified through in vitro cell or tissue tests.  Some 
foundational causes were identified through animal experiments, and other foundational causes 
through epidemiological studies.  Some foundational causes were based on individual case 
studies, while others were based on trials with large numbers of subjects.  By and large, those 
foundational causes associated with large numbers of papers published and large numbers of test 
subjects would have greater credibility.  However, as shown in Chapter 9, there may be (many) 
important foundational causes being witheld from the literature deliberately, so numbers of 
papers is not a definitive metric for credibility. 




8B. Taxonomy with Illustrative Examples 
8B1. Format 
 In the table below, as stated previously, each sub-category heading will typically be 
followed by a parenthesis containing pervasive Title text terms, MeSH terms, or CRN terms to 
effectively define the category.  The parenthesis will then be followed by article Titles that relate 
some of the foundational causes in the category to diseases or symptoms.  Each Title will be 
preceded by an asterisk (*).  These Titles are illustrative examples only, and represent a very 
small sample of the true impacts of the myriad foundational causes. 
 A word about the content of Titles.  There are two major problems I have encountered 
with biomedical article Titles, especially compared to the Titles of non-biomedical technical 
articles.  The biomedical Titles can be misleading.  Also, the biomedical Titles, especially for the 
larger-scale studies, tend to emphasize what was done rather than the significant results.  Thus, 
one reason many examples presented below use Titles reflecting case studies is that these types 
of studies tend to be more forthright in presenting unambiguous significant results.  The most 
egregious examples of misleading Titles were in the Occupational/ Environmental and Iatrogenic 
categories, and to some degree in the Food Additives component of the Lifestyle category, where 
the potential causes were mainly the products of high technology. 
 What do I mean by misleading?  A Title might have the form 'Association between 
Substance X and leukemia'.  In the Abstract, however, the conclusion may be 'this study found 
no association between Substance X and leukemia'.  This may be the tradition among biomedical 
article authors; however, I find it disingenuous, and it limits the value of Titles for identifying 
potential foundational causes or other important factors.  Any Titles shown in the illustrative 
examples in this chapter of the capitalized form 'ASSOCIATION BETWEEN SUBSTANCE X 
AND LEUKEMIA' should be interpreted as 'there was an association between substance X and 
Leukemia'.  These types of Titles are CAPITALIZED for further emphasis. 
 What do I mean by emphasizing what was done rather than significant results?  Most 
large-scale studies' Titles would be of the form 'a risk assessment of cancer for coke oven 
workers'.  In the Abstract, the conclusion might be 'there was an increased incidence of lung and 
bladder cancer with OR 2.5.'  Why is that not in the Title? 
 Because of these Title limitations, an adequately-resourced study would need to examine 
the Abstracts for foundational causes to get a fuller picture.  Using Titles only for text 
information extraction provides the tip of a much larger iceberg. 
8B2. Table 8-1 - Categories, Sub-Categories, and Illustrative Examples 
1. Lifestyle 
 Lifestyle includes choices mainly under individual control, and is divided arbitrarily into 
Diet, Activity, Substance Abuse, Other. 
1A. Diet 




 Poor diet is ubiquitous.  It is used to induce myriad diseases in test animals, and it is a 
critical disease factor from many epidemiological and case studies.  Components of poor diet 
include:  
1A1. Excesses 
-High salt/sodium (e.g., Dietary Sodium Chloride)  
*Telmisartan improves survival and ventricular function in SHR rats with extensive 
cardiovascular damage induced by dietary salt excess. 
*A CASE-CONTROL STUDY ON THE RELATIONSHIP BETWEEN SALT INTAKE AND 
SALTY TASTE AND RISK OF GASTRIC CANCER. 
*A high-salt diet further impairs age-associated declines in cognitive, behavioral, and 
cardiovascular functions in male Fischer brown Norway rats. 
*A randomized trial of dietary sodium restriction in CKD. 
*A 5-component mathematical model for salt-induced hypertension in Dahl-S and Dahl-R rats. 
*Dietary sodium restriction: a neglected therapeutic opportunity in chronic kidney disease. 
-High sugar/sucrose/glycemic load (e.g., High Fructose; High Glucose; Dietary Sucrose; 
Sweetening Agents) 
*Cardiovascular disease mortality: the deleterious effects of excess dietary sugar intake. 
*Mammalian target of rapamycin hyperactivity mediates the detrimental effects of a high sucrose 
diet on Alzheimer's disease pathology. 
*SUCROSE, HIGH-SUGAR FOODS, AND RISK OF ENDOMETRIAL CANCER--A 
POPULATION-BASED COHORT STUDY. 
*A causal role for uric acid in fructose-induced metabolic syndrome. 
*Adrenomedullin protects against fructose-induced insulin resistance and myocardial 
hypertrophy in rats. 
*Adverse effects of dietary fructose. 
*A dose of fructose induces oxidative stress during endurance and strength exercise. 
*A high-fructose diet induces hippocampal insulin resistance and exacerbates memory deficits in 
male Sprague-Dawley rats. 
*Androgens are necessary for the development of fructose-induced hypertension. 




*A high-sucrose diet induces fatty liver, but not deterioration of diabetes mellitus in Zucker 
diabetic fatty rats. 
*A high-sucrose isocaloric pair-fed model induces obesity and impairs NDUFB6 gene function 
in rat adipose tissue. 
*A sucrose-rich diet affects triglyceride metabolism differently in pregnant and nonpregnant rats 
and has negative effects on fetal growth. 
*3,4,5,6-Tetrahydroxyxanthone prevents vascular endothelial cell apoptosis induced by high 
glucose. 
*3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced 
proliferation of mesangial cells via modulation of Rho GTPase/ p21 signaling pathway: 
Implications for diabetic nephropathy. 
*Accelerated premature stress-induced senescence of young annulus fibrosus cells of rats by 
high glucose-induced oxidative stress. 
*Advanced glycation end products (AGE) induce the receptor for AGE in the colonic mucosa of 
azoxymethane-injected Fischer 344 rats fed with a high-linoleic acid and high-glucose diet. 
*Adverse effects of high-intensity sweeteners on energy intake and weight control in male and 
obesity-prone female rats. 
*Artificial sweeteners induce glucose intolerance by altering the gut microbiota. 
*The potential toxicity of artificial sweeteners. 
*MAY ARTIFICIAL SWEETENERS NOT SUGAR BE THE CULPRIT OF DRAMATIC 
INCREASE OF INFLAMMATORY BOWEL DISEASE IN CHINA? 
-High fat (e.g., Dietary Fats; High-Fat Diet)  
*Dietary fat without body weight gain increases in vivo MCF-7 human breast cancer cell growth 
and decreases natural killer cell cytotoxicity. 
*Will metformin postpone high-fat diet promotion of TRAMP mouse prostate cancer 
development and progression? 
*High-fat-diet-mediated dysbiosis promotes intestinal carcinogenesis independently of obesity. 
*Insulin reverses the high-fat diet-induced increase in brain abeta and improves memory in an 
animal model of Alzheimer disease. 
*12/15-lipoxygenase is required for the early onset of high fat diet-induced adipose tissue 
inflammation and insulin resistance in mice. 




*12/15-Lipoxygenase mediates high-fat diet-induced endothelial tight junction disruption and 
monocyte transmigration: a new role for 15(S)-hydroxyeicosatetraenoic acid in endothelial cell 
dysfunction. 
*17alpha-Estradiol and genistein inhibit high fat diet induced prostate gene expression and 
prostate growth in the rat. 
*17beta-Estradiol attenuates saturated fatty acid diet-induced liver injury in ovariectomized mice 
by up-regulating hepatic senescence marker protein-30. 
*A high fat diet in CF-1 mice: An experimental model for metabolic syndrome. 
*A high-fat diet activates oncogenic Kras and COX2 to induce development of pancreatic ductal 
adenocarcinoma in mice. 
*A high-fat diet during rat pregnancy or suckling induces cardiovascular dysfunction in adult 
offspring. 
-High protein/tryptophan (e.g., High Meat; Milk; Dairy; Purines; High Dietary Proteins; 
Seafood)  
*Advanced glycation end products and nephrotoxicity of high-protein diets. 
*DIETARY MEAT, ENDOGENOUS NITROSATION AND COLORECTAL CANCER. 
*Resistant starch may reduce colon cancer risk from red meat. 
*Higher red meat intake in young women increases breast cancer risk. 
*Red meat consumption is associated with an increased overall cancer risk: a prospective cohort 
study in Korea. 
*RED MEAT CONSUMPTION AND STOMACH CANCER RISK: A META-ANALYSIS. 
*INTAKE OF RED MEAT AND HETEROCYCLIC AMINES, METABOLIC PATHWAY 
GENES AND BLADDER CANCER RISK. 
*High meat consumption linked to gastric-cancer risk. 
*2-amino-1-methyl-6-phenylimidazo4,5-bpyridine, a carcinogen in high-temperature-cooked 
meat, and breast cancer risk. 
*Association of meat intake and meat-derived mutagen exposure with the risk of colorectal 
polyps by histologic type. 
*Carcinogenicity of mutagens from cooked meats. 
*High-protein-low-carbohydrate diet: deleterious metabolic and cardiovascular effects depend on 
age. 




*Dietary protein restriction and preservation of kidney function in chronic kidney disease. 
*Central vein occlusion caused by high-protein diet. 
*High dietary protein intake induces endothelial dysfunction in uninephrectomized rats. 
*Delayed anaphylaxis after ingestion of meat : Carbohydrate epitope galactose-alpha-1,3-
galactose as cause of severe anaphylactic reactions. 
 Most of the articles related to meat consumption emphasized adverse effects.  
Unfortunately, in most of these meat studies, especially epidemiological studies on humans, 
there was no separation of confounding effects. 
 Most meat available to the American public comes from CAFO (confined animal feeding 
operations).  These animals are raised confined in very close quarters.  To reduce infections from 
such close confinement, animals are given antibiotics, and to increase growth more rapidly, 
animals are given synthetic growth hormones.  Their feed is grain-based, not the grass they 
would have if pasture-raised. 
 In addition to the various chronic diseases associated with meat consumption, there were 
also many articles related to adverse effects of meat contamination.  Is the direct cause of 
resulting disease mentioned in the articles the meat (the carrier), or (typically) the bacteria? 
 Would the various infectious and chronic diseases associated with meat consumption in 
the articles be as copious and serious for pasture/ grass-fed animals not raised under confined 
conditions, and not given antibiotics and synthetic growth hormones? 
 Finally, most meat eaten is cooked, much of it at high temperatures, sometimes in the 
presence of additional fats.  High-temperature cooking, especially of animal foods that are high 
in protein and fat, results in substantial production of advanced glycation end products and other 
harmful substances.  How are the harmful effects of the cooking separated from the harmful 
effects of the meat?  I didn't see the separation in any papers I examined. 
 I accept the implications of the bulk of the literature on the adverse effects of meat 
consumption given what is consumed by the public today, especially the American public.  
However, it has not been demonstrated to my satisfaction that meat from 'organic' pasture-raised 
grass-fed animals not fed antibiotics and growth hormones and not cooked at high temperatures 
is equally harmful, and there is some evidence that a moderate amount may be beneficial. 
-High Cholesterol (e.g., Dietary Cholesterol) 
*Researchers find link between high cholesterol and breast cancer. 
*DIETARY CHOLESTEROL INTAKE AND CANCER. 
*Dietary cholesterol increases ventricular volume and narrows cerebrovascular diameter in a 
rabbit model of Alzheimer's disease. 




*High cholesterol levels are associated with coronary microvascular dysfunction. 
*A cloned pig model for examining atherosclerosis induced by high fat, high cholesterol diets. 
*A guanidinylated bioreducible polymer as a novel gene carrier to the corpus cavernosum of 
mice with high-cholesterol diet-induced erectile dysfunction. 
*A novel antihypoglycemic role of inducible nitric oxide synthase in liver inflammatory 
response induced by dietary cholesterol and endotoxemia. 
*Cardiac systolic and diastolic dysfunction after a cholesterol-rich diet. 
*Cholesterol accumulation caused by low density lipoprotein receptor deficiency or a 
cholesterol-rich diet results in ectopic bone formation during experimental osteoarthritis. 
*Combined effect of probucol and insulin on renal damage in diabetic rats fed a high cholesterol 
diet. 
-High Refined Carbohydrates (e.g., Dietary Carbohydrates; High Carbohydrate Diet; Wheat)  
*A high carbohydrate diet induces insulin resistance through decreased glucose utilization in 
ovariectomized rats. 
*DIETARY CARBOHYDRATES, REFINED GRAINS, GLYCEMIC LOAD, AND RISK OF 
CORONARY HEART DISEASE IN CHINESE ADULTS. 
*Nutrition and Alzheimer's disease: the detrimental role of a high carbohydrate diet. 
*HIGH CARBOHYDRATE DIETS AND ALZHEIMER'S DISEASE. 
*Naringin improves diet-induced cardiovascular dysfunction and obesity in high carbohydrate, 
high fat diet-fed rats. 
*A high carbohydrate meal yields a lower ischemic threshold than a high fat meal in patients 
with stable coronary disease. 
*A high fat/high carbohydrate diet induces aortic valve disease in C57BL/6J mice. 
*A high-carbohydrate diet in the immediate postnatal life of rats induces adaptations 
predisposing to adult-onset obesity. 
*Caffeine prevents cognitive impairment induced by chronic psychosocial stress and/or high fat-
high carbohydrate diet. 
*Sudden cardiac death may be caused by malnutrition. High carbohydrate diet may cause energy 
imbalance in athletes. 
*Increased consumption of refined carbohydrates and the epidemic of type 2 diabetes in the 
United States: an ecologic assessment. 




*Increasing evidence that diet impacts cognitive function. Reduce refined carbohydrates and 
sugar intake, increase protein and "good" fats consumption to help prevent cognitive impairment. 
-High temperature (e.g., Advanced glycation end products; Nitrosamines; Cooking)  
*A STATISTICAL REGRESSION MODEL FOR THE ESTIMATION OF ACRYLAMIDE 
CONCENTRATIONS IN FRENCH FRIES FOR EXCESS LIFETIME CANCER RISK 
ASSESSMENT. 
*DIETARY ACRYLAMIDE INTAKE AND THE RISK OF LYMPHATIC MALIGNANCIES: 
THE NETHERLANDS COHORT STUDY ON DIET AND CANCER. 
*NITROSAMINE AND RELATED FOOD INTAKE AND GASTRIC AND OESOPHAGEAL 
CANCER RISK: A SYSTEMATIC REVIEW OF THE EPIDEMIOLOGICAL EVIDENCE. 
*EXPOSURE TO N-NITROSO COMPOUNDS IN A POPULATION OF HIGH LIVER 
CANCER REGIONS IN THAILAND: VOLATILE NITROSAMINE (VNA) LEVELS IN THAI 
FOOD. 
*CONSUMPTION OF DEEP-FRIED FOODS AND RISK OF PROSTATE CANCER 
*Risk factors for lower urinary tract cancer: the role of total fluid consumption, nitrites and 
nitrosamines, and selected foods. 
*Advanced glycation end products increase carbohydrate responsive element binding protein 
expression and promote cancer cell proliferation. 
*Possible participation of advanced glycation end products in the pathogenesis of colorectal 
cancer in diabetic patients. 
*DIETARY CONSUMPTION OF MEAT, FAT, ANIMAL PRODUCTS AND ADVANCED 
GLYCATION END-PRODUCTS AND THE RISK OF BARRETT'S OESOPHAGUS. 
*A developmental nephron deficit in rats is associated with increased susceptibility to a 
secondary renal injury due to advanced glycation end-products. 
*Advanced glycation end product accumulation: a new enemy to target in chronic kidney 
disease? 
*A role for advanced glycation end products in diminished bone healing in type 1 diabetes. 
*Dietary advanced glycation end products are associated with decline in memory in young 
elderly 
*Oral glycotoxins are a modifiable cause of dementia and the metabolic syndrome in mice and 
humans 
*A study on serum advanced glycation end products and its association with oxidative stress and 
paraoxonase activity in type 2 diabetic patients with vascular complications. 




*ADVANCED GLYCATION END PRODUCTS AND DIABETIC CARDIOVASCULAR 
DISEASE 
*Abnormalities in platelets and vascular endothelial cells induced by glycated lipoproteins. 
*Accumulation of advanced glycation end products as a molecular mechanism for aging as a risk 
factor in osteoarthritis. 
*ADVANCED GLYCATION END PRODUCTS AND CARDIOVASCULAR DISEASE. 
*DIETARY ADVANCED GLYCATION END PRODUCTS AND AGING. 
-High/altered soy (e.g., Genistein)  
*Adverse effects on female development and reproduction in CD-1 mice following neonatal 
exposure to the phytoestrogen genistein at environmentally relevant doses. 
*A possible cause of Alzheimer's dementia - industrial soy foods. 
*Altered mammary gland development in male rats exposed to genistein and methoxychlor. 
*Change in mutagenic activity of genistein after a nitrite treatment. 
*Chronic dietary exposure to a low-dose mixture of genistein and vinclozolin modifies the 
reproductive axis, testis transcriptome, and fertility. 
*Early life exposure to genistein and daidzein disrupts structural development of reproductive 
organs in female mice. 
*Allergy or histamine intolerance? Cheilitis caused by soy sauce. 
*A soy diet accelerates renal damage in autoimmune MRL/Mp-lpr/lpr mice. 
*Anaphylaxis caused by hidden soybean allergens in pillows. 
*Baker's asthma related to soybean lecithin exposure. 
 The soybean results were mixed.  While Genistein had numerous adverse effects, there 
were also many papers describing its use to retard cancer. 
-High Supplements/Plant Extracts (e.g., Phytotherapy; N-Acetylcysteine; Capsaicin; Caffeine; 
Herbs/Chinese Herbal Medicine)  
*Multi-organ toxicity following ingestion of mixed herbal preparations: an unusual but 
dangerous adverse effect of phytotherapy. 
*Fatal renal failure due to the Chinese herb "GuanMu Tong'' (Aristolochia manshuriensis): 
Autopsy findings and review of literature 




*A case of drug induced hepatitis and interstitial pneumonia caused by a herbal drug, Dai-saiko-
to. 
*A case of drug induced liver injury caused by a herbal drug, bofu-tsu-sho-san. 
*A case of hepatitis and pneumonitis caused by Bofutsusyo-san herbal medicine. 
*Acute exposure to caffeine selectively disrupts context conditioning in rats. 
*Acute hemorrhagic myocardial necrosis and sudden death of rats exposed to a combination of 
ephedrine and caffeine. 
*Life-threatening cardiovascular toxicity following ingestion of Chinese herbal medicine. 
*Increased risk of urinary tract cancer in ESRD patients associated with usage of Chinese herbal 
products suspected of containing aristolochic acid. 
*Anaphylaxis due to caffeine. 
*A bradykinin (BK)1 receptor antagonist blocks capsaicin-induced ear inflammation in mice. 
*Age-related differences in the time course of capsaicin-induced hyperalgesia. 
*A new model for inflammatory colonic disease induced by capsaicin in rats. 
*Anaphylactic reaction to N-acetylcysteine after poisoning with paracetamol. 
*DMPS and N-acetylcysteine induced renal toxicity in mice exposed to mercury. 
 Another category where the results are mixed.  Variants of phytotherapy and Herbal 
Medicine have shown many positive benefits in the research literature, but they are not without 
their adverse impacts as well. 
-High selenium 
*A case-control study of the risk of cutaneous melanoma associated with three selenium 
exposure indicators. 
*Accidental death from acute selenium poisoning. 
*SELENIUM LEVELS IN RICE SAMPLES FROM HIGH AND LOW RISK AREAS FOR 
ESOPHAGEAL CANCER. 
*PROSTATE CANCER: NEW DATA ON RISKS OF SELENIUM AND VITAMIN E. 
*SELENIUM EXPOSURE AND DEPRESSIVE SYMPTOMS: THE CORONARY ARTERY 
RISK DEVELOPMENT IN YOUNG ADULTS TRACE ELEMENT STUDY. 
*Active oxygen generation as a possible mechanism of selenium toxicity. 




*Acute selenium poisoning by paradise nuts (Lecythis ollaria). 
*The toxicity of combination of selenium, fluoride and arsenic on rat embryos. 
 More mixed results.  Many papers on selenium toxicity were reported, but the larger 
fraction dealt with selenium in its anti-cancer role and protective role in metal poisoning.  
Selenium deficiency led to many problems.  Balance appears to be the key here; neither too 
much nor too little. 
-Food poisoning/Food Toxicity (e.g., Areca; Plant Oils; Yeast; Mushroom)  
*A case of anaphylactic reaction following matsutake mushroom ingestion: demonstration of 
histamine release reaction of basophils. 
*A case of chronic hypersensitivity pneumonitis induced by shiitake mushroom spores. 
*Acute encephalopathy caused by cyanogenic fungi in 2004, and magic mushroom regulation in 
Japan. 
*Acute renal failure as a sequela of mushroom poisoning with Cortinarius speciocissimus. 
*Areca nut extract induces pyknotic necrosis in serum-starved oral cells via increasing reactive 
oxygen species and inhibiting GSK3beta: an implication for cytopathic effects in betel quid 
chewers. 
*Betel quid and areca nut are carcinogenic without tobacco. 
*Genetic damage in cultured human keratinocytes stressed by long-term exposure to areca nut 
extracts. 
*A striking and frequent cause of premature thelarche in children: Foeniculum vulgare. 
*Accelerated atherosclerosis in apolipoprotein E-deficient mice fed Western diets containing 
palm oil compared with extra virgin olive oils: a role for small, dense high-density lipoproteins. 
*ASSOCIATION OF MUSTARD OIL AS COOKING MEDIA WITH CARCINOMA OF THE 
GALLBLADDER. 
 The sub-category above reflects the adverse effects of excesses of dietary components.  
Excesses of these components in both directions, both too much and too little, can be harmful.  In 
particular, excesses of fat, sugar/ glycemic loading, salt, protein, meat, calories, cholesterol, soy, 
herbs (especially Chinese herbs and the accompanying aristolochic acids), and processing/ 
cooking temperatures had adverse impacts across the disease spectrum.  The highly pervasive 
components of this diet sub-category tend to be high-fat, high-sugar, high-salt, high-meat, and 
the high-temperature cooking that results in harmful products (e.g., advanced glycation end 
products, heterocyclic amines and nitrosamines, polycyclic aromatic hydrocarbons, and 
acrylamides). 





 Many deficiencies listed in the literature are symptoms, not foundational causes in the 
present sense.  Thus, a Vitamin A deficiency may be due to insufficient Vitamin A intake 
(foundational cause), or some metabolic problem that results in reduced Vitamin A (symptom). 
(e.g., Malnutrition; Starvation; Dehydration) 
*Anaphylactic reaction in experimental malnutrition. 
*Chronic malnutrition caused by a corn-based diet lowers the threshold for pentylenetetrazol-
induced seizures in rats. 
*Chronic moderate hypoxia and protein malnutrition both induce growth retardation, but have 
distinct effects on arterial endothelium-dependent reactivity in the chicken embryo. 
*Coerulear activation by crh and its role in hypertension induced by prenatal malnutrition in the 
rat. 
*Cognitive function of children with cystic fibrosis: deleterious effect of early malnutrition. 
*Acute diaphragmatic changes induced by starvation in rats. 
*Energy-preserving effects of IGF-1 antagonize starvation-induced cardiac autophagy. 
*Osteoporosis in survivors of early life starvation. 
*A case of acute renal failure, rhabdomyolysis and disseminated intravascular coagulation 
associated with severe exercise-induced hypernatremic dehydration. 
*A convenient rabbit model of ocular epithelium damage induced by osmotic dehydration. 
*Aortic and cerebral trombosis caused by hypernatremic dehydration in an exclusively breast-fed 
infant. 
*Dehydration from outdoor work and urinary stones in a tropical environment. 
 Deficiencies of water, fiber, protein, legumes/ pulses, minerals, melatonin, selenium, 
iron, zinc, and other nutrients (sunlight, selenium in soil, germs/ hygiene hypothesis) had adverse 
effects, but the only deficiencies that reached the pervasive threshold were the more general ones 
listed above.  Even then, two of them, malnutrition and dehydration, could include both 
foundational causes (poor diet, insufficient water) and symptoms due to other foundational 
causes.  This is a problem that underlies most of the deficiencies mentioned above: is the 
deficiency due to low intake (a foundational cause) or is it a symptom of e.g. metabolic 
dysfunction resulting from other foundational causes?  This is one case where an improved query 
might be able to separate out the foundational causes, and raise some of the above substances to 
pervasive status. 
1A3. Food Additives/ Pollutants 




 Foods are modified from their original state to enhance taste, appearance, and shelf life, 
among other characteristics.  While some additives are harmless, many are accompanied by 
adverse effects.  Adverse reactions to additives may be underdiagnosed and under-researched.  
Many of the excesses and deficiencies mentioned in 1A1 and 1A2 are the result of substances 
being added or removed from the fresh whole food.  The large number of additives include 
phosphates/ phosphorous, glycerin, sodium glutamate, palmitate, 2,3-pentanedione, etc.  None of 
the specific additives reached the level of pervasive in the present study.  Depending on how one 
defines 'food additives', those with the widest impacts tend to include the major items listed 
under excesses in 1A1, such as fat, sugar, and salt, which tend to be added to foods for taste 
enhancement. 
*Phosphate additives in food a potential public health risk. High phosphate levels can lead to 
cardiovascular disease. 
*Bioavailable dietary phosphate, a mediator of cardiovascular disease, may be decreased with 
plant-based diets, phosphate binders, niacin, and avoidance of phosphate additives. 
*THE IMPACT OF PROCESSING MEAT AND FISH PRODUCTS ON PHOSPHORUS 
INTAKE IN CHRONIC KIDNEY DISEASE PATIENTS. 
*POTENTIAL HEALTH CONCERNS OF DIETARY PHOSPHORUS: CANCER, OBESITY, 
AND HYPERTENSION. 
*Induction of kidney and liver cancers by the natural food additive madder color in a two-year 
rat carcinogenicity study. 
*CARCINOGENIC RISK OF COPPER GLUCONATE EVALUATED BY A RAT MEDIUM-
TERM LIVER CARCINOGENICITY BIOASSAY PROTOCOL. 
*EVALUATION OF THE BUTTER FLAVORING CHEMICAL DIACETYL and a 
fluorochemical paper additive FOR MUTAGENICITY AND TOXICITY USING THE 
MAMMALIAN CELL GENE MUTATION ASSAY IN L5178Y MOUSE LYMPHOMA 
CELLS. 
*Hypothesis: Increased consumption of emulsifiers as an explanation for the rising incidence of 
Crohn's disease. 
*Low-concentration capsaicin promotes colorectal cancer metastasis by triggering ROS 
production and modulating Akt/mTOR and STAT-3 pathways. 
*Molecular mechanism of mutagenesis induced by olaquindox using a shuttle vector 
pSP189/mammalian cell system. 
*Monosodium glutamate neonatal treatment induces cardiovascular autonomic function changes 
in rodents. 
*Crohn's disease-associated adherent-invasive Escherichia coli adhesion is enhanced by 
exposure to the ubiquitous dietary polysaccharide maltodextrin. 




*SMOKED SAUSAGES AND FOOD ADDITIVES: EVALUATION OF TOTAL 
MUTAGENIC ACTIVITY. 
*Mutagenicity and DNA-damaging activity caused by decomposed products of potassium 
sorbate reacting with ascorbic acid in the presence of Fe salt. 





INTERPRETATION OF DIET RESULTS 
There are a number of caveats to be used in interpreting the results of the section on diet above 
(1A).  Many of these caveats also apply to interpreting the other sections in this taxonomy.  
First, the results reflect what is published in the Medline database.  As is pointed out 
repeatedly in Chapter 9, many foundational causes may not have reached the literature, or a 
skewed representation of foundational causes may have been placed into the literature.  Of 
those papers published on a topic, it is difficult to know which papers are credible.  The fact 
that a concept appears to meet one of the Gold Standards of research, namely, reproducibility/ 
repeatability, may or may not be relevant.  If a sponsor wants to distort a literature, it can fund 
diverse performers to arrive at similar conclusions. 
For diet in particular, these caveats are crucial.  In the USA (and other countries as well), we 
have large industries that support grains, animal husbandry, fruits, vegetables, etc, and 
government agencies that promote many of these products as well.  In many of e.g. the 
phytotherapy studies I examined in previous LRDI studies (focused on treatments), I noticed 
that  
1) publications from specific countries would tend to  
2) emphasize the positive effects on treatments from plants et al native to that country and  
3) de-emphasize the negative.   
Any adverse effects would typically come from research performed by scientists from other 
countries.  Then, the question arose whether these adverse effects were the result of good 
objective science or one competitor subjectively evaluating another competitor.  All these 
industries and governments have an interest in promoting their products, both for domestic use 
and export, and have 'deep pockets' for supporting research that could potentially influence the 
salability of their products. 
For example, under the diet category above, I concluded in part: "The highly pervasive 
components of this diet sub-category tended to be high-fat, high-sugar, high-salt, high-meat, 
and the high-temperature cooking that resulted in harmful products (e.g., advanced glycation 
end products, heterocyclic amines and nitrosamines, polycyclic aromatic hydrocarbons, and 
acrylamides)."  Each potential foundational cause on that list was based on there being more 
articles published in the literature on the adverse effects of the potential cause, more articles 
showing impacts across myriad diseases, high credibility articles, etc.  The list does not imply 
absolute consensus; for most of these foundational causes, there were always some articles 
stating a non-effect or positive effect.  There were just far less stating a positive effect than a 
negative effect. 
How do I interpret these differences?  Are they the results of good research, and just reflect 




different experimental conditions, or are they the results of manufactured research, cherry-
picking, and deliberate selection of windows of parameter space that will yield a desired 
answer?  Absent conducting my own experiments on each substance to validate the results, I 
need to make a judgment on what appears to be most credible given the weight of the 
evidence. 
As a specific example, there is much disagreement in the biomedical literature and the popular 
press as to what constitutes an optimal, or even desirable, diet for humans.  Two major and 
diametrically opposing camps today are the high-carb low-fat (and, in many cases, low animal 
protein) diets and the low-carb high-fat (and, in many cases, high animal protein) diets.  Each 
camp has published best-selling books on the NYT list, with each book containing hundreds of 
references in 'prestigious' medical journals purporting to show the benefits of the book's 
approach.  These books remind me of expert witnesses in a trial, with each side presenting its 
expert witnesses stating completely opposing viewpoints.  Unfortunately, we the public are 
forced to act like the judge and jury in deciding which set of dietary witnesses is more credible. 
The strong numerical preponderance of evidence published in the medical literature is on the 
side of high-fat high-meat high-refined-carbohydrates low-complex-carbohydrates as the 
culprits.  Other than the high-refined-carbohydrates being problematical, on which both camps 
seem to agree, disagreement is complete on the value of the other three types of food. 
The evidence for both sides is shaky.  Long-term effects (of these potential pervasive 
foundational causes) on humans in the context of exposure to the myriad other potential 
foundational causes have not been done.  To support their arguments, many researchers and 
clinicians refer to how our ancestors lived (e.g., Paleo diets, Hunter-Gatherers, etc), or how 
similar animal species live in the wild, in hopes of identifying more 'natural' and traditional 
diets.  However, many foods have been so grossly altered since the days of our primitive 
ancestors that their resemblance to foods available now is in name only, and usually the diets 
of similar species are 'cherry-picked' so the total combination of foods in their diet is not 
extrapolated to recommendations for human diets. 
Fruits and plant foods have been continuously altered for many decades to improve yield, taste, 
and appearance, to the point where pictures of these foods now compared to many thousands 
of years ago are entirely unrecognizable.  Animals for consumption are raised and fed under 
circumstances unrecognizable compared to centuries ago.  Cattle are raised in confined areas 
without exercise, fed grains rather than grass, and given growth hormones and antibiotics to 
increase weight and maintain 'health' over shorter periods of time until slaughter.  The meat is 
then cooked at high temperatures in the presence of additional fats, producing large amounts of 
advanced glycation end products and other harmful substances.  It's unclear whether any basis 
for consensus is possible, given the lack of credible data upon which to base a decision. 
The USDA, as well as many other diet authors, have taken a somewhat middle ground.  The 
USDA displays its recommendations graphically with a four level pyramid, with grains 
constituting the base, fruits and vegetables the second level, mainly high protein foods 
constituting the third level, and fats and sugars capping the pyramid.  Not surprisingly, the 




findings in this book are somewhat reflective of the pyramid structure. 
So, for readers who are proponents of the high-fat high-animal protein low-carb diet, and who 
see the different results presented in this book and in the USDA pyramid, you need to interpret 
the diet results based on the discussion and caveats above. 
The differences in the other taxonomy categories are not quite as polarized.  For example, most 
studies might conclude that e.g. Cadmium exposure causes serious diseases, and perhaps a few 
might not see an association with serious diseases.  Probably none would conclude that 
Cadmium has positive effects.  With the two diet extremes described above, we see a strong 
swing of the pendulum to each side. 
  






1B1. Sedentary Lifestyle 
(e.g., Immobile; Bed Rest; Restraint) 
*ASSOCIATION OF SEDENTARY BEHAVIOUR WITH COLON AND RECTAL CANCER: 
A META-ANALYSIS OF OBSERVATIONAL STUDIES. 
*TELEVISION VIEWING AND TIME SPENT SEDENTARY IN RELATION TO CANCER 
RISK: A META-ANALYSIS. 
*SEDENTARY BEHAVIOR AND INCIDENT CANCER: A META-ANALYSIS OF 
PROSPECTIVE STUDIES. 
*A comparative bear model for immobility-induced osteopenia. 
*A gravitational hypothesis of essential hypertension as a natural adaptation to increased 
gravitational stress caused by regular, prolonged sitting typical of modern life. 
*Anemia of immobility: caused by adipocyte accumulation in bone marrow. 
*SEDENTARY LIFESTYLE AND ITS RELATION TO CARDIOVASCULAR RISK 
FACTORS, INSULIN RESISTANCE AND INFLAMMATORY PROFILE. 
*Two-week cast immobilization induced chronic widespread hyperalgesia in rats. 
*TIME TREND OF PREVALENCE OF SELF-REPORTED CATARACT AND ITS 
ASSOCIATION WITH PROLONGED SITTING IN TAIWAN FROM 2001 AND 2013. 
*PROLONGED SITTING: IS IT A DISTINCT CORONARY HEART DISEASE RISK 
FACTOR? 
*"eThrombosis" - venous thromboembolism provoked by prolonged sitting position by a 
computer. A case series report of six patients. 
1B2. Exercise/Overexercise 
(e.g., Physiological Stress; Diving) 
*3-min step test and treadmill exercise for evaluating exercise-induced asthma. 
*40-year-old athlete with exercise-induced angina pectoris. 
*A case of acute renal failure, rhabdomyolysis and disseminated intravascular coagulation 
associated with severe exercise-induced hypernatremic dehydration. 




*Acute care for exercise-induced hyperthermia to avoid adverse outcome from exertional heat 
stroke. 
*Exercise-induced atrioventricular block. Significance of the ischemic component. Report of 4 
new cases. 
*A case of anterior cerebral artery dissection caused by scuba diving. 
*Facial baroparesis caused by scuba diving. 
*Oxygen toxicity in recreational and technical diving. 
1B3. Sleep 
(e.g., Sleep Deprivation) 
*Sleep deprivation impairs memory, tau metabolism, and synaptic integrity of a mouse model of 
Alzheimer's disease with plaques and tangles. 
*SLEEP DEPRIVATION, SLEEP APNEA AND CARDIOVASCULAR DISEASES. 
*A single night of partial sleep deprivation induces insulin resistance in multiple metabolic 
pathways in healthy subjects. 
*Cardiovascular function alterations induced by acute paradoxical sleep deprivation in rats. 
*Paradoxical sleep deprivation potentiates epilepsy induced by homocysteine thiolactone in adult 
rats. 
*Sleep deprivation after septic insult increases mortality independent of age. 
 The main sub-categories of Activity were exercise, sedentary, and sleep.  Exercise in the 
right amounts at the right intensity was viewed as beneficial, but excessive exercise in time and 
intensity (as well as related heat stroke) could be harmful.  Sedentary lifestyle (lack of exercise) 
was problematic, and mentioned quite often.  Prolonged sitting in all its variants appeared to be 
an under-recognized factor contributing to many diseases.  Its importance will probably increase 
substantially, with the advent of increased computer use for work and recreation and the 
attendent prolonged sitting required.  Insufficient sleep, both in quality and duration, was a 
problem area as well.  The effects of sedentary lifestyle on many diseases may be heavily under-
researched. 
1C. Substance Abuse 
1C1. Recreational Drugs 
(e.g., Substance Abuse; Smokeless Tobacco; Narcotics; Cocaine; Cannabis; Methamphetamine; 
Street Drugs; N-Methyl-3,4-methylenedioxyamphetamine; Marijuana Smoking; Hallucinogens) 




*Recent cocaine use is a significant risk factor for sudden cardiovascular death in 15-49-year-old 
subjects: a forensic case-control study. 
*Adverse cardiovascular, cerebrovascular, and peripheral vascular effects of marijuana: what 
cardiologists need to know. 
*MARIJUANA USE AND RISK OF LUNG CANCER: A 40-YEAR COHORT STUDY. 
*Cocaine-induced vasoconstriction in the human coronary microcirculation: new evidence from 
myocardial contrast echocardiography. 
*Population-based case-control study of recreational drug use and testis cancer risk confirms an 
association between marijuana use and nonseminoma risk. 
*Cocaine-induced coronary stent thrombosis. 
*Cocaine is a major risk factor for antipsychotic induced akathisia, parkinsonism and dyskinesia. 
*Chronic manganese toxicity due to substance abuse in Turkish patients. 
*Chronic non-neurological toxicity from volatile substance abuse. 
*Digestive system damage caused by substance abuse. 
*Substance abuse and toxicity. Fetal drug syndrome. 
*Carcinogenic components of smokeless tobacco and tobacco-free cigarettes. 
*Possible carcinogenicity of smokeless tobacco. 
*SMOKELESS TOBACCO AND THE RISK OF STROKE. 
*Kidney diseases caused by contrast media and narcotics. 
*Rhabdomyolysis during acute poisoning with drugs and narcotics. Experience with 7 clinical 
cases. 
*A case of cocaine-induced basilar artery thrombosis. 
*A problem of physiology. Cardiac toxicity of cocaine. 
*Acute angle closure glaucoma precipitated by intranasal application of cocaine. 
*Cluster headache induced by cocaine. 
*A novel cause of eosinophilic pneumonia: recreational marijuana exposure. 
*A case of cannabis-induced pancreatitis. 
*Acute and chronic cognitive disorders caused by cannabis use. 




*1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine pretreatment attenuates methamphetamine-
induced dopamine toxicity. 
*A fatal case of myocardial damage due to misuse of the "designer drug" MDMA. 
*Acute hepatitis induced by Ecstasy. 
1C2. Smoking 
(e.g. Tobacco Smoke Pollution; Nicotine; Smoke) 
*A Bayesian approach to assess interaction between known risk factors: the risk of lung cancer 
from exposure to asbestos and smoking. 
*A case of smoking-induced chest pain improved with beta2-stimulant. 
*A modified Ames assay reveals the mutagenicity of native cigarette mainstream smoke and its 
gas vapour phase. 
*A new experimental model of cigarette smoke-induced emphysema in Wistar rats. 
*META-ANALYSIS OF PROSPECTIVE COHORT STUDIES OF CIGARETTE SMOKING 
AND THE INCIDENCE OF COLON AND RECTAL CANCERS. 
*Oral cancer in young Jordanians: potential association with frequency of narghile smoking. 
*Smoking at diagnosis is an independent prognostic factor for cancer-specific survival in head 
and neck cancer: findings from a large, population-based study. 
*CIGARETTE SMOKING AND THE RISK OF PANCREATIC CANCER: A CASE-
CONTROL STUDY. 
*THE RELATION BETWEEN CIGARETTE SMOKING AND RISK OF ACUTE MYELOID 
LEUKEMIA: AN UPDATED META-ANALYSIS OF EPIDEMIOLOGICAL STUDIES. 
*SMOKING AND INCREASED ALZHEIMER'S DISEASE RISK: A REVIEW OF 
POTENTIAL MECHANISMS. 
*Smoking exacerbates amyloid pathology in a mouse model of Alzheimer's disease. 
1C3. Alcohol 
(e.g., Ethanol) 
*TLR4-Dependent Tumor-Initiating Stem Cell-Like Cells (TICs) in Alcohol-Associated 
Hepatocellular Carcinogenesis. 
*Fetal alcohol exposure increases susceptibility to carcinogenesis and promotes tumor 
progression in prostate gland. 




*THE INTERPLAY BETWEEN ALCOHOL CONSUMPTION, ORAL HYGIENE, ALDH2 
AND ADH1B IN THE RISK OF HEAD AND NECK CANCER. 
*ALCOHOL DRINKING AND THE RISK OF COLORECTAL CANCER DEATH: A META-
ANALYSIS. 
*LIFETIME RISK OF DISTINCT UPPER AERODIGESTIVE TRACT CANCERS AND 
CONSUMPTION OF ALCOHOL, betel AND CIGARETTE. 
*ALCOHOL USE DISORDERS AND RISK OF PARKINSON'S DISEASE: FINDINGS 
FROM A SWEDISH NATIONAL COHORT STUDY 1972-2008. 
*A case of acute pancreatitis with hyperlipemia and hyperglycemia induced by alcohol abuse. 
*A cocktail for skin cancer: why alcohol and sun exposure do not mix. 
*Abdominal pain and renal failure after alcoholic intoxication. Intraperitoneal urinary bladder 
rupture after alcohol excess. 
*Acute esophageal necrosis caused by alcohol abuse. 
*Alcohol induced myocardial infarction in two young brothers. 
 Excessive alcohol use was implicated as a contributor to myriad diseases.  Results for 
very moderate use, especially beer and red wine, were somewhat mixed.  There may be a 
hormetic (beneficial) effect operating at very low doses (~ one drink per day), although 
consensus does not exist on that point. 
 Substance abuse included 'recreational' drugs of all types (cocaine, methamphetamine, 
etc), other substances such as laxatives, common household products not usually identified as 
recreational drugs (such as mothballs), and especially excessive cigarette smoking and alcohol.  
There were a large number of MeSH terms covering these substances, especially smoking and 
alcohol, only a very few of which are shown here.  Excess smoking and drinking are among the 
most highly pervasive of all foundational causes. 
1D. Other 
(e.g., Tattooing; Body Piercing) 
*Adverse effects of cosmetic tattooing: an illustrative case of granulomatous dermatitis 
following the application of permanent makeup. 
*Colonic abscess induced by India ink tattooing. 
*Tattoo Ink-Related Cutaneous Pseudolymphoma: A Rare but Significant Complication. Case 
Report and Review of the Literature 
*Melanoma on Tattoos: Two Finnish Cases 




*Light-induced mutagenicity in Salmonella TA102 and genotoxicity/cytotoxicity in human T-
cells by 3,3'-dichlorobenzidine: a chemical used in the manufacture of dyes and pigments and in 
tattoo inks. 
*A case of Staphylococcus aureus endocarditis after ear piercing in a patient with normal cardiac 
valve and a questionnaire survey on adverse events of body piercing in college students of 
Korea. 
*Dental and buccal complications of lip and tongue piercing. 
*Ear piercing as a risk factor for contact allergy to nickel. 
 The individual foundational causes identified with Lifestyle are usually studied in 
isolation, and synergistic effects are typically not identified.  Given the number of Lifestyle 
component combinations that could be synergistic, and adding in  
1) the foundational causes from the remaining categories identified here to the potential 
combinations and  
2) foundational causes that surface only when operating in synergy but which have not yet been 
identified here as individual foundational causes,  
it is clear that only the tip of the foundational causes iceberg is being exposed in this book. 
2. IATROGENIC 
 The 'side-effects' from drugs and the complications from surgery and invasive treatments 
predominated in this category.  One needs to be careful here.  The more frequently a drug is 
used, or the more frequently surgery or invasive treatments are employed, the more opportunity 
for side-effects and complications, and the more opportunity for publications describing these 
side-effects and complications.  This book does not provide an indication of how often such side-
effects and complications would occur as a percentage of use. 
 However, diseases resulting from Iatrogenic causes have been estimated independently, 
and appear quite large.  For example, the report Death by Medicine 
(http://www.webdc.com/pdfs/deathbymedicine.pdf) estimates: "the number of people having in-
hospital, adverse reactions to prescribed drugs to be 2.2 million per year. The number of 
unnecessary antibiotics prescribed annually for viral infections is 20 million per year. The 
number of unnecessary medical and surgical procedures performed annually is 7.5 million per 
year. The number of people exposed to unnecessary hospitalization annually is 8.9 million per 
year. 
 The most stunning statistic, however, is that the total number of deaths caused by 
conventional medicine is an astounding 783,936 per year. It is now evident that the American 
medical system is the leading cause of death and injury in the US. (By contrast, the number of 
deaths attributable to heart disease in 2001 was 699,697, while the number of deaths attributable 
to cancer was 553,251.5)" 




 Other statistics on Iatrogenic disease are available; the numbers tend to be large.  The 
main categories of drugs and surgeries are presented in this section, along with illustrative 
examples of adverse effects from members of these drug and surgery categories.  Large numbers 
of substances were found in the drug class sub-categories highlighted below, and far more would 
be expected in the recommended follow-on study. 
 Specific drugs that are pervasive foundational causes are not listed within the parentheses 
following the drug category.  Because of the myriad reasons listed in Chapter 9, I believe there 
are many more substances (especially drugs and chemicals) that are pervasive foundational 
causes operationally that have either not appeared, or have not been adequately represented, in 
the published literature.  I did not want to leave the impression that the drug classes listed 
represent the totality of pervasive foundational causes that are drugs, which can sometimes be 
the (erroneous) message that readers remember after viewing a list in print.  In the illustrative 
Titles following each category, any specific drugs listed may or may not be pervasive 
foundational causes.  The illustrative Titles were selected to represent the pervasive drug class, 
not any specific pervasive drug. 
 The Iatrogenic drug sub-category differed from the two categories that follow: biotoxic 
and environmental/ occupational exposure.  For drugs that addressed symptoms related to a 
given disease, the Iatrogenic effects ranged in publication frequency from rare to modest (in the 
disease core literature), and for drugs that primarily addressed symptoms not related to the 
disease of interest, publication frequency related to Iatrogenic effects was high (in the disease 
core literature). 
 Thus, for example, an antineoplastic drug that co-occurred with a cancer sub-type would 
rarely be shown having an adverse impact on the cancer, and would most frequently be shown as 
having a side-effect causing some other disease/ symptom.  An antineoplastic drug that co-
occurred with a non-cancer disease would almost always be a side-effect from the drug used for 
treating cancer (unless the drug's application to the non-cancer disease was being explored in the 
study). 
 Thus, an antineoplastic drug/ drug category that co-occurred with Mild Cognitive 
Impairment (MCI) would almost always, if not always, reflect an MCI side effect resulting from 
cancer treatment.  Almost every paper (in the disease core literature) dealing with biotoxic and 
environmental/ occupational exposure is related to causing one or more disease-related 
symptoms. 
 Finally, for purposes of brevity, each drug was assigned to one class only.  However, 
some drugs could have been placed in multiple categories.  'Monoclonal antibodies', for example, 
were placed under Antineoplastic Agents, but are used in treatment of cancer, inflammation, 
autoimmune, and viral, to name a few. 
2A. Drugs 
2A1. Antineoplastic Agents 




 This is a very large category, both in sub-categories and numbers of specific drugs.  
However, these drugs are mainly used to treat life-threatening diseases, and the risks must be 
weighed against the benefits. 
(e.g., Monoclonal Antibodies; Antineoplastic Antimetabolites; Antineoplastic Antibiotics; 
Phytogenic Antineoplastic Agents; Hormonal Antineoplastic Agents; Cancer Chemotherapy; 
Cancer Therapy; Adjuvant Chemotherapy; Alkylating Antineoplastic Agents;Pyridines; 
Angiogenesis Inhibitors; Indoles; Protein Kinase Inhibitors; Taxoids; Quinazolines; 
Transplantation Conditioning; Organometallic Compounds; Organoplatinum Compounds; 
Nitriles; Recombinant Fusion Proteins; Pyrazines; Neoadjuvant Therapy; Anthracyclines; 
Photochemotherapy; Boronic Acids; Aromatase Inhibitors; Alkylating Agents; Hydroxyurea; 
Neoplasm Antibodies; Induced Hyperthermia; Benzamides; Arsenic Trioxide) 
*Adverse effects on cardiovascular status and lipid levels of albino Wistar rats treated with 
cisplatin and oxaliplatin in combination with 5 Fluorouracil. 
*Persistence of cisplatin-induced mutagenicity in hematopoietic stem cells: implications for 
secondary cancer risk following chemotherapy. 
*Prolonged use of bevacizumab may cause extensive coronary artery thrombosis. 
*Severe exacerbation of Crohn's disease during sunitinib treatment. 
*Selected nutraceutic screening by therapeutic effects on doxorubicin-induced chronic kidney 
disease. 
*Proanthocyanidins produce significant attenuation of doxorubicin-induced mutagenicity via 
suppression of oxidative stress. 
*Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a 
multicenter analysis. 
*Acute infusion reactions induced by monoclonal antibody therapy. 
*Anti-CTLA4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient.  
*Cutaneous adverse reactions to therapeutic monoclonal antibodies for cancer. 
*Immunotoxicity of monoclonal antibodies. 
*A biochemical perspective of methotrexate neurotoxicity with insight on nonfolate rescue 
modalities. 
*6-Gingerol prevents cisplatin-induced acute renal failure in rats. 
*5-Fluorouracil can cross brain-blood barrier and cause encephalopathy: should we expect the 
same from capecitabine? A case report on capecitabine-induced central neurotoxicity progressing 
to coma. 




*6-Thioguanine and S(6)-methylthioguanine are mutagenic in human cells. 
*A case of epirubicin-associated cardiotoxicity progressing to life-threatening heart failure and 
splenic thromboembolism. 
*A case of interstitial lung disease due to sunitinib. 
*A case of adenomyomatous polyp of the uterus associated with tamoxifen therapy. 
*A case of therapy for bevacizumab-induced hypertension. 
*Acute lung injury induced by arsenic trioxide in a patient with refractory myelodysplastic 
syndrome. 
*Acute ototoxicity from a single infusion of oxaliplatin. 
*Acute renal failure, gastrointestinal bleeding, and cardiac arrhythmia after administration of 
arsenic trioxide for acute promyelocytic leukemia. 
*Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib. 
*A case of sclerosing cholangitis caused by oral chemotherapy with S-1. 
*A case of secondary leukemia induced by chemotherapy with a CDDP-based regimen for 
gastric cancer 5 years following radical resection. 
*A case of severe enteritis induced by adjuvant chemotherapy for colon cancer. 
*A database for mucositis induced by cancer chemotherapy. 
2A2. Anti-Infective Agents 
 This also was a very large class. 
2A2a. Anti-Bacterial Agents/Anti-Fungal Agents/Anti-Parasite Agents 
(e.g., Sulfonamides; Imidazoles; Triazoles; Antitubercular Agents; Quinolines; Benzimidazoles; 
Local Anti-Infective Agents; Antimalarials; Quinolones; Fluoroquinolones; Oxazolidinones; 
Cephalosporins; Aminoglycosides; Anthelmintics; Antibiotic Prophylaxis) 
*A case of acute generalized exanthematous pustulosis due to amoxicillin-clavulanate with 
multiple positivity to beta-lactam patch testing. 
*Minocycline-induced arthritis. 
*A case of amoxicillin-induced hepatocellular liver injury with bile-duct damage. 
*LONG-TERM VORICONAZOLE AND SKIN CANCER: IS THERE CAUSE FOR 
CONCERN? 




*Retrospective review of vancomycin-induced nephrotoxicity in patients with leukemia. 
*An overlooked complication of vancomycin induced acute flaccid paralysis in a child with 
acute leukemia: a case report. 
*Voriconazole-induced pancreatitis in a patient of acute myeloid leukemia and invasive 
aspergillosis. 
*A case of anaphylaxis to oral minocycline. 
*Toxic epidermal necrolysis caused by cetuximab plus minocycline in head and neck cancer. 
*MINOCYCLINE-INDUCED BLACK THYROID GLAND: MEDICAL CURIOSITY OR A 
MARKER FOR PAPILLARY CANCER? 
*Minocycline-induced hyperpigmentation in rheumatoid arthritis. 
*Ofloxacin induced Sweet's syndrome in a patient with Crohn's disease. 
*A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of 
deaths and colectomies at a teaching hospital following increased fluoroquinolone use. 
*A Mexican population-based study on exposure to paracetamol and the risk of wheezing, 
rhinitis, and eeczema in childhood. 
*A probable association of acute dystonia with gemifloxacin administration. 
*A rare case of hepatitis associated with cefprozil therapy. 
*Acetaminophen and/or antibiotic use in early life and the development of childhood allergic 
diseases. 
*Acute eosinophilic pneumonia secondary to daptomycin: a report of three cases. 
*Ciprofloxacin-induced nephrotoxicity in patients with cancer. 
*Acute hepatitis associated with the use of levofloxacin. 
*Acute interstitial nephritis due to cefoperazone. 
*Acute myocardial infarction in a young male on methylphenidate, bupropion, and 
erythromycin. 
*Acute neurological deficits caused by cefipime: a case report and review of literature. 
*Chronic minocycline-induced autoimmunity in children. 
*Neuralgic amyotrophy associated with antibiotic therapy. 
2A2b. Antiviral/Antiretroviral Agents 




(e.g., Recombinant Proteins; Anti-HIV Agents; Highly Active Antiretroviral Therapy; Interferon-
alpha; Polyethylene Glycols/PEGylated; Interferon alfa-2b; Peginterferon alfa-2a; Interferon 
alfa-2a; Peginterferon alfa-2b; Immunoglobulin G; Reverse Transcriptase Inhibitors; 
Organophosphonates; Protease Inhibitors) 
*A case of Bell's palsy associated with peginterferon Alfa-2a and ribavirin therapy for chronic 
hepatitis C virus infection. 
*Recovery after L-DOPA treatment in peginterferon and ribavirin induced parkinsonism. 
*Prolonged treatment with interferon alpha and peginterferon induces rheumatoid arthritis 
syndrome and erythema nodosum. 
*Arthritis induced by interferon-alpha therapy in a patient with essential thrombocythemia. 
*Ginsenosides block HIV protease inhibitor ritonavir-induced vascular dysfunction of porcine 
coronary arteries. 
*Gender differences in adenine-induced chronic kidney disease and cardiovascular 
complications in rats. 
*Interferon-alpha-induced thrombotic microangiopathy in patients with chronic myelogenous 
leukemia. 
*Efavirenz directly modulates the oestrogen receptor and induces breast cancer cell growth. 
*A case of gynecomastia due to entecavir. 
*Acute hemorrhagic colitis associated with oral administration of oseltamivir for the treatment of 
influenza A. 
*Acute renal failure related to intravenous acyclovir. 
*A case of visual hypoemotionality induced by interferon alpha-2b therapy in a patient with 
chronic myeloid leukemia. 
*Acute portal thrombosis in patients with hepatitis C treated with pegylated interferon and 
ribavirin. 
*Acyclovir-induced nephrotoxicity: the role of the acyclovir aldehyde metabolite. 
*Adefovir dipivoxil-induced Fanconi syndrome and hypophosphatemic osteomalacia associated 
with muscular weakness in a patient with chronic hepatitis B. 
*Anemia associated with antiviral therapy in chronic hepatitis C: incidence, risk factors, and 
impact on treatment response. 
*Autoimmune thyroiditis and delayed onset psoriasis in association with combination therapy for 
chronic hepatitis C infection. 




*A case of lactic acidosis caused by stavudine in an AIDS patient. 
*Absence seizures associated with efavirenz initiation. 
*Antiretroviral medications associated with elevated blood pressure among patients receiving 
highly active antiretroviral therapy. 
*Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency 
HIV Study. 
*Antiretroviral-therapy-associated lipoatrophy: current status and future directions. 
2A3. Anti-Inflammatory Agents 
(e.g., Non-Steroidal Anti-Inflammatory Agents; Pyrazoles; Cyclooxygenase Inhibitors; 
Lactones) 
*Acetaminophen increases blood pressure in patients with coronary artery disease. 
*A case of acute pancreatitis caused by 5-aminosalicylic acid suppositories in a patient with 
ulcerative colitis. 
*A NSAID-associated alimentary tract disease in patients with rheumatism in Russia. 
*Acute coronary syndrome after diclofenac induced coronary spasm. 
*Acute Delta(9)-tetrahydrocannabinol blocks gastric hemorrhages induced by the nonsteroidal 
anti-inflammatory drug diclofenac sodium in mice. 
*Acute interstitial nephritis due to mesalazine. 
*Celecoxib exacerbates hepatic fibrosis and induces hepatocellular necrosis in rats treated with 
porcine serum. 
*Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on 
upper gastrointestinal tract. 
*Adverse respiratory reactions to aspirin and nonsteroidal anti-inflammatory drugs. 
*A case of peritoneal TB causing renal failure in a patient with rheumatoid arthritis and initial 
negative PPD after treatment with infliximab. 
*Infliximab-induced psoriasis in treatment of Crohn's disease-associated ankylosing spondylitis: 
case report and review of 142 cases. 
*Adenosine-induced coronary vasospasm following drug-eluting stent implantation. 
*Adverse effects of nonsteroidal anti-inflammatory drugs on the colon. 
*Acute coronary syndrome caused by infliximab in a patient with ankylosing spondylitis. 




*Hepatitis B virus reactivation induced by infliximab administration in a patient with Crohn's 
disease. 
*Aggravation of exercise-induced intestinal injury by Ibuprofen in athletes. 
*Analgesic use and the risk of hearing loss in women. 
*Adalimumab-induced acute interstitial lung disease in a patient with rheumatoid arthritis. 
*Aspirin-induced asthma: clinical aspects, pathogenesis and management. 
*Probable diffuse retinopathy caused by adalimumab in a patient with Crohn's disease. 
2A4. Cardiovascular Agents 
(e.g., Anti-Arrhythmia Agents; Vasodilator Agents; Phosphodiesterase Inhibitors; Cardiotonic 
Agents; Vasopressin) 
*Do stress responses promote leukemia progression? An animal study suggesting a role for 
epinephrine and prostaglandin-E2 through reduced NK activity. 
*Bilateral injection of isoproterenol into hippocampus induces Alzheimer-like 
hyperphosphorylation of tau and spatial memory deficit in rat. 
*24 h-kinetics of iodide uptake in amiodarone induced hypothyroidism. 
*A characterization of amiodarone-induced pulmonary toxicity in F344 rats and identification of 
surfactant protein-D as a potential biomarker for the development of the toxicity. 
*Acute amiodarone hepatotoxicity. 
*Amiodarone-induced liver cirrhosis and parkinsonism: a case report. 
*Acute Amiodarone-induced Lung Toxicity. 
*Amiodarone-induced delirium in advanced cancer: a case report. 
*Amiodarone-induced thyrotoxicosis with thyroid papillary cancer in multinodular goiter: case 
report. 
*Adenosine deaminase and adenosine attenuate ventricular arrhythmias caused by 
norepinephrine. 
*A calcium stimulated cysteine protease involved in isoproterenol induced cardiac hypertrophy. 
*Aegle marmelos fruit extract attenuates isoproterenol-induced oxidative stress in rats. 
*Cardio protective effect of vitamin A against isoproterenol-induced myocardial infarction. 
*Isoproterenol-induced myocardial fibrosis in relation to myocyte necrosis. 




*A case of dobutamine-induced coronary arterial spasm with ST-segment elevation. 
*Dermal cellulitis--a hypersensitivity reaction from dobutamine hydrochloride. 
*Dobutamine induced cardiogenic shock due to systolic anterior motion after mitral valve repair. 
*Dobutamine-induced eosinophilia. 
*ADVERSE EFFECTS OF PROPRANOLOL ON REPRODUCTIVE FUNCTION IN ADULT 
MALE MICE. 
*Musical hallucinations induced by propranolol. 
*Severe asthma attack induced by propranolol. 
*Severe hyperkalemia induced by propranolol. 
2A5. Central Nervous System Agents 
 This is a very large category of both sub-categories and specific agents. 
2A5a. Analgesics and Pain Relievers 
(e.g., Aspirin; Analgesics; Opioid Analgesics; Local Anesthetics; General Anesthesia; 
Psychotropic Drugs; Acetaminophen; Non-Narcotic Analgesics; Anesthesia; Nerve Block; 
Inhalation Anesthetics; Vasoconstrictor Agents; Spinal Anesthesia; Epidural Analgesia; Amides; 
Conscious Sedation; Dental Anesthesia; Methyl Ethers) 
*Isoflurane, a commonly used volatile anesthetic, enhances renal cancer growth and malignant 
potential via the hypoxia-inducible factor cellular signaling pathway in vitro. 
*ASSOCIATION OF INTENSIVE MORPHINE TREATMENT AND INCREASED STROKE 
INCIDENCE IN PROSTATE CANCER PATIENTS: A POPULATION-BASED NESTED 
CASE-CONTROL STUDY. 
*Propofol induces proliferation and invasion of gallbladder cancer cells through activation of 
Nrf2. 
*Regulatory T cells: a possible promising approach to cancer recurrence induced by morphine. 
*Anesthetic sevoflurane causes neurotoxicity differently in neonatal naive and Alzheimer disease 
transgenic mice. 
*A case of aspirin-induced cough without bronchoconstriction. A new type of aspirin 
hypersensitivity. 
*A clinical study of Japanese patients with ulcer induced by low-dose aspirin and other non-
steroidal anti-inflammatory drugs. 




*A disease marker for aspirin-induced chronic urticaria. 
*Insulin Facilitates the Recovery of Myocardial Contractility and Conduction during Cardiac 
Compression in Rabbits with Bupivacaine-Induced Cardiovascular Collapse. 
*A severe inflammatory cutaneous reaction after continuous epidural analgesia. 
*A case of hepatitis attributable to repeated exposure to methoxyflurane during its use for 
procedural analgesia. 
*Acute analgesic-induced renal papillary necrosis. 
*Modest increase in risk of acute coronary syndrome associated with morphine use in cancer 
patients: a population-based nested case-control study. 
*Pre-treatment of bupivacaine-induced cardiovascular depression using different lipid 
formulations of propofol. 
*Subdural haemorrhage is associated with recent morphine treatment in patients with cancer: a 
retrospective population-based nested case-control study. 
*Anesthetic induction with etomidate, rather than propofol, is associated with increased 30-day 
mortality and cardiovascular morbidity after noncardiac surgery. 
*A case of liver dysfunction after isoflurane anesthesia. 
*A fatal case of fulminant hepatic necrosis following sevoflurane anesthesia. 
*Allergic reaction to local anesthetic agents of the amide group. 
*Anesthetic-induced neurotoxicity of the neonate: time for clinical guidelines? 
*Anesthetic-induced myocardial ischemia: the isoflurane-coronary steal controversy. 
*Cerebral and cardiac toxicity of locoregional anaesthetics. 
2A5b. Movement Stabilizers 
(e.g., Central Muscle Relaxants; Neuromuscular Agents) 
*A case of eperisone hydrochloride (myonal)--induced drug eruption leading to erythema and 
angioedema. 
*A case of torsades de pointes induced by severe QT prolongation after an overdose of eperisone 
and triazolam in a patient receiving nifedipine. 
*A case report of unusual vasculitic reaction after Methocarbamol injection. 
*Acute intoxications with carisoprodol. 




*Acute pancreatitis in the course of meprobamate poisoning. 
*Eosinophilic pleurisy induced by dantrolene. 
*A case report of acute polyradiculoneuritis developing after multiple injections of botulinum 
toxin for cervical dystonia. 
*Acute deterioration of bulbar function after botulinum toxin treatment for sialorrhoea in 
amyotrophic lateral sclerosis. 
*Hourglass deformity after botulinum toxin type A injection. 
2A5c. Depressants/Antidepressants and Stimulants 
(e.g., Depressants; Central Nervous System Depressants; Antidepressants; Serotonin Uptake 
Inhibitors; Tricyclic Antidepressive Agents; Cyclohexanols; Serotonin Receptor Agonists; 
Stimulants; Benzhydryl Compounds) 
*The role of adenosine receptors and endogenous adenosine in citalopram-induced 
cardiovascular toxicity. 
*Propafenone associated severe central nervous system and cardiovascular toxicity due to 
mirtazapine: a case of severe drug interaction. 
*Citalopram-induced hyponatraemia and parkinsonism: potentially fatal side-effects not to be 
missed. 
*Fluoxetine-induced tardive dyskinesia in a patient with Parkinson's disease. 
*Delirium associated with duloxetine in a depressed patient with Alzheimer's dementia. 
*Venlafaxine induced acute myocardial infarction with normal coronary arteries. 
*Topiramate-associated acute glaucoma in a migraine patient receiving concomitant citalopram 
therapy: a case-report. 
*Methylphenidate (Ritalin)-associated cataract and glaucoma. 
*A metric of maternal prenatal risk drinking predicts neurobehavioral outcomes in preschool 
children. 
*Acute paternal alcohol use affects offspring development and adult behavior. 
*Adult rats prenatally exposed to ethanol have increased gluconeogenesis and impaired insulin 
response of hepatic gluconeogenic genes. 
*A case of prolonged seizure activity after combined use of bupropion and clomipramine. 
*A case of SSRI-induced hyponatremia. 




*Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic 
antidepressants: a meta-analysis. 
*Bupropion as an antidote for serotonin reuptake inhibitor-induced sexual dysfunction. 
*Cellular correlates of enhanced anxiety caused by acute treatment with the selective serotonin 
reuptake inhibitor fluoxetine in rats. 
*A fatal case of hyperthermia due to tricyclic antidepressant intoxication. 
*Antidepressant drugs: disturbing and potentially dangerous adverse effects. 
*Antidepressant-induced liver injury. 
*Antidepressant-induced sexual dysfunction in men. 
*Antidepressant-induced mania in obsessive compulsive disorder. 
*Nephropathy induced by stimulants and narcotics (heroin, amphetamine, etc). 
*A case of acute cardiomyopathy and pericarditis associated with methylphenidate. 
*Adverse effects of methylphenidate on the reproductive axis of adolescent female rats. 
*Acute myocardial infarction related to methylphenidate for adult attention deficit disorder. 
*Methylphenidate induces lipid and protein damage in prefrontal cortex, but not in cerebellum, 
striatum and hippocampus of juvenile rats. 
2A5d. Mood Stabilizers 
(e.g., Anticonvulsants; Neuroprotective Agents; Lithium Compounds; Histone Deacetylase 
Inhibitors; Antipsychotic Agents; Piperazines; Piperidines; Thiazoles; Antimanic Agents; 
Dibenzothiazepines; Anti-Anxiety Agents; Hypnotic Agents; Benzodiazepines; 
Neurotransmitters; Dopamine; Acetylcholine; Cholinesterase Inhibitors; Antiparkinson Agents; 
Cholinergic Antagonists; Dopamine Agonists; Gamma-Aminobutyric Acid/ GABA; Anti-
Asthmatic Agents; Bronchodilator Agents; Nicotinic Agonists; Muscarinic Antagonists; 
Dopamine Uptake Inhibitors; Adrenergic Uptake Inhibitors; Dopamine Agents) 
*Clozapine treatment associated with increased risk of acute myeloid leukemia (AML). 
*Thalidomide induced acute worsening of Parkinson's disease. 
*Neuroleptic malignant syndrome induced by phenytoin in a patient with drug-induced 
Parkinsonism. 
*Antiepileptic drug-induced encephalopathy. 
*Myocarditis associated with clozapine studied by cardiovascular magnetic resonance. 




*Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. 
*Aripiprazole associated with severe exacerbation of Parkinson's disease. 
*Delayed topiramate-induced bilateral angle-closure glaucoma. 
*Acute dystonia, akathisia, and parkinsonism induced by ziprasidone. 
*VALPROIC ACID-INDUCED PARKINSONISM IN THE ELDERLY: A COMPREHENSIVE 
REVIEW OF THE LITERATURE. 
*Anticonvulsant-induced rickets and nephrocalcinosis. 
*A case of drug-induced interstitial pneumonia due to phenytoin. 
*A case of fetal carbamazepine syndrome with right hemihypoplasia of the entire body. 
*Acute childhood pancreatitis caused by valproate. 
*A case of clozapine-induced paralytic ileus. 
*Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment 
of schizophrenia. 
*Clozapine-related myocarditis and cardiomyopathy in an Australian metropolitan psychiatric 
service. 
*Quetiapine-induced leucopenia and thrombocytopenia. 
*Quetiapine-induced diabetes with metabolic acidosis. 
*Olanzapine-induced vasculitis. 
*Olanzapine-induced eccrine squamous syringometaplasia. 
*Thalidomide neuropathy in childhood. 
*Amantadine-induced livedo reticularis: a report of two cases. 
*Bradykinesia in patients with Parkinson's disease having levodopa-induced dyskinesias. 
*Orexins cause epileptic activity. 
*Substance P accelerates hypercellularity and angiogenesis in tendon tissue and enhances 
paratendinitis in response to Achilles tendon overuse in a tendinopathy model. 
2A6. Immunologic Factors 
2A6a. Immunosuppressive Agents/Immunosuppression 
(e.g., Immunotherapy; Mycophenolic Acids) 




*Cyclosporin-induced toxic neuromyopathy. 
*Cyclosporin-induced sebaceous hyperplasia in renal transplant patients. 
*mTOR inhibitor-associated stomatitis (mIAS) in three patients with cancer treated with 
everolimus. 
*Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in 
patients with renal cell cancer: predictors, management, and outcomes. 
*Increased risk of everolimus-associated acute kidney injury in cancer patients with impaired 
kidney function. 
*Lymphomatoid granulomatosis associated with azathioprine therapy in Crohn disease. 
*HEMATOLOGIC TOXICITIES ASSOCIATED WITH MTOR INHIBITORS 
TEMSIROLIMUS AND EVEROLIMUS IN CANCER PATIENTS: A SYSTEMATIC 
REVIEW AND META-ANALYSIS. 
*Azathioprine-induced hepatotoxicity in a patient with Crohn's disease. 
*Acute Pancreatitis Induced by Azathioprine and 6-mercaptopurine Proven by Single and Low 
Dose Challenge Testing in a Child with Crohn Disease. 
*Azathioprine-induced carcinogenesis in mice according to Msh2 genotype. 
*AZATHIOPRINE: ASSOCIATION WITH THERAPY-RELATED MYELODYSPLASTIC 
SYNDROME AND ACUTE MYELOID LEUKEMIA. 
*Significant association of coronary artery calcification in stent delivery route with restenosis 
after sirolimus-eluting stent implantation. 
*Prednisone-induced osteoporosis: an overlooked and undertreated adverse effect. 
*Prednisone induces cognitive dysfunction, neuronal degeneration, and reactive gliosis in rats. 
*Tacrolimus induced diabetic ketoacidosis in nephrotic syndrome. 
*Tacrolimus induced subacute cerebellar ataxia. 
*Sirolimus (rapamycin) induced proteinuria in a patient undergoing allogeneic hematopoietic 
stem cell transplant. 
*Severe sirolimus-induced acute hepatitis in a renal transplant recipient. 
2A6b. Immunostimulation Agents 
(Immunologic Factors; Immunologic Adjuvants; Immunization) 
*A case of imiquimod-induced alopecia. 




*Activation of psoriasis in patients undergoing treatment with interferon-beta. 
*Cardiac arrhythmia induced by interferon beta-1a. 
*Acute colchicine intoxication complicated with extramedullary hematopoiesis due to filgrastim 
in a child. 
*Acute myocardial infarction caused by filgrastim: a case report. 
2A6b1. Vaccines/ Vaccination 
(e.g., Influenza Vaccines; BCG Vaccine; Viral Vaccines; Cancer Vaccines) 
*A case of influenza vaccination induced Guillain Barre syndrome with normal cerebrospinal 
fluid protein and improvement on treatment with corticosteroids. 
*A case of ulcerative colitis relapsed by influenza vaccination. 
*A case series of children with apparent mercury toxic encephalopathies manifesting with 
clinical symptoms of regressive autistic disorders. 
*A dose-response relationship between organic mercury exposure from thimerosal-containing 
vaccines and neurodevelopmental disorders. 
*A positive association found between autism prevalence and childhood vaccination uptake 
across the U.S. population. 
*Abnormal measles-mumps-rubella antibodies and CNS autoimmunity in children with autism. 
*Acute disseminated encephalomyelitis following 2009 H1N1 influenza vaccination. 
*Acute exacerbation of idiopathic pulmonary fibrosis after pandemic influenza A (H1N1) 
vaccination. 
*Acute hepatitis B in a healthcare worker: a case report of genuine vaccination failure. 
*Acute immune thrombocytopenic purpura as adverse reaction to oral polio vaccine (OPV). 
*Acute pancreatitis caused by parotiditis vaccine. 
*Acute systemic inflammation induced by influenza A (H1N1) vaccination causes a 
deterioration in endothelial function in HIV-infected patients. 
*Acute transverse myelitis and acute motor axonal neuropathy developed after vaccinations 
against seasonal and 2009 A/H1N1 influenza. 
*Adverse ocular effects following influenza vaccination. 
*Adverse reactions following immunization with MMR vaccine in children at selected provinces 
of Iran. 




*Administration of aluminium to neonatal mice in vaccine-relevant amounts is associated with 
adverse long term neurological outcomes 
*Adverse reactions to anthrax vaccine (eg, optic neuritis) may be more complex or delayed than 
reported initially by Payne et al (2006). 
*ALUMINUM-INDUCED ENTROPY IN BIOLOGICAL SYSTEMS: IMPLICATIONS FOR 
NEUROLOGICAL DISEASE 
*Anaphylactoid reaction after typhoid vaccination. 
*Arthritis induced by antihepatitis B vaccine. 
*BCG vaccine-associated suppurative lymphadenitis. 
*BCG vaccine-induced lupus vulgaris. 
*Childhood invasive pneumococcal disease caused by non-7-valent pneumococcal vaccine 
(PCV7) serotypes under partial immunization in Taiwan. 
*DO ALUMINUM VACCINE ADJUVANTS CONTRIBUTE TO THE RISING 
PREVALENCE OF AUTISM? 
*Febrile seizures after 2010-2011 influenza vaccine in young children, United States: a vaccine 
safety signal from the vaccine adverse event reporting system. 
*HEPATITIS B TRIPLE SERIES VACCINE AND DEVELOPMENTAL DISABILITY IN US 
CHILDREN AGED 1–9 YEARS 
*HEPATITIS B VACCINATION OF MALE NEONATES AND AUTISM 
*Methodological issues and evidence of malfeasance in research purporting to show thimerosal 
in vaccines is safe. 
*Narcolepsy--rare disease that has received increased attention. Pandemrix vaccination caused a 
higher incidence among children and adolescents. 
*Persistent behavioral impairments and alterations of brain dopamine system after early 
postnatal administration of thimerosal in rats. 
*POSSIBLE IMMUNOLOGICAL DISORDERS IN AUTISM: CONCOMITANT 
AUTOIMMUNITY AND IMMUNE TOLERANCE. 
*RISK OF GUILLAIN-BARRE SYNDROME FOLLOWING PANDEMIC INFLUENZA 
A(H1N1) 2009 VACCINATION IN GERMANY. 
*SEROLOGICAL ASSOCIATION OF MEASLES VIRUS AND HUMAN HERPESVIRUS-6 
WITH BRAIN AUTOANTIBODIES IN AUTISM. 




*THIMEROSAL EXPOSURE IN INFANTS AND NEURODEVELOPMENTAL 
DISORDERS: AN ASSESSMENT OF COMPUTERIZED MEDICAL RECORDS IN THE 
VACCINE SAFETY DATALINK. 
*Thimerosal in childhood vaccines contributes to accumulating mercury toxicity in the kidney 
*Vaccination induced neutropenia. 
*Vaccination-induced autoimmune hepatitis. 
*Vaccination-induced autoimmune vitiligo is a consequence of secondary trauma to the skin. 
*Vaccination-induced cutaneous pseudolymphoma. 
*Vaccine-induced enhancement of viral infections. 
*Vaccine-induced necrobiotic granuloma. 
2A7. Hematologic Agents 
2A7a. Coagulants 
(e.g., Electrocoagulation; Hemostatics; Laser Coagulation) 
*Bipolar forceps: a hemostatic tool for patients with electrocoagulation-induced dental pain. 
*Ventricular fibrillation caused by electrocoagulation during laparoscopic surgery. 
*Ameliorative effect of NAP on laser-induced retinal damage. 
*Gas embolism following bronchoscopic argon plasma coagulation: a case series. 
*A case of thrombocytopenia after microwave coagulation therapy for multiple metastatic liver 
tumors. 
*Acute ischemic cholecystitis after transarterial chemoembolization with drug-eluting beads. 
*Aprotinin in lung transplantation is associated with an increased incidence of primary graft 
dysfunction. 
*Hydronephrosis after embolization of internal iliac artery aneurysms. 
2A7b. Anticoagulants 
(e.g., Platelet Aggregation Inhibitors; Fibrinolytic Agents; Thiophenes; Low-Molecular-Weight 
Heparin) 
*A case of drug-induced pneumonia caused by clopidogrel. 




*Combined clopidogrel and proton pump inhibitor therapy is associated with higher 
cardiovascular event rates after percutaneous coronary intervention: a report from the BASKET 
trial. 
*Warfarin induces cardiovascular damage in mice. 
*Clopidogrel-induced hepatotoxicity and fever. 
*Clopidogrel-associated acute migratory arthritis following kidney-pancreas transplantation. 
*DABIGATRAN ETEXILATE AND RISK OF MYOCARDIAL INFARCTION, OTHER 
CARDIOVASCULAR EVENTS, MAJOR BLEEDING, AND ALL-CAUSE MORTALITY: A 
SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED 
TRIALS. 
*Dabigatran-induced upper intestinal bleeding in a patient with chronic kidney disease. 
*A case of heparin-induced thrombocytopenia that worsened preexisting cerebral infarction. 
*Heparin-induced aldosterone suppression and hyperkalemia. 
*Heparin-induced life-threatening hyperkalemia. 
*Impact of heparin-induced thrombocytopenia on acute coronary artery thrombosis in patients 
undergoing PCI. 
*Acute renal failure due to hypersensitivity interstitial nephritis induced by warfarin sodium. 
*Fatal warfarin-induced skin necrosis after total hip arthroplasty. 
*Warfarin-induced brachytelephalangic chondrodysplasia punctata. 
*Warfarin-induced Venous Limb Gangrene. 
*Agranulocytosis caused by ticlopidine and its mechanism. 
*Cholestatic hepatitis and anemia induced by ticlopidine. 
*Ticlopidine-induced lymphocytic colitis. 
2A7c. Other 
(e.g., Angiogenesis Inhibitors; Erythropoietin; Hematinics; Folic Acid; Chelating Agents; 
Platelet Transfusion; Benzoates) 
*A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic 
drug E7080. 
*A case of erythropoietin induced hypertension in a bilaterally nephrectomized patient. 




*Epoetin-induced autoimmune pure red cell aplasia. 
*Erythropoietin induced visual hallucinations after bone marrow transplantation. 
*Erythropoietin-induced deep vein thrombosis in myelodysplastic syndrome. 
*Epoetin alpha-induced acute generalized exanthematous pustulosis and desensitisation. 
2A8. Steroids/ Hormones 
(e.g., Glucocorticoids; Adrenal Cortex Hormones; Angiotensin; Estrogens; Insulin; Estradiol; 
Insulin-Like Growth Factor; Growth Hormone; Estrogen Replacement Therapy; Hormone 
Replacement Therapy; Hydrocortisone/ Cortisol; Anabolic Agents; Human Growth Hormone; 
Testosterone; Androgens; Triamcinolone Acetonide; Diethylstilbestrol) 
*Natural Antioxidants Exhibit Chemopreventive Characteristics through the Regulation of CNC 
b-Zip Transcription Factors in Estrogen-Induced Breast Carcinogenesis. 
*Bisphenol-A and diethylstilbestrol exposure induces the expression of breast cancer associated 
long noncoding RNA HOTAIR in vitro and in vivo. 
*Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate 
cancer cell proliferation. 
*Long-term follow-up of bilateral steroid-induced osteonecrosis of the lateral femoral condyles 
in a patient with Crohn's disease. 
*DNA diploidy in AIDS-related and steroid-induced Kaposi's sarcoma. 
*Molecular mechanisms of sex steroid-induced growth of cancer cells. 
*17Beta-estradiol promotes aggressive laryngeal cancer through membrane-associated estrogen 
receptor-alpha 36. 
*A case of steroid-induced glaucoma after radial keratotomy. 
*Management of steroid-induced hyperglycemia in hospitalized patients with cancer: a review. 
*Steroid induced atrial fibrillation. 
*Steroid induced diabetes mellitus in patients receiving prednisolone for haematological 
disorders. 
*Steroid induced glaucoma and cataract. 
*Alendronate for steroid-induced osteopenia in children with acute lymphoblastic leukaemia or 
non-Hodgkin's lymphoma: results of a pilot study. 
*Steroid induced osteoporosis. 




*Steroid induced psychosis in systemic lupus erythematosus: a possible role of serum albumin 
level. 
*Glucocorticoid Induced Cerebellar Toxicity in the Developing Neonate: Implications for 
Glucocorticoid Therapy during Bronchopulmonary Dysplasia. 
*Glucocorticoid induces micro-fat embolism in the rabbit: a scanning electron microscopic 
study. 
*Insulin increases retinal hemorrhage in mild oxygen-induced retinopathy in the rat: inhibition 
by riluzole. 
*Insulin induced fetal hypoglycaemia and fetal and maternal plasma prostaglandin 
concentrations in sheep in late gestation. 
*Insulin-induced proliferation of bladder cancer cells is mediated through activation of the 
epidermal growth factor system. 
*Insulin-induced renal dysfunction in regular Sabra rats. 
*Insulin: a novel agent in the pathogenesis of prostate cancer. 
*Insulin therapy contributes to the increased risk of colorectal cancer in diabetes patients: a 
meta-analysis.  
*Acromegaly induced by growth hormone replacement therapy. 
*Cardiovascular risk associated with hormone replacement therapy: some critical questions 
about the type of estrogen used in most clinical trials. 
*Growth hormone treatment induces mammary gland hyperplasia in aging primates. 
*Diethylstilbestrol liver carcinogenicity and modification of DNA in rats. 
*Diethylstilbestrol-induced uterine sarcoma in mice. 
2A9. Antihypertensive Agents 
(e.g., Enzyme Inhibitors; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme 
Inhibitors; Calcium Channel Blockers; Diuretics; Tetrazoles; Angiotensin II Type 1 Receptor 
Blockers; Benzazepines) 
*Nifedipine promotes the proliferation and migration of breast cancer cells. 
*Verapamil is associated with an increased risk of cancer in the elderly: the Rotterdam study. 
*ASSOCIATION OF CALCIUM CHANNEL BLOCKER USE WITH LOWER 
HEMOGLOBIN LEVELS IN CHRONIC KIDNEY DISEASE. 




*Treatment of calcium channel blocker-induced cardiovascular toxicity with drug scavenging 
liposomes. 
*Preoperative use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers is 
associated with increased risk for acute kidney injury after cardiovascular surgery. 
*Acebutolol-induced subacute cutaneous lupus erythematosus. 
*Sildenafil induced choreoathetosis in men with Parkinson's disease. 
*Atenolol hepatotoxicity: report of a complicated case. 
*Beta-blocker use is associated with fragility fractures in postmenopausal women with coronary 
heart disease. 
*ACE inhibitor-induced angioedema. 
*ACE inhibitor-induced hypoglycemia. 
*Angiotensin converting enzyme inhibitor toxicity causing interstitial pneumonitis and 
cholestatic hepatitis. 
*Angiotensin converting enzyme inhibitor induced hyperkalaemic paralysis. 
*Acute toxic effects of sustained-release verapamil in chronic renal failure. 
*Verapamil-induced hepatotoxicity. 
*Verapamil-induced acute right heart failure. 
*Agranulocytosis induced by captopril. 
*Captopril-induced acute pancreatitis. 
*Captopril-induced cholestatic jaundice. 
*Captopril-induced bone marrow suppression in two cardiac patients with trisomy 21. 
*Follicular mucinosis secondary to captopril-induced photoallergy. 
2A10. Gastrointestinal Agents 
(e.g., Proton Pump Inhibitors; Anti-Ulcer Agents; Cathartics; Phosphates) 
*Gastric acid blockade with omeprazole promotes gastric carcinogenesis induced by 
duodenogastric reflux. 
*Acute kidney injury following proton pump inhibitor therapy. 




*Long-term proton pump inhibitor use is associated with vascular calcification in chronic kidney 
disease: a cross-sectional study using propensity score analysis. 
*Proton-pump inhibitors are associated with increased cardiovascular risk independent of 
clopidogrel use: a nationwide cohort study. 
*A case series of proton pump inhibitor-induced hypomagnesemia. 
*Agranulocytosis induced by proton pump inhibitors. 
*Central nervous system side effects after proton pump inhibitor treatment. 
*Acute pancreatitis associated with omeprazole. 
*Autoimmune haemolytic anaemia due to Omeprazole. 
*Esomeprazole-induced photoallergic dermatitis. 
*Lansoprazole-induced microscopic colitis: an increasing problem? Results of a prospecive case-
series and systematic review of the literature. 
*Ranitidine is associated with infections, necrotizing enterocolitis, and fatal outcome in 
newborns. 
*Acute phosphate nephropathy following oral sodium phosphate bowel purgative: an 
underrecognized cause of chronic renal failure. 
*Severe hyperphosphatemia and hypocalcemia following the rectal administration of a 
phosphate-containing Fleet pediatric enema. 
2A11. Lipid Regulating Agents 
(e.g., Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Hypolipidemic Agents; 
Anticholesteremic Agents; Heptanoic Acids) 
*Atorvastatin-induced early-onset rhabdomyolysis in a patient with nephrotic syndrome. 
*ASSOCIATION OF STATIN USE WITH CATARACTS: A PROPENSITY SCORE-
MATCHED ANALYSIS. 
*Atorvastatin associated liver disease. 
*Atorvastatin induced multiple organ failure. 
*Piriformis muscle syndrome: an unusual adverse effect of atorvastatin. 
*Simvastatin-induced rhabdomyolysis in an HIV-infected patient with coronary artery disease. 
*Current overview of statin-induced myopathy. 




*Adverse drug reaction: rosuvastatin as a cause for ischaemic colitis in a 64-year-old woman. 
*Side effects of the HMG-CoA reductase inhibitors (statins). Lupus erythematosus induced by 
Atorvastatin therapy. 
*Cytogenetic status and oxidative DNA-damage induced by atorvastatin in human peripheral 
blood lymphocytes: standard and Fpg-modified comet assay. 




*Severe acute cholestatic hepatitis with prolonged cholestasis and bile-duct injury following 
atorvastatin therapy: a case report. 
*Simvastatin has deleterious effects on human first trimester placental explants. 
*Statin induced diabetes and its clinical implications. 
*Statin-induced fibrotic nonspecific interstitial pneumonia. 
*Statins accelerate the onset of collagen type II-induced arthritis in mice. 
*Statins can induce myasthenia gravis. 
2A12. Dermatologic Agents 
(e.g., Photosensitizing Agents; Hyaluronic Acid/ Hyaluronan; Salicylic Acid) 
*A cerebellar demyelinating lesion following treatment of acne with isotretinoin. 
*Allergic contact dermatitis to pimecrolimus. 
*Contact allergy from vitamins in cosmetic products. 
*Drug-induced ocular side-effects with isotretinoin. 
*Efalizumab-induced autoimmune pancytopenia. 
*Exogenous ochronosis and striae atrophicae following the use of bleaching creams. 
*Infliximab associated new-onset psoriasis. 
*Isotretinoin (Ro-Accutane) teratogenesis. A case report. 
*Imiquimod: liver damage: topical use, systemic effects. 




*Imiquimod-induced vitiligo after treatment of nodular basal cell carcinoma. 
*Imiquimod 5% cream induced psoriasis: a case report, summary of the literature and 
mechanism. 
*Severe systemic reaction to topical imiquimod. 
2A13. Anti-Bone-Loss Agents 
(e.g., Bone Density Conservation Agents; Diphosphonates; Zoledronic acid) 
*A case of zoledronate-induced tubulointerstitial nephritis with Fanconi syndrome. 
*SALMON CALCITONIN USE AND ASSOCIATED CANCER RISK. 
*Innegligible musculoskeletal disorders caused by zoledronic acid in adjuvant breast cancer 
treatment: a meta-analysis. 
*Pamidronate-induced kidney injury in a patient with metastatic breast cancer. 
*Oral osteonecrosis associated with the use of zoledronic acid: first case of a patient with 
advanced pancreatic cancer and bone metastases. 
*A case report: zoledronic acid-induced anterior uveitis. 
*Acute retinal pigment epithelial detachment secondary to pamidronate administration. 
*Alendronate-associated femoral insufficiency fractures and femoral stress reactions. 
*Alendronate-associated ulnar and tibial fractures: a case report. 
*Alendronate-induced synovitis. 
*Biphosphonate-induced osteonecrosis of the jaws: CT and MRI spectrum of findings in 32 
patients. 
*Bisphosphonate-associated arthritis. 
*Bisphosphonates and risk of upper gastrointestinal cancer--a case control study using the 
General Practice Research Database (GPRD). 
*Oral ulcers, a little known adverse effect of alendronate: review of the literature. 
*Seizures associated with zoledronic acid for osteoporosis. 
*Zoledronic acid-induced transient hepatotoxicity in a patient effectively treated for Paget's 
disease of bone. 
2A14. Antidiabetic Agents 




(e.g., Hypoglycemic Agents; Thiazolidinediones; Pyrrolidines) 
*ASSESSING THE ASSOCIATION OF PIOGLITAZONE USE AND BLADDER CANCER 
THROUGH DRUG ADVERSE EVENT REPORTING. 
*Rosiglitazone, a PPAR gamma agonist: potent promoter of hydroxybutyl(butyl)nitrosamine-
induced urinary bladder cancers. 
*EFFECT OF ROSIGLITAZONE ON THE RISK OF MYOCARDIAL INFARCTION AND 
DEATH FROM CARDIOVASCULAR CAUSES. 
*Antihyperglycemic treatment in diabetics with coronary disease: increased metformin-
associated mortality over a 5-year follow-up. 
*A case of drug-induced hepatic injury associated with sitagliptin. 
*A case of fatal intoxication from metformin. 
*A case of glyburide-induced leukocytoclastic vasculitis. 
*A case of lipoatrophy with insulin detemir. 
*Acute pulmonary edema due to rosiglitazone use in a patient with diabetes mellitus. 
*Acute tubulointerstitial nephritis following treatment with exenatide. 
*Metformin-associated lactic acidosis. 
*Metformin-induced vitamin B12 deficiency presenting as a peripheral neuropathy. 
*Pemphigus vulgaris triggered by glibenclamide and cilazapril. 
*Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies. 
*Pneumatosis coli induced by acarbose administration for diabetes mellitus. Case report and 
literature review. 
2A15. Antirheumatic Agents 
*A case of cavitating pneumococcal pneumonia developed during the treatment with etanercept 
for rheumatoid arthritis. 
*A case of cervical spine meningioma following etanercept use in a patient with RA. 
*A case of tuberculous arthritis following the use of etanercept. 
*Acute coronary syndrome after infliximab infusion. 
*Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment 
with infliximab. 




*Acute encephalomyelitis with multiple herpes viral reactivations during abatacept therapy. 
*Acute myeloid leukemia after infliximab: a case report. 
*Adalimumab-induced acute myelogenic leukemia. 
*Adalimumab-induced autoimmune hepatitis. 
*Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? observational report on 
six patients: occurrence of uveitis following etanercept treatment. 
*Leflunomide-induced DRESS syndrome with renal involvement and vasculitis. 
*Leflunomide-induced peripheral neuropathy. 
*Leflunomide-induced pulmonary hypertension in a young woman with rheumatoid arthritis: a 
case report. 
*Acute renal and hepatic failure associated with allopurinol treatment. 
*Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal 
necrolysis in Europe and Israel. 
2A16. Anti-Allergic Agents 
(e.g., Androstadienes) 
*Acute asthma attack caused by ophthalmic application of antiallergic agents. 
*Use of cetirizine in a 23-month-old male causes insomnia. 
*Cetirizine-induced dystonic reaction in a 6-year-old boy. 
*Delayed hypersensitivity reactions to corticosteroids. 
*Epinephrine-induced myocardial infarction in severe anaphylaxis: is nonselective beta-blockade 
a contributory factor? 
*Exogenous Cushing's syndrome as a serious side-effect of therapy with ritonavir an inhaled 
fluticasone. 
*First-generation H1 antihistamines found in pilot fatalities of civil aviation accidents, 1990-
2005. 
*Inflammation and neurological adverse drugs reactions: a case of long lasting impaired 
consciousness after oxatomide administration in a patient with gastroenteritis. 
*Inhaled corticosteroid-induced hair depigmentation in a child. 
*Oculogyric crisis in patients taking cetirizine. 




*Steroid-induced ocular hypertension with loteprednol etabonate 0.2%--a case report. 
2A17. Anti-Hypotensive Agents 
(e.g., Norepinephrine) 
*Cardiogenic shock with stunned myocardium during triple-H therapy treated with intra-aortic 
balloon pump counterpulsation. 
*High-dose norepinephrine induces disruption of myocardial extracellular matrix and left 
ventricular dilatation and dysfunction in a novel feline model. 
*Intracerebral haemorrhage and postpartum cerebral angiopathy associated with the 
administration of sulprostone and norepinephrine. 
*IS NOREPINEPHRINE AN ETIOLOGICAL FACTOR IN SOME TYPES OF CANCER? 
*Major haemodynamic incident during continuous norepinephrine infusion: Beware of the 
infusion line. An avoidable postoperative hypertensive peak?. 
*Norepinephrine-induced pressor diuresis blockade as a possible cause of hypertension. 
2A18. Antithyroid Agents 
(e.g., Propylthiouracil) 
*A case of MPO-ANCA positive vasculitis associated with diffuse alveolar hemorrhage and 
various cardiac conducting system abnormalities following propylthiouracil treatment. 
*A case of hypersensitivity syndrome induced by methimazole for Graves' disease. 
*A serious adverse effect: sepsis due to carbimazole. 
*Acute agranulocytosis from thiamazole: points for improvement in daily practice. 
*Acute pancreatitis induced by methimazole in a patient with Graves' disease. 
*Acute-on-chronic liver failure due to thiamazole in a patient with hyperthyroidism and trilogy 
of Fallot: case report. 
*Antenatal carbimazole and choanal atresia: a new embryopathy. 
*Antineutrophil cytoplasmic antibody (Anca)-associated autoimmune disease induced by 
propylthiouracil. 
*Antithyroid drug-induced aplastic anemia. 
*Aplasia cutis congenita and other anomalies associated with methimazole exposure during 
pregnancy. 





*Propylthiouracil-induced overt hepatic injury in patients with hyperthyroidism. 
2B. Radiotherapy 
(e.g., Radiosurgery; Brachytherapy; Adjuvant Radiotherapy; Cranial Irradiation; Conformal 
Radiotherapy; Intensity-Modulated Radiotherapy; Radiopharmaceuticals; Iodine Radioisotopes; 
Chemoradiotherapy; Whole-Body Irradiation) 
*A case of delayed facial palsy following gamma knife radiosurgery for intractable trigeminal 
neuralgia. 
*A nonhuman primate model of human radiation-induced venocclusive liver disease and 
hepatocyte injury. 
*Acute neurological complications following gamma knife surgery for vestibular schwannoma. 
Case report. 
*Delayed radiation-induced vasculitic leukoencephalopathy. 
*Adult survivors of childhood acute lymphoblastic leukaemia with GH deficiency have normal 
self-rated quality of life but impaired neuropsychological performance 20 years after cranial 
irradiation. 
*Cerebral cavernoma: an emerging long-term consequence of external beam radiation in 
childhood. 
*Chemotherapy- and radiotherapy-induced oral mucositis: pathobiology, epidemiology and 
management. 
*Cranial irradiation as an additional risk factor for anthracycline cardiotoxicity in childhood 
cancer survivors: an analysis from the cardiac risk factors in childhood cancer survivors study. 
*Acute cardiac impairment associated with concurrent chemoradiotherapy for esophageal 
cancer: magnetic resonance evaluation. 
*Chemoradiotherapy for anal cancer in HIV patients causes prolonged CD4 cell count 
suppression. 
*Delayed carotid blow-out syndrome: a new complication of chemoradiotherapy treatment in 
pharyngolaryngeal carcinoma. 
*Murine acute leukemia cell line with megakaryocytic differentiation (MK-8057) induced by 
whole-body irradiation in C3H/He mice: cytological properties and kinetics of its leukemic stem 
cells. 
*The differences between interstitial pneumonia following whole-body irradiation and radiation-
induced pneumonitis. 




*10 Gy total body irradiation increases risk of coronary sclerosis, degeneration of heart structure 
and function in a rat model. 
*Basal cell skin cancer after total-body irradiation and hematopoietic cell transplantation. 
*Chondrosarcoma arising within a radiation-induced osteochondroma several years following 
childhood total body irradiation: case report. 
2C. Surgery; Invasive Treatments 
The following categorization is not unique.  Some procedures could be assigned to multiple 
categories. 
2C1. Transplantation 
(e.g., Transplantation; Kidney Transplantation; Liver Transplantation; Hematopoietic Stem 
Cell Transplantation; Bone Marrow Transplantation; Heart Transplantation; Stem Cell 
Transplantation; Lung Transplantation; Organ Transplantation; Homologous Transplantation; 
Cell Transplantation; Peripheral Blood Stem Cell Transplantation; Pancreas Transplantation; 
Bone Transplantation; Cord Blood Stem Cell Transplantation) 
 Transplantation is an extremely large category of foundational causes, and these 
foundational causes operate on different levels.  There are foundational causes due to the 
transplant preparation process, due to the surgery, due to the immune suppression drugs, and 
enabled by the transplant (the transplant left the person more susceptible to disease). 
*13-cis-retinoic acid-induced eosinophilia following autologous bone marrow transplantation for 
neuroblastoma. 
*2 fatal cases of pneumococcal septicemia after bone marrow transplantation. 
*A case of bronchiolitis obliterans caused by allogeneic hematopoietic stem cell transplantation 
diagnosed with a body plethysmograph. 
*A fatal case of cerebral oedema with hyponatraemia and massive polyuria after renal 
transplantation. 
*A retrospective study of ocular side effects in children undergoing bone marrow 
transplantation. 
*Abdominal complications after bone marrow transplantation in children: sonographic and CT 
findings. 
*Accelerated bone mineral density loss occurs with similar incidence and severity, but with 
different risk factors, after autologous versus allogeneic hematopoietic cell transplantation. 
*Acute and chronic pulmonary complications following autologous bone marrow transplantation 
in non-Hodgkin's lymphoma. 




*Acute leukemia, a rare but fatal complication after liver transplantation. 
*Acute neurological complications after hematopoietic stem cell transplantation in children. 
*Acute renal failure following lung transplantation: risk factors, mortality, and long-term 
consequences. 
*Cardiac morbidity and mortality related to orthotopic liver transplantation. 
*Chronic graft-versus-host disease and late effects after hematopoietic stem cell transplantation. 
*Chronic kidney disease after lung transplantation: incidence, risk factors, and treatment. 
*Fatal Kaposi sarcoma after allogeneic stem cell transplant. 
2C2. CardioVascular 
(e.g., Stents; Cardiac Surgical Procedures; Heart Surgery; Catheterization; Bypass; Coronary 
Artery Bypass; Vascular Surgical Procedures; Blood Vessel Prosthesis Implantation; Central 
Venous Catheterization; Therapeutic Embolization; Cardiopulmonary Bypass; Heart Valve 
Prosthesis Implantation; Angioplasty; Coronary Balloon Angioplasty; Blood Vessel Prosthesis; 
Endovascular Procedures; Balloon Angioplasty; Artificial Pacemaker; Thrombolytic Therapy; 
Peripheral Catheterization; Heart-Assist Devices; Angiography; Atrial Pacing; Carotid 
Endarterectomy; Implantable Defibrillators; Cardiovascular Surgical Procedures; Fontan 
Procedure; Drug-Eluting Stents; Balloon Occlusion; Sclerotherapy; Cardiopulmonary 
Resuscitation; Thrombectomy; Revascularization) 
 Very large category. 
*Abdominal organ injury after cardiac surgery. 
*Acute kidney injury and chronic kidney disease after cardiac surgery. 
*Acute gastric volvulus: an unreported long-term complication of pericardial drainage. 
*Acute kidney injury and long-term risk of stroke after coronary artery bypass surgery. 
*Adverse cerebral outcomes after coronary bypass surgery. 
*Atrial fibrillation after coronary artery bypass grafting in elderly patients: incidence and risk 
factor analysis. 
*Cardiopulmonary bypass as a cause of free radical-induced oxidative stress and enhanced 
blood-borne isoprostanes in humans. 
*A case of contrast-induced pancreatitis following cardiac catheterization. 
*Bilateral femoral neuropathy caused by iliacus hematomas during anticoagulation after cardiac 
catheterization. 




*Cardiac catheterization-induced acute radiation dermatitis presenting as a fixed drug eruption. 
*Catheter-induced pulmonary artery rupture in the setting of cardiopulmonary bypass. 
*Stent-induced thromboembolism. 
*Stent-induced coronary artery stenosis characterized by multimodal nonlinear optical 
microscopy. 
*A hypothesis regarding vascular acoustic emission accompanying arterial injury induced by 
balloon angioplasty. 
*Acute myocardial ischaemia and cardiogenic shock after percutaneous transluminal coronary 
angioplasty; risk factors for and results of emergency coronary bypass. 
*Coronary angioplasty induces a systemic inflammatory response. 
2C3. Orthopedic 
(e.g., Orthopedic Procedures; Hip Replacement Arthroplasty; Prostheses and Implants; 
Osteotomy; Spinal Fusion; Prosthesis Implantation; Knee Replacement Arthroplasty; Surgical 
Decompression; Laminectomy; Diskectomy; Arthroscopy; Hip Prosthesis; Bone Screws; 
Replacement Arthroplasty; Bioprosthesis; Internal Fixators; Prosthesis Failure; Knee Prosthesis) 
*A case of delayed recurrent hemarthrosis after posterolateral reconstruction of the knee with a 
staple fixation at the lateral femoral epicondyle. 
*Acute bowel ischemia following spinal surgery. 
*Acute thrombotic thrombocytopenic purpura following orthopedic surgery: case report and 
review of the literature. 
*Cardiac complications following hip fracture surgery. 
*Acute crystal-induced arthritis following arthroplasty. 
*Acute kidney injury following total joint arthroplasty: retrospective analysis. 
*Allergic reaction to components of bone cement after total knee arthroplasty. 
*Fatal fat embolism following femoral head resection in total hip arthroplasty. 
*Fatal massive adrenal hemorrhage after bilateral total knee arthroplasty. 
*Hyponatremia after primary hip and knee arthroplasty: incidence and associated risk factors. 
*Severe bone defects and reduced mineralization caused by massive metallosis after total knee 
arthroplasty: histopathologic and bone morphometric findings. 
*Anterior interosseus nerve injury following elbow arthroscopy. 




*Fatal pulmonary embolus after knee arthroscopy. 
*Septic arthritis following arthroscopy: clinical syndromes and analysis of risk factors. 
*Life-threatening airway edema resulting from prolonged shoulder arthroscopy. 
2C4. Gastrointestinal 
(e.g., Laparoscopy; Digestive System Surgical Procedures; Endoscopy; Gastric Bypass; 
Bariatric Surgery; Esophagectomy; Gastroplasty; Gastrectomy; Colectomy; Laparotomy; 
Gastrointestinal Endoscopy; Gastrostomy; Gastrointestinal Intubation; Ileostomy; Colostomy; 
Restorative Proctocolectomy; Fundoplication; Appendectomy; Gastroscopy) 
*Bile duct injury following laparoscopic cholecystectomy. 
*Bladder dysfunction after gynecologic laparoscopic surgery for benign disease. 
*Fatal intestinal ischaemia following laparoscopic cholecystectomy. 
*Heart arrest caused by CO2 embolism during a laparoscopic cholecystectomy. 
*High incidence of trocar site hernia after laparoscopic or robotic Roux-en-Y gastric bypass. 
*Malnutrition-induced myopathy following Roux-en-Y gastric bypass. 
*Rectal epithelial cell mitosis and expression of macrophage migration inhibitory factor are 
increased 3 years after Roux-en-Y gastric bypass (RYGB) for morbid obesity: implications for 
long-term neoplastic risk following RYGB. 
*Acute kidney injury following bariatric surgery. 
*Acute liver failure after bariatric surgery. A case report and literature review. 
*Anemia after bariatric surgery: more than just iron deficiency. 
*Beriberi after bariatric surgery: not an unusual complication. Report of two cases and literature 
review. 
*Dramatic reduction in sperm parameters following bariatric surgery: report of two cases. 
*Liver transplantation for subacute hepatocellular failure due to massive steatohepatitis after 
bariatric surgery. 
2C5. Kidney/ Urologic 
(e.g. Renal Dialysis; Peritoneal Dialysis; Urinary Catheterization; Nephrectomy; Laparoscopic 
Cholecystectomy; Prostatectomy; Cholecystectomy; Urologic Surgical Procedures; Urinary 
Diversion; Suburethral Slings; Cystectomy; Lithotripsy; Percutaneous Nephrostomy) 




*A boy undergoing maintenance hemodialysis who developed mediastinal lymph node 
tuberculosis. 
*A case of phlegmesia cerulea dolens after dialysis catheter insertion. 
*Accelerated atherosclerosis in haemodialysis patients; correlation of endothelial function with 
oxidative DNA damage. 
*Acute calciphylaxis precipitated by the initiation of hemodialysis. 
*A case of uretero-aortic fistula after the urinary diversion. 
*Anaphylactic reactions to chlorhexidine during urinary catheterisation. 
*Catheter-associated urinary tract infection. 
*Adverse effect of radical prostatectomy on nocturia and voiding frequency symptoms. 
*A case of pulmonary embolism and a case of ileus as complications after laparoscopic radical 
prostatectomy. 
*Addressing and managing erectile dysfunction after prostatectomy for prostate cancer. 
*Deep vein thrombosis caused by pelvic lymphocyst following radical prostatectomy: a case 
report. 
*Nephrectomy induced chronic renal insufficiency is associated with increased risk of 
cardiovascular death and death from any cause in patients with localized cT1b renal masses. 
2C6. Brain/Neural 
(e.g., Neurosurgical Procedures; Ventriculoperitoneal Shunt; Craniotomy; Electric Stimulation 
Therapy; Deep Brain Stimulation; Spinal Puncture; Electric Stimulation; Spinal Injections) 
*Acute parotitis following sitting position neurosurgical procedures: review of five cases. 
*Analysis of the factors contributing to diabetes insipidus after surgeries for 
craniopharyngiomas. 
*Bilateral bulbar palsy and postural hypotension following surgery for fourth ventricle 
subependymoma. 
*Baroreflex failure after chemodectoma resection. 
*Brachial neuritis: an under-recognized cause of upper extremity paresis after cervical 
decompression surgery. 
*Acute massive pulmonary hemorrhage after craniotomy in a patient with systemic lupus 
erythematosus. 




*Acute respiratory arrest following partial suboccipital cranioplasty for cerebellar ptosis from 
Chiari malformation decompression. 
*A report of paraparesis following spinal cord stimulator trial, implantation and revision. 
*Complete heart block with ventricular asystole during left vagus nerve stimulation for epilepsy. 
*Explosive-aggressive behavior related to bilateral subthalamic stimulation. 
*Late onset cervical myelopathy secondary to fibrous scar tissue formation around the spinal 
cord stimulation electrode. 
*Sleep-related breathing disorder in children with vagal nerve stimulators. 
2C7. Dental/ Oral/ Nose/ Ear 
(e.g., Tooth Extraction; Oral Surgical Procedures; Dental Implants; Tonsillectomy; 
Otorhinolaryngologic Surgical Procedures; Laryngectomy; Endosseous Dental Implantation; 
Root Canal Therapy; Cochlear Implantation) 
*An unusual complication of osteotome sinus floor elevation: benign paroxysmal positional 
vertigo. 
*A case of Candida mediastinitis after dental extraction. 
*Asphyxial death related to postextraction hematoma in an elderly man. 
*Bacterial meningitis after tooth extraction. 
*Bilateral idiopathic sensorineural hearing loss following dental surgery. 
*Bell's palsy following primary tooth extraction. A case report. 
*Cervicofacial emphysema after dental treatment with emphasis on the anatomy of the cervical 
fascia. 
*Chronic osteomyelitis following an uncomplicated dental extraction. 
*Accidental displacement of dental implants into the maxillary sinus: a report of nine cases. 
*Dental implant failure associated with bacterial infection and long-term bisphosphonate usage: 
a case report. 
*Dental implants and squamous cell carcinoma in the at risk patient--report of three cases. 
*Mandibular fractures associated with endosteal implants. 
2C8. Gynecologic 
(e.g., Cesarean Section; Hysterectomy; Gynecologic Surgical Procedures; Ovariectomy) 




*A case of bifocal endometriosis involving a pfannenstiel incision. 
*A case of Mycoplasma hominis infection after bladder injury during cesarean section. 
*A fatal case of hypovolemic shock after cesarean section. 
*Abdominal wall mycetoma presented as obstructed incisional hernia of cesarean section in 
eastern Sudan. 
*Adrenal insufficiency after laparoscopic hysterectomy in a patient with primary 
antiphospholipid syndrome. 
*Abnormal vaginal cytology in HIV-infected and at-risk women after hysterectomy. 
*Biofeedback therapy for female patients with constipation caused by radical hysterectomy or 
vaginal delivery. 
*Bladder dysfunction after simple hysterectomy: urodynamic and neurological evaluation. 
*17 beta-Estradiol and tamoxifen prevent the over-glycosylation of rat trabecular bone collagen 
induced by ovariectomy. 
*A change in liver metabolism but not in brown adipose tissue thermogenesis is an early event in 
ovariectomy-induced obesity in rats. 
*A potential role for the bone marrow mesenchymal stem cell in the pathogenesis of 
osteoporosis by ovariectomy in rat. 
*Genistein supplementation and estrogen replacement therapy improve endothelial dysfunction 
induced by ovariectomy in rats.  
2C9. Respiratory/Thorax 
(e.g., Intratracheal Intubation; Pneumonectomy; Thoracotomy; Thoracic Surgical Procedures; 
Tracheostomy; Video-Assisted Thoracic Surgery; Sternotomy; Artificial Pneumoperitoneum; 
Mechanical Ventilation) 
*Acute lung injury and acute respiratory distress syndrome following pneumonectomy. 
*Bronchial artery dissection and fatal hemothorax following pneumonectomy. 
*Cardiovascular and respiratory complications after pneumonectomy. 
*Acute life-threatening airway obstruction with pseudomembrane formation after percutaneous 
dilational tracheostomy. 
*Analysis of the risk factors causing tracheal stenosis after tracheotomy for mechanical 
ventilation in 560 patients. 




*Bilateral pneumothoraces and pulmonary oedema following tracheostomy induced by acute 
tracheal obstruction. 
*Fatal re-expansion pulmonary edema in a young adult following tube thoracostomy for 
spontaneous pneumothorax. 
*Increased age is an independent risk factor for radiographic aspiration and laryngeal penetration 
after thoracotomy for pulmonary resection. 
*Lung injury after thoracotomy. 
*Cardiovascular complications after lung surgery. 
*Postoperative psychiatric disorders in general thoracic surgery: incidence, risk factors and 
outcomes. 
2C10. Liver/ Spleen 
(e.g., Hepatectomy; Splenectomy) 
*Acute iatrogenic Budd-Chiari syndrome following hepatectomy for hepatolithiasis: a report of 
two cases. 
*Bacterial translocation in acute liver failure induced by 90 per cent hepatectomy in the rat. 
*Bile leakage after hepatectomy for hepatolithiasis: risk factors and management. 
*Hypersplenism induced by hepatectomy. 
*Hypophosphataemia after major hepatectomy and the risk of post-operative hepatic 
insufficiency and mortality: an analysis of 719 patients. 
*Iron chelation prevents lung injury after major hepatectomy. 
*Adverse effect of splenectomy on recurrence in total gastrectomy cancer patients with 
perioperative transfusion 
*Angioedema caused by splenectomy with malignant lymphoma followed by multiple myeloma 
7 years later. 
*Earlier onset of delta-retrovirus-induced leukemia after splenectomy. 
*Fatal infection after splenectomy despite reimplantation of splenic tissue. 
*Fatal venous thromboembolism after splenectomy: pathogenesis and management. 
*High incidence of thrombosis of the portal venous system after laparoscopic splenectomy: a 
prospective study with contrast-enhanced CT scan. 
2C11. Ocular 




(e.g., Cataract Extraction; Ophthalmologic Surgical Procedures; Phacoemulsification; 
Vitrectomy; Laser Keratomileusis In Situ; Intraocular Lens Implantation) 
*A case of endophthalmitis associated with limbal relaxing incision. 
*A sudden total loss of vision after routine cataract surgery. 
*Adult retinopathy of prematurity: retinal complications from cataract surgery. 
*A case of acquired Brown syndrome after surgical repair of a medial orbital wall fracture. 
*Acute angle closure glaucoma after oculoplastic surgery. 
*Atypical necrotizing scleritis after strabismus surgery. 
*Binocular photophobia after surgical treatment in intermittent exotropia. 
*Corneal ectasia after LASIK despite low preoperative risk: tomographic and biomechanical 
findings in the unoperated, stable, fellow eye. 
*LASIK-induced optic neuropathy. 
*Bacterial contamination of the vitreous cavity associated with transconjunctival 25-gauge 
microincision vitrectomy surgery. 
*Factors contributing to corneal complications after vitrectomy in diabetic patients 
2C12. Breast 
(e.g., Mammaplasty; Mastectomy; Breast Implants) 
*Augmentation mammaplasty: postoperative cephalosporin-induced hepatitis. 
*Granulomatous pleurisy after mammaplasty, induced by polyacrylamide gel. 
*A case of toxic shock syndrome following a DIEP breast reconstruction. 
*Cardiac arrest following hydrogen peroxide irrigation of a breast wound. 
*Clarithromycin attenuates mastectomy-induced acute inflammatory response. 
*Hematoma after mastectomy with immediate reconstruction: an analysis of risk factors in 883 
patients. 
*Allergic contact dermatitis to synthetic rubber following breast augmentation. 
*An uncommon complication of secondary augmentation mammoplasty: bilaterally massive 
engorgement of breasts after pregnancy attributable to postinfection and blockage of mammary 
ducts. 




*Anaplastic large cell lymphoma associated with breast implants: a report of 13 cases. 
*Anaplastic large cell lymphoma and breast implants: five Australian cases. 
*Galactorrhea after aesthetic breast augmentation with silicone implants: report of two cases and 
management of postoperative galactorrhea. 
2C13. Dermal/ Tissue/ Neck 
(e.g., Neck Dissection; Herniorrhaphy) 
*A case of increased intracranial pressure after unilateral modified radical neck dissection. 
*A new shoulder orthosis for paralysis of the trapezius muscle after radical neck dissection: a 
preliminary report. 
*Acupuncture for pain and dysfunction after neck dissection: results of a randomized controlled 
trial. 
*Bilateral chylothorax following left-sided radical neck dissection. 
*A new classification for seroma after laparoscopic ventral hernia repair. 
*Aortic injury during laparoscopic esophageal hiatoplasty. 
*First cases of giant pseudocyst complicating inguinal hernia repair. 
*Late onset mesh infection following laparoscopic inguinal hernia repair. 
2C14. Thyroid 
(e.g., Thyroidectomy) 
*Blockage of gonadotropin-induced first ovulation caused by thyroidectomy and its possible 
mechanisms in rats. 
*Exacerbation of idiopathic paroxysmal kinesigenic dyskinesia in remission state caused by 
secondary hypoparathyroidism with hypocalcemia after thyroidectomy: evidence for ion 
channelopathy. 
*Hypothyroidism during neonatal and perinatal period induced by thyroidectomy of the mother 
causes depressive-like behavior in prepubertal rats. 
*Hypocalcaemia following total thyroidectomy: early post-operative parathyroid hormone assay 
as a risk stratification and management tool. 
*Hypoparathyroid risk after total thyroidectomy. 
*Influence of Superior Laryngeal Nerve Injury on Glottal Configuration/Function of 
Thyroidectomy-Induced Unilateral Vocal Fold Paralysis. 




*Respiratory complications after thyroidectomy and the need for tracheostomy in patients with a 
large goitre. 
2C15. Pancreas 
(e.g., Pancreaticoduodenectomy; Pancreatectomy) 
*A preoperative biliary stent is associated with increased complications after 
pancreatoduodenectomy. 
*Delayed gastric emptying after pylorus-preserving pancreatoduodenectomy is strongly related 
to other postoperative complications. 
*Haemorrhage following pancreaticoduodenectomy: risk factors and the importance of sentinel 
bleed 
*Necrotizing pancreatitis caused by pancreatoduodenectomy. 
*Pancreatic fibrosis correlates with exocrine pancreatic insufficiency after 
pancreatoduodenectomy. 
*High surgical morbidity following distal pancreatectomy: still an unsolved problem. 
*Pancreatic fistula after distal pancreatectomy: incidence, risk factors and management. 
*Treatment of isolated pancreatic islets to reverse pancreatectomy-induced and insulin-
dependent type I diabetes in humans: a 6-year experience. 
2C16. General 
(e.g., Blood Transfusion; Erythrocyte Transfusion; Reconstructive Surgical Procedures; 
Ablation; Catheter Ablation; Indwelling Catheters; Artificial Respiration; Surgical Anastomosis; 
Operative Surgical Procedures; Drainage; Minimally Invasive Surgical Procedures; Laser 
Therapy; Reoperation; Graft; Ligation; Shunt; Enteral Nutrition; Surgical Mesh; Lymph Node 
Excision; Parenteral Nutrition; Device Removal; Cryosurgery; Microsurgery; Tissue and Organ 
Harvesting; Sutures; Reoperation; Surgical Instruments; Intravenous Infusions; Suction; Surgical 
Stapling; Amputation; Resuscitation) 
*Acute lung injury following blood transfusion: expanding the definition. 
*A case of fatal graft-versus-host disease following blood transfusion in esophageal cancer 
documented by homozygous changes of HLA typing. 
*Adverse effects of blood transfusion. 1. Posttransfusion hepatitis. 
*A case of delayed massive hemothorax caused by the rupture of a pulmonary artery 
pseudoaneurysm after radiofrequency ablation of lung tumors. 




*A case of diaphragmatic hernia induced by radiofrequency ablation for hepatocellular 
carcinoma. 
*Acute fatal pulmonary vein occlusion after catheter ablation of atrial fibrillation. 
*A case of external iliac arteriovenous fistula and high-output cardiac failure after endovenous 
laser treatment of great saphenous vein. 
*Amaurosis after lower eyelid laser blepharoplasty. 
*Arterio-venous fistula following endovenous laser ablation for varicose veins. 
*Bilateral cataract and corectopia after laser eyebrow corrected epilation. 
*A case of inappropriate sinus tachycardia after atrio-ventricular nodal reentrant tachycardia 
cryoablation successfully treated by ivabradine. 
*Panniculitis due to alpha 1-antitrypsin deficiency induced by cryosurgery. 
*A case of delayed recurrent hemarthrosis after posterolateral reconstruction of the knee with a 
staple fixation at the lateral femoral epicondyle. 
*Early rectal stenosis following stapled rectal mucosectomy for hemorrhoids. 
*Cardiac morbidity and operative mortality following lower-extremity amputation: the 
significance of multiple Eagle criteria. 
*High mortality risks after major lower extremity amputation in Medicare patients with 
peripheral artery disease 
*Mortality following lower extremity amputation in minorities with diabetes mellitus. 
2C17. Other 
(e.g., Chinese Herbal Drugs; Oral Contraceptives; Hormonal Oral Contraceptives; Vascular 
Endothelial Growth Factor; Fertilization in Vitro; Induced Abortion; Genetic Therapy; Assisted 
Reproductive Techniques; Ovulation Induction; Intrauterine Devices; Female Contraceptive 
Agents; Combined Oral Contraceptives; Ophthalmic Solutions; Contact Lenses; Bone Cements; 
Polymethyl Methacrylate; Nonprescription Drugs; Interferon-beta; Physical Stimulation; 
Antiemetics; Narcotic Antagonists; Prodrugs; Delayed-Action Preparations; Kainic Acid; 
Peroxynitrite) 
*A case of drug-induced pneumonitis associated with chinese herbal drugs and valsartan. 
*A case of ischemic colitis associated with the herbal food supplement ma huang. 
*Aconite poisoning over 5 years: a case series in Hong Kong and lessons towards herbal safety. 
*Acute hepatitis induced by Chinese hepatoprotective herb, xiao-chai-hu-tang. 




*A 21-year-old white woman diagnosed with cerebral venous sinus thrombosis related to oral 
contraceptive and Factor V Leiden. 
*Central retinal vein occlusion in young women: rare cases with oral contraceptive pills as a risk 
factor. 
*Oral contraceptive causing renal artery thrombosis. 
*A case of panic disorder induced by oral contraceptive. 
*Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into 
nonhuman primates. 
*Arthritis gene therapy's first death. 
*Genotoxicity of retroviral hematopoietic stem cell gene therapy. 
*A case report of acute interstitial nephritis associated with antibiotic-impregnated orthopedic 
bone-cement spacer. 
*Acute tissue toxicity of PMMA bone cements. 
*Allergic reaction to components of bone cement after total knee arthroplasty. 
*Acute respiratory distress syndrome associated with pulmonary cement embolism following 
percutaneous vertebroplasty with polymethylmethacrylate. 
*7-chlorokynurenic acid prevents in vitro epileptiform and neurotoxic effects due to kainic acid. 
*A blueberry-enriched diet provides cellular protection against oxidative stress and reduces a 
kainate-induced learning impairment in rats. 
*Acute effects of MK801 on kainic acid-induced seizures in neonatal rats. 
*Aged garlic extract inhibits peroxynitrite-induced hemolysis. 
*Curcumin attenuates peroxynitrite-induced neurotoxicity in spiral ganglion neurons. 
*Hydrogen peroxide- and peroxynitrite-induced mitochondrial DNA damage and dysfunction in 
vascular endothelial and smooth muscle cells. 
 There are many more classes of drugs identified than are shown here, and they cover the 
full spectrum of drugs.  The most highly pervasive drug categories include antineoplastic agents, 
anti-infective agents, anti-inflammatory agents, cardiovascular agents, central nervous system 
agents, immunologic factors, hematologic agents, and steroids/ hormones.  Moderately pervasive 
drug categories include antihypertensive agents, gastrointestinal agents, lipid regulating agents, 
dermatologic agents, vaccines/ vaccination, anti-bone-loss agents, antidiabetic agents, and 
antirheumatic agents.  Pervasive drug categories include anti-allergic agents, anti-hypotensive 
agents, antithyroid agents. 




 There are many specific drugs identified with very high frequencies.  The main message 
here is that drugs across the board are not benign.  Individually, drugs can contribute to causing 
serious disease.  Drug combinations (with both drugs and non-drugs) may have the potential to 
exacerbate the adverse effects of individual drugs through synergistic effects. 
 A substantial number of adverse effects/ complications from surgical and other treatment 
procedures are identified.  These include both acute and longer-term chronic effects.  The most 
highly pervasive surgeries include transplantation, cardiovascular, orthopedic, gastrointestinal, 
kidney/ urologic, and brain/ neural.  Moderately pervasive surgeries include dental/ oral/ nose/ 
ear, gynecologic, respiratory/ thorax, and liver/ spleen.  Pervasive surgeries include ocular, 
breast, dermal/ tissue/ neck, thyroid, pancreas, and general procedures.  As in the case of drugs, 
these absolute numbers of complications must be considered in light of the numbers of 
procedures performed. 
 Radiotherapy has an extremely large number of side-effects/complications. 
 2D. Diagnostic Agents/ Procedures 
 2D1.  Contrast Media  
(e.g., Iodine) 
*A case of cardiac arrest with ST elevation induced by contrast medium. 
*A case of contrast-induced encephalopathy using iodixanol. 
*A case of idiopathic colitis developed after barium enema. 
*Acute kidney injury with iodinated contrast. 
*Acute hyperglycemia and contrast-induced nephropathy in primary percutaneous coronary 
intervention. 
*Acute orbital edema causing reversible blindness after the administration of intravenous 
contrast agent in a patient with thyroid eye disease. 
*Anaphylactoid reactions to radiocontrast media. 
*Case of fatal toxic epidermal necrolysis due to cardiac catheterization dye. 
*Contrast-induced transient cortical blindness. 
 2D2.  Radiation 
 2D2a. Ionizing 
(e.g., X-Ray Computed Tomography (CT)) 




*An association between cerebral aneurysm re-bleed and CT angiography--more than a 
coincidence? 
*Cancer risk in 680,000 people exposed to computed tomography scans in childhood or 
adolescence: data linkage study of 11 million Australians. 
*Cancer risks from diagnostic radiology. 
*CT scans in childhood: leukaemia, brain tumours. 
*Risk estimates for meningiomas and other late effects after diagnostic X-ray exposure of the 
skull. 
*Leukemia among medical diagnostic X-ray workers in China. 
*Theoretical increase of thyroid cancer induction from cervical spine multidetector computed 
tomography in pediatric trauma patients. 
 There is a very extensive literature on radiation doses from CT scans, the dose-disease 
translation, and ways to reduce the dosage and eliminate unnecessary scans.  There are also 
many papers on the adverse effects of the contrast media used as part of the CT scan, but since 
the taxonomy contains a category for contrast media, they are not included here. 
2D2b. Non-Ionizing 
(e.g., Magnetic Resonance Imaging (MRI)) 
*An unusual burn during routine magnetic resonance imaging. 
*Arteriovenous fistula complication following MRI. 
*Deleterious effects of MRI on chondrocytes. 
*Efficacy of diphenhydramine in the prevention of vertigo and nausea at 7 T MRI. 
*Genotoxic effects of 3 T magnetic resonance imaging in cultured human lymphocytes. 
*Hearing loss after noise exposure. 
*Iatrogenic hyperthermia during cardiac magnetic resonance imaging. 
*MRI magnetic field stimulates rotational sensors of the brain. 
*Spontaneous dissociation during functional MRI experiments. 
 There were many papers addressing the impact of MRI on implantable devices, many of 
these impacts being adverse, but only biological issues were used for these examples. 
2D3. Invasive 




(e.g., Biopsy; Cardiac Catheterization; Colonoscopy; Bronchoscopy; Digestive System 
Endoscopy) 
*A case of iatrogenic tension pneumoperitoneum following colonoscopy in a patient with 
cytomegalovirus colitis. 
*Acute appendicitis caused by colonoscopy. 
*Acute colonoscopy-induced splenic rupture presenting to the emergency department. 
*Chilaiditi syndrome precipitated by colonoscopy: a case report and review of the literature. 
*Colonoscopy-induced ischemic colitis in patients without risk factors. 
*Fatal dysnatraemia caused by elective colonoscopy. 
*Fatal massive air embolism following diagnostic colonoscopy. 
*Hepatic injury following colonoscopy. 
*Ileocolic intussusception precipitated by diagnostic colonoscopy: a case report. 
*Mechanical small bowel obstruction precipitated by colonoscopy. 
*Tako-tsubo cardiomyopathy following colonoscopy: insights on pathogenesis. 
*An unusual complication during bronchoscopy: hypotension, global ST segment elevation, and 
acute severe left ventricular systolic dysfunction. 
*Bilateral pneumothorax after bronchoscopy without biopsy--a rare complication: case 
presentation and literature review. 
*Bronchoscopic suctioning may cause lung collapse: a lung model and clinical evaluation. 
*Cardiogenic shock secondary to Tako-tsubo syndrome after debridement of malignant 
endobronchial obstruction. 
*Uvular necrosis as an unusual complication of bronchoscopy via the nasal approach. 
*Double balloon endoscopy associated pancreatitis: a description of six cases. 
*Esophageal perforation as a complication of esophagogastroduodenoscopy. 
*Intramural duodenal hematoma after upper gastrointestinal endoscopy. 
*A case report of cerebral air embolism after esophagogastroduodenoscopy: diagnosis and 
management in the emergency department. 




 There are many papers on problems induced by the bowel preparation solutions prior to 
colonoscopy.  The focus of the examples is on the problems induced by the mechanical 
procedure itself. 
2D4. Other 
(e.g., Diagnostic Errors) 
*Can rt-PA be administered to the wrong patient? Two patients with somatoform disorder. 
*Delay and misdiagnosis in sub-massive and non-massive acute pulmonary embolism. 
*Effects of disease misclassification on exposure-disease association. 
*Fatal outcome of belated diagnosis of an acral lentiginous melanoma. 
*Gleason pattern 5 is frequently underdiagnosed on prostate needle-core biopsy. 
*Mistakes in diagnostics and treatment of soft tissue sarcomas. 
*Overdiagnosis and mistreatment of malaria among febrile patients at primary healthcare level in 
Afghanistan: observational study. 
*Traumatic pulmonary arteriovenous fistula may be misdiagnosed with residual shunt after 
patent foramen ovale closure. 
 The main diagnostic sources are radio-contrast agents, especially iodinated agents, and 
the invasive procedures.  The general category of diagnostic errors has some causative problems, 
but the major focus tends to be on worse outcomes as a result of missed diagnoses.  Ionizing 
radiation, especially for treatment but even for diagnostics, is also causative. 
3. BIOTOXIC AGENTS 
3A. Mycotoxins 
(e.g., Aflatoxin) 
*A rapid screening method to test apoptotic synergisms of ochratoxin A with other nephrotoxic 
substances. 
*A time-series study of sick building syndrome: chronic, biotoxin-associated illness from 
exposure to water-damaged buildings. 
*A toxicogenomics approach to identify new plausible epigenetic mechanisms of ochratoxin a 
carcinogenicity in rat. 
*Airway toxicity of house dust and its fungal composition. 




*Cognitive impairment associated with toxigenic fungal exposure": a critique and critical 
analysis. 
*2-(allylthio)pyrazine inhibition of aflatoxin B1-induced hepatotoxicity in rats: inhibition of 
cytochrome P450 2B- and 3A2-mediated bioactivation. 
*5-Methylcytosine in CpG sites and the reactivity of nearest neighboring guanines toward the 
carcinogen aflatoxin B1-8,9-epoxide. 
*Aflatoxin and hepatitis B virus biomarkers: a paradigm for complex environmental exposures 
and cancer risk. 
*Aflatoxin B1 exposure, hepatitis B virus infection, and hepatocellular carcinoma in Taiwan. 
3B. Exotoxins 
(e.g., Lipopolysaccharides; Envenomation; Histamine; Amyloid; Amyloid Beta; N-Methyl-D-
Aspartate; Retinoic Acid; Botulinum Toxin; Catecholamine; Collagen; Arginine; Albumin; 
Testosterone; Androgen; Thrombin; 4-hydroxy-2-nonenal; Excitatory Amino Acid Agonists; 
Glutamic Acid; Arachidonic Acid; Ovalbumin) 
 For purposes of the present analysis, a substance was considered an exotoxin if it was 
administered externally during experiments.  Thus, amyloid beta, an endogenous substance, 
could be viewed as an endotoxin when internal processes are being discussed, but also as an 
exotoxin when given in laboratory experiments. 
*1,8-cineol attenuates LPS-induced acute pulmonary inflammation in mice. 
*A comparison of lipopolysaccharide-induced hepatitis in ethanol-fed Wistar and Lewis rats. 
*A mouse model of severe acute pancreatitis induced by caerulein plus lipopolysaccharide. 
*2-Deoxy-D-glucose reverses the Indian red scorpion venom-induced cardiopulmonary 
abnormalities in anesthetized rats. 
*A case of neurotoxicity following envenomation by the Sidewinder Rattlesnake, Crotalus 
cerastes. 
*A model for venom-induced consumptive coagulopathy in snake bite. 
*A case of histamine poisoning related to the consumption of Iwashi preserved herring. 
*A comparison of sevoflurane with halothane, enflurane, and isoflurane on bronchoconstriction 
caused by histamine. 
*Histamine-induced coronary artery spasm: the concept of allergic angina. 
*3-Nitropropionic acid exacerbates N-methyl-D-aspartate toxicity in striatal culture by multiple 
mechanisms. 




*N-methyl-D-aspartate (NMDA)-induced seizures in developing rats. 
*NMDA- and beta-amyloid1-42-induced neurotoxicity is attenuated in serine racemase knock-
out mice. 
*1 alpha-hydroxyvitamin D3 inhibits type II collagen-induced arthritis in rats. 
*Collagen-induced thrombosis in large vessels using native prothrombotic substrates. 
*Collagen: a potential factor involved in the pathogenesis of glaucoma. 
*Enteral glutamine supplementation impairs intestinal blood flow in rats. 
*A preliminary experimental study on the cardiac toxicity of glutamate and the role of alpha-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor in rats. 
*Glutamate-induced cell death in HT22 mouse hippocampal cells is attenuated by paxilline, a 
BK channel inhibitor. 
3C. Bacteria/Fungi/Parasites 
(e.g., Escherichia coli; Staphylococcus aureus; Streptococcus; Streptococcus pyogenes; 
Streptococcus agalactiae; Staphylococcus epidermidis; Staphylococcus; Mycobacterium 
tuberculosis; Pseudomonas aeruginosa; Salmonella; Aspergillus; Clostridium; Chlamydia 
trachomatis; Mycoplasma; Helicobacter pylori; Candida albicans; Streptococcus pneumoniae; 
Bacillus Calmette-Guerin; Klebsiella; Klebsiella pneumoniae; Campylobacter; Schistosoma; 
Yersinia; Parasite; Vibrio Cholerae/Cholera) 
*2 newborn infants with septicemia caused by multiresistant Streptococcus mitis. 
*A case of infective endocarditis in a farmer caused by Streptococcus equinus. 
*A case of meningitis caused by Streptococcus pyogenes in a previously healthy woman. 
*Streptococcus viridans-induced crystalline keratopathy and fungal keratitis. 
*A case of community-onset meningitis caused by hospital methicillin-resistant Staphylococcus 
aureus successfully treated with linezolid and rifampicin. 
*Acute lymphadenitis with cellulitis caused by Staphylococcus lugdunensis. 
*Acute lung injury induced by Staphylococcal enterotoxin B: disruption of terminal vessels as a 
mechanism of induction of vascular leak. 
*Fatal meningitis due to Staphylococcus cohnii. Case report. 
*A case of endocarditis caused by Clostridium entering through the gastrointestinal system. 
*A review of mortality due to Clostridium difficile infection. 




*Acute aortic dissection caused by Clostridium septicum aortitis. 
*A case of fatal disseminated infection caused by Mycobacterium bovis BCG strain and the 
identification of the isolate by spoligotyping. 
*Acute granulomatous tubulointerstitial nephritis caused by intravesical BCG. 
*A case with hepatitis and interstitial pneumonitis caused by intravesical bacillus Calmette-
Guerin (BCG) instillation. 
3D. Viruses 
(e.g., Human Immunodeficiency Virus; Cytomegalovirus; Herpes Viruses; Human Herpesvirus 
4; Hepatitis Virus; Hepatitis B virus; Epstein Barr Virus; Influenza Viruses; Adenovirus; 
Papillomavirus; Hepacivirus; Retrovirus; Human Herpesvirus 6; Human Herpesvirus 8; Human 
Herpesvirus 1; Human T-lymphotropic virus 1; Papillomaviridae; Parvovirus; Varicella Zoster 
Virus; Human Herpesvirus 3; Human Herpesvirus 2) 
*A case of arthritis caused by cytomegalovirus after kidney transplantation. 
*Acute pericarditis caused by cytomegalovirus in a normal host. 
*CMV antigenemia following bone marrow transplantation: risk factors and outcomes. 
*Cytomegalovirus-induced gastrointestinal disease in previously healthy adults. 
*Acute retinal necrosis caused by herpes simplex virus type 2 in children: reactivation of an 
undiagnosed latent neonatal herpes infection. 
*Herpes simplex virus-induced cardiomyopathy successfully treated with acyclovir. 
*Herpes simplex virus-induced epithelial damage and susceptibility to human immunodeficiency 
virus type 1 infection in human cervical organ culture. 
*A case of acute myocarditis caused by pandemic (H1N1) 2009 influenza virus. 
*2009 pandemic influenza A (H1N1): pathology and pathogenesis of 100 fatal cases in the 
United States. 
*Acute epiglottitis caused by Haemophilus influenzae type b in children: presentation of 21 
cases. 
*A Case of Associated Laryngeal Paralysis Caused by Varicella Zoster Virus without Eruption. 
*A delayed life-threatening complication after uneventful varicella infection: transient complete 
heart block. 
*Acute meningitis caused by reactivation of the varicella-zoster virus without cutaneous lesions. 
Contribution to the serologic diagnosis. 




 Bacteria and viruses were dominant in this class.  Bacteria are somewhat ubiquitous, so 
the flexibility of cause removal for this sub-category is much less than for the Lifestyle and 
Iatrogenic categories.  Unlike the Iatrogenic drug category, where the disease causative nature of 
the drug depended on whether the drug was used as a treatment for a specific disease, the 
causative nature of the bacteria and viruses was unambiguous.  Almost every Title containing a 
bacterium or virus described a disease or symptom caused by the bacterium or virus.  Thousands 
of examples could have been shown! 
3E. Other 
(e.g., Toxic Plants) 
*A review of the hepatotoxic plant Lantana camara. 
*Aortoesophageal fistula--an unusual complication of esophagitis caused by Dieffenbachia 
ingestion. 
*Case of colchicine intoxication caused by tubers of Gloriosa superba. 
*Chewing of betel, areca and tobacco: perceptions and knowledge regarding their role in head 
and neck cancers in an urban squatter settlement in Pakistan. 
*Full thickness burn caused by exposure to giant hogweed: delayed presentation, histological 
features and surgical management. 
*Genotoxic damage in Maras powder consumers from Kahramanmaras province of Turkey. 
*Grayanotoxin poisoning from Rhododendron simsii in an infant. 
*Hypotension, bradycardia and syncope caused by honey poisoning. 
*Unilateral mydriasis due to Angel's trumpet. 
4. OCCUPATIONAL/ENVIRONMENTAL EXPOSURES 
4A. Chemicals/Materials 
4A1.  Industrial/Household Chemicals/Materials 
4A1a. Hydrocarbons 
(e.g., Benzo(a)pyrene; Naphthalenes; Polycyclic Aromatic Hydrocarbons; Toluene; 7 12-
dimethylbenz(a)anthracene; Petroleum) 
*A CASE-CONTROL STUDY OF ASPHALT AND TAR EXPOSURE AND LUNG CANCER 
IN MINORITIES. 
*Environmental polycyclic aromatic hydrocarbon (PAH) exposure and DNA damage in Mexican 
children. 




*Cancer risk from occupational and environmental exposure to polycyclic aromatic 
hydrocarbons. 
*Carcinogenic potencies of polycyclic aromatic hydrocarbons for back-door neighbors of 
restaurants with cooking emissions. 
*7,12-dimethylbenzaanthracene-induced malignancies in a mouse model of menopause. 
*7,12-dimethylbenzaanthracene-induced 'early' squamous cell carcinoma in the Golden Syrian 
hamster: evaluation of an animal model and comparison with 'early' forms of human squamous 
cell carcinoma in the upper aero-digestive tract. 
*Obesity increases the incidence of 7,12-dimethylbenz(a)anthracene-induced mammary tumors 
in an ovariectomized Zucker rat model. 
*7,12-Dimethylbenz(a)anthracene-induced myelotoxicity differs in mice selected for high or low 
acute inflammatory response: relationship with aryl hydrocarbon receptor polymorphism. 
*Elevated cancer mortality in a German cohort of bitumen workers: extended follow-up through 
2004. 
*CANCER INCIDENCE IN AN OCCUPATIONAL COHORT EXPOSED TO BITUMEN 
FUMES. 
*A common carcinogen benzoapyrene causes neuronal death in mouse via microglial activation. 
*Cancer preventive potential of Momordica charantia L. against benzo(a)pyrene induced fore-
stomach tumourigenesis in murine model system. 
*Capsaicin modulates pulmonary antioxidant defense system during benzo(a)pyrene-induced 
lung cancer in Swiss albino mice. 
*A mild progression type of naphthalene-induced cataract in brown-Norway rats. 
*Protective effect of Coleus aromaticus Benth (Lamiaceae) against naphthalene-induced 
hepatotoxicity. 
*Hemolysis from exposure to naphthalene mothballs. 
*Cardiac autonomic dysfunction in rotogravure printers exposed to toluene in relation to 
peripheral nerve conduction. 
*Developmental neurotoxicity after toluene inhalation exposure in rats. 
*Erythropsia following exposure to toluene. 
*A case-control study of leukemia among petroleum workers. 
*Cancer incidence of workers in the Swedish petroleum industry. 




*Urinary bladder cancer and the petroleum industry: a quantitative review. 
*Residential proximity to petroleum storage tanks and associated cancer risks: Double Kernel 
Density approach vs. zonal estimates. 
*Polycyclic aromatic hydrocarbons in residential dust and risk of childhood acute lymphoblastic 
leukemia. 
4A1b. Solvents 
(e.g., Acetamides; Trichloroethylene; Methanol) 
*Carcinogenicity of trichloroethylene, tetrachloroethylene, some other chlorinated solvents, and 
their metabolites. 
*OCCUPATIONAL TRICHLOROETHYLENE EXPOSURE AND KIDNEY CANCER RISK: 
A META-ANALYSIS. 
*OCCUPATIONAL TRICHLOROETHYLENE EXPOSURE AND RISK OF LYMPHATIC 
AND HAEMATOPOIETIC CANCERS: A META-ANALYSIS. 
*Preexistence of chronic tubular damage in cases of renal cell cancer after long and high 
exposure to trichloroethylene. 
*A case of optic neuropathy after short-term linezolid use in a patient with acute lymphocytic 
leukemia. 
*Acute oral poisoning due to chloracetanilide herbicides. 
*First case of lacosamide-induced psychosis. 
*A case of occupational hypersensitivity pneumonitis associated with trichloroethylene. 
*EXPOSURE TO CHLORINATED SOLVENTS AND LUNG CANCER: RESULTS OF THE 
ICARE STUDY. 
4A1c. Chemical Compounds 
(Chlorine Compounds; Carbon Compounds; Carbon Monoxide; Carbon Dioxide; Sodium 
Compounds; Hydrogen Compounds; Hydrogen Peroxide; Hydrochloride Compounds; Silicon 
Compounds; Silica/Silicon Dioxide; Magnesium Compounds; Nitrogen Compounds; 
Nitrates/Nitrites; Manganese Compounds; Ethylene Compounds; Chromium Compounds; Sulfur 
Compounds; Sulfides) 
*A case of hepatocellular carcinoma related with exposure to vinyl chloride monomers. 
*A fatal case of hypermagnesemia caused by ingesting magnesium chloride as a folk remedy. 
*Acute poisoning caused by chlorinated solvents. 




*CARCINOGENIC HAZARD OF CHLOROFORM AND OTHER DRINKING WATER 
CHLORINATION BY-PRODUCTS. 
*Cardiac arrhythmias induced by chloral hydrate in rhesus monkeys. 
*Neurotoxicity of allyl chloride in rats. Dose-effect relationship following long-term exposure. 
*A case of delayed post-anoxic encephalopathy after acute carbon monoxide poisoning. 
*A case of carbon monoxide poisoning presenting with supraventricular tachycardia. 
*Acute liver toxicity by carbon tetrachloride in HSP70 knock out mice. 
*Carbon tetrachloride-induced nephrotoxicity and protective effect of betaine in Sprague-
Dawley rats. 
*Carbon dioxide-induced panic attacks and quantitative electroencephalogram in panic disorder 
patients. 
*Carbon dioxide-induced retinopathy in the neonatal rat. 
*Pulmonary embolism caused by CO2. 
*Carcinogenic hazards from inhaled carbon black, titanium dioxide, and talc not containing 
asbestos or asbestiform fibers: recent evaluations by an IARC Monographs Working Group. 
*Nano-sized carbon black exposure exacerbates atherosclerosis in LDL-receptor knockout mice. 
*PNEUMOCONIOSIS IN CARBON BLACK WORKERS. 
*Carbon disulfide exposure and neurotoxic sequelae among viscose rayon workers. 
*Cardiovascular disturbances in workers exposed to carbon disulfide. 
*A case of sodium bromate intoxication with cerebral lesion. 
*A severe case of interstitial nephritis caused by sodium valproate. 
*Adverse effects of sodium chloride on bone in the aging human population resulting from 
habitual consumption of typical American diets. 
*LUNG CANCER INCIDENCE AMONG NORWEGIAN SILICON CARBIDE INDUSTRY 
WORKERS: ASSOCIATIONS WITH PARTICULATE EXPOSURE FACTORS. 
*Carcinogenic properties of silicon carbide whiskers. 
*A CD36 synthetic peptide inhibits silica-induced lung fibrosis in the mice. 
*Cancer mortality in women with probable exposure to silica: a death certificate study in 24 
states of the U.S. 




*Association of indoor nitrogen dioxide exposure with respiratory symptoms in children with 
asthma. 
*Nitrogen dioxide is genotoxic in urban concentrations. 
*In vitro neurotoxic and DNA-damaging properties of nitrogen mustard. 
*Chromium-induced genotoxicity and interference in human lymphoblastoid cell (TK6) repair 
processes. 
*Hexavalent chromium and lung cancer in the chromate industry: a quantitative risk assessment. 
*Chromium (VI) induces insulin resistance in 3T3-L1 adipocytes through elevated reactive 
oxygen species generation. 
 This particular sub-category is very broad, and thousands of examples could have been 
generated, given the large numbers of these myriad chemical compounds in the literature.  All 
the chemical types mentioned had copious adverse effects, especially compounds containing 
chlorine, nitrogen, chromium, and carbon. 
4A1d. Other 
(e.g., Chemical Water Pollutants; Arsenic; Dioxides; Asbestos; Phosphate; Selenium; 
Streptozotocin; Dioxin; Methyl Compounds; Ozone; Coal; Organophosphates; Polychlorinated 
Biphenyl/PCB; Hydrogen Sulfide; Sulfones; Coloring Agents; Mining; Bisphenol A; 
Xenobiotics; Tetrachlorodibenzodioxin; Endocrine Disruptors; Chemical Warfare Agents; 
Benzenesulfonates; Formaldehyde; Cosmetic Techniques; Ozone; Cosmetics; Fluorocarbons; 
Disinfectants; Nitrogen Dioxide; Polymers; Silicones; Carbon Tetrachloride; MPTP; Fluoride; 
Wood; Dextran Sodium Sulfate; Methylmercury; Phenol; Bromine; Arsenite; 
Tetradecanoylphorbol Acetate; Welding) 
*Abnormal development of motor neurons in perfluorooctane sulphonate exposed zebrafish 
embryos. 
*Acute and chronic toxicities of Irgarol alone and in combination with copper to the marine 
copepod Tigriopus japonicus. 
*A case of neuropathy mimicking Guillain-Barre syndrome after arsenic intoxication. 
*A case of scrotal superficial basal cell carcinoma caused by chronic arsenic exposure. 
*Asbestos-induced malignant pulmonary and pleural diseases. 
*Can features of phosphate toxicity appear in normophosphatemia? 
*Phosphate-induced vascular calcification: role of pyrophosphate and osteopontin. 
*Dietary phosphate restriction ameliorates endothelial dysfunction in adenine-induced kidney 
disease rats. 




*Dioxin induces genomic instability in mouse embryonic fibroblasts. 
*Dioxin strongly immunotoxic. 
*Chloracne after exposure to dioxin. 
*Acute lung disease after exposure to fly ash. 
*Coal workers' pneumoconiosis with progressive massive fibrosis. 
*Carcinogenic effects of polychlorinated biphenyls (PCBs) and their derivatives, including 
carcinogenicity to the lung. 
*Polychlorinated Biphenyl (PCB) carcinogenicity with special emphasis on airborne PCBs. 
*Coal dust exposure and mortality from ischemic heart disease among a cohort of U.S. coal 
miners. 
*Lung cancer mortality is elevated in coal-mining areas of Appalachia. 
*Adverse effects of formaldehyde vapor on mouse sperm parameters and testicular tissue. 
*Bone marrow injury induced via oxidative stress in mice by inhalation exposure to 
formaldehyde. 
*1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is 
antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level. 
*MPTP-induced duodenal ulcers in rat. Prevention by reuptake blockers for serotonin and 
norepinephrine, but not dopamine. 
*Cancer incidence and magnetic field exposure in industries using resistance welding in Sweden. 
*Aluminum welding fume-induced pneumoconiosis. 
*Risk of lung cancer according to mild steel and stainless steel welding. 
4A2.  Agricultural Chemicals 
(e.g., Pesticides; Herbicides; Insecticides; Triazines; Morpholines; Organophosphorus 
Compounds) 
*A case-control study on correlation of pesticide exposure with childhood acute leukemia. 
*Pesticide exposure and amyotrophic lateral sclerosis. 
*Pesticide exposure and risk for Parkinson's disease. 
*Acute fatal paraquat poisoning. 




*Paraquat- and rotenone-induced models of Parkinson's disease. 
*Paraquat-induced pulmonary fibrosis starts at an early stage of inflammation in rats. 
*Chlorpropham induces mitochondrial dysfunction in rat hepatocytes. 
*Herbicide exposure and the risk of transitional cell carcinoma of the urinary bladder in Scottish 
Terriers. 
*Hepatotoxicity induced by sub-acute exposure of rats to 2,4-Dichlorophenoxyacetic acid based 
herbicide "Desormone lourd". 
*Pesticide exposure and endocrine dysfunction in the cotton crop agricultural workers of 
southern Punjab, Pakistan. 
*DNA damage and cholinesterase activity in occupational workers exposed to pesticides. 
 The industrial, household, and agricultural chemicals are a major cause of disease.  There 
were large numbers of chemicals identified, especially at lower frequencies.  Many of these are 
ubiquitous in daily life, and eliminating exposure to them may be a challenge. 
4A3. Materials 
4A3a. Heavy metal 
(e.g., Lead; Iron/Iron Overload; Zinc; Cadmium; Copper; Mercury; Lithium; Silver; Aluminum; 
Gold; Nickel; Titanium; Cobalt) 
*Cadmium exposure and cancer mortality in the Third National Health and Nutrition 
Examination Survey cohort. 
*Heavy metal poisoning: the effects of cadmium on the kidney. 
*Acute pulmonary toxicity and body distribution of inhaled metallic silver nanoparticles. 
*Potential health risks of heavy metals in cultivated topsoil and grain, including correlations with 
human primary liver, lung and gastric cancer, in Anhui province, Eastern China. 
*Roles of EGFR, PI3K, AKT, and mTOR in heavy metal-induced cancer. 
*Cancer mortality among female and male workers occupationally exposed to inorganic lead in 
the printing industry. 
*Acute cardiovascular toxic effects of copper in anesthetized rabbits. 
*Copper-induced immunotoxicity involves cell cycle arrest and cell death in the spleen and 
thymus. 
*Aluminum exposure and Alzheimer's disease. 




*Aluminum toxicity in patients with chronic renal failure. 
*Cardiac oxidative damage in mice following exposure to nanoparticulate titanium dioxide. 
*Asthma caused by hard metals: responsibility of titanium. 
*Acute exposure to cobalt induces transient methemoglobinuria in rats. 
*Cobalt chloride induces hepatotoxicity in adult rats and their suckling pups. 
*Carcinogenic nickel induces genes involved with hypoxic stress. 
*Carcinogenicity of nickel is the result of its binding to RNA and not to DNA. 
*LUNG CANCER RISK ASSOCIATED WITH OCCUPATIONAL EXPOSURE TO NICKEL, 
CHROMIUM VI, AND CADMIUM IN TWO POPULATION-BASED CASE-CONTROL 
STUDIES IN MONTREAL. 
4A3b. Particulates 
(e.g., Dust; Air Pollutants; Occupational Air Pollutants; Traffic; Aerosols; Diesel Exhaust; 
Vehicle Emissions) 
*Ambient air pollution is associated with the increased incidence of breast cancer in US. 
*AMBIENT EXPOSURE TO CRITERIA AIR POLLUTANTS AND FEMALE LUNG 
CANCER IN TAIWAN. 
*AMBIENT EXPOSURE TO CRITERIA AIR POLLUTANTS AND RISK OF DEATH FROM 
BLADDER CANCER IN TAIWAN. 
*AIR POLLUTION FROM TRAFFIC AND CANCER INCIDENCE: A DANISH COHORT 
STUDY. 
*Accelerated silicosis in workers exposed to agate dust in Guangzhou, China. 
*Acute pulmonary alveolar proteinosis due to exposure to cotton dust. 
*Adenocarcinomas of the nose after exposure to wood dust. 
*Airborne occupational allergic contact dermatitis from coal dust. 
*Acquired dyschromatopsia among petrochemical industry workers exposed to benzene. 
*Acute respiratory health effects of air pollution on children with asthma in US inner cities. 
*Air pollution shortens life expectancy and health expectancy for older adults: the case of China. 
*Ambient air pollution alters heart rate regulation in aged mice. 






*Acute inhalation toxicity of cerium oxide nanoparticles in rats. 
*Amorphous nanosilica induce endocytosis-dependent ROS generation and DNA damage in 
human keratinocytes. 
*An increase in mouse tumor growth by an in vivo immunomodulating effect of titanium dioxide 
nanoparticles. 
*Carcinogenicity of inhaled nanoparticles. 
*Cardiovascular effects of pulmonary exposure to titanium dioxide nanoparticles in ApoE 
knockout mice. 
*Nanoparticles and colloids as contributing factors in neurodegenerative disease. 
*Adverse effects of industrial multiwalled carbon nanotubes on human pulmonary cells. 
*Oxidative damage of single-walled carbon nanotubes in striaturn and hippocampi of mice. 
*Teratogenicity of multi-wall carbon nanotube (MWCNT) in ICR mice. 
*Using carbon nanotubes to induce micronuclei and double strand breaks of the DNA in human 
cells. 
*Metallic nickel nanoparticles may exhibit higher carcinogenic potential than fine particles in 
JB6 cells. 
*Genotoxicity and carcinogenicity risk of carbon nanotubes. 
*Focal amplification of HOXD-harboring chromosome region is implicated in multiple-walled 
carbon nanotubes-induced carcinogenicity. 
*The carcinogenic potential of nanomaterials, their release from products and options for 
regulating them. 
4B. Physical/Mechanical 
4B1. Electromagnetic Radiation 
4B1a. Ionizing 
(e.g., Gamma Rays) 
*Repair of ionizing radiation-induced DNA damage and risk of second cancer in childhood 
cancer survivors. 




*Differential expression of cell adhesion molecules in an ionizing radiation-induced breast 
cancer model system. 
*Ionizing radiation-induced gamma-H2AX activity in whole blood culture and the risk of lung 
cancer. 
*Molecular characterisation of murine acute myeloid leukaemia induced by 56Fe ion and 137Cs 
gamma ray irradiation. 
*Gamma-ray-induced mutagen sensitivity and risk of sporadic breast cancer in young women: a 
case-control study. 
*Radiation-induced carcinogenesis: mechanistically based differences between gamma-rays and 
neutrons, and interactions with DMBA. 
*MicroRNA-21 is involved in ionizing radiation-promoted liver carcinogenesis. 
*Urinary bladder carcinogenesis induced by chronic exposure to persistent low-dose ionizing 
radiation after Chernobyl accident. 
*Risk factors for induction of breast cancer by X-rays and their implications for breast screening. 
*Enhanced risks of cancer from protracted exposures to X- or gamma-rays: a radiobiological 
model of radiation-induced breast cancer. 
4B1b. Non-Ionizing 
(e.g., Electromagnetic Fields; Electromagnetic Fields Radiofrequency) 
*RISKS OF CARCINOGENESIS FROM ELECTROMAGNETIC RADIATION OF MOBILE 
TELEPHONY DEVICES. 
*RESIDENCE NEAR POWER LINES AND MORTALITY FROM NEURODEGENERATIVE 
DISEASES: LONGITUDINAL STUDY OF THE SWISS POPULATION. 
*Disturbance of the immune system by electromagnetic fields-A potentially underlying cause for 
cellular damage and tissue repair reduction which could lead to disease and impairment. 
*Potential health risks due to telecommunications radiofrequency radiation exposures in Lagos 
State Nigeria. 
*POOLED ANALYSIS OF CASE-CONTROL STUDIES ON MALIGNANT BRAIN 
TUMOURS AND THE USE OF MOBILE AND CORDLESS PHONES INCLUDING LIVING 
AND DECEASED SUBJECTS. 
*A population-based prospective cohort study of personal exposure to magnetic fields during 
pregnancy and the risk of miscarriage. 
*Exposure to magnetic fields and the risk of poor sperm quality. 




*Maternal exposure to magnetic fields during pregnancy in relation to the risk of asthma in 
offspring. 
*Acceleration of the development of benzopyrene-induced skin-cancer in mice by microwave-
radiation. 
*Low-frequency electromagnetic-radiation enhances the induction of rat mammary-tumors by 
nitrosomethyl urea. 
*Leukemia following occupational exposure to 60-Hz electric and magnetic fields among 
Ontario electric utility workers. 
*Electromagnetic fields enhance chemically-induced hyperploidy in mammalian oocytes. 
*Exposure to a 50 Hz electromagnetic field induces activation of the Epstein-Barr virus genome 
in latently infected human lymphoid cells. 
*New data for proving the presence of significant effects of electromagnetic exposure (to 
autoimmune changes in rats). 
*A possible association between fetal/neonatal exposure to radiofrequency electromagnetic 
radiation and the increased incidence of autism spectrum disorders (ASD). 
*Autism-relevant social abnormalities in mice exposed perinatally to extremely low frequency 
electromagnetic fields. 
*Autism and EMF? Plausibility of a pathophysiological link - Part I. 
*Combined exposure of ELF magnetic fields and X-rays increased mutant yields compared with 
X-rays alone in pTN89 plasmids. 
*Microwave-radiation enhances the teratogenic effect of cytosine-arabinoside in mice. 
4B1b1. Non-Visible 
(e.g., Ultraviolet Rays; Ultraviolet B) 
*3-Aminobenzamide can act as a cocarcinogen for ultraviolet light-induced carcinogenesis in 
mouse skin. 
*A possible link between neural tube defects and ultraviolet light exposure. 
*A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. 
*Action spectrum and recovery for in vitro UV-induced cataract using whole lenses. 
*Animal model of ultraviolet-radiation-induced recurrent herpes simplex virus infection. 




*ASSOCIATION BETWEEN INCIDENCE OF NON-HODGKIN'S LYMPHOMA AND 
SOLAR ULTRAVIOLET RADIATION IN ENGLAND AND WALES. 
*Does exposure to UV radiation induce a shift to a Th-2-like immune reaction? 
*Facial nerve neuritis secondary to ultraviolet radiation. 
*Ultraviolet irradiation induced brain oedema in rats. A microgravimetric study. 
4B1b2. Visible 
(e.g., Sunlight/Light; Laser) 
*17beta-Estradiol Ameliorates Light-Induced Retinal Damage in Sprague-Dawley Rats by 
Reducing Oxidative Stress. 
*ARE SOME MELANOMAS CAUSED BY ARTIFICIAL LIGHT? 
*A case of linear immunoglobulin A bullous dermatosis in a patient exposed to sun and an 
analgesic. 
*A case of tetany due to exposure to the sun 
*A fatal case of sun exposure in a multiple sclerosis patient. 
*Acute neuropathy after exposure to sun in a patient treated with St John's Wort. 
*Allergic hypersensitivity skin reactions following sun exposure. 
*Association between light exposure during the night and myopia in children. 
*Blue light has a dark side. Light at night is bad for your health, and exposure to blue light 
emitted by electronics and energy-efficient lightbulbs may be especially so. 
*Chronic exposure to dim light at night suppresses immune responses in Siberian hamsters. 
*Circadian desynchrony and metabolic dysfunction; did light pollution make us fat? 
*Clinical evidence for light-induced thermal damage in cortical cataracts. 
*Dark nights reverse metabolic disruption caused by dim light at night. 
*Fatal air embolism as a complication of laser-induced hyperthermia. 
*A laser-induced mouse model of chronic ocular hypertension to characterize visual defects. 
*Acute effects of anti-inflammatory drugs on neodymium:yttrium aluminum garnet laser-
induced uveitis in dogs. 




*Anti-angiogenic effects of non-peptide integrin alphavbeta3 specific antagonist on laser-
induced choroidal neovascularization in mice. 
*Aqueous humor dynamics in monkeys with laser-induced glaucoma. 
*Argon laser-induced retinal herniation. 
*CO2 and Nd:YAG laser-induced pulmonary parenchymal lung injury in a rabbit model. 
*Cortical microcirculation in a new model of focal laser-induced secondary brain damage. 
*Cutaneous lupus erythematosus following laser-induced thermal injury. 
4B2. Sound 
(e.g., Noise; Ultrasound) 
*0098 Occupational deafness due to co-exposure to noise and ototoxic agents. 
*0274 Occupational noise exposure and the prevalence of hyperglycemia. 
*Noise-induced perilymph fistula. 
*Noise-induced duodenal lesions: a light and electron microscopy study of the lesions of the rat 
duodenal mucosa exposed to low frequency noise. 
*Music: a new cause of primary spontaneous pneumothorax. 
*Myocardial fibrosis in rats exposed to low frequency noise. 
*Low frequency noise and stress: bronchitis and cortisol in children exposed chronically to 
traffic noise and exhaust fumes. 
*Cardiac arrhythmia and injury induced in rats by burst and pulsed mode ultrasound with a gas 
body contrast agent. 
*Cardiopulmonary function in rats with lung hemorrhage induced by pulsed ultrasound 
exposure. 
*Changes in mouse behavior induced by fetal exposure to diagnostic ultrasound. 
*Changes in Na and K ions in mouse liver following in vivo exposure to ultrasound. 
*Comparison of mouse and rabbit lung damage exposure to 30 kHz ultrasound. 
*Damage to cultured corneal endothelium caused by ultrasound during phacoemulsification. 
*Diagnostic ultrasound activation of contrast agent gas bodies induces capillary rupture in mice. 
*Hemolysis in vivo from exposure to pulsed ultrasound. 




4B3. Temperature; Heat/Cold 
(e.g., Cold; Burn; Hypothermia; Hot Temperature; Cold Temperature) 
*31P-magnetic resonance spectroscopic study on the effect of glycerol on cold-induced brain 
edema. 
*5-Hydroxytryptamine 1A receptors inhibit cold-induced sympathetically mediated cutaneous 
vasoconstriction in rabbits. 
*A breathing filter exchanging heat and moisture prevents asthma induced by cold air. 
*Acute estrogen administration can reverse cold-induced coronary Raynaud's phenomenon in 
systemic sclerosis. 
*Acute myocardial infarction induced by alternating exposure to heat in a sauna and rapid 
cooling in cold water. 
*Acute rhabdomyolysis due to prolonged exposure to the cold. 
*Angiotensinogen gene knockout delays and attenuates cold-induced hypertension. 
*Cold air-induced rhinitis. 
*Cold exposure exacerbates the development of diabetic polyneuropathy in the rat. 
*Cold-induced hyperthyroidism produces oxidative damage in rat tissues and increases 
susceptibility to oxidants. 
*0401 Repeated pre and post-shift urinalyses show kidney dysfunction among Costa Rican 
sugarcane cutters exposed to heat stress. 
*A possible role of NF-kappaB and HSP72 in skeletal muscle hypertrophy induced by heat stress 
in rats. 
*A single, mild, transient scrotal heat stress causes hypoxia and oxidative stress in mouse testes, 
which induces germ cell death. 
*Chronic heat stress weakened the innate immunity and increased the virulence of highly 
pathogenic avian influenza virus H5N1 in mice. 
*Heat-induced liver injury in old rats is associated with exaggerated oxidative stress and altered 
transcription factor activation. 
*Heat-induced squamous cell carcinoma of the lower extremities in a wildlands firefighter. 
*Mapping an X-linked locus that influences heat-induced febrile seizures in mice. 
*Placental glucose transport in heat-induced fetal growth retardation. 




4B4. Force/ Pressure/ Physical Trauma 
(e.g., Hypoxia; Hyperbaric Oxygen; Traumatic Brain Injury; Spinal Cord Injury; Vibration) 
*Hypoxia-induced metastasis of human melanoma cells: involvement of vascular endothelial 
growth factor-mediated angiogenesis. 
*150-kDa oxygen-regulated protein (ORP150) suppresses hypoxia-induced apoptotic cell death. 
*15-Lipoxygenase promotes chronic hypoxia-induced pulmonary artery inflammation via 
positive interaction with nuclear factor-kappaB. 
*Hypoxia-induced dysfunction in developing rat neocortex. 
*A model for predicting central nervous system oxygen toxicity from hyperbaric oxygen 
exposures in humans. 
*Acute respiratory distress syndrome after prolonged hyperbaric oxygen therapy: a case of 
pulmonary oxygen toxicity?. 
*Brain blood flow modulates the neurotoxic action of hyperbaric oxygen via neuronal and 
endothelial nitric oxide. 
*Central nervous system oxygen toxicity during routine hyperbaric oxygen therapy. 
*Exogenously administered and endogenously produced melatonin reduce hyperbaric oxygen-
induced oxidative stress in rat lung. 
*Enhancement of glucose toxicity by hyperbaric oxygen exposure in diabetic rats. 
*Focal status epilepticus induced by hyperbaric oxygen therapy. 
*Genotoxicity of hyperbaric oxygen. 
*A p1 aneurysm and diabetes insipidus caused by traumatic brain injury. 
*A population-based study of risk of epilepsy after hospitalization for traumatic brain injury. 
*A tension pneumocephalus caused by severe traumatic brain injury. 
*Agrin expression during synaptogenesis induced by traumatic brain injury. 
*Astereopsis caused by traumatic brain injury. 
*0068 Occupational exposure to hand-transmitted vibration and risk of Dupuytren's contracture. 
*A follow up study of vascular disorders in vibration-exposed forestry workers. 
*Adverse effects of whole-body vibration on gastric motility. 




*Back disorders and health problems among subway train operators exposed to whole-body 
vibration. 
*Back pain and exposure to whole body vibration in helicopter pilots. 
*Vibration-induced nystagmus - A sign of unilateral vestibular deficit. 
*Vibration-induced carpal-tunnel syndrome. 
*Vibration-induced hearing loss: mechanical and physiological aspects. 




*18 cases of asthma induced by hamster or guinea-pig bred as pets. 
*Asthma caused by a pet bat. 
*Dermatophytes transmitted by pets and cattle. 
*Ocular and subcutaneous dirofilariasis in a Sri Lankan infant: an environmental hazard caused 
by dogs and mosquitoes. 
*The danger of contracting salmonellosis from exotic pets. 
*Control of injuries caused by dogs: a public health perspective. 
*Outbreak of urban rabies transmitted by dogs in Santa Marta, northern Colombia. 
*Bite-related and septic syndromes caused by cats and dogs. 
*Zoonotic sporothricosis transmitted by cats in Rio de Janeiro, Brazil. A case report. 
*Zoonotic parasitosis transmitted by dogs in the Chaco Salteno, Argentina. 
*Cutaneous zoonoses transmitted by dogs and cats. 
*A study on wounds caused by cats as basic materials of cat scratch disease. 
*Dog and cat bite-associated infections in children. 
*Zoonoses transmitted by mouse and rat maintained as laboratory or pet animals. 
 The particles and different forms of radiation emitted to the environment are broadly-
based, and in many cases have become part of the average lifestyle.  Avoiding exposure to these 




emissions (e.g., electromagnetic fields, vehicle exhausts, noise, metals in agriculture, etc) would 
require a major change in lifestyle (and probably location) for most people. 
 The 'Other' category was an amalgam of traumatic injuries due to pets and various 
diseases transmitted by pets (or animals in general).  It could also have been placed in the 
appropriate Biotoxin sub-categories. 
5. PSYCHOSOCIAL/SOCIOECONOMIC 
5A. Psychological 
(e.g., Psychological Stress; Abuse; Child Abuse; Spouse Abuse; Combat; Fear; War; Work 
Schedule Tolerance) 
*A high-fat meal increases cardiovascular reactivity to psychological stress in healthy young 
adults. 
*Cardiovascular disease caused by earthquake-induced stress: psychological stress and 
cardiovascular disease. 
*Chronic psychological stress induces vascular inflammation in rabbits. 
*Psychological stress induces chemoresistance in breast cancer by upregulating mdr1. 
*Abuse and violence during home care work as predictor of worker depression. 
*Association of maternal exposure to childhood abuse with elevated risk for autism in offspring. 
*Childhood abuse, household dysfunction, and the risk of attempted suicide throughout the life 
span: findings from the Adverse Childhood Experiences Study. 
*Childhood abuse, neglect, and household dysfunction and the risk of illicit drug use: the adverse 
childhood experiences study. 
*Clinical management of bladder dysfunction caused by sexual abuse. 
*Epileptic seizures induced by sexual abuse. Pathogenic and pathoplastic factors. 
*Migraine headaches induced by sexual abuse. 
*Adverse childhood experiences, posttraumatic stress disorder symptoms, and emotional 
intelligence in partner aggression. 
*Association between domestic violence and miscarriage: a population-based cross-sectional 
study among women of childbearing ages, Sivas, Turkey. 
*Association of various reproductive rights, domestic violence and marital rape with depression 
among Pakistani women. 




 There were large numbers of papers focused on variants of abuse, including child abuse, 
sexual abuse, and partner abuse.  Most titles were insufficiently descriptive of health 
consequences of abuse. 
5B. Sociological 
(e.g., Educational Status) 
*Cardiovascular risk factors in relation to educational level in 36 000 men and women in The 
Netherlands. 
*Educational inequalities in the co-occurrence of mental health and substance use problems, and 
its adult socio-economic consequences: a longitudinal study of young adults in a community 
sample. 
*Education and race-ethnicity differences in the lifetime risk of alcohol dependence. 
*Education and the risk of Alzheimer's disease: findings from the study of dementia in Swedish 
twins. 
*Education, occupation, noise exposure history and the 10-yr cumulative incidence of hearing 
impairment in older adults. 
*Education, socioeconomic and lifestyle factors, and risk of coronary heart disease: the PRIME 
Study. 
*Educational inequalities associated with health-related behaviours in the adult population of 
Singapore. 
*Educational level and obstructive lung disease given smoking habits and occupational airborne 
exposure: a Norwegian community study. 
*Effect of socioeconomic status on mortality after bacteremia in working-age patients. A Danish 
population-based cohort study. 
*Health literacy is associated with healthy eating index scores and sugar-sweetened beverage 
intake: findings from the rural Lower Mississippi Delta. 
*Low educational performance is associated with drunk driving: a 31-year follow-up of the 
northern Finland 1966 birth cohort. 
*Maternal education is an independent determinant of cariogenic feeding practices in the first 
year of life. 
*Maternal educational level and risk of gestational hypertension: the Generation R Study. 
5C. Economic 
(e.g., Socioeconomic Factors; Socioeconomic Status; Poverty) 




*Addictive diseases and poverty. 
*Assessment of interrelationship between poverty and blindness in Maiduguri, Nigeria. 
*Association between poverty and malaria in randomly selected families in Dar es Salaam. 
*Associations of educational attainment, occupation and community poverty with knee 
osteoarthritis in the Johnston County (North Carolina) osteoarthritis project. 
*Associations of neighborhood concentrated poverty, neighborhood racial/ethnic composition, 
and indoor allergen exposures: a cross-sectional analysis of los angeles households, 2006-2008. 
*Associations of subsite-specific colorectal cancer incidence rates and stage of disease at 
diagnosis with county-level poverty, by race and sex. 
*Cancer and poverty: breaking the cycle. 
*Cervical cancer, a disease of poverty: mortality differences between urban and rural areas in 
Mexico. 
*Diseases of poverty with high mortality in infants and children: malaria, measles, lower 
respiratory infections, and diarrheal illnesses. 
 Stress in all its variants was a major causative factor.  Psychological stress in all its 
components was deleterious, and the sociological and economic types seemed to play less of a 
direct role. 
6. GENETICS (Categories Only) 
6A. Polymorphism/ Genotypes/ Haplotypes 
6B. Mutations 
6C. Linkages 











UNDER-REPORTING OF ADVERSE EVENTS 
 The previous chapters (1-8) focus on identifying and displaying the pervasive 
foundational causes of disease.  The primary message these chapters convey is the foundational 
causes that can be extracted from the published literature are voluminous, and cover a wide 
swath.  Their secondary message, which may be of equal importance, is there may be a large 
number of foundational causes that, for myriad reasons, have either not entered the published 
literature or have entered in distorted form. 
 The present chapter provides the reasoning and 'evidence' to support the latter assertions.  
It initially presents myriad reasons for foundational causes being absent from, or distorted in, the 
published literature, and follows the conceptual arguments with specific examples.  The costs 
(and other consequences) of these omissions and distortions, both in human terms and 
financially, can be significant, as shown by one example in section 9C5. 
 Structurally, this chapter contains six sections.  9A, Technical Reasons for Under-
Reporting of Adverse Events, focuses on technical/ text mining issues limiting the identification 
of foundational causes in the biomedical literature.  9B, Policy Implications of Under-Reporting 
of Adverse Events, focuses on (mainly) non-technical issues limiting foundational causes from 
entering the literature.  9C, Illustrative Examples of Under-Reporting of Adverse Events, 
provides some examples of how the research literature becomes deliberately deficient and 
distorted.  9D, Clinical Trials Implications of Under-Reporting of Adverse Events, shows 
deficiencies in clinical trials outcomes due to  
1) insufficient attention devoted to identifying foundational causes experienced by the trial 
participants,  
2) data deficiencies, and  
3) oversight deficiencies.   
9E, Epilog, provides final thoughts on this chapter and its importance. 
 The first two types of limitations need to be considered especially when estimating the 
discrepancy between  
1) foundational causes extracted from the published literature and  
2) the full spectrum of foundational causes operating to produce the global disease burden. 




9A. Technical Reasons for Under-Reporting of Adverse Events 
 The actual numbers of direct foundational causes identified in this book may be 
substantial under-representations of the total direct foundational causes that exist globally, for 
many operational reasons.  Several key reasons for these under-representations are discussed in 
the following sections:  
1) Absence from Database;  
2) Text Mining Limitations;  
3) Foundational Cause Differences among Diseases;  
4) Indirect Foundational Causes;  
5) Ease of Identifying Foundational Causes; and  
6) Under-Representation of Foundational Causes. 
9A1. Absence from Database 
 A foundational 'cause' for a disease will enter the Medline database only after it has been 
researched, a connection has been shown between the foundational cause and disease, and the 
foundational cause evidence has been published in the appropriate venue for Medline (neglecting 
articles with negative foundational 'cause' results).  Thus, if a potential foundational 'cause' for a 
disease has not been researched, or its relevant data has not been entered into a tracking database, 
or has not been published in the appropriate venue, it won't show up in our studies as a 
foundational 'cause'. 
 The importance of a well-designed tracking database cannot be over-emphasized.  It has 
been estimated that, in some cases, the poor reporting characteristic of passive surveillance 
databases could under-represent potential causes by one or two orders of magnitude! 
(http://www.whale.to/vaccines/ploy1.html) 
 Additionally, as 6B (the Background section on 'causes of multiple diseases)' implies, 
there is a vast body of literature describing the under-reporting of adverse events.  The under-
reporting means that some foundational causes will not appear at all in the literature, and other 
foundational causes will be linked to only a sub-set of the actual number of diseases impacted. 
9A2. Text Mining Limitations 
 The present text mining approach makes extensive use of both MeSH and text linking 
terms.  Even if evidence of foundational cause has been published and is accessible in Medline, it 
may not show up as a foundational 'cause' in the approach used in this book (especially at the 
lower frequencies of occurrence), if it is not associated with the relevant linking terms that allow 
foundational 'causes' to be extracted algorithmically.  The 'dot product' components of the 
queries, which intersect external lists of potential foundational causes with the full lists of MeSH 




or text terms in the present source databases, are designed to circumvent this linking term 
limitation, to some extent. 
 Many articles have no MeSH terms assigned.  The foundational 'causes' in these articles 
will not show up in either of our MeSH-derived databases.  If the appropriate MeSH Qualifiers 
have not been assigned in the articles that do contain MeSH terms, the foundational 'causes' will 
not be identified through the extraction process in the MeSH Qualifiers-derived database.  
Similarly, if the Titles do not contain the appropriate linking terms, the foundational 'causes' will 
not be identified in the Titles text-derived database by the linking term component of the query.  
Neither the CRN database nor the (relatively) unambiguous MeSH Headings-derived database 
had linking terms.  In both cases, only the highest frequency terms were inspected visually for 
evaluation of causality, and lower frequency terms were accessed through the 'dot product' 
extraction process mentioned above. 
9A3. Foundational Cause Differences among Diseases 
 There seem to be some diseases and symptoms that include a wider spectrum of 
foundational causes.  It may be there are more foundational causes of these diseases and 
symptoms, or that more research effort has been devoted to examining a wider range of 
foundational causes.  Thus, the results can only show which items have been reported (and 
appropriately assigned) to be foundational causes of diseases and symptoms; the results cannot 
rule out that diseases without those items listed as foundational causes are in fact not caused  (at 
least in part) by those items.  Given the linkages among the immune, neural, endocrine, 
circulatory, etc systems, one would expect some ripple-down effect from a foundational cause 
that impacted any one of these systems to the other systems, and therefore expect that an 
identified foundational cause of one disease would have impacts of different degrees on many 
diseases. 
9A4. Indirect Foundational Causes 
 One potential sub-set of unlisted or unidentified foundational causes constitutes what I 
have termed indirect foundational causes.  In other words, these indirect foundational causes of a 
disease may be potential direct foundational causes of the disease that have not yet been 
identified through research.  If this is true, having a systematic approach to identifying potential 
direct foundational causes of disease would open up vast areas for future biomedical research.  
This book presents such a systematic approach. 
9A5. Ease of Identifying Foundational Causes 
 Some types of foundational causes may be under-represented in relation to more 
numerous foundational causes that are easier to research and identify.  For example, the shorter 
the time elapsed between the foundational cause and the disease, the easier it is to make the 
connection.  The stronger the effect of the foundational cause on the disease, the easier it is to 
extract the connection from the data.  The more a foundational cause acts in a stand-alone mode, 
with less need for synergy with other foundational causes, the easier it is to connect the 
foundational cause with the disease(s).  Conversely, the more a foundational cause acts in 




synergy with myriad other causes, the more difficult it is to identify the contribution of any 
specific foundational cause to the disease. 
 Additionally, the less controlled the experiments for determining foundational cause, the 
more ambiguity and uncertainty in the data, and the less strong conclusions can be made about 
whether a foundational cause has been identified.  Some foundational causes are more amenable 
to quantification, like known chemical or radiation or carcinogen exposures.  Others are far more 
difficult to quantify, such as psychological or socioeconomic foundational causes, and therefore 
more difficult to connect to disease(s) with any degree of certainty.  Finally, the more expensive 
the research required to identify a foundational cause, the fewer data that will be available to 
conclusively confirm that a foundational cause exists. 
9A6. Under-Representation of Foundational Causes 
 Truly, in the detailed pervasive foundational causes data presented in Chapter 8, the 
absence of evidence is not evidence of absence.  All the foundational cause number bands 
presented should be viewed as threshold values, with the real number bands larger, and, in some 
cases, much larger.  Given that some of the number bands of foundational causes are quite large 
despite the aforementioned obstacles, the extreme pervasiveness of these foundational causes 
must be inferred. 




9B. Policy Implications of Under-Reporting of Adverse Events 
9B1. Overview 
 This section provides more detail about under-reporting of adverse events and the larger 
issues of deficiencies and distortions in the premier biomedical published literature.  This topic is 
sufficiently serious that any results and conclusions derived from analyses of the biomedical 
literature have to be placed within the context of the credibility of that literature.  The following 
analysis in the present section is an evolution and expansion from two sources: a Letter to the 
Editor of JASIST [126], and a plenary presentation to a Forensic Science Research Evaluation 
Workshop on 26-27 May 2015, held in Washington, DC. 
 The larger issue is policy implications of an inadequate literature, where 'inadequacy' 
covers distortions, deficiencies, and any other weaknesses that drive a wedge between a fully 
credible literature and the partially credible literature that exists today.  The analytic approach 
presented in this chapter consists of four sequential steps:  
1) identify the characteristics of a literature adequate to support policy,  
2) show how each of these characteristics gets degraded to an inadequate literature,  
3) identify incentives for an inadequate literature, and  
4) show policy implications of an inadequate literature.   
The fifth step is not addressed, namely, identify amelioration strategies. 
9B2. Inadequate Literature 
9B2a. Characteristics of an Adequate Literature 
 Characteristics of an adequate literature for policy purposes include: 
1) all critical research problems necessary for credible policy are addressed/ funded;  
2) all research performed is credible and high quality;  
3) all research findings are submitted for publication;  
4) all high quality research submissions are published;  
5) all published articles are available to the general public;  
6) all accessible articles are easily retrieved. 
 Each of the above characteristics will now be examined, and those factors that degrade 
each characteristic to one representing an inadequate literature will be enunciated. 
9B2b. Critical Research not Funded 




 Some critical research problems are not addressed/ funded, for myriad reasons:  
1) the funds available to the sponsor organization are insufficient to cover all critical research 
areas;  
2) the process for setting funding priorities within the sponsor organization is poor;  
3) there are external pressures effectively limiting what topics can be funded, including  
-3a) industry pressure to suppress topics that may have commercial sensitivity, and/ or  
-3b) government pressure to suppress topics that may have political sensitivity.   
The pressures may operate intra-organizationally or inter-organizationally. 
9B2c. Research not Submitted for Publication 
 Some research findings are not submitted for publication, for myriad reasons:  
1) the topic may have national security classification, or classification for other reasons;  
2) the topic may be organizationally proprietary;  
3) the organization or individual performing the research may have little or no publishing 
tradition, and have equally little motivation to publish;  
4) there are costs associated with submissions for publication, both in time and money, which 
some organizations may not be willing to spend. 
 Most disturbing is the potentially deliberate suppression of research findings.  This may 
result from:  
1) negative findings, which many organizations/ journals/ researchers are reluctant to publish;  
2) adverse events, which many industrial organizations in the biomedical community and, as will 
be shown, even some governmental organizations in the biomedical community, are reluctant to 
publish;  
3) commercial sensitivity, which includes items 1) and 2) above, as well as other factors, all of 
which industry would rather not be published;  
4) political sensitivity, which includes items 1) and 2) above, as well as other factors, all of 
which government would rather not be published; and,  
5) unethical research, whose performers would rather not be published, and whose quality may 
be relatively low due to lack of research oversight and lack of reproducibility. 
9B2d. Poor Research Published; Good Research not Published 
 Some research that enters the literature may be of low quality, due to: 




1) poor peer review (where the peer review process and/ or the peer reviewers are of low quality) 
or no peer review;  
2) contribution to the journal Editor's pre-determined agenda. 
Some high quality research may not get published due to:  
1) poor peer review or biased peer review;  
2) non-contribution to the journal Editor's pre-determined agenda. 
 Additionally, some high quality research may not get published because the journal 
Editor does not view it as having the potential to increase the journal's Impact Factor.  In recent 
years, the Impact Factor (one measure of a journal's papers' citability) has become an important 
objective.  On many journal Web pages, the first item mentioned is the most recent Impact 
Factor. 
 While there are many determinants of a paper's citability [127], a key driver is the sheer 
number of researchers working in the topical field of the paper.  All other things being equal, 
more researchers addressing a particular topic translates into more people potentially available to 
cite any paper on that particular topic.  And, the number of researchers working on a particular 
topic is driven mainly by the funding available for that topic, which in turn is supplied primarily 
by the government and secondarily by industry.  Thus, in the end, the Impact Factor and the 
citations are strongly influenced by the limited choice of sponsored topics of interest to 
government and industry. 
 In the biomedical community, as I showed in a citation analysis of a major medical 
journal [128] (but which applies to other medical journals as well), high-tech products garner the 
lion's share of citations.  This includes high-tech drugs (large high-tech drug clinical trials 
receive, on average, the highest citations), high-tech surgery, high-tech diagnostics, high-tech 
therapy, etc.  While high-tech products may have strong useful applicability to treating wounds 
and injuries, and for diagnosing wounds, injuries, and disease, it is less clear that they have 
equally strong applicability to the prevention and reversal of chronic disease.  So, while high 
Impact Factor may be valuable for improving a journal's reputation, readership, and, especially, 
sponsorship, the value of high citations as a marker for identifying concepts that will aid in the 
prevention and reversal of chronic diseases is less than clear. 
9B2e. Manufactured Research 
 Finally, some/ much research that enters the published literature may be deliberately 
distorted or skewed; I call such research "manufactured research".  The purpose of this 
manufactured research is to both  
1) counter publications showing adverse effects from specific products and  
2) sow confusion among the public and decision-makers, not allowing the consensus required for 
policy.   




The book Merchants of Doubt describes this research manufacturing process quite well [129].  A 
few illustrative examples of some of the more egregious misrepresentations of science mentioned 
above, especially suppressed and manufactured research, will be presented in the next section. 
9B2f. Published Research not Easily Accessible 
 Even for the good research that finally gets published, it may not be easily accessible to 
the public and the decision-makers.  There are myriad reasons for this.  The research may have 
been published in relatively obscure media, such as  
1) a foreign language journal not in one of the major indexing databases, or  
2) an obscure English language journal not contained in one of these major databases. 
 The research may have been published in a good journal, and it is behind a high paywall.  
For example, if a person does not have access to the Science Citation Index (SCI) through some 
home institution, the cost for accessing any non-open access full-text article is usually high, and 
if one needs to access many of these articles, the cost could be prohibitive.  But, the SCI is only 
one example among many.  The ethics of taxpayers supporting most of the basic research behind 
these paywalls, and being prohibited financially from accessing it, is the subject for a separate 
analysis. 
 Finally, even though the database is available to the analyst, the desired information may 
still be inaccessible due to poor search engines/ algorithms.  This is an area in which I have 
worked for decades, and improving such algorithms has been a central feature of my research.  
Improved search algorithms are the bases of the text mining advances in both the present book 
and the preceding paper identifying foundational causes and treatments for chronic kidney 
disease [12]. 
9B2g. Incentives for Inadequate Literature 
 One reason for the existence of an inadequate literature is that there are many incentives 
for an inadequate literature. 
 For Industry, there are financial advantages (at least in the short-term) for concealing the 
adverse effects of their products and services. 
 For Government, the incentives are myriad.  The Federal agencies are run by political 
appointees, who are sensitive to the interests of the political parties that appointed them.  In 
many cases, it is in the career interests of these appointees to support corporate or individual 
large donor interests.  At the lower levels in these Federal agencies, it is in the career interests of 
the managers and staff to support upper level management interests for advancement.  For both 
upper and lower level bureaucrats, supporting corporate and large donor interests will also lay 
the groundwork for future industry employment. 
 For journal Editors, there are strong incentives to support corporate interests as well.  
Many journals are sponsored by professional societies or supported in part by advertising.  In 




turn, the professional societies tend to be supported strongly by industry.  Sponsors and 
advertisers are not interested in articles adverse to industrial products. 
 For research performers, there exist incentives to contribute to inadequate literature as 
well.  In the modern world of research, grants and publications are important for researcher 
advancement.  Grants allow purchase of cutting-edge equipment, hiring of graduate students and 
post-docs, travel to conferences, etc.  To have a continuous influx of grants, it is important to 
satisfy the interests of potential sponsors.  This may exclude the possibility of working on critical 
questions/ issues whose answers are not desired by these potential sponsors.  Moreover, it is 
important to satisfy existing sponsors in order to maintain the grants, which could lead to 
suppression and distortion of critical findings. 
 Further, in order to get published, it is necessary to satisfy journal Editors, which may 
involve not including results antithetical to the interests of the journal (and its sponsors or 
advertisers).  Finally, if academic or industrial research performers want to lay the groundwork 
for future industry employment and/ or consultancies, it would not be in their best interests to 
publish findings antithetical to the interests of industry. 
 The latter issue of laying the groundwork for future employment should not be under-
estimated.  When evaluating people to serve on research advisory panels, whether for peer 
review of future research investment strategy, peer review of proposals, peer review of programs, 
or journal manuscript peer reviews, the affiliations and relevant financial ties of prospective 
panelists are usually requested and stated, to identify and avoid potential conflicts-of-interest.  
However, stated affiliations can be very limiting and potentially misleading.  Most important is 
to understand the reviewer's 'intent'.  If the reviewer has no stated conflict-of-interest affiliations, 
but has plans to obtain grants or employment from some entity being involved with the review, 
then the outcome would be essentially pre-determined before the review.  Stated affiliations, 
while useful, are only a part of the picture of conflicts. 
 In this section, I have identified the incentives (for an inadequate literature) for four 
classes: Industry, Government, Journal Editors, Research Performers.  There are individuals who 
span multiple classes.  For example, a person who works in government may also be a research 
performer and a journal Editor.  The incentive (for an inadequate literature) associated with e.g. 
their government function may 'spill over' to their journal Editor and research performer roles.  
So, even though the journal may not have industry or government financial support as a source 
of potential bias, the potential biases arising from the government or research performer 
affiliations of the Editor could (in theory) influence the journal Editor role. 
9B3. Policy Implications of Inadequate Literature 
 There are myriad important drivers of policy.  The published literature, technical or 
otherwise, is only one of the drivers, and as will be shown, may not be the most important driver 
in many cases.  For present purposes, the policymaker is assumed to be a government employee, 
whose organization at the highest level is headed by a political appointee(s), and who is therefore 
influenced by major political determinants: campaign donors and the electorate.  For the 




following discussion, then, the three critical drivers of policy considered will be technical 
literature, interests of political donors, and interests of the electorate. 
 Four options that relate policy to technical literature will now be examined briefly. 
 Option 1: The topical area is non-sensitive commercially or politically (e.g., weather 
satellite research).  There is little incentive for much 'manufactured research'.  Donors and voters 
would agree with policy dictated by adequate literature; donors and voters agree with policy 
dictated by inadequate literature; policy reflects literature. 
 Option 2: The topical area is non-sensitive commercially or politically (e.g., age of 
universe research).  There is little incentive for much 'manufactured research'.  Donors and voters 
would be indifferent to policy dictated by adequate literature; donors and voters would be 
indifferent to policy dictated by inadequate literature; policy reflects literature. 
 Option 3: The topical area is sensitive commercially and/ or politically (e.g., climate 
change amelioration; EMF health impacts [130]).  There is incentive for much 'manufactured 
research', and my own studies have confirmed this.  In this case, donors and voters would 
disagree with policy dictated by adequate literature.  The donors are driven by profit, and the 
voters are addicted to the specific technology in this case (e.g., fossil fuels, wireless 
communications).  Thus, donors and voters agree with policy dictated by inadequate literature. 
 In the case of e.g. EMF health impacts, the policy on EMF exposures that would be 
required by an objective reading of the credible technical literature (severe restrictions on the use 
of wireless communications, etc) would not be acceptable to the vast majority of donors and 
voters.  And, in the case of e.g. climate change amelioration, the policy on CO2 emissions from 
fossil fuels that would be required by an objective reading of the credible technical literature 
(extremely severe restrictions on the use of fossil fuels for energy generation starting today, etc) 
would not be acceptable to the vast majority of donors and voters.  Thus, the policy in practice 
reflects the interests of the donors and voters, not the dictates of an adequate technical literature. 
 Option 4: The topical area is sensitive commercially and/ or politically (e.g., exposures/ 
treatments that cause disease [12]).  There is incentive for much 'manufactured research' in this 
case, and my own studies have confirmed this.  In this case, donors would disagree with policy 
dictated by an adequate literature, whereas the voters would agree with policy dictated by 
adequate literature.  The donors are driven by profit, whereas the voters are driven by the 
benefits of technology in this specific case.  Unlike the previous option, the voters are not 
addicted to the technology, since its application may be unpleasant in many cases. 
 The donors still agree with policy dictated by inadequate literature, whereas the voters 
agree with policy dictated by inadequate literature, only because they believe it is adequate.  
This means that some literatures may be highly manufactured to maintain voter support.  The 
policy reflects donors, not adequate technical literature. 
 In conclusion, the published technical literature is inadequate for myriad reasons, and the 
degree of inadequacy is unknown and may be unknowable.  The fraction of inadequacy due to 




deliberate misinformation is unknown, but may be large for topical areas with commercial or 
political sensitivity. 




9C. Illustrative Examples of Under-Reporting of Adverse Events 
9C1. Industry 
 There are literally thousands of industrial products, processes, practices, and services that 
could be contributing factors to myriad diseases in isolation or in combination, as the results in 
this book have shown.  It would be to the financial advantage of the responsible industries if the 
adverse effects resulting from these products, processes, practices, and services were concealed 
from the public and policymakers. 
 Myriad studies have been reported/ published showing how the science has been distorted 
by skewed literature, skewed panels, skewed media, etc.  Unfortunately, such evidence of 
skewing and distortion is extremely difficult to obtain.  Miscreants take great pains to conceal 
such wrong-doing, and many exposures of such activities are eventually revealed by whistle-
blowers or through lawsuits.  Because whistle-blowing tends typically to result in professional 
and financial suicide, only a very few are willing to risk the repercussions.  Thus, most of the 
science distortions remain hidden from public view. 
 Further, because of potential media involvement in science distortion and concealment 
(as will be shown in some of the examples in the present section), public disclosure of these 
misdeeds may not necessarily occur in the mainstream media outlets or the most prestigious 
science and technical journals.  As the reader will see, a few of the references I use are Web page 
URLs.  While these types of references are frowned upon in mainstream journal publications, 
unfortunately (in some of the more egregious examples), these Web sites are the only media 
sources sufficiently courageous to challenge the distorted (or expose the concealed) messages 
promulgated by government and industry. 
 Two examples of distorted science/ literature will be presented: tobacco smoking and 
asbestos.  Much of the incriminating evidence in both cases resulted from 'discovery' (in the legal 
sense) from lawsuits. 
 The extent of distorted science/ literature related to all industrial products and services is 
completely unknown at this point.  It could range from  
1) the modest number of industries already reported in the literature to have contributed to 
distorted science to  
2) the thousands of industries behind the thousands of potential contributing factors reported in 
this book. 
9C1a. Tobacco Smoking 
 Distortion of science by the tobacco industry has probably had the most extensive 
reporting and analysis.  Due to the 'discovery' required by the numerous lawsuits filed against the 
tobacco industry, there has resulted a treasure-trove of internal documents made available for 
people to analyze.  Many researchers have published analyses based on disclosure of these 
internal corporate documents. 




 Lisa Bero has written numerous articles on the distortion of science by the tobacco 
industry.  The following two excerpts [131] are a representative brief summary of how the 
science was distorted. 
 "A report prepared by the Roper Organization for the Tobacco Institute in 1978 noted 
that the industry’s best strategy for countering public concern about passive smoking was to fund 
and disseminate scientific research that countered research produced by other sources" 
 "Strategies that the tobacco industry uses to stimulate controversy about tobacco involve 
manipulating research at multiple stages. The tobacco industry, through its funding mechanisms, 
has attempted to control the research agenda and types of questions asked about tobacco. 
 The industry’s lawyers and executives have been involved in the design and conduct of 
industry-supported research as well as the suppression of research that has not been favorable to 
the industry." 
9C1b. Asbestos 
 Inhalation of asbestos fibers can lead to inflammation and scarring of the lungs.  This 
could increase the risk of lung cancer and mesothelioma, and possibly other cancers as well.  
Many lawsuits have been filed by potential victims for compensation. 
 Legal 'discovery' similar to that obtained in the tobacco lawsuits was obtained from 
lawsuits against asbestos manufacturers.  David Egilman has been one of the more prolific 
authors on distortion of science by the asbestos and related corporate community.  An excerpt 
from a recent paper [132] states: 
"MetLife established itself as an authority in public and industrial health in the early part of the 
twentieth century, gaining the trust of the public and government. They were able to use this trust 
and authority to avoid financial loss, including the firing of sick workers, and avoid legal liability 
by organizing a network of experts to testify on their behalf in silica- and asbestos-related 
damage suits. They further manipulated the results of scientific findings from major research 
institutions, delaying important knowledge about the asbestos-cancer relationship." 
9C2. Government 
 Because of the close and 'revolving-door' relationships between many government 
agencies and industry, some of the incentives to distort and conceal science become applicable to 
government as well.  Additionally, some technologies become critically important for 
government to conduct operations, and science can become distorted or concealed if the 
government places higher priority on continuance of the operations than on e.g. safety aspects. 
 In this section, three brief examples of potential government distortion of science are 
presented: EPA, CDC, and FDA. 
9C2a. EPA 




 In 1993, EPA generated a sludge rule that allows biosolids, or treated sewage sludge, to 
be used for different types of lands (farms, forests, playgrounds, parks, etc) [133].  These 
biosolids contain very toxic ingredients, in high concentrations, and have the potential for 
causing myriad types of damage.  Dr. David Lewis, a whistle-blower and ex-EPA senior 
researcher, exposed how EPA, in coordination with other Federal Agencies, research institutions, 
and advisory groups, suppressed public knowledge of these potential adverse effects for years 
[134]. 
 He initially did this exposure through published research articles.  Later testimony and 
depositions before Congress, before Department of Labor hearings, and during lawsuits revealed 
(under oath) the detailed participation of EPA officials and others in the science distortions.  Dr. 
Lewis was forced to retire and, in 2014, published a book (recounting his experiences) entitled 
Science for Sale [134].  Lewis: 
1) implied that EPA-sponsored research had to support EPA policy; 
2) implied that there was selective funding of scientists who supported EPA's sludge rule; 
3) showed myriad ways the science was distorted to present biosludge as safe; 
4) showed collusion among EPA and other Agencies. 
 The book is unique in its portrayal of collusion among the diverse groups mentioned in 
its sub-title: "How the US Government Uses Powerful Corporations and Leading Universities 
to Support Government Policies, Silence Top Scientists, Jeopardize Our Health, and Protect 
Corporate Profits".  The biosludge example presented here, the example of the MMR vaccine in 
the next section, and the example of EMF adverse effects from my detailed study [130] provide 
strong evidence that what we have operating (in these commercially and politically sensitive 
issues) is a Government-Industrial-Media-Complex that monopolizes the discourse and exerts 
strong influence on what the public knows and believes about these topics. 
 Dr. Lewis has only scratched the surface of the research required to show the full extent 
of adverse impacts of biosludge.  The application of biosludge does not occur in a vacuum.  
There are various pesticides, herbicides, and other potentially harmful chemicals applied to many 
of these biosludge-covered lands, depending on usage.  Location in polluted water and polluted 
air areas adds other layers of pollution and uncertainty.  There could be many types of pollutants 
operating synergistically with the biosludge to enhance damage; decoupling the influence of the 
biosludge would be a complex process.  One would have to identify the relevant windows in 
parameter space in which adverse events occurred, and an enormous number of tests would have 
to be performed to identify these windows, since the multi-causal problem is combinatorial in 
nature.  We found this to be the case in our EMF health impacts study [130], and it would be 
conceptually similar for biosludge. 
 Additionally, there could be adverse impacts on human beings (from these combinations 
of foundational causes that include biosludge as one contributing factor) that do not show up for 
years, or decades.  For example, latency periods for many cancers are on the order of decades.  




As another example, latency periods for serious diseases following relatively innocuous food 
poisoning may be years or decades [135]. 
 From first principles, why should we expect less from biosludge?  Health studies of many 
disease causative factors are done for a relatively short period compared to a human being's 
lifetime.  Long-term studies on short-lived animals might or might not be relevant for humans.  
Long-term studies (of many potential foundational causes) on humans remain to be done, and 
biosludge is no exception. 
9C2b. CDC 
9C2b1. CDC senior researcher allegations 
 On 27 August 2014, the following excerpted statement by Dr. William Thompson (a 
CDC Senior Researcher) appeared on the Web site of Morgan Verkamp, LLC, a legal 
organization representing Dr. Thompson [136]. 
 "I regret that my coauthors and I omitted statistically significant information in our 2004 
article published in the journal Pediatrics. The omitted data suggested that African American 
males who received the MMR vaccine before age 36 months were at increased risk for autism. 
Decisions were made regarding which findings to report after the data were collected, and I 
believe that the final study protocol was not followed..... 
 My concern has been the decision to omit relevant findings in a particular study for a 
particular sub- group for a particular vaccine. There have always been recognized risks for 
vaccination and I believe it is the responsibility of the CDC to properly convey the risks 
associated with receipt of those vaccines. 
 I have had many discussions with Dr. Brian Hooker over the last 10 months regarding 
studies the CDC has carried out regarding vaccines and neurodevelopmental outcomes 
including autism spectrum disorders. I share his belief that CDC decision-making and analyses 
should be transparent. I was not, however, aware that he was recording any of our 
conversations, nor was I given any choice regarding whether my name would be made public or 
my voice would be put on the Internet..... 
 I will not be answering  further questions at this time.  I am providing information to 
Congressman William Posey, and of course will continue to cooperate with Congress.  I have 
also offered to assist with reanalysis of the study data or development of further  studies.  For the 
time being, however, I am focused on my job and my family." 
 Dr. Hooker had approximately thirty phone conversations with Dr. Thompson, the last 
four of which were recorded by Dr. Hooker without Dr. Thompson's knowledge or approval.  
Excerpts from some of these recorded conversations have been placed on the Web. 
 Not only were the African-American children who received the MMR vaccine at 
substantially greater risk for autism (as alleged by Dr. Thompson), but, according to Dr. Hooker, 




Dr. Thompson mentioned that children of all races were shown to have an increased risk of 
'Isolated Autism'  
(young children, regardless of race, who had  
1) received the MMR vaccine on schedule, as recommended by the CDC, and 
2) had no other factors sometimes observed to accompany autism, such as cerebral palsy, mental 
retardation, and birth defects.). 
 The MMR vaccine-autism study to which Dr. Thompson referred had been performed 
shortly after the turn of the new millennium, and the stated results (no link between MMR 
vaccine and autism) had been published in the journal Pediatrics in 2004 [137].  As of 1 August 
2015, the article has not been retracted by Pediatrics, despite the serious allegations of intentional 
omission of critical data by one of its co-authors. 
 Thus, according to Dr. Thompson's allegations of 27 August 2014 (which have yet to be 
made (under oath) in an adversary proceeding such as a Court of Law or a Congressional 
Hearing), CDC had known for at least a decade that these two groups of children were at 
increased risk for autism from the MMR vaccine, and did not disclose this information to the 
public.  Internal CDC memos released (again, which have yet to be presented in some type of 
adversary proceedings) also showed the highest levels of CDC management had been informed 
of these problems with the MMR vaccine since the early 21st century 
(http://www.marketwatch.com/story/cdc-epidemiologist-whistleblower-confirms-new-review-
showing-vaccine-autism-link-2014-09-11). 
 According to Dr. Thompson's statement above, thousands of documents have been turned 
over to Congress.  Dr. Thompson has been awarded immunity to testify before Congress, but, as 
of this writing (almost one year after Dr. Thompson's statement), Congress has not yet scheduled 
a Hearing. 
 However, on 29 July 2015, as this book was about to go to press, the Congressman to 
whom Dr. Thompson provided the documents, Rep. William Posey (R-FL), made a five minute 
speech on the Floor of the House (https://www.youtube.com/watch?v=qxr-cv-JuI8).  He stated, 
in part (quoting from Dr. Thompson's own words): 
 "At the Sept 5th meeting we discussed in detail how to code race for both the sample and 
the birth certificate sample. At the bottom of table 7, it also shows that for the non-birth 
certificate sample, the adjusted race effect statistical significance was huge. 
 ‘All the authors and I met and decided sometime between August and September 2002, 
not to report any race effects from the paper. Sometime soon after the meeting, we decided to 
exclude reporting any race effects. The co-authors scheduled a meeting to destroy documents 
related to the study. The remaining four co-authors all met and brought a big garbage can 
into the meeting room, and reviewed and went through all the hardcopy documents that we 
had thought we should discard, and put them into a huge garbage can. However, because I 
assumed it was illegal and would violate both FOIA and DOJ requests, I kept hardcopies of all 




documents in my office, and I retain all associated computer files. I believe we intentionally 
withheld controversial findings from the final draft of the Pediatrics paper.’" 
 Because of the gravity of this revelation, and the added credibility of Dr. Thompson's 
allegations provided by a Congressman's endorsement on the Floor of the House, I decided to 
add an estimate of the human and financial costs that might result from this alleged withholding 
of critical information.  Section 9C5 addresses the potential consequences of this information 
having been withheld intentionally (assuming Dr. Thompson's allegations are validated). 
9C2c. FDA 
 Charles Seife is a journalism Professor at New York University.  He performed a study 
whose objectives were "to identify published clinical trials in which an FDA inspection found 
significant evidence of objectionable conditions or practices, to describe violations, and to 
determine whether the violations are mentioned in the peer-reviewed literature." [138].  He 
examined "publicly available documents, dated from January 1, 1998, to September 30, 2013, 
describing FDA inspections of clinical trial sites in which significant evidence of objectionable 
conditions or practices was found."  He found that "only 3 of the 78 publications (4%) that 
resulted from trials in which the FDA found significant violations mentioned the objectionable 
conditions or practices found during the inspection. No corrections, retractions, expressions of 
concern, or other comments acknowledging the key issues identified by the inspection were 
subsequently published."  He concluded that "when the FDA finds significant departures from 
good clinical practice, those findings are seldom reflected in the peer-reviewed literature, even 
when there is evidence of data fabrication or other forms of research misconduct."  He provided 
additional perspective in a Slate magazine article [139]. 
 In an interview with Truthout magazine [140], Dr. Ronald Kavanagh, a former drug 
reviewer for the FDA in the Center for Drug Evaluation and Research, describes some FDA 
safety shortcuts.  His comments complement the findings of Dr. Seife above, and both sets of 
comments reflect both  
1) good research not reaching the open literature and  
2) distorted findings being published. 
9C3. Journals 
 This section will present one example of alleged journal bias on publishing adverse 
effects.  As the reader will see, obtaining data to support allegations of bias is extremely difficult 
in this case, and validating allegations would be even more difficult. 
 Dr. Lous Slesin has been publishing a newsletter addressing myriad issues related to 
microwave radiation, and it is aptly entitled 'Microwave News' (MN).  I came across this 
newsletter during the course of our EMF health impacts study [130], and found the MN articles 
were quite accurate in the areas where they overlapped our study. 




 In 2006, MN published an article entitled “Radiation Research” and The Cult of Negative 
Results [141].  It was a unique study with major contributions from Dr. Henry Lai, a leading 
researcher in the technical area of the article.  The study's focus was essentially to ascertain how 
reflective of the microwave-induced genotoxicity publications in the larger technical literature 
were those published in the journal Radiation Research on this topic. 
 In short, MN found that:  
1) [In the larger technical literature on microwave-induced genotoxicity] "There is just about an 
even split between effect and no-effect papers";  
2) "A clear —and disconcerting— pattern emerges: 32 of the 35 studies that were paid for by the 
mobile phone industry and the U.S. Air Force show no effect. They make up more than 75% of 
all the negative studies. You don't need to be a statistician to infer that money, more often than 
not, secures the desired scientific result";  
3) "A similar loss of balance occurs when you look at only the papers published in Radiation 
Research.....Over the last 16 years, only one positive paper on microwave genotoxicity has 
appeared in Radiation Research. During the same time, the journal has published 21 negative 
genotox papers. (Australia's Pam Sykes, the lead author of the lone positive paper, was denied 
money for a follow-up and soon moved on to other research areas.)....80% of the negative papers 
(17 out of 21) published in Radiation Research were paid for by either industry or the U.S. Air 
Force." [141]. 
 At this point, the statements in MN are only allegations.  There could be journal bias, or 
the best papers submitted to the journal happen to be the ones showing the absence of an impact 
of microwaves on genotoxicity.  How could this issue be resolved? 
 One could (in theory) obtain the original peer reviews of all the manuscripts submitted to 
the journal on this topic, and re-evaluate them for bias.  Unfortunately, we would then have the 
issue of determining the biases of the second group of reviewers.  This cannot be determined 
easily.  Information on organizational and financial conflicts-of-interest might be available as 
suggestive of potential bias, but such information is incomplete and perhaps the tip of the 
iceberg.  The real metric is 'intent' of the reviewers; how does one measure 'intent'?  If a reviewer 
has a clean 'paper trail' in terms of potential conflicts, but hopes to apply for industry funding, 
consultation, or employment in the future, would that not affect his actions relative to a 
technology of interest to a company? 
 Additionally, even for reviewers who are unbiased, there is not always complete 
agreement.  Scientists can sometimes have very differing opinions on the value of the same 
concept.  Proving deliberate bias for a journal is extremely difficult, and may border on the 
impossible in practice. 
 I would, however, recommend that the reader access the MN article and read it carefully.  
It is one of the very few of this genre that one will see in print, and covers a wide range of issues 




related to potential bias.  How well this particular example reflects all, or any, other technical/ 
biomedical journals is unknown. 
9C4. Researchers 
 One example will be provided.  In 2010, a book titled Merchants of Doubt [129] was 
published.  This well-documented landmark publication examined myriad high-sensitivity 
technical issues, including smoking, climate change, acid rain, ozone hole, and DDT.  It showed 
how disinformation was promoted using well-known scientists and front organizations.  The 
disinformation was promoted through think tanks, government panels, and all types of media 
including the research literature.  The biosludge example presented in section 9C2a can be 
viewed as one example of how this disinformation is promoted/ disseminated.  The purpose of 
this disinformation is to spread confusion and promote doubt, thereby delaying any policy for 
action due to the (manufactured) absence of a consensus. 
9C5. Consequences of Under-Reporting of Adverse Events 
 Consequences of under-reporting or distorted reporting of adverse events could include:  
1) the numbers of people who become afflicted as a result of insufficient knowledge or distorted 
knowledge produced by the under-reporting;  
2) the numbers of people who die prematurely;  
3) the financial costs borne by the afflicted and/ or by society, etc.   
If the under-reporting is deliberate, and it becomes known to the public that it is deliberate, then 
a serious additional consequence could be potential loss of credibility of the under-reporting 
organization in the eyes of the public.  If the under-reporting organization is a government 
Agency, the potential loss of credibility could be disastrous! 
 For some of the examples presented in section 9C, the numerical estimates of potential 
damage may be quite large, but are rarely, if ever, provided.  And, even for advertised 
compensations awarded, the actual costs may not be reflected in any settlements. 
9C5a. Magnitude of impact of alleged CDC intentional withholding of critical information 
9C5a1. Domestic Impact 
 I will end section 9C with some estimated economic and health consequences of one of 
the lesser-known examples outlined previously: CDC intentional withholding of critical 
information (alleged by Dr. William Thompson, CDC) in order to not inform the public about 
sub-groups who have higher risk for autism from the MMR vaccine.  The assumption here is that 
Dr. Thompson's allegations [136] about CDC's intentional withholding of the adverse effects of 
the MMR vaccine relative to autism will be validated.  This section on estimated economic and 
health consequences of the CDC's alleged actions is relatively long and detailed compared to any 
of the other examples in 9C, and the estimated costs are extremely high. 




 The alleged intentional withholding of the link between the MMR vaccine and autism 
(the link being found in the very early 21st century by the CDC's study) resulted in many 
children (from specific sub-groups) being placed at higher risk for autism.  These children could 
have minimized this risk (had their parents been informed of the potential increased risk) through 
either alternative vaccinations, modified vaccination schedules, or no vaccinations.  Thus, there 
were potentially more children who suffered from autism as a result of the alleged intentional 
withholding of this critical information, and there were resulting health and economic 
consequences that accompanied the additional potential cases of autism. 
 The potential economic cost resulting from this alleged intentional withholding of critical 
information is the product of the number of children afflicted times the cost per victim.  Given 
that: 
1) Dr. Thompson has not released the documentation supporting his specific findings to the 
general public (but only to Congress, and perhaps other selected individuals), 
2) Congress has not held Hearings on Dr. Thompson's allegations yet, and none have been 
scheduled, 
3) there have been essentially no investigations into Dr. Thompson's allegations reported by the 
mainstream news media, 
then, obtaining primary source estimates of the number of children placed at higher risk for 
autism because of the alleged CDC intentional withholding of critical information becomes 
extremely difficult.  I am left with selecting the most credible secondary sources for these 
estimations, and will mention two secondary sources. 
 On 25 June 2015, Robert F. Kennedy, Jr published an Open Letter on Eurweb [142] 
stating: "Based upon all the population data and CDC’s most recent autism incidence estimates, 
at least 100,000 African-American male children could have been spared debilitating 
neurological injury if the CDC scientists had told the truth when the increased risk was first 
known to them in 2001." 
 Kennedy has: 
1) been studying the problem of adverse vaccine impacts for years, 
2) access to credible experts on this topic, 
3) discussed Dr. Thompson's revelations with Congressional staffers who have seen the 
documentation Dr. Thompson gave to Congress, 
4) recently published a book (with two M.D.s) on the adverse effects of Thimerosal in vaccines, 
and 
5) co-authored an upcoming book on the alleged CDC misconduct addressed here (Vaccine 
Whistleblower: Exposing Autism Research Fraud at the CDC) 






 Another secondary source is a Web site author [143].  The principal of this site has 
computed the number of African-American children placed at higher risk of autism, based on her 
interpretation of the increased risk numbers that Dr. Thompson presented on his lawyer's site.  
The principal has presented all the computational details of her estimate on the referenced site, 
and she arrives at (in her estimation) a conservative estimate of 250,000 African-American 
children at increased risk due to the CDC's alleged intentional withholding of critical 
information. 
 Kennedy has not provided the computations used to generate the 100,000 African-
American injured children estimate, so the two sets of computations cannot be compared.  The 
discrepancy between the estimate in [143] and that of Kennedy may be due to the differing 
interpretation of the increased risk suggested by Dr. Thompson.  For purposes of my analysis, I 
will take the far more conservative estimate of Kennedy. 
 I start with an estimate of 100,000 African-American children who developed autism 
(between 2001 and 2015) due to the CDC's alleged intentional withholding of its findings of 
increased risk starting about 2001.  The human costs are more than mere statistics.  The 100,000 
are innocent human beings who, in many cases, could have become great artists, engineers, 
doctors, lawyers, etc, and who were robbed of these opportunities because critical information 
was allegedly withheld by the CDC. 
 The next question is: what are the economic costs associated with these 100,000 
additional cases of autism?  There are at least three main components of potential cost: 
1) the cost of care for an autistic person; 
2) the cost of medication and other medical treatments and services for an autistic person; 
3) the wages lost over a lifetime by an autistic person. 
 A 2014 study [144] estimates a lifetime cost for a person (in the USA) with autism on the 
order of $1.4 to 2.4M (depending on the level of seriousness of the disease).  However, as stated 
in the body of the full-text of [144] (but not in the Abstract), these numbers are discounted 
present values, using a discount rate of 3.5%.  For each age group examined (0-5; 6-17; >=18), 
the authors assume a mean annual cost for each age group, held constant over the age group 
period.  So, for example, for adults with intellectual disability in the USA, the authors assume an 
annual mean cost of ~$88K per year, constant for ~50 years. 
 I have two major problems with the results: 
1) the numbers used for the cost streams are low; 




2) use of a discount rate of 3.5% for computing present value, in parallel with the assumption of 
living accommodation and medical costs constant over decades, is neither realistic nor consistent 
internally. 
 For problem 1), one of the cost stream components in [144] is 'productivity loss', which is 
essentially lost wages from having autism and being unable to work the same way as a person 
without autism.  From Table 4 [144], the 'productivity loss' for an adult 'individual with ASD', 
with Intellectual Disability, from the USA, is $10,718 per year.  This number is slightly over 
$5.00 per hour for full-time employment, or about 2/3 of the USA minimum wage!  For a 
severely disabled person, who would reflect the upper end of the lifetime autism cost range 
(estimated at ~$2.4M in [144]), it would seem more realistic to use the median USA wage (of 
~$28K per year) as the 'productivity loss'.  That is more than double the 'productivity loss' stream 
used in [144] to estimate costs!  Some of the other cost stream components used are 
underestimated as well. 
 For problem 2), given the increases in healthcare and assisted-living costs over the past 
few decades, one would expect to see projected healthcare and assisted-living accommodation 
costs rising far faster than 3.5% per year.  For example, a study published recently (in Health 
Affairs by economists in the Office of the Actuary at the Centers for Medicare and Medicaid 
Services) projected healthcare costs to rise an average of 5.8% over the next decade [145].  
Further, the potential of rapidly increasing health insurance premiums could portend even 
substantially higher growth in health care costs [146]. 
 A 2015 study [147] on autism costs effectively cancels out growth rates and discount 
rates by assuming a discount rate of zero (no discounting): "Because both the burden and GDP 
grow over time, we do not apply discount rates.  We assume a societal perspective." 
 Assuming healthcare and assisted-living accommodation costs to be inflating at the 
discount rate is more realistic for autism cost projections than the approach used in [144], 
although still very optimistic.  If we sum an undiscounted cost stream to arrive at total lifetime 
costs, using the annual costs stated in [144], the total (very optimistic) undiscounted lifetime 
costs for the high end in the USA are ~$6M.  Given the unrealistically low numbers the authors 
also use for annual 'productivity loss' et al, the real lifetime costs (at the high end, for the USA) 
are at least triple those presented by the authors.  For purposes of the present cost estimates, I 
will use a much more conservative estimate of twice the [144] authors' published numbers, with 
a mean of about $4M lifetime cost per capita for all USA autism afflicted.  As I will show in the 
next paragraph, both the $4M conservative lifetime cost per capita and the $2M extremely 
conservative lifetime cost per capita (based on the numbers in [144]) result in astronomical total 
costs. 
 For 100,000 African-American children in the USA over the period 2001-2015, using the 
approximate mean lifetime cost per capita of $4M from the above computations yields a total 
lifetime cost for the sub-group of roughly $400B!  Using the approximate mean lifetime cost per 
capita of $2M based on the numbers in [144] would have yielded a total lifetime cost for the sub-
group of roughly $200B.  Either cost figure is astronomical, especially when the narrowness of 
the afflicted group is considered.  Even if we followed [147] and used an undiscounted cost 




stream for the computations, we would have obtained total lifetime costs approaching $500B.  
The overall conclusions are essentially the same irrespective of which of these cost streams we 
assume; for purposes of further computation, the conservative assumption of $4M lifetime cost 
per capita will be used. 
 That $400B total lifetime cost estimate neglects the other sub-group identified at risk in 
the CDC study, children of all races who developed Isolated Autism from the MMR vaccine 
(according to Dr. Thompson's revelations to Dr. Hooker).  This latter sub-group would be about 
seven or eight times as large as the African-American sub-group, since it includes all races, and 
the economic costs could be numerically larger than the African-American sub-group, depending 
on the level of increased risk for Isolated Autism. 





As a side note, the NVICP (National Vaccine Injury Compensation Program), which is a special 
Court set up to compensate the vaccine injured, has paid out approximately $3.2B since 1988 for 
injuries from all vaccines.  Approximately 9% of all compensated claims were for the MMR 
vaccine, for all groups, so the total MMR compensation would be somewhat less (perhaps 
substantially less) than $1B since 1988.  Compare that with the ~$400B cost estimate above for 
African-American children for the 2001-2015 time period for the USA for the MMR vaccine 
only.  That's a small fraction of one percent of the total costs being compensated for this one 
group over one period.  Other sub-groups potentially injured from the MMR vaccine, such as 
children with Isolated Autism, are not included in the $400B estimate! 
So, if the lifetime autism cost for this one afflicted sub-group is ~$400B over its lifetime, and the 
Trust Fund compensation has been on the order of one-tenth of one percent of the lifetime autism 
cost (or less), then on the order of 99.9% (or more) of the total lifetime autism costs are being 
borne by sources other than the Trust Fund.  Who are these sources?  The main sources would 
appear to be the afflicted (and their families) and the taxpayers, through their support of myriad 
social services. 
Thus, 99.9+% of the ~$400B total lifetime autism costs is the effective subsidy 
provided (for this one narrow sub-group only) by the 1986 Act and confirmed by 
the 2011 Supreme Court decision! 
 
9C5a2. Global Impact 
 The ~$400B total lifetime autism costs above are for one parameter (timing of 
vaccination) for one sub-group for one vaccine for one disease for one time period in one 
country.  What would the numbers look like if the impacts were integrated over this narrow sub-
group globally? 
 There are over 1.1B people living in Africa.  Assume 1B are similar racially to the US 
African-Americans, with respect to their response to the MMR vaccine.  There are roughly 40M 
African-Americans, about thirty percent of the total African diaspora globally.  The fraction in 
each region that gets the MMR vaccine is roughly the same.  So, taking Kennedy's conservative 
estimate of 100,000 cases of MMR vaccine-induced autism for African-Americans (over the 
fourteen years that the CDC was allegedly aware of this increased risk), and multiplying 
conservatively by about twenty-five, we have a total of about 2.5M cases of autism induced in 
Africans (or people of African descent) globally over fourteen years.  That's about 180,000 cases 
of autism globally per year from that potential single MMR vaccine impact on one disease on 
one sub-group on one parameter! 
 The dollars globally won't scale up from the African-American costs because Africa has a 
far lower standard of living than the USA, as do some of the other locations of the African 




diaspora.  But, even if the African (and its diaspora) component scales up with 1/10 the unit costs 
of the African-American costs, overall the total (avoidable) lifetime costs since about 2001 are on 
the order of almost $1.4T! 
 However, while limiting the costs to the period 2001-2015 may be valid for the specific 
CDC omission alleged by Dr. Thompson, these are not the only additional costs for the African-
American sub-group from the MMR vaccine if a longer time perspective is taken.  The MMR 
vaccine was licensed in the USA in 1971.  Assuming the sensitivity of the afflicted sub-groups to 
the MMR vaccine has remained approximately constant for the past forty years, then had the 
MMR vaccine been monitored sufficiently pre- and especially post-licensing, and the actual test 
results provided openly to the public, we should have known conservatively about the racial 
disparity (and other affected sub-groups, such as Isolated Autism) by ~1980 (or before).  Thus, 
the African-American and global sub-group estimates should not start in 2001, but rather ~1980. 
 It is difficult to extrapolate the 2001-2015 estimates back to 1980, in order to obtain 
specific cost damages.  The vaccination rates from 1980-2000 might have been less (especially 
in the less developed countries), and the synergies resulting from other toxic substance ingestions 
or exposures combined with the MMR vaccine could have been very different (given the rapid 
introduction of new potentially toxic technologies in the past few decades, and the large ramp-up 
of vaccines to the recommended schedule).  The only conclusion at this point is that the $400B 
estimated lifetime costs for African-Americans alone, and $1.4T estimated lifetime costs for 
Africans and those of African heritage world-wide, are a floor for the actual costs of this one 
narrow impact of the MMR vaccine (assuming Dr. Thompson's allegations are validated), and 
possibly a very low floor. 
9C5a3. Other Sub-Groups Affected 
 The above numbers would be augmented by the cases of Isolated Autism for all races, 
which must be scaled up from the USA total population to the global population (roughly a 
factor of twenty).  I have not seen any numerical estimates for Isolated Autism increased risk 
resulting from the MMR vaccine domestically or globally, and Dr. Thompson provided no 
numbers publically on the level of increased risk.  I therefore cannot make an economic estimate 
of the additional costs due to Isolated Autism, but, as stated previously, they could be large 
because of the size of the all-races pool compared to that of the African-American pool. 





Dr. Thompson's statement does not exclude other impacts from the MMR vaccine on 
increased risk of autism or any other disease as well.  All we know is that he admitted to 
knowledge of two sub-groups at increased risk for autism for one parameter (timing of 
vaccination) on his lawyer's Web site and to Dr. Hooker.  There could be other affected sub-
groups beyond those of which he admitted to knowledge. 
More generally, if Dr. Thompson's allegations are validated (implying involvement of multiple 
levels of the CDC organization), it would then be reasonable to ask: 
what other CDC studies of any type were either deliberately not funded or conducted (or, if 
conducted, manipulated) to downplay or suppress the adverse effects of other vaccines or 
other pharmaceutical substances? 




APPENDIX TO 9C5a 
9C5a-A1. Pediatrics 2004 study deficiencies 
9C5a-A1a. Baseline 
 The CDC study is a case-control study [137], with the main goal of identifying any 
effects of timing of the MMR vaccination on autism occurrence in the total group and selected 
sub-groups.  That study did not provide baseline information on autism incidence resulting from 
the MMR vaccine. 
 To generate baseline information, CDC would have had to 
1) design and implement a study comparing an MMR-vaccinated group with an unvaccinated 
group, and 
2) ascertain the level of autism (and other diseases) caused in toto by the MMR vaccine.  
Conceivably, that could have been equal to, or much greater than, any marginal timing effect that 
was reported in the actual study performed. 
 Reviewers of this book raised the ethical issue of conducting an experiment with a 
placebo (unvaccinated cohort) where an alternative treatment is available.  The ethical issue of 
denying available treatment for a non-vaccinated cohort of participants in a clinical trial could be 
readily avoided by using children 
1) who had not been vaccinated in the past by design, or 
2) whose parents choose not to have them vaccinated today and when the study is conducted. 
 Finding a credible non-vaccinated cohort is a non-issue today, when many non-
vaccinated children are available.  Given the recent flurry of activity by governments to mandate 
vaccinations and remove most exemptions, this cohort of non-vaccinated children will probably 
shrink considerably with the passage of time, and it will become much more difficult to assess 
the safety of vaccines as a result.  It is rather paradoxical that a major resource required for 
ascertaining the safety of vaccines (an unvaccinated cohort) is being rapidly eliminated by the 
forced introduction and implementation of vaccines whose safety has not yet been established! 
9C5a-A1b. Synergy and Long-Term 
 According to the National Vaccine Information Center, there are 69 doses of 16 vaccines 
on the present recommended vaccination schedule.  According to other organizations' estimates, 
there are hundreds of vaccines in the pipeline awaiting licensing and subsequent addition to the 
schedule.  Any specific combinations of vaccines proposed could not be assumed to be safe 
based on isolated vaccine results (due to potential synergistic effects), and would have to be 
tested in the combination(s) recommended.  That was our finding from the EMF health effects 
study [130] as well, where combinations of substances could have adverse effects not seen when 
using the individual substances. 




 For the 69 doses of the 16 vaccines recommended in the present vaccination schedule, 
what safety studies have been performed examining the synergistic effects of these 69 doses of 
vaccine over the recommended sequencing and timing intervals, including the effects of myriad 
other toxins to which the child is exposed over this time period?  What long-term human health 
effects studies have been performed with the current mix of vaccines and myriad other toxins, 
given that the vaccine combinations on the recommended schedule have expanded rapidly over 
the past few years, and the combinations are essentially new? 
 Two typical examples of safety/ efficacy studies of vaccine combinations reported in the 
peer-reviewed literature are the following (Titles presented): 
 1. Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose 
primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated 
polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenicity. 
 2. Immunogenicity and safety of measles-mumps-rubella, varicella and Haemophilus 
influenzae type b vaccines administered concurrently with a fourth dose of heptavalent 
pneumococcal conjugate vaccine compared with the vaccines administered without heptavalent 
pneumococcal conjugate vaccine. 
 The CDC recommendations include the dose for each vaccination, and the timing/ 
sequencing of the vaccinations.  The combinations listed above do not constitute the full 
recommended vaccine spectrum, either in number of vaccines or timing.  I have not found 
published safety studies that include the full recommended vaccination pattern. 
 In the above two efficacy and 'safety' studies, antibody levels are measured after a short 
period of time, which gives some measure of vaccine efficacy.  Side-effects over this short 
period are documented as well, and (in most of these combination studies I have seen reported in 
the literature) are judged to be 'well-tolerated'.  Long-term effects are typically not measured (but 
sometimes they are; see below). 
 During the data acquisition phase (of the overall present pervasive foundational causes 
study), I observed reports of adverse impacts from myriad  foundational causes spanning the full 
time spectrum from seconds to decades.  We know that e.g. some cancers can have latency 
periods on the order of three-five decades, and other serious diseases can have decadal latency 
periods as well.  Why would one expect deliberate stimulation of relatively immature immune 
systems with multiple toxins not to have some long-term consequences as well? 
 In fact, there has been a modest amount of reported research examining long-term 
adverse impacts of immunization.  The following research article Titles reflect a small sampling 
of this reported research, and provide some indication of the findings: 
*Public should be told that vaccines may have long term adverse effects 
*The timing of immunization affects the development of diabetes in rodents 
*Subacute meningoencephalitis in a subset of patients with AD after A beta 42 immunization 




*Vaccination Safety Update: Long Term Side Effects Due to Vaccination And 
Pharmacovigilance 
*Epidemiology of autoimmune reactions induced by vaccination 
*Autoimmune diseases and vaccinations 
*Autoimmunity, environmental exposure and vaccination: is there a link? 
*Systemic immunotoxicity reactions induced by adjuvanted vaccines 
*The spectrum of post-vaccination inflammatory CNS demyelinating syndromes 
*Long-term epidemiologic longitudinal study on the effect of vaccines on public inoculation 
 These studies either demonstrate long-term impacts resulting from vaccines, or, in some 
cases, conclude that long-term effects cannot be ruled out.  How much would the economic costs 
(of adverse impacts from the MMR vaccine alone) be increased if long-term effects of the MMR 
vaccine were studied objectively? 
9C5a-A2. CDC and Vaccine Manufacturer Structural Disincentives 
 There are some structural disincentives for the vaccine production, distribution, and 
regulation/ safety monitoring infrastructure whose removal would improve the situation 
dramatically.  These disincentives include CDC structural deficiencies and vaccine manufacturer 
incentive deficiencies. 
9C5a-A2a. Structural Deficiencies 
 CDC has at least two major roles relative to vaccines.  First, it co-manages VAERS 
(vaccine adverse events reporting system) with FDA.  VAERS is a passive monitoring system, 
and, like all similar systems, suffers from substantial under-reporting of adverse events.  I have 
seen different estimates on the degree of under-reporting, and all are in the single digit 
percentage range.  In other words, the actual numbers of adverse reactions to vaccines are one 
to two orders of magnitude higher than those reported in VAERS! 
 Second, the CDC distributes vaccines through the Vaccines for Children Program and 
Section 317 Program.  The latter two programs are presently on the order of four billion dollars 
per year combined. 
 Thus, we have a serious conflict when the CDC has responsibility for both  
1) distributing a significant amount of vaccines and  
2) monitoring the safety of these vaccines.   
 Its incentives for distribution could, in theory, over-ride or compromise its incentives for 
insuring safety of vaccines.  Placing the safety monitoring in an organization separate from the 




distribution organization would go a long way toward eliminating the conflict and correcting this 
problem. 
9C5a-A2b. Incentive Deficiencies 
 In 1986, Congress passed the National Childhood Vaccine Injury Act, which effectively 
removed liability from the vaccine manufacturers (and people who administer the vaccines) for 
defects or injury (as upheld by the Supreme Court in 2011).  Shortly thereafter, a National 
Vaccine Injury Compensation Program was established, whose main purpose is to offer 
compensation to those injured by vaccines.  It is funded by the Vaccine Injury Compensation 
Trust Fund.  In turn, the Trust Fund is funded by a $0.75 excise tax on each dose of a vaccine 
targeted toward a specific disease. 
 This has created a distorted set of incentives for the vaccine manufacturers, and a source 
of serious problems for the public.  The manufacturers can maximize profits by having as many 
new vaccines as can be licensed added to the recommended vaccination schedule. 
 The FDA licenses and regulates new vaccines, and the CDC monitors health effects and 
safety after vaccination.  If Dr. Thompson's allegations are correct, the system has some serious 
monitoring problems.  Repealing the 1986 Act so that vaccines are treated the same as drugs 
from a legal perspective would help to remove this strong disincentive. 
9C5a-A3. Recommendations 
 I have made no recommendations on any of the examples in this chapter.  However, I 
find the gap between  
1) the potential enormity of the MMR vaccine injury problem and  
2) the information about the potential seriousness of the problem released to the public 
so large that I believe it is incumbent on me to make recommendations based on the findings 
presented here.  The problem of MMR vaccine adverse impacts is ongoing, and awareness 
among the public has been heightened by Congressman Posey's recent speech. 
 I have spent years managing (and conducting peer reviews of) major projects and 
programs (and publishing some of those peer review experiences [154]).  Based on those myriad 
experiences, I offer the following recommendations for providing better information on vaccines 
to the public. 






1. Damage Control: The initial release of Dr. Thompson's allegations on 27 August 2014 
resulted in a major credibility problem for the CDC.  The allegations implied: 
a) collusion at myriad vertical levels of the CDC management to  
b) intentionally withhold information from the public that  
c) would have shown a link between the MMR vaccine and autism for selected sub-groups. 
The impact of the allegations was contained for about a year because of: 
a) the effective information blackout by the mainstream media and  
b) the lack of Congressional Hearings. 
However, Congressman Posey's comments of 29 July 2015 (on the Floor of the House) raised 
awareness of the CDC credibility problem substantially.  I have noticed a major difference in the 
types of comments on this issue posted on the Web since his speech.  Some of those posters who 
initially defended the CDC against Dr. Thompson's allegations have become far more muted in 
their defense.  There needs to be some real damage control in the near future. 
First, the copious documents provided to Congress by Dr. Thompson should be released to the 
American public without delay.  These documents were funded by the taxpaying public, they do 
not involve national security, and their presence on the Web would help eliminate the rampant 
confusion and speculation concerning their specific content. 
Second, the Department of Health and Human Services (HHS) Office of the Inspector General 
(OIG) (or other independent organization) needs to conduct a thorough investigation of Dr. 
Thompson's allegations.  Surprisingly, given the gravity of this issue and Dr. Thompson's 
allegations, I have seen no mention of any OIG investigation of this issue either in the 
mainstream media or in the alternative media.  My inquiry to the OIG produced a non-committal 
response.  If an investigation is ever done, the OIG investigatory team needs to include external 
participants with independence on the vaccine safety issue. 
Third, there need to be Congressional Hearings on this issue to bring the facts out in the open, 
and attempt to resolve the validity of Dr. Thompson's allegations.  Further delay will only 
heighten the public's concerns about broad-scale information suppression by the CDC. 
2. Moratorium: Dr. Thompson's allegations have raised questions not only about the safety of 
the MMR vaccine, but about the credibility of CDC safety studies for all other vaccines.  
Presently, there are vaccine mandates in most states as a requirement for school attendance, and 
there are laws in some states removing most of the exemptions from these mandates.  If Dr. 
Thompson's allegations are correct, we presently have the State effectively imposing myriad 




diseases upon children through these mandates.  Until vaccines have been shown to be safe, the 
following precautionary steps are recommended. 
First, declare a moratorium on  
1) all vaccine mandates and on  
2) the implementation of laws restricting exemptions. 
Second, create a situation similar to that existing for cigarettes.  Warnings would be included 
with each vaccine package, such as e.g. information concerning the potential of increased risk for 
autism among certain sub-groups from use of MMR vaccine.  If parents choose to have their 
children vaccinated, they would still have that option, but children could attend school if their 
parents chose not to exercise the vaccination option. 
3. New Study: There needs to be a credible study examining the safety of vaccines as 
administered in recommended combination, sequence, and timing.  The public has no assurance 
that any of the vaccine studies conducted to date (or sponsored) by the CDC had any more 
objectivity or credibility than that inferred from Dr. Thompson's allegations on the MMR 
vaccine study. 
First, the proposed study should be conducted by an organization independent of the CDC.  It 
should include an advisory board whose views on vaccines cover the full range of the vaccine 
advocacy/ non-advocacy spectrum.  There would be substantial benefits if international members 
were included, independent of the vaccine manufacturers or government regulatory agencies. 
Second, it should be designed to identify disease incidence rates, as well as other important 
outputs.  This would require including a large cohort of unvaccinated children as well as 
vaccinated.  The ethical issue of denying available treatment for a cohort of participants in a 
clinical trial could be avoided by  
a) using children who had not been vaccinated in the past by design, or  
b) using children whose parents choose not to have them vaccinated today and when the study is 
conducted. 
Third, it should include a very broad regional representation, as well as ethnic, racial, etc.  The 
MMR vaccine study was limited to the Atlanta Metro area, and could have included problems 
peculiar to that region only.  Hypothetically, if e.g. Vitamin D deficiency exacerbated the 
adverse effects of MMR vaccines (as it seems to do for multiple sclerosis and other diseases), 
then we would expect that children living in higher latitudes would be at greater risk to adverse 
effects from MMR vaccine.  Representative sampling would minimize such potential distortions. 
Fourth, it should have large statistical power, which will allow identification of important sub-
group problems.  This means a large number of participants in both the vaccinated and 
unvaccinated groups. 




Fifth, it should include long-term effects as well as short-term.  This may require aggressive 
proactive gathering of vaccination data from people vaccinated years or decades ago, and not 
have sole reliance on the results from passive surveillance databases.  This type of approach will 
of necessity be relatively expensive, but given the potential (multi) trillion-dollar costs estimated 
in section 9C5 for possible damages from one vaccine for one parameter for one group over one 
period, even a relatively expensive large credible study will have an extremely high benefit/ cost 
ratio. 
Sixth, it should include examination of effects of combinations of vaccines, not only individual 
vaccines, as well as effects of the timing and sequencing patterns of these vaccines.  In our EMF 
study [130], we found that sequencing of members of combinations could make a difference in 
whether or not a disease occurred. 
Seventh, a parallel study should be commissioned to examine the benefits of vaccinations, such 
that credible benefit/ cost studies can then be performed.  I have seen studies that showed disease 
incidence rate trends plummeting before vaccines for the specific disease were introduced (due 
to improvements in nutrition, hygiene, etc), and the low present incidence rates for some of these 
diseases could have resulted from extrapolation of the pre-vaccination incidence rate trends.  In 
other words, the rapid reduction of the specific diseases examined could have been coincidental 
with the introduction of the vaccines, not a result of the introduction of the vaccines. 
The benefits study should include an oversight committee composed of representatives from all 
parts of the vaccine advocacy/ non-advocacy spectrum, as well as performers representing the 
full vaccine advocacy spectrum, and have the flexibility of including both majority and minority 
opinions. 
4. Monitoring: Part of the vaccine safety uncertainty problem has been due to weak monitoring 
of vaccine adverse events.  The VAERS system is a passive surveillance system, and may be 
under-reporting adverse vaccine events by at least an order of magnitude. 
First, the monitoring efforts need to be increased in parallel with all the other actions 
recommended, and an active surveillance system needs to be implemented. 
Second, an oversight committee for the monitoring system needs to be established, composed of 
people representing all regions of the vaccine advocacy spectrum. 
5. Infrastructure: The CDC has a serious conflict in having responsibility for both  
1) distributing a significant amount of vaccines and  
2) monitoring the safety of these vaccines. 
Its incentives for distribution might, at least in theory, over-ride or compromise its incentives for 
insuring safety of vaccines. 
First, the CDC vaccine safety monitoring function should be placed in an organization separate 




from the organization responsible for the vaccine distribution function. 
6. Legislative: The National Childhood Vaccine Injury Act of 1986 effectively removed liability 
from the manufacturers (and people who administer the vaccines) for defects or injury from 
vaccines (as upheld by the Supreme Court in 2011).  This has created a distorted set of incentives 
for the vaccine manufacturers, and a source of serious problems for the public.  The 
manufacturers can maximize profits by having as many new vaccines as can be licensed added to 
the recommended vaccination schedule.  The argument for this Act was that the vaccine 
manufacturers would stop developing and producing vaccines unless they could obtain an 
effective liability waiver. 
First, the 1986 Act should be repealed, so that vaccines are treated the same as drugs from a 
legal perspective.  Repeal would remove this strong disincentive. 
Second, the National Vaccine Injury Compensation Program and its associated Court (with no 
jury) should be eliminated, and replaced by the same jury trial structure applicable to drug 
injuries. 
Third, if the cost-benefit vaccine study proposed above shows a net benefit for vaccines, the 
government should consider alternative options for developing and manufacturing vaccines, 
under the constraint that the manufacturer (whether private or public) would be held legally 
liable for vaccine injuries.  If the private sector is unwilling to develop and produce vaccines 
under these conditions, then the government should consider taking over the development, 
production, and distribution of vaccines as an option. 
7. Final Comments: The recommendations above are only a partial set.  Much more could be 
presented, and should be promulgated by an independent commissioned group for correcting 
these extremely serious problems.  As I have shown for one very narrow example, the damage 
done already by alleged intentional withholding of critical information by the CDC could be in 
the trillions of dollars globally over the lifetime of those afflicted so far.  Integrated over all 
vaccines, for all parameters, for all sub-groups, for all countries, for all time periods since 
vaccine introduction, this could amount to many trillions of dollars in damage, to say nothing of 
the unnecessary human suffering involved.  Every day these modifications to the present 
administration of vaccines are delayed, billions of dollars in unnecessary costs from vaccine 
damage are potentially being added, as well as thousands of children condemned to suffer 
unnecessarily. 
 




9D. Clinical Trials Implications of Under-Reporting of Adverse Events 
9D1. Inadequacy of Foundational Cause Accounting 
 Clinical trials are very important for determining the efficacy of treatments for  disease.  
While much effort and attention are expended on insuring a credible statistical structure for the 
trials, and some co-morbidity of the test subjects is taken into account, much less attention is 
typically placed on the potential foundational causes of disease being experienced/ pursued by 
the test subjects.  Why is this important?  I will demonstrate its perceived importance through 
examination of one interesting data point. 
 Dr. Terri Wahls is on the medical faculty of the University of Iowa.  She developed 
Multiple Sclerosis (MS) and eventually became non-ambulatory.  Her book [148] describing her 
experiences shows pictures of her giving classroom lectures from a wheelchair. 
 At that point, she decided to research the biomedical literature to ascertain whether MS 
could be reversed.  Based on her research, she concluded that a major contributing factor to her 
MS was poor diet.  She speculated that the MS could be halted/ eliminated using mainly a dietary 
improvement approach, and the motor control damage from the MS could be reversed using a 
technique called Neuromuscular Electrical Stimulation (NMES).  Heretofore, NMES had only 
been used for athletes' rehabilitation from injury. 
 Dr. Wahls eventually integrated nutritional enhancement with NMES.  Her experience 
was that she used NMES and made very slow progress, then improved her diet and made rapid 
progress.  This comports with the LRDI holistic medical hypothesis: removal of cause is a 
necessary, but not sufficient, condition for restorative treatment to be effective.  This appears to 
be exactly what happened in Dr. Wahls' case; the cause (poor diet) was removed and the 
restorative treatment (NMES) became effective. 
 If one separates the sequence of events necessary for healing into  
1) disease cause removal,  
2) disease symptom removal, and  
3) disease damage removal, 
explanation becomes somewhat easier.  Dr. Wahls eliminated the major cause of her MS (poor 
diet), and the symptoms associated with MS disappeared (pain, fatigue, etc).  However, the 
damage from MS (gait and motor control problems) remained, to some extent.  To reverse that 
damage, she had two major options.  She could let nature take its course and reverse the 
symptoms of the damage.  This alone might work, but natural biological processes can take a 
long time for healing.  For faster results, she could use some external form of treatment to 
accelerate healing.  She chose NMES, and, in combination with improved nutrition, was able to 
accelerate healing. 




 Now comes one of the more critical insights from this book.  Assume we rate the quality 
of diets from one to a hundred, where one is the lowest.  Assume further that Dr. Wahls had an 
average American diet before she contracted MS; her diet pre-2000 (before being diagnosed with 
MS) was perhaps a 40.  Then, she was diagnosed with MS, started to deteriorate, and changed to 
a Paleolithic diet in 2003 (there are various incarnations of the so-called Paleo diet, but they 
consist mainly of fish, grass-fed pasture raised meats, vegetables, fruit, roots, and nuts, and 
exclude grains, legumes, dairy products, salt, refined sugar, and processed oils).  Assuming she 
followed it strictly, I would rate it about 95, based on our past LRDI (mainly dietary) findings for 
different diseases. 
 Then, in 2007, she started NMES.  Her progress, if any, was minimal.  When she 
switched to her present strict diet, which a pro-Paleo advocate might rate at 99, the NMES results 
increased dramatically. 
 If she had received the NMES when her diet was 40, there probably would have been 
zero gain, since the poor diet was continually destroying the myelin sheath (the electrically 
insulating layer around the axon of a neuron whose degradation is a characteristic of MS).  Even 
receiving the NMES when her diet was ~95 didn't do very much.  It was only when her diet 
approached near-pristine status (from a pro-Paleo perspective) that real change occurred.  So, if 
someone were to run clinical trials of the efficacy of NMES on many MS patients, the spectrum 
of responses they would see would be a mirror of the quality of the diet (or, more generally, the 
degree of cause removal from whatever source), and tell relatively little about the efficacy of 
NMES. 
 This means that if we see clinical trial results of a new 'treatment' performed on a number 
of patients who have the average American diet, and the test results don't show much 
improvement, it may tell nothing about the quality of the treatment, irrespective of the 
randomized double-blindedness of the trials!  If all the test subjects were like Dr. Wahls pre-
Paleo, with a ~40 level diet, and they had received NMES, we probably would conclude that 
NMES does not work for MS.  The more accurate conclusion might be that it doesn't work for 
people with MS when the dominant cause(s) is still being experienced; in fact, why would one 
expect it to work under those conditions? 
 But, that's the reality of many medical 'treatments' today.  The foundational cause is not 
addressed, 'treatments' are administered, and there is a wide range of responses.  The so-called 
'incurable' diseases, like MS, are never 'cured' because the true foundational causes are never 
removed! 
9D2. Inadequacy of Data 
 In November 2004, Dr. David Graham (Associate Director for Science, Office of Drug 
Safety, Center for Drug Evaluation and Research, Department of Health and Human Services, 
Food and Drug Administration-FDA), a safety researcher, testified before Congress about 
potential hazards of numerous drugs, including Accutane, Arava, Bextra, Crestor and Meridia.  
His main testimony, however, addressed adverse effects of Vioxx, an arthritis/ pain drug.  His 
testimony, and the hearing, can be seen in full at the following link, and for those who have not 




seen this testimony, I highly recommend it (http://www.c-span.org/video/?184513-1/vioxx-
medication-withdrawal). 
 From the above Hearing's transcript, Dr. Graham testified, in part: "Prior to approval of 
Vioxx, a study was performed by Merck named 090. This study found nearly a 7-fold increase in 
heart attack risk with low dose Vioxx. The labeling at approval said nothing about heart attack 
risks. In November 2000, another Merck clinical trial named VIGOR found a 5-fold increase in 
heart attack risk with high-dose Vioxx......In 2002, a large epidemiologic study reported a 2-fold 
increase in heart attack risk with high-dose Vioxx.....In March of 2004, another epidemiologic 
study reported that both high-dose and low-dose Vioxx increased the risk of heart attacks 
compared to Vioxx’s leading competitor, Celebrex. Our study, first reported in late August of 
this year found that Vioxx increased the risk of heart attack and sudden death by 3.7 fold for 
high-dose and 1.5 fold for low-dose, compared to Celebrex. A study report describing this work 
was put on the FDA website on election day. Among many things, this report estimated that 
nearly 28,000 excess cases of heart attack or sudden cardiac death were caused by Vioxx. I 
emphasize to the Committee that this is an extremely conservative estimate. FDA always claims 
that randomized clinical trials provide the best data. If you apply the risk-levels seen in the 2 
Merck trials, VIGOR and APPROVe, you obtain a more realistic and likely range of estimates 
for the number of excess cases in the US. This estimate ranges from 88,000 to 139,000 
Americans. Of these, 30-40% probably died. For the survivors, their lives were changed forever. 
It’s important to note that this range does not depend at all on the data from our Kaiser-FDA 
study. Indeed, Dr. Eric Topol at the Cleveland Clinic recently estimated up to 160,000 cases of 
heart attacks and strokes due to Vioxx, in an article published in the New England Journal of 
Medicine." 
 How many of these injuries and premature deaths could have been avoided?  The answer 
depends on when the FDA first 'knew' about potential adverse events, and what is meant by 
'knew'.  Merck documents show possibility of adverse cardiovascular events in the late 1990s, as 
Dr. Graham's comments about 090 implied.  But, as Dr. Graham's testimony again shows, even 
when the FDA knew of these problems a few years later, it did not take action to withdraw the 
drug from the market.  Merck voluntarily withdrew the drug in Fall 2004. 
 The two medical experts who testified before Congress along with Dr. Graham believed 
that: 
1) larger tests should have been performed  
2) more representative of the potential user population 
3) for a longer period of time. 
All three witnesses questioned the need for priority/ accelerated approval that FDA gave to 
Vioxx. 
 In 2009, a retrospective study of what was known about Vioxx (rofecoxib) at various 
points in time concluded [149]: "Cumulative pooled analysis of all randomized, placebo-




controlled trials demonstrates a trend toward increased cardiovascular risk associated with 
rofecoxib compared with placebo as early as December 2000, the comparison reaching a P 
value of .05 by June 2001, nearly 3(1/2) years before the manufacturer's voluntary market 
withdrawal."  Had more extensive pre-licensing open testing been required, the problems with 
Vioxx might have surfaced before the license was granted.  Why are trials not conducted 
independently of the sponsor, and why are all internal test results not required to be made 
available to the public? 
 The Vioxx example is somewhat different conceptually from the others presented in this 
chapter.  In the Vioxx case, the literature was 'inadequate' at the time of decision-making because 
the regulators did not wait for adequate data to be generated.  In some sense, this criticism may 
be valid for most drugs, chemicals, and other potentially harmful substances being considered for 
approval. 
 Latency times for serious diseases can be on the order of decades from initial exposure, 
a time scale incongruous with data available for many/ most substances waiting for approval.  
For extremely serious diseases, the risk of drugs tested for relatively short periods (relative to 
potential decadal human latency periods) may be acceptable, but for most non-emergency 
applications, accepting such risk is difficult to rationalize. 
9D3. Clinical Trials Off-Shored to Developing Countries 
9D3a. Ethical Concerns 
 In the past few decades, there has been a steady increase in the off-shoring of clinical 
trials to developing countries.  Costs for these trials are cheaper than in the developed countries, 
many patients are 'treatment-naive' (having had less medical care and drugs than people in the 
developed countries), there is a plethora of sick people readily available, oversight tends to be 
less strict, and ethical standards may be relaxed. 
 For example, placebos (rather than an available alternative treatment) may be used in a 
control group to show a greater advantage for the drug being tested than if an alternative 
treatment were used in the control group.  Typically, in the developed nations, it would be 
viewed as unethical if a placebo were to be used on sick people if an alternative treatment to the 
drug being tested were available.  In some/ many cases, the poor and sick will be used as the 
'guinea pigs', but will not be able to afford the expensive drugs that will eventually be used by 
the affluent developed nations. 
 Some of these questionable clinical trials have been documented (to some extent) over 
the past decade or two (e.g., [150-151]), and both of these references tell a similar story.  
Reference [151] (SOMO briefing paper on ethics in clinical trials) contains the following in its 
summary: "the paper aims to illustrate problems in the ethical conduct of clinical trials. It does 
not provide an analysis of clinical trials in general or of the scale of ethical violations. Indeed, 
the scale of the problem is unknown, because it cannot be estimated how many unethical 
clinical trials escape public attention and therefore remain unnoticed." 




 This reference states further: "the nature of ethical concerns appears to be rather 
diverse.....The lack of voluntary, informed participation and adequately informed consent are 
probably the most common problems. Cases of trials that did not undergo adequate ethical 
review or failed to report serious adverse events indicate flaws in the regulation of clinical trials. 
Tests with experimental drugs of which the safety for testing in humans had not yet been fully 
established may be among the most alarming examples."  These should be viewed as a sample of 
the myriad ethical concerns/ violations.  Also, in this study, there were a few clinical trials from 
developed nations described. 
9D3b. Accuracy of Trial Findings 
 There is a question about accuracy of reporting on these third-world clinical trials.  I have 
shown some of the problems with displaying all the relevant data in USA clinical trials, where 
there tends to be substantial oversight and reasonable transparency.  In the third-world clinical 
trials, the transparency situation is quite different.  As [151] states about such transparency: 
"Furthermore, despite recent initiatives to increase transparency about drug trials, the design of 
most studies is still not publicly available.........Therefore this principle was also not used as a 
selection criterion for the overview of unethical clinical trials in this paper. The lack of 
transparency does limit the amount of information available on the studies described below, 
because in most cases it appears the study design is indeed not publicly available.". 
 References [150-151] were generated from secondary sources and/ or talking to 
principals in the study.  I would suspect that all the major participants in clinical trials in third-
world countries would be very reluctant to reveal negative information to outsiders, such as the 
authors of the above two studies.  These authors were neither sponsors nor regulators. 
9D3c. Clinical Trial Sample Representation of Drug User Community 
 There is another issue with third-world clinical trials related to how well the trials 
represent the eventual user community.  In section 9D1, I showed how the outcome of a 
treatment clinical trial could be strongly dependent on the spectrum of co-morbidities present in 
the trial population.  One could re-word that statement such that the outcome of a clinical trial 
could vary depending on the genetic makeup, the dietary practices, other cultural practices that 
include foundational causes, exposures unique to a given location, etc.  Thus, if a drug is tested 
in a foreign country very different from the USA, one could question the relevance of these test 
results to USA citizens. 
 As reference [152] states, when describing the results of a mainly overseas-tested 
cardiovascular drug: "But it certainly did nothing to dispel concerns that trials conducted 
overseas may be sloppier or that genetic, cultural, and environmental differences from 
Americans mean the data are of questionable relevance to U.S. patients." 





 This chapter has presented myriad conceptual reasons for, and many illustrative examples 
of, under-reporting of adverse events and negative findings in the biomedical literature.  
Obviously, the only evidentiary conclusions that can be drawn relate to the credibility of the 
specific examples presented.  How much can these conclusions be generalized?  In other words, 
how much of the published biomedical literature can we trust, if any?  And, how do we 
recognize which part of the published literature is credible? 
 I have presented some examples of whistle-blowers who were willing to risk their 
careers, their finances, and, in some cases, perhaps their lives, to present their cases to the media.  
I have shown some examples of testimony before the Congress of the United States.  Yet, in 
spite of myriad media coverage and dramatic Congressional testimony, very little has been done 
to improve the situation.  The recent examples presented in this chapter are testimony to this 
inaction. 
 Chapter 9 has emphasized the 'dark side' of research and medicine, and the role that a 
distorted literature has played in this process.  I want to end this chapter on a more hopeful and 
positive note.  The following boxed comments provide a glimpse of what can be done in the 
here-and-now to reverse chronic disease, in selected cases. 
 





REVERSING CHRONIC DISEASE 
The main focus of this book is identifying the full spectrum of foundational causes of disease, in 
order to implement the holistic medical principle that 'removal of cause is a necessary, but not 
sufficient, condition for restorative treatment to be effective'.  Presently, the full spectrum of 
foundational causes for any chronic disease have not been identified to anywhere near the extent 
they have been identified in 
1) reference [12], 
2) this book, or 
3) ongoing studies we are conducting on other serious diseases. 
Therefore, the testing and proof-of-principle demonstration of the full holistic medical principle 
above on preventing and reversing chronic disease has not been possible. 
However, there are examples where chronic disease reversal has occurred when some major 
foundational causes have been identified and removed.  These examples do not include large 
numbers of participants, since these types of non-traditional approaches to disease reversal do 
not attract large amounts of government or industry sponsorship.  I will summarize two recent 
examples briefly. 
The first example is Dr. Wahls' reversal of advanced multiple sclerosis [148], summarized in 
9D1.  She used a combination of strict diet and NMES treatment to  
1) halt the disease and  
2) reverse the damage from the disease. 
This was a good example of how cause removal allowed restorative treatment to be effective, as 
predicted by the holistic medical principle above. 
The second example involves reversal of Alzheimer's Disease,  amnestic mild cognitive 
impairment, or subjective cognitive impairment [153].  Dr. Dale Bredesen, a researcher at the 
Mary S. Easton Center for Alzheimer’s Disease Research, Department of Neurology, University 
of California, Los Angeles, has developed a therapeutic regimen using a total systems approach 
to 'treat' the three related diseases listed above. 
Nine of the first ten patients who utilized this program/ regimen "displayed subjective or 
objective improvement in cognition beginning within 3‐6 months, with the one failure being a 
patient with very late stage AD.  Six of the patients had had to discontinue working or were 
struggling with their jobs at the time of presentation, and all were able to return to work or 
continue working with improved performance.  Improvements have been sustained, and at this 
time [mid-2014] the longest patient follow‐up is two and one‐half years from initial treatment, 




with sustained and marked improvement.....The results also suggest that, at least early in the 
course, cognitive decline may be driven in large part by metabolic processes." [153] 
Dr. Bredesen used a combination of  
1) foundational cause removal,  
2) substitution of healthful practices for the harmful foundational causes, and  
3) supplementation based on biomarker deficiencies  
to achieve these results.  This combination included dietary improvement, exercise and sleep 
enhancement, stress removal, etc. 
The therapeutic regime for each patient was presented in [153].  Unfortunately, it was not 
possible for the reader to decouple the effects of cause removal from supplementation to identify 
which was dominant in the healing process.  In other words, could the same results, or even 
better, have been obtained with cause removal alone?  As I have pointed out previously in this 
book, an identified deficiency of e.g. a vitamin or mineral could be due to  
1) insufficient intake of the relevant vitamin or mineral, or  
2) a dysfunctional metabolic process that results in the deficiency of the vitamin or mineral. 
Thus, adding supplements may or may not contribute to eliminating the underlying foundational 
causes of the deficiencies. 
I have a number of other specific problems with [153], including selection of the sample, size of 
the sample, etc.  However, the central point is that Dr. Bredesen appears to have reversed (to 
some extent) selected cases of Alzheimer's Disease and Cognitive Impairment, which from my 
perspective is a major accomplishment that overshadows any perceived deficiencies in approach.  
Further research in this area could pinpoint the role of cause removal and supplementation 
addition in the healing process, and could overcome any criticisms one could have on the 
approach. 
Based on the CKD study [12], the results of the larger study presented in this book, and other 
analyses I have performed, I would estimate the number of foundational causes for Alzheimer's 
Disease to be on the same order of magnitude as the number of foundational causes for CKD 
(~800 direct foundational causes, plus many more indirect).  Follow-on research to Dr. 
Bredesen's approach should include the full panoply of these foundational causes as candidates 
for elimination.  It could very well be possible to reverse even the more advanced supposedly 
intractable cases of Alzheimer's Disease that Dr. Bredesen's limited approach could not, if the 
full panoply of these foundational causes were considered for elimination.  And, the approach 
outlined in this book would be potentially applicable to any chronic disease, not limited to 
Alzheimer's Disease or CKD. 
The final point is that we may not have to wait for decades in the hope that 'cures' for 





Alzheimer's Disease or other chronic diseases will someday be achieved.  For selected/ 
many/ most people, such 'cures' may potentially be here and now, waiting to 
be demonstrated in large trials!  As in the case of Dr. Wahls, these potential 'cures' are 
not simple 'magic bullets'.  They involve personal motivation, discipline, and hard work.  In 
many cases, they involve rejecting lifelong habits and traditions, and addictions to harmful 
substances and behaviors.  For those who are willing to make these sacrifices, 
potential disease reversal may be within their grasp! 





REFERENCES FOR CHAPTERS 1-9 
1. Kostoff RN.  Literature-Related Discovery: introduction and background.  Technological 
Forecasting and Social Change.  75:2.  165-185.  2008. 
2. Kostoff RN, Briggs MB, Solka JA, Rushenberg RL.  Literature-Related Discovery: 
methodology.  Technological Forecasting and Social Change.  75:2.  186-202.  2008. 
3. Kostoff RN.  Literature-Related Discovery and Innovation - update.  Technological 
Forecasting and Social Change.  79:4.  789-800.  2012. 
4. Kostoff RN, Block JA, Stump JA, Johnson D.  Literature-Related Discovery: potential 
treatments for Raynaud’s Phenomenon.  Technological Forecasting and Social Change.  75:2.  
203-214.  2008. 
5. Kostoff RN.  Literature-Related Discovery: potential treatments for cataracts.  Technological 
Forecasting and Social Change.  75:2.  215-225.  2008. 
6. Kostoff RN, Briggs MB.  Literature-Related Discovery: potential treatments for Parkinson’s 
Disease.  Technological Forecasting and Social Change.  75:2.  226-238.  2008. 
7. Kostoff RN, Briggs MB, Lyons T.  Literature-Related Discovery: potential treatments for 
Multiple Sclerosis.  Technological Forecasting and Social Change.  75:2.  239-255.  2008. 
8. Kostoff RN, Block JA, Solka JA, Briggs MB, Rushenberg RL, Stump JA, Johnson D, Wyatt 
JR.  Literature-Related Discovery: lessons learned, and future research directions.  Technological 
Forecasting and Social Change.  75:2.  276-299.  2008.  
9. Kostoff RN.  Literature-Related Discovery: common factors for Parkinson's Disease and 
Crohn's Disease.  Scientometrics.  100:3.  623-657.  2014. 
10. Kostoff RN.  Literature-Related Discovery: Potential treatments and preventatives for SARS.  
Technological Forecasting and Social Change.  78:7.  1164-1173.  2011. 
11. Kostoff RN, Los LI.  Literature-Related Discovery techniques applied to ocular disease: a 
vitreous restoration example.  Current Opinion in Ophthalmology.  24:6.  606-610.  2013. 
12. Kostoff RN, Patel U.  Literature-Related Discovery and Innovation: Chronic kidney disease.  
Technological Forecasting and Social Change.  91.  341-351.  
http://dx.doi.org/10.1016/j.techfore.2014.09.013.  2015. 
13. Kostoff RN, Solka JA, Rushenberg RL, Wyatt JR.  Literature-Related Discovery: water 
purification.  Technological Forecasting and Social Change.  75:2.  256-275.  2008. 
14. Kostoff RN, Block JA, Solka JA, Briggs MB, Rushenberg RL, Stump JA, Johnson D, Wyatt 
JR.  Literature-Related Discovery.  ARIST.  43.  243-285.  2008. 




15. Kostoff RN.  Where is the discovery in literature-based discovery?  in Bruza, P., and Weeber, 
M., eds.  Literature-Based Discovery.  Springer.  2008. 
16. Valdes-Perez RE.  Principles of human–computer collaboration for knowledge discovery in 
science.  Artif. Intell. 107.  335–346.  1999. 
17. Kostoff RN.  Stimulating innovation, in: Larisa.V. Shavinina (Ed.), International Handbook 
of Innovation.  Elsevier Social and Behavioral Sciences.  Oxford, UK.  388–400.  2003. 
18. Swanson DR.  Fish oil, Raynauds Syndrome, and undiscovered public knowledge.  
Perspectives in Biology and Medicine.  30:1.  7-18.  1986. 
19. Blake C.  Text mining.  Annual Review of Information Science and Technology.  45.  123-
155.  2011. 
20. Smalheiser NR.  Literature-Based Discovery: Beyond the ABCs.  Journal of the American 
Society for Information Science and Technology.  63:2.  218-224.  2012. 
21. Cohen T, Widdows D, Schvaneveldt RW, Davies P, Rindflesch TC.  Discovering discovery 
patterns with predication-based semantic indexing.  Journal of Biomedical Informatics.  45:6.  
1049-1065.  DOI: 10.1016/j.jbi.2012.07.003. 2012. 
22. Hu XH, Zhang XD, Yoo I, Wang XF, Feng JL.  Mining hidden connections among 
biomedical concepts from disjoint biomedical literature sets through semantic-based association 
rule.  International Journal of Intelligent Systems.  25:2.  207-223.  DOI: 10.1002/int.20396.  
2010. 
23. Miller CM, Rindflesch TC, Fiszman M, Hristovski D, Shin D, Rosemblat G, Zhang H, Strohl 
KP.  A closed literature-based discovery technique finds a mechanistic link between 
hypogonadism and diminished sleep quality in aging men.  Sleep.  35:2.  279-85.  2012. 
24. Hristovski D, Rindflesch T, Peterlin B.  Using literature-based discovery to identify novel 
therapeutic approaches.  Cardiovasc Hematol Agents Med Chem. 11:1.  14-24.  2013. 
25. Lim SS,  Vos T, Flaxman AD et al.  A comparative risk assessment of burden of disease and 
injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a 
systematic analysis for the Global Burden of Disease Study 2010.  Lancet.  380:9859  2224-
2260/  2012. 
26. Lopez, AD.  Reducing risks to health: what can we learn from the Global Burden of Disease 
2010 Study?  International Journal of Public Health.  58:5.  645-646.  DOI: 10.1007/s00038-013-
0503-0.  2013. 
27. Murray CJL, Abraham J, Ali MK, et al.  The State of US Health, 1990-2010 Burden of 
Diseases, Injuries, and Risk Factors.  JAMA-Journal of the American Medical Association.  
310:6.  591-608.  DOI: 10.1001/jama.2013.13805.  2013. 




28. Murray CJL, Lopez AD.  Measuring the Global Burden of Disease.  New England Journal of 
Medicine.  369:5.  448-457.  2013. 
29. Murray CJL, Ezzati M, Flaxman AD, et al.  GBD 2010: design, definitions, and metrics.  
Lancet.  380:9859.  2063-2066.  2012. 
30. Lozano R, Naghavi M, Foreman K, Global and regional mortality from 235 causes of death 
for 20 age groups in 1990 and 2010:a systematic analysis for the Global Burden of Disease Study 
2010. Lancet.  380.  2095-2128.  2012. 
31. Danaei G, Ding EL, Mozaffarian D et al.  The preventable causes of death in the United 
States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors.  PLoS Med. 
6.  e1000058.  2009. 
32. Ikeda N, Inoue M, Iso H et al.  Adult mortality attributable to preventable risk factors for 
non-communicable diseases and injuries in Japan: a comparative risk assessment.  PLoS Med.  9.  
e1001160.  2012. 
33. Ezzati M, Riboli E.  Can noncommunicable diseases be prevented? Lessons from studies of 
populations and individuals. Science.  337. 1482-1487.  2012. 
34. Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ.  Selected major risk factors 
and global and regional burden of disease. Lancet.  360.  1347-1360.  2002. 
35. Ezzati M, Riboli E.  Global Health: Behavioral and dietary risk factors for noncommunicable 
diseases.  New England Journal of Medicine.  369:10.  954-964.  DOI: 
10.1056/NEJMra1203528. 2013. 
36. Wang WJ.  Quantifying relevance of input features.  Lecture Notes in Computer Science.  
2412.  588-593.  2002. 
37. Amin SU, Agarwal K, Beg R.  Genetic neural network based data mining in prediction of 
heart disease using risk factors.  2013 IEEE Conference on Information and Communication 
Technologies (ICT 2013).  1227-1231.  2013. 
38. Ushida Y, Kato R, Niwa K et al.  Combinational risk factors of metabolic syndrome 
identified by fuzzy neural network analysis of health-check data.  BMC Medical Informatics and 
Decision Making.  12.  Article Number: 80.  2012. 
39. Barisic I, Wilhelm V, Stambuk N et al.  Machine learning based analysis of biochemical and 
morphologic parameters in patients with dialysis related amyloidosis.  Croatica Chemica Acta.  
75:4.  935-944.  2002. 
40. Du JP, Guo WS.  Data mining on patient data.  Proceedings of the 2005 International 
Conference on Neural Networks and Brain.  VOLS 1-3.  84-87.  2005. 
41. Pfaff M, Weller K, Woetzel D et al.  Prediction of cardiovascular risk in hemodialysis 
patients by data mining.  Methods of Information in Medicine.  43:1.  106-113.  2004. 




42. Cole TS, Frankovich J, Iyer S et al.  Profiling risk factors for chronic uveitis in juvenile 
idiopathic arthritis: a new model for EHR-based research.  Pediatric Rheumatology.  11.  Article 
Number: 45.  2013. 
43. Rodin A, Mosley TH, Clark AG et al.  Mining genetic epidemiology data with Bayesian 
networks application to APOE gene variation and plasma lipid levels.  Journal of Computational 
Biology.  12:1.  1-11.  2005. 
44. Koskela TH, Ryynanen OP, Soini EJ.  Risk factors for persistent frequent use of the primary 
health care services among frequent attenders: A Bayesian approach.  Scandinavian Journal of 
Primary Health Care.  28:1.  55-61.  2010. 
45. Zhao D, Weng C.  Combining PubMed knowledge and EHR data to develop a weighted 
bayesian network for pancreatic cancer prediction.  Journal of Biomedical Informatics.  44:5.  
859-868.  2011. 
46. Aussem A, de Morais SR, Corbex M.  Analysis of nasopharyngeal carcinoma risk factors 
with Bayesian networks.  Artificial Intelligence in Medicine.  54:1.  53-62.  2012. 
47. Bertke SJ, Meyers AR, Wurzelbacher SJ et al.  Development and evaluation of a Naive 
Bayesian model for coding causation of workers' compensation claims.  Journal of Safety 
Research.  43:5-6.  327-332.  2012. 
48. Karaolis M, Moutiris JA, Papaconstantinou L et al.  AKAMAS: Mining association rules 
using a new algorithm for the assessment of the risk of coronary heart events.  2009 9th 
International Conference on Information Technology and Applications in Biomedicine.  514-
519.  2009. 
49. Ordonez C, Zhao K.  Evaluating association rules and decision trees to predict multiple target 
attributes.  Intelligent Data Analysis.  15:2.  173-192.  2011. 
50. Samanta B, Bird GL, Kuijpers M et al.  Prediction of periventricular leukomalacia. Part I: 
Selection of hemodynamic features using logistic regression and decision tree algorithms.  
Artificial Intelligence in Medicine.  46:3.  201-215.  2009. 
51. Karaolis MA, Moutiris JA, Hadjipanayi D et al.  Assessment of the risk factors of coronary 
heart events based on data mining with decision trees.  IEEE Transactions on Information 
Technology in Biomedicine.  14:3.  559-566.  2010. 
52. Marschollek M, Goevercin M, Rust S et al.  Mining geriatric assessment data for in-patient 
fall prediction models and high-risk subgroups.  BMC Medical Informatics and Decision 
Making.  12.  Article Number: 19.  2012. 
53. Kim TN, Kim JM, Won JC et al.  A decision tree-based approach for identifying urban-rural 
differences in metabolic syndrome risk factors in the adult Korean population.  Journal of 
Endocrinological Investigation.  35:9.  847-852.  2012. 




54. Meng XH, Huang YX, Rao DP et al.  Comparison of three data mining models for predicting 
diabetes or prediabetes by risk factors.  Kaohsiung Journal of Medical Sciences.  29:2.  93-99.  
2013. 
55. Friedman C, Liu HF, Shagina L.  A vocabulary development and visualization tool based on 
natural language processing and the mining of textual patient reports.  Journal of Biomedical 
Informatics.  36:3.  189-201.  2003. 
56. Anno S.  GIS/data mining applied for identification of environmental risk factors for 
diseases.  Management Information Systems.  8.  49-54.  2004. 
57. Tanaka L, Aronson AR, Weeber M.  Mining the epidemiological literature for risk factors 
and incidence data of Kawasaki disease.  AMIA 2002 Symposium, Proceedings: Biomedical 
Informatics: One Discipline.  1178-1178.  2002. 
58. Garcia MO, Guzman FA.  Searching for drug-related adverse events in PubMed/medline 
using the MeSH term "Drug Toxicity".  DRUG SAFETY.  31:10.  889-889.  5.  2008. 
59. Golder S, Loke Y, McIntosh HM.  Poor reporting and inadequate searches were apparent in 
systematic reviews of adverse effects.  Journal of Clinical Epidemiology.  61:5.  440-448.  DOI: 
10.1016/j.jclinepi.2007.06.005.  2008. 
60. Golder S, Loke YK.  Search strategies to identify information on adverse effects: a 
systematic review.  Journal of the Medical Library Association.  97:2.  84-92.  DOI: 
10.3163/1536-5050.97.2.004.  2009. 
61. Tanon AA, Champagne F, Contandriopoulos AP, Pomey MP, Vadeboncoeur A, Nguyen, H.  
Patient safety and systematic reviews: finding papers indexed in MEDLINE, EMBASE and 
CINAHL.  Quality & Safety in Health Care.  19:5.  452-461.  DOI: 10.1136/qshc.2008.031401.  
2010. 
62. Egan M, MacLean A, Sweeting H, Hunt K.  Comparing the effectiveness of using generic 
and specific search terms in electronic databases to identify health outcomes for a systematic 
review: a prospective comparative study of literature search methods.  BMJ OPEN.  2:3.  
e001043.  DOI: 10.1136/bmjopen-2012-001043.  2012. 
63. Golder S, Loke YK.  Sensitivity and precision of adverse effects search filters in MEDLINE 
and EMBASE: a case study of fractures with thiazolidinediones.  Health Information and 
Libraries Journal.  29:1.  28-38.  DOI: 10.1111/j.1471-1842.2011.00972.x.  2012. 
64. Golder S, Loke YK, Zorzela L.  Some improvements are apparent in identifying adverse 
effects in systematic reviews from 1994 to 2011.  Journal of Clinical Epidemiology.  66:3.  253-
260.  DOI: 10.1016/j.jclinepi.2012.09.013.  2013. 
65. Sampson M, Zhang L, Morrison A, Barrowman NJ, Clifford TJ, Platt RW, Klassen TP, 
Moher D.  An alternative to the hand searching gold standard: validating methodological search 




filters using relative recall.  BMC Medical Research Methodology.  6:33.  DOI:10.1186/1471-
2288-6-33.  2006. 
66. Harbour J, Fraser C, Lefebvre C, Glanville J, Beale S, Boachie C, Duffy S, McCool R, Smith 
L.  Reporting methodological search filter performance comparisons: a literature review.  Health 
Information and Libraries Journal.  31:3.  176-194.  DOI: 10.1111/hir.12070.  2014. 
67. Waffenschmidt S, Janzen T, Hausner E, Kaiser T.  Simple search techniques in PubMed are 
potentially suitable for evaluating the completeness of systematic reviews.  Journal of Clinical 
Epidemiology.  66:6.  660-665.  DOI: 10.1016/j.jclinepi.2012.11.011.  2013. 
68. Damarell RA, Tieman J, Sladek RM, Davidson PM.  Development of a heart failure filter for 
Medline: an objective approach using evidence-based clinical practice guidelines as an 
alternative to hand searching.  BMC Medical Research Methodology.  11.  Article Number: 12.  
DOI: 10.1186/1471-2288-11-12.  2011. 
69. McKibbon KA, Wilczynski NL, Haynes RB.  Retrieving randomized controlled trials from 
Medline: a comparison of 38 published search filters.  Health Information nd Libraries Journal.  
26:3.  187-202.  2009. 
70. Haase A, Follmann M, Skipka G, Kirchner H.  Developing search strategies for clinical 
practice guidelines in SUMSearch and Google Scholar and assessing their retrieval performance.  
BMC Medical Research Methodology.  7.  28.  2007. 
71. Mahady SE, Schlub T, Bero L, Moher D, Tovey D, George J, Craig JC.  Side effects are 
incompletely reported among systematic reviews in gastroenterology.  J Clin Epidemiol. 68:2.  
144-53.  DOI: 10.1016/j.jclinepi.2014.06.016.  2015. 
72. Livingston M, Callinan S.  Underreporting in alcohol surveys: whose drinking is 
underestimated?  Journal of Studies on Alcohol and Drugs.  76:1.  158-67.  2015. 
73. Zorzela L, Golder S, Liu YL, Pilkington K, Hartling L, Joffe A, Loke Y, Vohra S.  Quality of 
reporting in systematic reviews of adverse events: systematic review.  BMJ-British Medical 
Journal.  348.  Article Number: f7668.  DOI: 10.1136/bmj.f7668.  2014. 
74. Mhaskar RS,  Reljic T, Wao H, Kumar A, Miladinovic B, Djulbegovic B.  Treatment-related 
harms: What was planned and what was reported? National Cancer Institute's Co-operative 
group phase III randomized controlled trials: a systematic review.  Journal of Clinical 
Epidemiology.  67:3.  354-356.  DOI: 10.1016/j.jclinepi.2013.07.006.  2014. 
75. Sivendran S, Latif A, McBride RB, Stensland KD, Wisnivesky J, Haines L, Oh WK, Galsky 
MD.  Adverse event reporting in cancer clinical trial publications.  Journal of Clinical Oncology.  
32:2.  83-89.  DOI: 10.1200/JCO.2013.52.2219.  2014. 
76. Hughes S, Cohen D, Jaggi R.  Differences in reporting serious adverse events in industry 
sponsored clinical trial registries and journal articles on antidepressant and antipsychotic drugs: a 




cross-sectional study.  BMJ Open.  4:7.  Article Number: e005535.  DOI: 10.1136/bmjopen-
2014-005535.  2014. 
77. Riviere S, Penven E, Cadeac-Birman H, Roquelaure Y, Valenty M.  Underreporting of 
musculoskeletal disorders in 10 regions in France in 2009.  American Journal of Industrial 
Medicine.  57:10.  1174-80.  DOI:10.1002/ajim.22364.  2014. 
78. Varallo FR, Guimaraes SOP, Abjaude SAR, Mastroiann, PC.  Causes for the underreporting 
of adverse drug events by health professionals: a systematic review.  Revista da Escola de 
Enfermagem da U S P.  48:4.  739-47.  2014. 
79. Kilander C, Mattsson F, Ljung R, Lagergren J, Sadr-Azodi O.  Systematic underreporting of 
the population-based incidence of pancreatic and biliary tract cancers.  Acta Oncologica.  53:6.  
822-9. DOI:10.3109/0284186X.2013.857429.  2014. 
80. Onishi A, Furukawa TA.  Publication bias is underreported in systematic reviews published 
in high-impact-factor journals: metaepidemiologic study. Journal of Clinical Epidemiology.  
67:12.  1320-6.  2014. 
81. Podolsky DK, Nagarkar PA, Reed WG, Rohrich RJ.  Public reporting of patient safety 
metrics: ready or not? Plastic and Reconstructive Surgery.  134:6.  981e-5e.  2014. 
82. DeLong MR, Hughes DB, Blau JA, Hollenbeck ST.  Publication bias and the under-reporting 
of complications in the literature: have we dug our own pay-for-performance grave?  Plastic and 
Reconstructive Surgery.  134:4.  Suppl 1.  42-3.  2014. 
83. Wuellner SE, Bonauto DK.  Exploring the relationship between employer recordkeeping and 
underreporting in the BLS Survey of Occupational Injuries and Illnesses.  American Journal of 
Industrial Medicine.  57:10.  1133-43.  2014. 
84. Huan LN, Tejani AM, Egan G.  Biomedical journals lack a consistent method to detect 
outcome reporting bias: a cross-sectional analysis.  Journal of Clinical Pharmacy and 
Therapeutics.  39:5.  501-6.  2014. 
85. Imam MA, Barke S, Stafford GH, Parkin D, Field RE.  Loss to follow-up after total hip 
replacement: a source of bias in patient reported outcome measures and registry datasets?  Hip 
international: The Journal of Clinical and Experimental Research on Hip Pathology and Therapy.  
24:5.  465-72.  2014. 
86. Tucker S, Diekrager D, Turner N, Kelloway, EK.Work-related injury underreporting among 
young workers: prevalence, gender differences, and explanations for underreporting.  Journal of 
Safety Research.  50.  67-73.  2014. 
87. Fusar-Poli P, Radua J, Frascarelli M, Mechelli A, Borgwardt S, Di Fabio F, Biondi M, 
Ioannidis JPA, David SP.  Evidence of reporting biases in voxel-based morphometry (VBM) 
studies of psychiatric and neurological disorders. Human Brain Mapping.  35:7.  3052-65.  2014. 




88. Dwan K, Altman DG, Clarke M, Gamble C, Higgins JPT, Sterne JAC, Williamson PR, 
Kirkham JJ.  Evidence for the selective reporting of analyses and discrepancies in clinical trials: 
a systematic review of cohort studies of clinical trials.  PLoS Medicine.  11:6.  e1001666.  2014. 
89. Klatsky AL, Udaltsova N, Li Y, Baer D, Nicole Tran H, Friedman GD.  Moderate alcohol 
intake and cancer: the role of underreporting.  Cancer Causes & Control : CCC.  25:6.  693-9.  
2014. 
90. Roberto G, Zanoni G.  Disease-related adverse events following non-live vaccines: 
investigation of a newly described reporting bias through the analysis of the WHO Global ICSR 
Database, VigiBase.  Vaccine.  32:26.  3328-35.  2014. 
91. Ioannidis JPA, Munafo MR, Fusar-Poli P, Nosek BA, David SP.  Publication and other 
reporting biases in cognitive sciences: detection, prevalence, and prevention.  Trends in 
Cognitive Sciences.  18:5.  235-41.  2014. 
92. Shu Q, Tao H, Fu J, Zhang R, Zhou J, Cheng Z.  The differences between doctors' and 
nurses' attitudes toward adverse event reporting and assessments of factors that inhibit reporting.  
American Journal of Medical Quality.  29:3.  262-3.  2014. 
93. Clavien PA, Puhan MA.  Biased reporting in surgery.  The British Journal of Surgery.  101:6.  
591-2.  2014. 
94. Wiedermann CJ.  Reporting bias in trials of volume resuscitation with hydroxyethyl starch.  
Wiener klinische Wochenschrift.  126:7-8.  189-94.  2014. 
95. Stock S, Nicolakakis N, Raiq H, Messing K, Lippel K, Turcot A.  Underreporting work 
absences for nontraumatic work-related musculoskeletal disorders to workers' compensation: 
results of a 2007-2008 survey of the Quebec working population.  American Journal of Public 
Health.  104:3.  e94-e101.  2014. 
96. Castle, IJP, Yi HY, Hingson RW, White, AM.  State variation in underreporting of alcohol 
involvement on death certificates: motor vehicle traffic crash fatalities as an example.  Journal of 
Studies on Alcohol and Drugs.  75:2.  299-312.  2014. 
97. [Anonymous].  Paucity of negative clinical trials reports and publication bias.  Journal of the 
Canadian Academy of Child and Adolescent Psychiatry.  23:1.  7.  2014. 
98. Saini P, Loke YK, Gamble C, Altman DG, Williamson PR, Kirkham JJ.  Selective reporting 
bias of harm outcomes within studies: findings from a cohort of systematic reviews.  BMJ.  349.  
g6501.  2014. 
99. Page MJ, McKenzie JE, Kirkham J, Dwan K, Kramer S, Green S, Forbes A.  Bias due to 
selective inclusion and reporting of outcomes and analyses in systematic reviews of randomised 
trials of healthcare interventions. The Cochrane Database of Systematic Reviews.  10.  
MR000035.  2014. 




100. Hughes S, Cohen D, Jaggi R.  Differences in reporting serious adverse events in industry 
sponsored clinical trial registries and journal articles on antidepressant and antipsychotic drugs: a 
cross-sectional study.  BMJ.  4:7.  e005535.  2014. 
101. Mansouri A, Ahmadvand A, Hadjibabaie M, Javadi M, Khoee SH, Dastan F, Gholami K.  A 
review of medication errors in Iran: sources, underreporting reasons and preventive measures.  
Iranian Journal of Pharmaceutical Research:IJPR.  13:1.  3-17.  2014. 
102. Gibbons CL, Mangen MJJ, Plass D, Havelaar AH, Brooke RJ, Kramarz P, Peterson KL, 
Stuurman AL, Cassini A, Fevre EM, Kretzschmar MEE.  Measuring underreporting and under-
ascertainment in infectious disease datasets: a comparison of methods.  BMC Public Health.  14.  
147.  2014 
103. Sclar DA, Lieberman PL.  Anaphylaxis: underdiagnosed, underreported, and undertreated.  
The American Journal of Medicine.  127:1.  S1-5.  2014. 
104. Kaufman MB.  Drug-induced pancreatitis: A potentially serious and underreported problem.  
P & T : A Peer-Reviewed Journal for Formulary Management.  38:6.  349-51.  2013. 
105. Heleno B, Thomsen MF, Rodrigues DS, Jorgensen KJ, Brodersen J.  Quantification of 
harms in cancer screening trials: literature review.  BMJ-British Medical Journal.  347.  Article 
Number: f5334.  DOI: 10.1136/bmj.f5334.  2013. 
106. Page MJ, McKenzie JE, Forbes A.  Many scenarios exist for selective inclusion and 
reporting of results in randomized trials and systematic reviews.  Journal Of Clinical 
Epidemiology.  66:5.  524-537.  DOI: 10.1016/j.jclinepi.2012.10.010.  2013. 
107. Maggi CB, Griebeler IH, Dal Pizzol TD.  Adverse events reported in randomized clinical 
trials of drug therapies: the information is still insufficient.  Journal of Clinical Epidemiology.  
66:7.  802-803.  DOI: 10.1016/j.jclinepi.2012.12.006.  2013. 
108. Miller DR.  Failure to report harms and adverse events in clinical trials: Why does the 
problem continue?  Canadian Journal of Anesthesia-Journal Canadien D Anesthesie.  59:11.  
1007-1012.  DOI: 10.1007/s12630-012-9777-6.  2012. 
109. Warren FC, Abrams KR, Golder S, Sutton AJ.  Systematic review of methods used in meta-
analyses where a primary outcome is an adverse or unintended event.  BMC Medical Research 
Methodology.  12.  Article Number: 64.  DOI: 10.1186/1471-2288-12-64.  2012. 
110. Moore TJ, Bennett CL.  Underreporting of hemorrhagic and thrombotic complications of 
pharmaceuticals to the U.S. Food and Drug Administration: empirical findings for warfarin, 
clopidogrel, ticlopidine, and thalidomide from the Southern Network on Adverse Reactions 
(SONAR).  Seminars in Thrombosis and Hemostasis.  38:8.  905-7.  DOI:10.1055/s-0032-
1328890.  2012. 




111. Datta Gupta N, Jurges H.  Do workers underreport morbidity? The accuracy of self-reports 
of chronic conditions.  Social Science & Medicine.  75:9.  1589-94.  
DOI:10.1016/j.socscimed.2012.07.013.  2012. 
112. Craig BM, Rollison DE, List AF, Cogle CR.  Underreporting of myeloid malignancies by 
United States cancer registries.  Cancer Epidemiology, Biomarkers & Prevention.  21:3.  474-81.  
DOI:10.1158/1055-9965.EPI-11-1087.  2012. 
113. Smyth RMD, Kirkham JJ, Jacoby A, Altman DG, Gamble C, Williamson PR.  Frequency 
and reasons for outcome reporting bias in clinical trials: interviews with trialists.  British Medical 
Journal.  342.  Article Number: c7153.  DOI: 10.1136/bmj.c7153.  2011. 
114. Haidich AB, Birtsou C, Dardavessis T, Tirodimos I, Arvanitidou M.  The quality of safety 
reporting in trials is still suboptimal: Survey of major general medical journals.  Journal of 
Clinical Epidemiology.  64:2.  124-135.  DOI: 10.1016/j.jclinepi.2010.03.005.  2011. 
115. Howland RH.  What you see depends on where you're looking and how you look at it 
publication bias and outcome reporting bias.  Journal of Psychosocial Nursing and Mental Health 
Services.  49:8.  13-15.  DOI: 10.3928/02793695-20110705-06.  2011. 
116. Hemkens LG, Grouven U, Bender R, Sawicki PT.  Insufficient evaluation of adverse events 
is not a proof of safety.  Diabetologia.  53:4.  790-792.  DOI: 10.1007/s00125-009-1654-7.  
2010. 
117. Ioannidis JP.  Adverse events in randomized trials: neglected, restricted, distorted, and 
silenced.  Arch Intern Med. 169:19.  1737-9.  DOI: 10.1001/archinternmed.2009.313.  2009. 
118. Lee PE, Fischer HD, Rochon PA, Gill SS, Herrmann N, Bell CM, Sykora K, Anderson GM.  
Published randomized controlled trials of drug therapy for dementia often lack complete data on 
harm.  Journal of Clinical Epidemiology.  61:11.  1152-1160.  DOI: 
10.1016/j.jclinepi.2007.09.012.  2008. 
119. Bernal-Delgado E, Fisher ES.  Abstracts in high profile journals often fail to report harm.  
BMC Medical Research Methodology.  8.  Article Number: 14.  2008. 
120. Corriols M, Marin J, Berroteran J, Lozano LM, Lundberg I, Thorn A.  The Nicaraguan 
Pesticide Poisoning Register: constant underreporting.  International Journal of Health Services : 
Planning, Administration, Evaluation.  38:4.  773-87.  DOI:10.2190/HS.38.4.k.  2008. 
121. Bonde JPE.  Work-related cancer still underreported.  Ugeskrift for laeger.  169:18.  1657.  
2007. 
122. Markman M.  Chemotherapy-induced peripheral neuropathy: underreported and 
underappreciated.  Current pain and headache reports.  10:4.  275-8.  DOI:10.1007/s11916-006-
0032-0. 2006. 




123. Ioannidis JPA, Lau J.  Completeness of safety reporting in randomized trials - An 
evaluation of 7 medical areas.  JAMA-Journal of the American Medical Association.  285:4.  
437-443.  DOI: 10.1001/jama.285.4.437.  2001. 
124. Rosenman KD, Gardiner JC, Wang J, Biddle J, Hogan A, Reilly MJ, Roberts K, Welch E.  
Why most workers with occupational repetitive trauma do not file for workers' compensation.  
Journal Of Occupational and Environmental Medicine.  421.  25-34.  DOI: 10.1097/00043764-
200001000-00008.  2000. 
125. Ottervanger JP, Valkenburg HA, Grobbee DE, Stricker BHC.  Differences in perceived and 
presented adverse drug reactions in general practice.  Journal of Clinical Epidemiology.  51:9.  
795-799.  1998. 
126. Kostoff RN.  Where is the research in the research literature?  JASIST. 63:8.  1675-1676.  
DOI: 10.1002/asi.22613.  2012. 
127. Kostoff, RN.  Citation analysis for research performer quality.  Scientometrics.  53:1.  49-
71.  2002. 
128. Kostoff, RN.  The difference between highly and poorly cited medical articles in the journal 
Lancet.  Scientometrics.  72: 3.  513–520.  2007. 
129. Oreskes N, Conway EM.  Merchants of Doubt: How a Handful of Scientists Obscured the 
Truth on Issues from Tobacco Smoke to Global Warming.  24 May 2011.  Bloomsbury Press. 
130. Kostoff RN, Lau CGY.  Combined biological and health effects of electromagnetic fields 
and other agents in the published literature.  Technological Forecasting & Social Change.  80:7.  
1331-1349.  2013. 
131. Bero LA.  Tobacco industry manipulation of research.  Public Health Reports.  120: 2.  200-
208.  2005. 
132. Egilman DS, Bird T, Lee C.  MetLife and its corporate allies: dust diseases and the 
manipulation of science.  International Journal of Occupational and Environmental Health.  19:4.  
287-303.  DOI:10.1179/2049396713Y.0000000033.  2013. 
133. Federal Register.  40 CFR Part 257 et al.  Standards for the Use or Disposal of Sewage 
Sludge; Final Rules. http://water.epa.gov/scitech/wastetech/biosolids/upload/fr2-19-93.pdf.  19 
February 1993. 
134. Lewis DL.  Science for Sale: How the US Government Uses Powerful Corporations and 
Leading Universities to Support Government Policies, Silence Top Scientists, Jeopardize Our 
Health, and Protect Corporate Profits.  Skyhorse Publishing.  3 June 2014. 




135. McKenna M.  Food poisoning's hidden legacy.  Scientific American.  
http://www.scientificamerican.com/article/food-poisonings-hidden-legacy/?page=3.  2012. 
136. Morgan Verkamp, LLC.  Press Release.  Statement of William W. Thompson, Ph.D., 
Regarding the 2004 Article Examining the Possibility of a Relationship Between MMR Vaccine 
and Autism.  http://www.morganverkamp.com/august-27-2014-press-release-statement-of-
william-w-thompson-ph-d-regarding-the-2004-article-examining-the-possibility-of-a-
relationship-between-mmr-vaccine-and-autism/.  27 August 2014. 
137. DeStefano F, Bhasin TK, Thompson WW, Yeargin-Allsopp M, Boyle C.  Age at first 
measles-mumps-rubella vaccination in children with autism and school-matched control 
subjects: a population-based study in metropolitan Atlanta.  Pediatrics.  113:2.  259-66.  
DOI:10.1542/peds.113.2.259.  2004. 
138. Seife C.  Research misconduct identified by the US Food and Drug Administration: out of 
sight, out of mind, out of the peer-reviewed literature.  JAMA internal medicine.  175:4.  567-77.  
DOI:10.1001/jamainternmed.2014.7774.  2015. 




9 February 2015. 
140. Rosenberg M.  Former FDA Reviewer Speaks Out About Intimidation, Retaliation and 
Marginalizing of Safety.  Truthout.  http://www.truth-out.org/news/item/10524-former-fda-
reviewer-speaks-out-about-intimidation-retaliation-and-marginalizing-of-safety.  29 July 2012. 
141. Slesin L.  “Radiation Research” and The Cult of Negative Results.  Microwave News.  
http://microwavenews.com/RR.html.  31 July 2006. 
142. EURWeb.  The CDC’s Latest ‘Tuskegee Experiment’ Prompts Open Letter from Bobby 
Kennedy Jr.  http://www.eurweb.com/2015/06/the-cdcs-latest-tuskegee-experiment-prompts-
open-letter-from-bobby-kennedy-
jr/#3MiAy0sLai0qyq1m.99http://www.eurweb.com/2015/06/the-cdcs-latest-tuskegee-
experiment-prompts-open-letter-from-bobby-kennedy-jr/.  25 June 2015. 
143. VaxTruth.  How Many African-American Children Have Been Harmed by CDC Fraud?.  
http://vaxtruth.org/2014/08/how-many-african-american-children-have-been-harmed-by-cdc-
fraud/.  26 August 2014. 




144. Buescher AVS, Cidav Z, Knapp M, Mandell DS.  Costs of Autism Spectrum Disorders in 
the United Kingdom and the United States.  JAMA Pediatrics.  168:8.  721-728.  DOI: 
10.1001/jamapediatrics.2014.210.  2014. 
145. Keehan SP, Cuckler GA, Sisko AM, Madison AJ, Smith SD, Stone DA.  Poisal JA, Wolfe 
CJ, Lizonitz JM.  National Health Expenditure Projections, 2014–24: Spending Growth Faster 
Than Recent Trends.  Health Affairs.  10.1377/hlthaff.2015.0600.  2015. 
http://content.healthaffairs.org/content/early/2015/07/15/hlthaff.2015.0600 
146. Pear R.  Health insurance companies seek big rate increases for 2016.  New York Times.  3 
July 2015.  http://www.nytimes.com/2015/07/04/us/health-insurance-companies-seek-big-rate-
increases-for-2016.html?_r=0. 
147. Leigh JP, Du J.  Brief Report: Forecasting the economic burden of autism in 2015 and 2025 
in the United States. Journal of Autism and Developmental Disorders.  2015.  DOI: 
10.1007/s10803-015-2521-7. 
148. Wahls TL.  Minding My Mitochondria: how I overcame secondary progressive multiple 
sclerosis (MS) and got out of my wheelchair.  TZ Press.  2010. 
149. Ross JS; Madigan D; Hill KP; Egilman DS; WangY; Krumholz HM.  Pooled analysis of 
rofecoxib placebo-controlled clinical trial data: lessons for postmarket pharmaceutical safety 
surveillance.  Archives of Internal Medicine.  169:21.  1976-85.  
DOI:10.1001/archinternmed.2009.394.  2009. 
150. Shah S.  The Body Hunters: testing new drugs on the world's poorest patients.  The New 
Press.  New York, New York.  September 1, 2006. 
151. Schipper I, Weyzig F.  Examples of unethical trials.  SOMO.  http://somo.nl/publications-
en/Publication_2534.  February 2008. 
152. Gever J.  FDA faulted for spotty oversight of data coming from overseas.  MedPage Today.  
http://abcnews.go.com/Health/Wellness/fda-approves-drugs-based-foreign-data-
researchers/story?id=10996370&singlePage=true.  24 June 2010. 
153. Bredesen DE.  Reversal of cognitive decline: A novel therapeutic program.  Aging.  6:9.  
2014. 
154.  Kostoff RN.  Defense Technical Information Center. 
 
Science and Technology Peer Review: GPRA 






Research Program Peer Review: Purposes, Principles, Practices, Protocols 
http://www.dtic.mil/dtic/tr/fulltext/u2/a424141.pdf 
 
Science and Technology Metrics 
http://www.dtic.mil/dtic/tr/fulltext/u2/a432576.pdf 
 
The Handbook of Research Impact Assessment 
http://www.dtic.mil/dtic/tr/fulltext/u2/a296021.pdf 
 
Science and Technology Peer Review: Advanced Technology Development Program Review 
http://www.dtic.mil/docs/citations/ADA418830 




GLOSSARY OF TERMS 
Pubmed MeSH tree 
Pubmed is a search engine for the Medline database, generated by the national Library of 
Medicine, National Institutes of Health.  Medline is a bibliographic database mainly covering 
biomedical articles.  MeSH (Medical Subject Headings) is a controlled vocabulary (essentially 
keywords organized into a taxonomy) for indexing the Pubmed articles.  The MeSH tree is the 
structure defining the taxonomy. 
MeSH Qualifiers 
Words added to MeSH Heading terms that narrow the scope of the term.  If Mercury is a MeSH 
Heading term, and the Qualifier of interest is 'adverse effects', then the full MeSH term becomes 
mercury/adverse effects.  There are 83 MeSH Qualifiers in the 2015 edition of Pubmed. 
MeSH Headings No Explode 
If MeSH Headings are entered into a Pubmed search, they will retrieve not only records 
containing the exact MeSH Heading specified, but also records containing any other MeSH 
Headings listed below the MeSH Heading entered (into the query) in the MeSH tree.  MeSH 
Heading No Explode means that only records containing the exact MeSH Heading entered into 
the search query will be retrieved. 
Text Mining 
Extraction of useful information from large volumes of text 
Hierarchical Taxonomy 
A classification scheme different nested levels of detail 
Passive Surveillance 
Obtaining data from voluntary reports of patients or healtcare providers 
Latent Variables 
Variables that are not measured directly, but are hidden.  They can be inferred from variables 
measured directly. 
EPA 








Centers for Disease Control and Prevention, the USA's "leading public health agency", whose 




US Food and Drug Administration, a Federal Agency responsible for protecting and promoting 
public health through the regulation and supervision of food safety, tobacco products, dietary 
supplements, prescription and over-the-counter pharmaceutical drugs (medications), vaccines, 
biopharmaceuticals, blood transfusions, medical devices, electromagnetic radiation emitting 
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